WorldWideScience

Sample records for hepatitis por virus

  1. Infección aguda por el VHB Acute infection by Hepatitis B Virus

    Directory of Open Access Journals (Sweden)

    F. Alegre

    2004-01-01

    Full Text Available El espectro clínico de la infección aguda por el virus de la hepatitis B es muy amplio, con cuadros que van desde una hepatitis anictérica y subclínica a una hepatitis ictérica aguda grave e incluso, en algunos casos, a una hepatitis fulminante. El diagnóstico depende en gran medida del grado de sospecha clínica de la hepatitis, estableciéndose el origen etiológico por el virus B mediante el estudio de marcadores serológicos y/o DNA en sangre. Aunque en la mayor parte de los casos la evolución de la hepatitis aguda por virus B es favorable, con resolución espontánea de la clínica en 4-8 semanas, no es infrecuente en ciertos casos, sobre todo en la infancia, la progresión a hepatitis crónica. No existe ningún tratamiento específico para la infección aguda por virus B que reduzca su gravedad o prevenga su evolución a hepatitis crónica. Se recomienda, no obstante, el reposo relativo, y la administración de una dieta hipercalórica. En las hepatitis agudas graves debe indicarse ingreso hospitalario; en casos de hepatitis fulminante ingreso en UCI para monitorización intensiva y valoración de trasplante hepático si no se produce mejoría espontánea. En el presente artículo se revisa, de forma breve y esquemática, la clínica, el diagnóstico, el pronóstico y el tratamiento de la infección aguda por el virus de la hepatitis B.The clinical spectrum of acute hepatitis B virus infection is very broad, with clinical manifestations that range from anicteric and sub-clinical hepatitis to severe acute icteric hepatitis and even, in some cases, to fulminant hepatitis. Diagnosis depends to a large extent on the degree of clinical suspicion of hepatitis, establishing the aetiological origin of the B virus through the study of serological markers and/or DNA in the blood. Although in the majority of cases there is a favourable evolution of acute hepatitis B virus infection, with spontaneous resolution of the clinical manifestations

  2. Infección crónica por el VHB Chronic Hepatitis B Virus infection

    Directory of Open Access Journals (Sweden)

    C. Carretero

    2004-01-01

    Full Text Available Existen muchos factores implicados en la patogénesis de la infección crónica por el virus de la hepatitis B (VHB, como por ejemplo características del virus, la ingesta de etanol, la coinfección con otros virus (VHC, VIH, VHD, e intervenciones terapéuticas como el uso de fármacos citotóxicos o inmunosupresores, o agentes antivirales específicos. Las características clínicas, patológicas y serológicas de la hepatitis crónica por VHB, además, son muy heterogéneas. Se puede reconocer la infección crónica por VHB ante la persistencia del antígeno Australia (HBsAg durante más de seis meses. La presencia de HBeAg se suele asociar a la replicación viral activa y puede ser medida por la cantidad de DNA-VHB presente en el suero o bien por la expresión hepática de HBcAg. El daño hepático que se produce en la hepatitis crónica por VHB no es tanto por el efecto del virus sobre los hepatocitos sino por la reacción inmune que éste provoca en el huésped. Por ello puede verse cierta correlación inversamente proporcional entre la intensidad de la replicación viral y el grado de inflamación hepática. La presencia de hepatitis crónica activa en la biopsia inicial no se ha asociado al desarrollo de cirrosis así como tampoco el diagnóstico histológico de hepatitis crónica persistente puede asegurar que se vaya a desarrollar cirrosis en un futuro.Many factors are involved in the pathogenesis of chronic hepatitis B virus infection (HBV, such as, for example, characteristics of the virus, ethanol intake, coinfection with other viruses (HCV, HIV, HDV, and therapeutic interventions such as the use of cytotoxic drugs or immunosuppressors, or specific antiviral agents. The clinical, pathological and serological characteristics of chronic hepatitis B virus infection are besides very heterogeneous. Chronic HBV infection can be recognised facing persistence of the Australia antigen (HBsAg for more than six months. The presence of HBeAg is

  3. Infección crónica por el VHB Chronic Hepatitis B Virus infection

    OpenAIRE

    Carretero, C.; M. Herráiz

    2004-01-01

    Existen muchos factores implicados en la patogénesis de la infección crónica por el virus de la hepatitis B (VHB), como por ejemplo características del virus, la ingesta de etanol, la coinfección con otros virus (VHC, VIH, VHD), e intervenciones terapéuticas como el uso de fármacos citotóxicos o inmunosupresores, o agentes antivirales específicos. Las características clínicas, patológicas y serológicas de la hepatitis crónica por VHB, además, son muy heterogéneas. Se puede reconocer la infecc...

  4. Infección aguda por el VHC Acute hepatitis C virus infection

    Directory of Open Access Journals (Sweden)

    A. Martínez Echeverría

    2004-01-01

    Full Text Available La infección aguda por el virus C de la hepatitis produce un cuadro clínico y bioquímico no específico e indistinguible de los causados por otros virus hepatotropos. El diagnóstico específico de la hepatitis aguda por virus C se basa en la detección en sangre del RNA-VHC mediante una técnica de reacción en cadena de la polimerasa cuyo resultado será positivo a partir de 1-2 semanas tras el contacto inicial con el virus. Los anticuerpos frente al VHC se detectan más tardíamente (a las 7-8 semanas por término medio no siendo útiles, como determinación aislada, para distinguir infección aguda de infección crónica o aclaramiento del virus (espontáneo o tras tratamiento. El 55-85% de los pacientes con infección aguda por el VHC no aclaran el virus y desarrollan una infección crónica con riesgo de evolución a cirrosis y de desarrollo de hepatocarcinoma. Por ello, la tendencia actual es tratar con interferón a todos aquellos pacientes en los que el RNA-VHC se mantenga positivo más allá de 3-4 meses tras el diagnóstico de la infección aguda.Acute hepatitis C virus infection produces clinical and biochemical features that is non-specific and indistinguishable from those caused by other hepatotropic viruses. The specific diagnosis of acute hepatitis C virus infection is based on the detection of serum RNA-HCV through a technique of PCR whose result will be positive after 1-2 weeks of the initial contact with the virus. The anti-bodies against HCV are detected later (after 7-8 weeks on average, and are not useful, as an isolated determination, in distinguishing acute infection from chronic infection or in clearing the virus (spontaneous or following treatment. Fifty-five to eighty-five percent of patients with acute HCV infection do not clear the virus and develop a chronic infection with risk of evolution to cirrhosis and of developing hepatocellular carcinoma. For this reason, the present tendency is to treat with interferon

  5. Infección crónica por el VHC Chronic Hepatitis C virus infection

    Directory of Open Access Journals (Sweden)

    M. Iñarrairaegui

    2004-01-01

    Full Text Available Tras la infección aguda por el virus de la hepatitis C (VHC, un porcentaje importante de pacientes no aclara el virus y desarrollan una hepatitis crónica C. Los síntomas, cuando existen, suelen ser inespecíficos. Aproximadamente un tercio de los pacientes presentan además manifestaciones extrahepáticas de la infección, debidas fundamentalmente al linfotropismo del virus C. De éstas destacan, por su clara asociación con el VHC, la crioglobulinemia mixta y la producción de autoanticuerpos (autoAc. Otras enfermedades como el linfoma no Hodgkin (LNH o la tiroiditis autoinmune no tienen una asociación claramente establecida. Aunque la mayoría de los pacientes con hepatitis crónica C tienen niveles ligeros o moderadamente elevados y fluctuantes de transaminasas, hasta un tercio de los infectados pueden presentar niveles persistentemente normales de transaminasas. El diagnóstico de la infección crónica por el VHC se basa en pruebas serológicas, que detectan la presencia de anticuerpos frente al VHC, y en pruebas virológicas que detectan RNA del VHC, que confirman la existencia de infección activa. Por último, un aspecto importante en la infección crónica por el VHC, tras el diagnóstico, es establecer el estadio de fibrosis y el grado de inflamación, ya que ambas características son muy importantes para predecir la evolución natural y la necesidad de tratamiento. Hoy en día esta información sólo puede obtenerse mediante biopsia hepática, que está indicada en pacientes con infección crónica por el VHC y transaminasas elevadas. Su indicación en pacientes con transaminasas normales permanece todavía controvertida.Following acute hepatitis C virus infection (HCV, a significant percentage of patients do not clear the virus and develop a chronic hepatitis C. The symptoms, when they exist, are usually unspecific. Besides, approximately one third of the patients present extrahepatic manifestations of the infection, basically

  6. Inmunopatogenia y fisiopatología de la hepatitis por virus B

    Directory of Open Access Journals (Sweden)

    Luis Daniel Quesada-Mora

    2008-11-01

    Full Text Available Virus B, familia Hepadnaviridae, no citopático directo. La lesión hepatocelular es por la respuesta inmunológica a los antígenos virales. Respuesta inmune muy agresiva da hepatitis fulminante. En los crónicos hay débil respuesta de los linfocitos T citotóxicos CD 8, predominante la respuesta humoral de sustancias Th-2 (IL4,5,10. Factores que afectan la evolución: a. mutación del virus; b co-infección con otros virus; c estado inmune del paciente. Fases de la evolución a cronicidad: a fase inmunotolerante: mucho virus y Ag positivo, seroconversiόn dura años, seroconversiόn de e es de 15% en 20 años; b fase de aclaramiento inmune: seroconversiόn de e de 10 20% por año; c estado de portador inactivo: mayoría de pacientes crónicos, son Ag negativos, anti e positivos; d hepatitis crónica e negativos: ADN alto con elevación de ALT, la mayoría son mutaciones core y pre core no produciendo antígeno. e resolución de infección crónica, 0.5-2% aclaran el antígeno de superficie, pero podrían hacer carcinoma hepatocelular en el futuro, siendo anti-HBs positivos.

  7. Anemia hemolítica autoinmune postinfección por virus de la hepatitis A. Informe de caso; Autoimmune haemolytic anaemia associated to hepatitis A. Case report

    Directory of Open Access Journals (Sweden)

    Claudia Lucía Sossa Melo, MD

    2010-01-01

    Full Text Available La anemia hemolítica autoinmune se asocia con una variedad de virus hepatotrópicos, en particular citomegalovirus (CMV, virus del Epstein-Barr y de la hepatitis B. No es frecuente dentro de la historia natural de la hepatitis A, la aparición de anemia hemolítica, y cuando se presenta, generalmente se asocia a deficiencia de glucosa-6-fosfato deshidrogenasa. Presentamos el caso de un paciente de sexo masculino sin hemólisis previa, con astenia e ictericia de dos meses de evolución y hepatomegalia 14 cm por debajo del reborde costal derecho. Los hallazgos en los exámenes de laboratorios mostraron anemia hemolítica con Coombs directo positivo, anticuerpos tipo inmunoglobulina M contra el virus de la hepatitis A positivos, niveles de bilirrubinas 20 veces y aminotrasferasas cuatro veces por arriba del rango normal; con estos datos el paciente fue diagnosticado como hepatitis A complicada con anemia hemolítica y probable hepatitis autoinmune asociada, por lo que se inició manejo con corticoides, alcanzándose mejoría clínica. Resaltamos la importancia de descartar la infección por el virus de la hepatitis A como posible etiología de anemia hemolítica autoinmune.______________________________________________________________________ Acute auto inmune haemolytic anaemia is associated with a variety of hepatotropic viruses, in particular cytomegalovirus, Epstein Barr virus and hepatitis B. The typical course of hepatitis A is rarely complicated with glucose-6-phosphate dehydrogenase deficiency. Wepresent the case of a man without previous haemolysis, he had been unwell for two months with fatigue and jaundice, the liver edge was palpable and tender 14 cm below the costal margin. Clinical chemistry showed haemolytic anaemia with positive direct coombs test, immunoglobulin M antibodies to hepatitis A virus were detected, the total bilirrubin concentration 20 times the upper and transaminase 4 times upper limit for normal levels; with this

  8. Carcinoma hepatocelular y linfoma folicular en paciente cirrótico por virus de la hepatitis C

    OpenAIRE

    García, L.; Boschero, F.; Río, V. del; Balbín, E.; Espeche, W.

    2016-01-01

    El virus de la hepatitis C (VHC) tiene demostrado poder oncogénico. Su asociación con Carcinoma Hepatocelular (CHC) en pacientes con cirrosis hepática es bien conocida como también con el Linfoma no Hodgkin indolente. Es poco frecuente que estas tres entidades se presenten simultáneamente. El objetivo de este reporte es describir la presentación clínica, la metodología diagnóstica y la evolución de un paciente que presentó concomitantemente infección crónica por virus C, cirrosis, hepatocarci...

  9. Historia natural de la infección por el VHC Natural history of hepatitis C virus infection

    OpenAIRE

    2004-01-01

    El curso generalmente indolente, lento y prolongado de la infección por el virus de la hepatitis C ha limitado la realización de estudios que valoren su historia natural. Dichos estudios han tenido como objetivo la probabilidad de muerte por enfermedad hepática, cirrosis hepática (compensada o descompensada) y/o hepatocarcinoma, o el desarrollo de una fibrosis hepática importante (substrato anatomopatológico indispensable para el desarrollo de las complicaciones de la cirrosis hepática). A pe...

  10. Baja prevalencia de la infección por el virus de la hepatitis C en una población de reclusos, Maracaibo, Venezuela

    Directory of Open Access Journals (Sweden)

    Francisca Monsalve

    2009-12-01

    Conclusiones. La prevalencia de la infección por el virus de la hepatitis C en esta población fue baja, lo que evidencia la baja circulación del virus en el reclusorio. El principal factor de riesgo para la adquisición de la infección, al parecer, es el uso de drogas intravenosas.

  11. Manejo de la coinfección por virus de la hepatitis B y VIH en el Perú

    Directory of Open Access Journals (Sweden)

    Vivian Levy

    2007-10-01

    Full Text Available En el Perú, los hombres que tienen sexo con hombres (HSH deben ser incorporados a los grupos de riesgo para la infección por virus de hepatitis B (HBV, los cuales también incluye a personas provenientes de áreas endémicas de HBV, trabajadores de atención en salud y trabajadores/as sexuales, que potencialmente puedan estar infectadas por el VIH. Debido a que en estos grupos comparten riesgos para la transmisión sexual, la coinfección con HBV y VIH, es común particularmente en HSH y en heterosexuales de alto riesgo. Se debe tener mucho cuidado en el tratamiento para la infección crónica por el HBV en pacientes que tienen, además, coinfección con el VIH. Los principales objetivos del tratamiento de la infección con HBV son suprimir la replicación del virus, mejorar las funciones hepáticas y minimizar la emergencia de resistencia medicamentosa al HBV y al VIH. En el presente artículo se revisa la epidemiología del HBV en el Perú, la historia natural de la coinfección con HBV-VIH y se describe las opciones actuales de tratamiento en el contexto peruano.

  12. Hepatitis virus panel

    Science.gov (United States)

    ... page: //medlineplus.gov/ency/article/003558.htm Hepatitis virus panel To use the sharing features on this page, please enable JavaScript. The hepatitis virus panel is a series of blood tests used ...

  13. Hepatitis B virus (image)

    Science.gov (United States)

    Hepatitis B is also known as serum hepatitis and is spread through blood and sexual contact. It is ... population. This photograph is an electronmicroscopic image of hepatitis B virus particles. (Image courtesy of the Centers for ...

  14. Epidemiología de la infección por el virus de la hepatitis B en dos poblaciones del departamento del Magdalena

    Directory of Open Access Journals (Sweden)

    Fernando De La Hoz

    1991-12-01

    Full Text Available Durante 1989 se llevó a cabo una encuesta de seroprevalencia de infección por el virus de la hepatitis B (VHB en dos poblaciones del departamento del Magdalena (costa norte de Colombia: Cerro Azul y Varela, las cuales presentaban historia reciente de casos de hepatitis fulminante (HF causada por co y sobre infección del virus de la hepatitis Delta (VHD en portadores del antígeno de superficie del VHB (HBsAg. De acuerdo con los resultados obtenidos, en la población con mayor número de casos fulminantes, Cerro Azul,la infección por VHB empieza desde la infancia temprana, probablemente por transmisión horizontal y alrededor de los 15 años, ya la mitad de la población ha sido infectada por VHB. En ella los principales factores asociados con la infección fueron: la carencia de un sistema de disposición de excretas, el hacinamiento y el antecedente de algún familiar muerto por Hepatitis. En la segunda población, Varela, menos afectada por la hepatitis fulminante, la infección por VHB ocurre a edades mas tardías: desde los 15 años en adelante, y alrededor de los 30 años, la mitad de la población ha sido infectada por este virus. En ella los factores que hallamos asociados a la infección por VHB son; el sexo masculino, la carencia de un sistema de eliminación de excretas, el antecedente de transfusión sanguínea y la aplicación de medicamentos parenterales ambulatorios.

  15. Determinación mediante inmunohistoquímica de infección por virus de la fiebre amarilla y virus de la hepatitis b

    Directory of Open Access Journals (Sweden)

    Cecilia Morón C

    2003-03-01

    Full Text Available La inmunohistoquímica (IHQ constituye una herramienta para definir la etiología en el síndrome icterohemorrágico. Objetivo: Identificar mediante IHQ la presencia en hígado del antígeno de superficie de la hepatitis B y del virus de la fiebre amarilla. Materiales y métodos: Se incluyeron muestras de tejido hepático procedentes de 55 fallecidos por síndrome icterohemorrágico, remitidos entre enero de 2000 y diciembre de 2001 al Instituto Nacional de Salud, (Lima, Perú. Resultados: La prueba se realizó únicamente en 46 muestras, 33% (15/46 fueron diagnosticados por histopatología como fiebre amarilla, de ellos, 9 casos fueron positivos por IHQ para fiebre amarilla, siendo 2 de ellos también positivos para HBsAg. Histológicamente, se reportaron 6 casos como hepatitis con necrosis submasiva o masiva, que por IHQ fueron sólo 2 casos positivos para fiebre amarilla. En 39% (18/46 no se llegó al diagnóstico etiológico de la hepatitis, y finalmente hubo 2 casos con diagnóstico histopatológico de ádenocarcinoma hepático y sólo se obtuvo positividad por IHQ para HBsAg en uno. Conclusión: La IHQ es una alternativa para la confirmación diagnóstica de hepatitis B y fiebre amarilla.

  16. Transplante hepático en pacientes con cirrosis por VHB y VHC Liver transplantation in patients with cirrhosis secondary to Hepatitis B Virus and Hepatitis C Virus injections

    OpenAIRE

    Lucena, J.F. (Juan F.); J. I. Herrero

    2004-01-01

    La cirrosis hepática asociada al virus C constituye la principal indicación de trasplante hepático en Europa y EEUU, representando en adultos hasta el 50% de las indicaciones, mientras que la cirrosis asociada al virus B representa alrededor del 10%. Las indicaciones de trasplante en los pacientes con infección por virus B y C son la hepatitis fulminante, la cirrosis descompensada y la aparición de hepatocarcinoma. Las dos infecciones pueden recidivar tras el trasplante. La evolución de la re...

  17. Transplante hepático en pacientes con cirrosis por VHB y VHC Liver transplantation in patients with cirrhosis secondary to Hepatitis B Virus and Hepatitis C Virus injections

    Directory of Open Access Journals (Sweden)

    J. F. Lucena

    2004-01-01

    Full Text Available La cirrosis hepática asociada al virus C constituye la principal indicación de trasplante hepático en Europa y EEUU, representando en adultos hasta el 50% de las indicaciones, mientras que la cirrosis asociada al virus B representa alrededor del 10%. Las indicaciones de trasplante en los pacientes con infección por virus B y C son la hepatitis fulminante, la cirrosis descompensada y la aparición de hepatocarcinoma. Las dos infecciones pueden recidivar tras el trasplante. La evolución de la reinfección en el injerto es variable y puede incluir alteraciones no significativas de las pruebas de función hepática, hepatitis crónica activa y cirrosis. Con menor frecuencia se desarrolla una forma particularmente grave denominada "hepatitis colestásica fibrosante" que produce una rápida evolución al fallo del injerto. La inmunoglobulina contra el virus B y la lamivudina disminuyen el riesgo de reinfección. El factor principal asociado a la recidira de la hepatitis B es la replicación viral activa antes del trasplante, por lo que actualmente se considera una contraindicación para el transplante. Para el tratamiento de la reinfección por el virus de la hepatitis B se ha utilizado INF-a con resultados desalentadores. Más recientemente se han usado lamivudina y adefovir. La recidiva del virus de la hepatitis C postrasplante es universal y su evolución hacia la cirrosis es más rápida que en pacientes inmunocompetentes, siendo la disfunción del injerto la causa más frecuente de mortalidad y de indicación de retrasplante. Se han descrito factores relacionados con la gravedad de la recidiva que incluyen factores relacionados con el donante, el receptor, el virus, la inmunosupresión y la cirugía. No existen tratamientos preventivos de la recidiva de la hepatitis C postrasplante. En el tratamiento de la reinfección por virus de la hepatitis C se han usado INF-a y rivabirina tanto en forma única como combinada con resultados variables

  18. Anemia hemolítica autoinmune postinfección por virus de la hepatitis A. Informe de caso; Autoimmune haemolytic anaemia associated to hepatitis A. Case report

    OpenAIRE

    Claudia Lucía Sossa Melo, MD; Sara Inés Jiménez Sanguino, MD; Carlos Andrés Pérez Martínez, MD; Amaury Alexis Amaris Vergara, MD; Luis Antonio Salazar Montaña, MD; Ángela Peña Castellanos, MD; Jesica Liliana Pinto Ramírez; Laura Andrea Rincón Arenas

    2010-01-01

    La anemia hemolítica autoinmune se asocia con una variedad de virus hepatotrópicos, en particular citomegalovirus (CMV), virus del Epstein-Barr y de la hepatitis B. No es frecuente dentro de la historia natural de la hepatitis A, la aparición de anemia hemolítica, y cuando se presenta, generalmente se asocia a deficiencia de glucosa-6-fosfato deshidrogenasa. Presentamos el caso de un paciente de sexo masculino sin hemólisis previa, con astenia e ictericia de dos meses de evolución y hepatomeg...

  19. Anemia hemolítica autoinmune postinfección por virus de la hepatitis A. Informe de caso; Autoimmune haemolytic anaemia associated to hepatitis A. Case report

    OpenAIRE

    Claudia Lucía Sossa Melo, MD; Sara Inés Jiménez Sanguino, MD; Carlos Andrés Pérez Martínez, MD; Amaury Alexis Amaris Vergara, MD; Luis Antonio Salazar Montaña, MD; Ángela Peña Castellanos, MD; Jesica Liliana Pinto Ramírez; Laura Andrea Rincón Arenas

    2010-01-01

    La anemia hemolítica autoinmune se asocia con una variedad de virus hepatotrópicos, en particular citomegalovirus (CMV), virus del Epstein-Barr y de la hepatitis B. No es frecuente dentro de la historia natural de la hepatitis A, la aparición de anemia hemolítica, y cuando se presenta, generalmente se asocia a deficiencia de glucosa-6-fosfato deshidrogenasa. Presentamos el caso de un paciente de sexo masculino sin hemólisis previa, con astenia e ictericia de dos meses de evolución y hepatomeg...

  20. Tamizaje por hepatocarcinoma y estrategia de seguimiento en portadores del virus de hepatitis B

    Directory of Open Access Journals (Sweden)

    Javier Cabas-Sánchez

    2008-11-01

    Full Text Available La utilización del ultrasonido abdominal y la alfafetoproteína juntas se consideran las pruebas de tamizaje aceptadas como más útiles en él seguimiento de los portadores crónicos del virus B. Se debe separar los pacientes de alto riesgo (sexo masculino, cirróticos, historia familiar de hepatocarcinoma, mayores de 45 años y los de bajo riesgo para determinar el tiempo de seguimiento, siendo cada 3 meses para los primeros y de cada 6 meses para los segundos. Cuando se detecte alguna imagen anormal, el uso de tomografía de 3 fases y resonancia magnética complementan la definición de las imágenes para definir una conducta terapéutica.

  1. Hepatitis G virus

    Institute of Scientific and Technical Information of China (English)

    Vasiliy Ivanovich Reshetnyak; Tatiana Igorevna Karlovich; Ljudmila Urievna Ilchenko

    2008-01-01

    A number of new hepatitis viruses (G,TT,SEN) were discovered late in the past century.We review the data available in the literature and our own findings suggesting that the new hepatitis G virus (HGV),disclosed in the late 1990s,has been rather well studied.Analysis of many studies dealing with HGV mainly suggests the lymphotropicity of this virus.HGV or GBV-C has been ascertained to influence course and prognosis in the HIV-infected patient.Until now,the frequent presence of GBV-C in coinfections,hematological diseases,and biliary pathology gives no grounds to determine it as an "accidental tourist" that is of no significance.The similarity in properties of GBV-C and hepatitis C virus (HCV) offers the possibility of using HGV,and its induced experimental infection,as a model to study hepatitis C and to develop a hepatitis C vaccine.

  2. Hepatite crônica por vírus C: Parte 1. Considerações gerais Hepatitis C virus: Part 1. General considerations

    Directory of Open Access Journals (Sweden)

    Vinício Paride CONTE

    2000-07-01

    necessariamente ausência de vírus da hepatite C no fígado. A associação de autoimunidade à hepatite C é questionável. Os marcadores imunes são freqüentemente detectados em baixos níveis. A modulação da resposta imune ao envelope protéico E2, após injeção de plasmídios DNA, tem sido usada para induzir respostas imunes específicas ao vírus da hepatite C. O espectro de tais respostas poderia ser ampliada mediante combinação de plasmídios, vias de administração e outras formas de imunógenos codificados (vacinas a base de peptídios. Tais estratégias podem vir a ser importantes, em breve, no combate aos altamente mutantes vírus da hepatite C. O papel patogênico dos novos vírus G e TT das hepatites está em estudos, porém é de consenso que suas associações com doença hepática ativa é fortuita.Hepatitis C virus was identified in 1989 as the main causative agent of non-A, non-B and was followed by the recognition of a high prevalence of hepatitis C virus infection after transfusion of infected blood or blood products and in association with intravenous drug abuse. The availability of sensitive and reliable techniques to screen blood for hepatitis C virus has reduced the incidence of post-transfusion hepatitis. True healthy carriers of hepatitis C virus did not exist. Aproximately 95% of hepatitis C virus infected individuals can be identified by third generation anti- hepatitis C virus testing. Retrospective studies of iatrogenic hepatitis C virus infection are the main source of the natural history of the disease. The distribution of different hepatitis C virus genotypes varies according to the grographic region. In South America, Europe, The United States and Japan hepatitis C virus genotypes 1, 2 and 3 account for the majority of the infections, being (subtype 1b the most prevalent. Epidemiological parameters (age, risk factors and duration of infection may be associated with hepatitis C virus genotypes (intravenous drug abuse with types 1-a and 3

  3. Hepatitis C Virus Genotypes

    OpenAIRE

    Kayhan Azadmanesh; Safie Amini; Seyed-Moayed Alavian; Malek Hossein Ahmadipour

    2005-01-01

    IntroductionHepatitis C virus (HCV) is an important cause of chronic liver disease. HCV causes 20% of acute hepatitis cases, 70% of all chronic hepatitis cases, 40% of all cases of liver cirrhosis, 60% of hepatocellular carcinomas, and 30% of liver transplants in Europe(1). It is also recognized as the leading cause of liver transplantation in the world(2). Only 20% of infected individuals will recover from this viral infection, while the rest become chronically infected(3). While the majorit...

  4. Tiroiditis autoinmune inducida por interferón en pacientes con infección por virus de la hepatitis C. Interferon-induced autoimmune thyroiditis in a patient with hepatitis C virus infection

    Directory of Open Access Journals (Sweden)

    José L. Pinto

    2011-06-01

    Full Text Available Se reporta el caso de un varón de 43 años de edad, sin antecedentes patológicos de importancia, que acudió por elevación asintomática de la alanino aminotransferasa (ALT. El paciente negó ser bebedor crónico de alcohol. Se hizo el diagnóstico serológico de infección activa por hepatitis C y la biopsia de hígado reveló inflamación crónica activa. Con estos resultados, se inició tratamiento con interferón-alfa y ribavirina. Durante el tratamiento de 48 semanas, el paciente presentó anticuerpos antitiroideos positivos con variaciones en sus niveles de tirotropina (TSH y hormonas tiroideas. En el seguimiento postratamiento, el paciente continuó con hipertiroidismo por enfermedad de Graves. La tiroiditis autoinmune es una complicación frecuente del uso de interferón en pacientes con hepatitis C. En algunos casos se presenta como hipertiroidismo por enfermedad de Graves. Se debe evaluar la función tiroidea y los anticuerpos antitiroideos antes y durante el tratamiento con interferón.A 43 year old man presented with asymptomatic elevation of alanine aminotransferase (ALT and no relevant past history. The patient denied being a chronic alcohol drinker. Work-up revealed an active hepatitis C, and liver biopsy showed active inflammation. Treatment was started with interferon-alfa and ribavirin. During the 48 weeks of treatment, the patient developed positive thyroid antibodies with varying level of thyrotropin (TSH and thyroid hormones. At follow-up after treatment, the patient continued with hyperthyroidism due to Graves’ disease. Autoimmune thyroiditis is a common complication of using interferon in patients with hepatitis C. In some cases, it is presented as hyperthyroidism because of Graves’ disease. Thyroid function and thyroid antibodies should be evaluated before and during treatment with interferon.

  5. Tiroiditis autoinmune inducida por interferón en pacientes con infección por virus de la hepatitis C. Interferon-induced autoimmune thyroiditis in a patient with hepatitis C virus infection

    OpenAIRE

    Pinto, José L.; Miguel E. Pinto

    2011-01-01

    Se reporta el caso de un varón de 43 años de edad, sin antecedentes patológicos de importancia, que acudió por elevación asintomática de la alanino aminotransferasa (ALT). El paciente negó ser bebedor crónico de alcohol. Se hizo el diagnóstico serológico de infección activa por hepatitis C y la biopsia de hígado reveló inflamación crónica activa. Con estos resultados, se inició tratamiento con interferón-alfa y ribavirina. Durante el tratamiento de 48 semanas, el paciente presentó anticuerpos...

  6. Infección oculta por el virus de la hepatitis B en hijos de madres positivas al HBsAg

    Directory of Open Access Journals (Sweden)

    Marité Bello-Corredor

    2016-04-01

    Full Text Available La infección oculta por el virus de la hepatitis B (IOB, se caracteriza por la presencia en suero o plasma del genoma viral (ADN-VHB y anticuerpos contra la proteína de la cápside (anti-HBc en ausencia del antígeno de superficie (HBsAg, marcador que tradicionalmente se emplea para identificar la presencia del virus. Con el objetivo de caracterizar la presencia de IOB en hijos de madres positivas al HBsAg, se estudiaron 291 muestras séricas de niños con la condición de ser HBsAg (- y anticuerpos anti-HBsAg (anti-HBs menores de 50 UI/L, conservadas en la seroteca del Laboratorio de Referencia Nacional de Hepatitis Virales. Se realizaron ensayos para determinar la exposición al virus (anti-HBc, a los sueros anti-HBc (+ se les realizó Reacción en Cadena de la Polimerasa en Tiempo Real (RCP-TR para determinar y cuantificar el ADN-VHB. La prevalencia de exposición al VHB (anti-HBc fue 16,8% (49/291. El ADN viral se cuantificó en el 14% (6/43 de los casos anti-HBc (+, observándose cargas virales que oscilaban entre 2,15 x 101 hasta 3,42 x 101 UI/mL. La prevalencia de la IOB para el total de los pacientes analizados fue 2,1% (6/291, considerada relativamente baja. No se encontró asociación significativa entre las variables sociodemográficas analizadas tales como: edad, sexo y provincia de procedencia. La IOB está presente en hijos de madres positivas al HBsAg, a pesar de la profilaxis contra la hepatitis B. Por lo tanto, se requiere de pesquisajes adecuados para detectar dicha entidad. Las implicaciones clínicas y epidemiológicas de la misma, requieren de un estrecho monitoreo y atención de estos pacientes. Este estudio se realiza por primera vez en Cuba y aporta conocimientos útiles para el diagnóstico, prevención y control de esta enfermedad en niños.

  7. Tratamiento de la infección crónica por el VHB Treatment of chronic Hepatitis B virus infection

    Directory of Open Access Journals (Sweden)

    N. Carreño

    2004-01-01

    Full Text Available El tratamiento del paciente con hepatitis crónica por virus B (VHB debe realizarse bajo el conocimiento de que el porcentaje de pacientes infectados por el virus B que desarrollan hepatitis crónica se mantiene entre el 5-10%. De ellos, el 10-30% presentarán infección crónica con replicación viral activa, lesión hepática necroinflamatoria, evolución a cirrosis hepática y riesgo de desarrollar hepatocarcinoma. Por este motivo la meta del tratamiento es lograr la negativización del HBeAg, la seroconversión a anti-HBe y la reducción de la replicación viral a valores indetectables (estimados por niveles de DNA-VHB, durante períodos prolongados de tiempo. Cuando se obtiene una pérdida sostenida del HBeAg y la reducción de la replicación viral, se consigue una remisión bioquímica, clínica e histológica. Las alternativas terapéuticas en la infección crónica por el virus B hasta el momento son la inmunomodulación con interferón alfa y el bloqueo de la replicación viral con lamivudina o adefovir dipivoxil. Hay que diferenciar la respuesta bioquímica, definida como un descenso de las transaminasas hasta valores normales, de la respuesta virológica, que se refiere a un descenso de los niveles de DNA-VHB por debajo de 105 copias/ml. Finalmente, se define la respuesta completa como la respuesta virológica y bioquímica con negativización del HBsAg. Si se obtiene una respuesta sostenida durante varios meses, es predecible una respuesta histológica con reducción en la intensidad de la lesión hepática y ausencia o estabilización en el proceso de fibrosis. La respuesta sostenida, debe durar no menos de 6 a 12 meses tras acabar el tratamiento.The treatment of the patient with chronic hepatitis B virus infection (HBV must be carried out with the knowledge that the percentage of patients infected with the B virus that develop chronic hepatitis remains between 5-10%. Of these, 10-30% will present chronic infection with active

  8. Hepatitis C Virus.

    Science.gov (United States)

    Kim, Arthur

    2016-09-06

    This issue provides a clinical overview of hepatitis C virus, focusing on transmission, prevention, screening, diagnosis, evaluation, and treatment. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance of additional science writers and physician writers.

  9. Hepatitis-C virus (HCV)

    OpenAIRE

    Suwarso, Suwarso

    2015-01-01

    A new problem on hepatitis for Indonesian is hepatitis-C virus (HCV). This infection is endemic, majority sub-clinic and progressive in chronic. Viral transmission is primarily via a parenteral route, while other routes are still in debate.Diagnostic approach should be focused on how this virus developed.KeyWords: hepatitis-C virus molecular biology Westem-blot-HCV blood transfusion epidemiology

  10. Hepatitis Delta Virus: A Peculiar Virus

    OpenAIRE

    Carolina Alves; Cristina Branco; Celso Cunha

    2013-01-01

    The hepatitis delta virus (HDV) is distributed worldwide and related to the most severe form of viral hepatitis. HDV is a satellite RNA virus dependent on hepatitis B surface antigens to assemble its envelope and thus form new virions and propagate infection. HDV has a small 1.7 Kb genome making it the smallest known human virus. This deceivingly simple virus has unique biological features and many aspects of its life cycle remain elusive. The present review endeavors to gather the available ...

  11. Factores de riesgo para la infección por el virus de la hepatitis C en la Costa Caribe colombiana: un estudio de casos y controles

    Directory of Open Access Journals (Sweden)

    Ismael de Jesús Yepes

    2016-12-01

    Full Text Available Introducción. Se estima que aproximadamente 6,8-8,9 millones de personas están infectadas por el virus de la hepatitis C en Latinoamérica, de los cuales menos del 1% llega a recibir tratamiento antiviral. Los estudios realizados hasta ahora en Colombia han intentado determinar la prevalencia de la enfermedad en algunos grupos de riesgo, lo que ha impedido la identificación de otros factores potencialmente implicados en el contagio. Objetivos. Identificar factores de riesgo tradicionales y no tradicionales para hepatitis C crónica en la Costa Caribe colombiana. Materiales y métodos. Estudio de casos y controles (1:3 emparejados por empresa promotora de salud, edad (+/- 10 años, realizado en primer nivel de atención de la consulta de hepatología y gastroenterología. Todos los pacientes con Elisa positivo se realizaron una carga viral confirmatoria. Un análisis de regresión logística multivariante identificó los predictores independientes de infección. Resultados. La transfusión sanguínea (OR 159,2; IC 95% 35,4 – 715; p <0,001 y el antecedente de hospitalización antes de 1994 (OR 4,7; IC 95% 1,3 – 17,1; p = 0,018 se identificaron como los dos únicos predictores independientes de infección. Conclusión. Es necesario comprobar la reproducibilidad de estos resultados y realizar estudios de costo-efectividad antes de recomendar su utilización en el diseño de nuevas estrategias de cribado.

  12. Blood transfusion and hepatitis viruses

    African Journals Online (AJOL)

    transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: ... and mouse liver cells by a conjugate of adenine arabinoside monophosphate with ... C virus antibody in patients with autoimmune hepatitis and other chronic liver .... to be derived·from the genome of an agent associated with.

  13. Infección simultánea por el virus de la hepatitis E y de otras hepatitis virales en Colombia y su caracterización genotípica

    Directory of Open Access Journals (Sweden)

    Dioselina Peláez

    2016-08-01

    Conclusiones. La mayor seropositividad se registró para las hepatitis A y E. La frecuencia de la infección simultánea con el virus de la hepatitis E y otros virus hepatótropos indica que este patógeno puede ser más frecuente de lo esperado. La circulación del genotipo 3a implica que esta enfermedad puede presentarse en forma de brote y de zoonosis en Colombia.

  14. Serological markers and risk factors for hepatitis B and C viruses in patients infected with human immunodeficiency virus Marcadores serológicos y factores de riesgo para los virus de la hepatitis B y C en individuos infectados por el VIH

    Directory of Open Access Journals (Sweden)

    Alvaro Hoyos-Orrego

    2006-12-01

    Full Text Available Both hepatitis B and hepatitis C viruses (HBV and HCV infection are common in HIV-infected individuals as a result of shared risk factors for acquisition. A serological study for HBV and HCV was performed in 251 HIV-positive individuals from Medellín, Colombia. A qualitative RT-PCR for HCV was done in 90 patients with CD4+ T-cell count La infección por los virus de la hepatitis B y hepatitis C (VHB y VHC es frecuente en individuos infectados por el VIH como resultado de compartir factores de riesgo para su contagio. Se realizó un estudio serológico para el VHB y VHC en 251 individuos VIH positivos de la ciudad de Medellín, Colombia. En 90 pacientes con un recuento de linfocitos T < 150 células por mm³ se hizo una PCR-RT cualitativa para el VHC. Se encontraron marcadores serológicos para la infección por el VHB en 97 (38.6% pacientes. Treinta y seis de 97 (37.1% tuvieron un anti-HBc aislado. El análisis multivariado indicó que los factores de riesgo significativos asociados a la presencia de estos marcadores fueron: edad (OR = 1.05, 95% IC: 1.01-1.08, pediculosis púbica (OR = 1.83, 95% IC: 1.01-3.33, hombres que tienen sexo con hombres y mujeres (OR = 3.23, 95% IC: 1.46-7.13 y hombres que tienen sexo solo con hombres (OR = 3.73, 95% IC: 1.58-8.78. El mismo análisis restringido a mujeres mostró que la sífilis fue el único factor de riesgo significativo. Por lo tanto, la infección por el VHB fue considerablemente asociada a conductas sexuales de alto riesgo. El VHC se presentó en solo 2 (0.8% de los pacientes VIH. Ambos pacientes fueron positivos por la PCR-RT y los anti-VHC. La baja frecuencia de la coinfección VIH/VHC fue probablemente debido al bajo uso de drogas intravenosas en esta población. El hallazgo frecuente de anti-HBc como marcador aislado asegura estudios moleculares para descartar la presencia de infección críptica por el VHB.

  15. Viral kinetics of the Hepatitis C virus

    NARCIS (Netherlands)

    F.C. Bekkering (Frank)

    2001-01-01

    textabstractHepatitis A virus and hepatitis B virus were identified as the cause of infectious hepatitis and serum hepatitis respectively in the beginning of the seventies. After introduction of screening tests for hepatitis A and B 4 only 25% of the cases of post transfusion hepatitis were found to

  16. Viral kinetics of the Hepatitis C virus

    NARCIS (Netherlands)

    F.C. Bekkering (Frank)

    2001-01-01

    textabstractHepatitis A virus and hepatitis B virus were identified as the cause of infectious hepatitis and serum hepatitis respectively in the beginning of the seventies. After introduction of screening tests for hepatitis A and B 4 only 25% of the cases of post transfusion hepatitis were found to

  17. Utilización de los donantes añosos en pacientes trasplantados por cirrosis por virus C Old donors in liver transplantation for chronic hepatitis C

    Directory of Open Access Journals (Sweden)

    V. Aguilera

    2007-10-01

    Full Text Available Introducción: la historia natural de la hepatitis C recurrente tras el trasplante hepático (TH es muy heterogénea, existiendo un porcentaje no despreciable de pacientes con evolución desfavorable. La identificación de factores asociados con peor evolución puede ayudar a mejorar el pronóstico de estos pacientes. La edad del donante se perfila como uno de los factores más importantes, pero es una variable difícilmente modificable. Objetivos: a describir la historia natural de los receptores VHC (+ en función de la edad del donante ( 10%; c relacionados con la cirugía: tiempos isquemia fría y recalentamiento, duración intervención, número de concentrados de hematíes trans-fundidos; y d relacionados con el post-trasplante: inmunosupresión, analítica en el post-TH precoz (Background: the natural history of recurrent hepatitis C after liver transplantation (LT is extremely variable, with progression to allograft failure in a substantial proportion of patients. The identification of factors associated with this poorer outcome may improve results. While donor age has been identified as one of the most important factors, the actual options to modify this variable are limited. Objectives: a to describe the natural history of HCV(+ liver transplant recipients depending on donor age ( 1 during the first year post-LT, development of a cholestatic form of recurrent hepatitis C, and /or graft failure due to HCV during the first five years post-LT. Factors analyzed as potentially associated with recurrent hepatitis C included: a recipient-related: demographics (age, sex, pre-transplantation (hepatocellular carcinoma, Child-Pugh classification, history of alcohol, HBV serological markers, antiviral treatment, nutritional status, biochemical variables; b donor-related: demographics (age, sex, cause of death, grade of steatosis defined as minimal vs. moderate-severe > 10%; c surgery-related: cold preservation and rewarming time, duration of

  18. Tenosinovitis por virus Chikungunya

    Directory of Open Access Journals (Sweden)

    Alfredo Seijo

    2014-12-01

    Full Text Available Se presenta a la consulta un hombre proveniente de la República Dominicana con una tenosinovitis del extensor del dedo medio derecho; en la convalecencia inmediata, segunda curva febril luego de 48 horas de permanecer asintomático de una enfermedad febril aguda, y marcada astenia, exantema pruriginoso, poliartralgias con impotencia funcional y rigidez articular generalizada. Los exámenes bioquímicos no aportaron datos de interés para el diagnóstico. La serología para virus dengue fue negativa. La detección de IgM y de anticuerpos neutralizantes para virus Chikungunya (CHIKV fueron positivos.

  19. Alteraciones hidrocarbonadas en los pacientes con infección crónica por el virus de la hepatitis C: estudio de prevalencia y de los mecanismos etiopatogénicos

    OpenAIRE

    Lecube Torelló, Albert

    2005-01-01

    Existen cada vez más evidencias de que el virus de la hepatitis C favorece el desarrollo de diabetes. Objetivos: 1.- Analizar la prevalencia de las alteraciones del metabolismo hidrocarbonado (diabetes y glucemia anómala en ayunas) en los pacientes con infección crónica por el VHC (n=498) y compararla con la que presentan los pacientes con otras enfermedades hepáticas (n=144), considerando el grado de lesión hepática (hepatitis crónica o cirrosis) y los genotipos del VHC en el análisis de los...

  20. Human Immunodeficiency Virus and Hepatitis C Virus Co-infection ...

    African Journals Online (AJOL)

    Human Immunodeficiency Virus and Hepatitis C Virus Co-infection in Cameroon: ... were analyzed using molecular biology techniques that involved RT-PCR, ... There is evidence of genetic diversity of HIV and HCV; virulent hepatitis C virus ...

  1. Hepatitis Virus Infections in Poultry.

    Science.gov (United States)

    Yugo, Danielle M; Hauck, Ruediger; Shivaprasad, H L; Meng, Xiang-Jin

    2016-09-01

    Viral hepatitis in poultry is a complex disease syndrome caused by several viruses belonging to different families including avian hepatitis E virus (HEV), duck hepatitis B virus (DHBV), duck hepatitis A virus (DHAV-1, -2, -3), duck hepatitis virus Types 2 and 3, fowl adenoviruses (FAdV), and turkey hepatitis virus (THV). While these hepatitis viruses share the same target organ, the liver, they each possess unique clinical and biological features. In this article, we aim to review the common and unique features of major poultry hepatitis viruses in an effort to identify the knowledge gaps and aid the prevention and control of poultry viral hepatitis. Avian HEV is an Orthohepevirus B in the family Hepeviridae that naturally infects chickens and consists of three distinct genotypes worldwide. Avian HEV is associated with hepatitis-splenomegaly syndrome or big liver and spleen disease in chickens, although the majority of the infected birds are subclinical. Avihepadnaviruses in the family of Hepadnaviridae have been isolated from ducks, snow geese, white storks, grey herons, cranes, and parrots. DHBV evolved with the host as a noncytopathic form without clinical signs and rarely progressed to chronicity. The outcome for DHBV infection varies by the host's ability to elicit an immune response and is dose and age dependent in ducks, thus mimicking the pathogenesis of human hepatitis B virus (HBV) infections and providing an excellent animal model for human HBV. DHAV is a picornavirus that causes a highly contagious virus infection in ducks with up to 100% flock mortality in ducklings under 6 wk of age, while older birds remain unaffected. The high morbidity and mortality has an economic impact on intensive duck production farming. Duck hepatitis virus Types 2 and 3 are astroviruses in the family of Astroviridae with similarity phylogenetically to turkey astroviruses, implicating the potential for cross-species infections between strains. Duck astrovirus (DAstV) causes

  2. Hepatitis C virus proteins

    Institute of Scientific and Technical Information of China (English)

    Jean Dubuisson

    2007-01-01

    Hepatitis C virus (HCV) encodes a single polyprotein,which is processed by cellular and viral proteases to generate 10 polypeptides. The HCV genome also contains an overlapping +1 reading frame that may lead to the synthesis of an additional protein. Until recently,studies of HCV have been hampered by the lack of a productive cell culture system. Since the identification of HCV genome approximately 17 years ago, structural,biochemical and biological information on HCV proteins has mainly been obtained with proteins produced by heterologous expression systems. In addition, some functional studies have also been confirmed with replicon systems or with retroviral particles pseudotyped with HCV envelope glycoproteins. The data that have accumulated on HCV proteins begin to provide a framework for understanding the molecular mechanisms involved in the major steps of HCV life cycle. Moreover,the knowledge accumulated on HCV proteins is also leading to the development of antiviral drugs among which some are showing promising results in early-phase clinical trials. This review summarizes the current knowledge on the functions and biochemical features of HCV proteins.

  3. Hepatitis B virus morphogenesis

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    The hepatitis B virus (HBV) particle consists of an envelope containing three related surface proteins and probably lipid and an icosahedral nucleocapsid of approximately 30 nm diameter enclosing the viral DNA genome and DNA polymerase. The capsid is formed in the cytosol of the infected cell during packaging of an RNA pregenome replication complex by multiple copies of a 21-kDa C protein. The capsid gains the ability to bud during synthesis of the viral DNA genome by reverse transcription of the pregenome in the lumen of the particle. The three envelope proteins S,M, and L shape a complex transmembrane fold at the endoplasmic reticulum, and form disulfide-linked homoand heterodimers. The transmembrane topology of a fraction of the large envelope protein L changes posttranslationally, therefore, the N terminal domain of L (preS) finally appears on both sides of the membrane.During budding at an intracellular membrane, a short linear domain in the cytosolic preS region interacts with binding sites on the capsid surface. The virions are subsequently secreted into the blood. In addition, the surface proteins can bud in the absence of capsids and form subviral lipoprotein particles of 20 nm diameter which are also secreted.

  4. Hepatitis B virus replication

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    Hepadnaviruses, including human hepatitis B virus (HBV), replicate through reverse transcription of an RNA intermediate, the pregenomic RNA (pgRNA). Despite this kinship to retroviruses, there are fundamental differences beyond the fact that hepadnavirions contain DNA instead of RNA. Most peculiar is the initiation of reverse transcription: it occurs by protein-priming, is strictly committed to using an RNA hairpin on the pgRNA,ε, as template, and depends on cellular chaperones;moreover, proper replication can apparently occur only in the specialized environment of intact nucleocapsids.This complexity has hampered an in-depth mechanistic understanding. The recent successful reconstitution in the test tube of active replication initiation complexes from purified components, for duck HBV (DHBV),now allows for the analysis of the biochemistry of hepadnaviral replication at the molecular level. Here we review the current state of knowledge at all steps of the hepadnaviral genome replication cycle, with emphasis on new insights that turned up by the use of such cellfree systems. At this time, they can, unfortunately,not be complemented by three-dimensional structural information on the involved components. However, at least for the s RNA element such information is emerging,raising expectations that combining biophysics with biochemistry and genetics will soon provide a powerful integrated approach for solving the many outstanding questions. The ultimate, though most challenging goal,will be to visualize the hepadnaviral reverse transcriptase in the act of synthesizing DNA, which will also have strong implications for drug development.

  5. Perinatal hepatitis B virus detection by hepatitis B virus-DNA analysis.

    OpenAIRE

    De Virgiliis, S; Frau, F; Sanna, G; Turco, M P; Figus, A L; Cornacchia, G; Cao, A.

    1985-01-01

    Maternal transmission of hepatitis B virus infection in relation to the hepatitis B e antigen/antibody system and serum hepatitis B virus-DNA were evaluated. Results indicate that hepatitis B virus-DNA analysis can identify hepatitis B serum antigen positive mothers who may transmit infection to their offspring.

  6. Perinatal hepatitis B virus detection by hepatitis B virus-DNA analysis.

    Science.gov (United States)

    De Virgiliis, S; Frau, F; Sanna, G; Turco, M P; Figus, A L; Cornacchia, G; Cao, A

    1985-01-01

    Maternal transmission of hepatitis B virus infection in relation to the hepatitis B e antigen/antibody system and serum hepatitis B virus-DNA were evaluated. Results indicate that hepatitis B virus-DNA analysis can identify hepatitis B serum antigen positive mothers who may transmit infection to their offspring. Images Figure PMID:3970570

  7. Perinatal hepatitis B virus detection by hepatitis B virus-DNA analysis.

    OpenAIRE

    De Virgiliis, S; Frau, F; Sanna, G; Turco, M P; Figus, A L; Cornacchia, G; Cao, A

    1985-01-01

    Maternal transmission of hepatitis B virus infection in relation to the hepatitis B e antigen/antibody system and serum hepatitis B virus-DNA were evaluated. Results indicate that hepatitis B virus-DNA analysis can identify hepatitis B serum antigen positive mothers who may transmit infection to their offspring.

  8. Púrpura trombocitopénico inmune asociado a infección por virus hepatitis C en paciente hemofílico: Caso clínico

    OpenAIRE

    Pilleux C,Lilian; MARTÍNEZ G,ALEJANDRA; DONOSO S,MARIO; CARRASCO L,CRISTIAN

    2010-01-01

    Hepatitis C Virus (HCV) is a cause of secondary chronic immune thrombocytopenic purpura (ITP). We report a 43 year old man with mild Hemophilia A, who received blood transfusions during childhood, that consulted for epistaxis and ecchymoses. The laboratory showed a platelet count of 23.000/mm³, positive HCV serology and elevated transaminases. Steroids administered in pulses followed by oral doses resulted in a partial response requiring a second pulse and association of azathioprine. A stero...

  9. El virus de la hepatitis B

    Directory of Open Access Journals (Sweden)

    Jorge Boshell Samper

    1991-12-01

    Full Text Available El virus de la hepatitis B humana (HBV pertenece a la familia de los Hepadnaviridae, la cual reune una serie de agentes virales que a la fecha infectan aves y mamíferos y que tienen un tropismo exquisito por el hígado. En la tabla No. 1 se señalan las propiedades más sobresalientes de la familia, la cual agrupa a sus integrantes por las características de su estructura, por sus mecanismos de replicación similares, porque las interacciones que cada miembro tiene con la célula que infecta son notoriamente iguales y porque las repercusiones de esa infección tienen un interés biológico y médico muy particulares. En la tabla No. 2 se enumeran los primeros cuatro virus integrantes de esta familia.

  10. Hepatitis virus vaccines: present status.

    Science.gov (United States)

    Krugman, S.

    1982-01-01

    During the past decade there has been extraordinary progress toward the development of vaccines for the prevention of type A and type B hepatitis. The successful propagation of hepatitis A virus in cell culture in 1979 was followed by the preparation of experimental live attenuated hepatitis A vaccines that have been shown to induce antibody in marmosets and chimpanzees and protect immunized marmosets against challenge with hepatitis A virus. The first human immunization trials will begin in mid-1982. An inactivated hepatitis B vaccine that was licensed in the United States in November 1981 has been shown to be safe, immunogenic, and effective. When this vaccine becomes available for use in July 1982, it will be recommended for persons who are considered to be at increased risk of contracting hepatitis B infection. Future generations of hepatitis B vaccines may be prepared from hepatitis B surface antigen derived from DNA recombinant technology or by in vitro synthesis of HBs Ag determinants by chemical means. PMID:6295013

  11. Prophylaxis and treatment of hepatitis B infection in the setting of liver transplantation Profilaxis y tratamiento de la infección por el virus de la hepatitis B en relación con el trasplante hepático

    Directory of Open Access Journals (Sweden)

    Delia D'Avola

    2011-03-01

    Full Text Available Without any treatment, the prognosis of hepatitis B in liver transplant recipients is very poor. So, antiviral prophylaxis is very important in patients with hepatitis B who undergo liver transplantation. Before liver transplantation, a suppression of viral replication has to be achieved by nucleos(tide analogs. Drugs used in the prophylaxis of post-transplant hepatitis B include immunoglobulin against HBV and nucleos(tide analogs. Prophylaxis against graft infection must be based on the individual risk of recurrence. When prophylactic measures have failed and graft infection has occurred, treatment of recurrent hepatitis B may be based on the resistance profile of the virus and previous antiviral exposure. Finally, lamivudine seems to be very effective in the prevention of de novo hepatitis B in patients transplanted with a graft from an anti-HBc positive donor.La infección por el virus de la hepatitis B en los receptores de trasplante hepático tiene un pronóstico malo en ausencia de tratamiento farmacológico. Por ello, en los pacientes trasplantados por una hepatopatía por virus B, la profilaxis de esta infección es imprescindible. Antes del trasplante, debe intentarse suprimir la replicación viral con un análogo de nucleót(sidos. Tras el trasplante, la profilaxis de la recidiva de la hepatitis B se basa en el uso de los análogos de nucleót(sidos y la inmunoglobulina frente al virus de la hepatitis B; la pauta de profilaxis debe basarse en el riesgo de recidiva de la hepatitis B que tenga cada paciente. En el caso de que se produzca una hepatitis B tras el trasplante, el tratamiento con análogos de nucleót(sidos debe basarse en los estudios de resistencia. Por último, en los pacientes trasplantados que reciben un injerto de un donante antiHBc-positivo, la profilaxis con lamivudina parece ser muy eficaz.

  12. Hepatitis E virus coinfection with hepatotropic viruses in Egyptian children.

    Science.gov (United States)

    Zaki, Maysaa El Sayed; Salama, Osama Saad; Mansour, Fathy Awaad; Hossein, Shaimaa

    2008-06-01

    Major hepatotropic viruses continue to be important causes of acute viral hepatitis in developing countries. This work was carried out to detect the seroprevalence of hepatitis E virus (HEV) markers in children with acute viral hepatitis due to hepatotropic viruses (A, B and C) and non-A, non-B, non-C acute hepatitis, and to ascertain the influence of HEV superinfection in individuals infected with hepatitis viruses (A, B and C). We studied prospectively 162 children with sporadic acute hepatitis who reported to our hospital. Thirteen healthy controls were also included in the study. Laboratory investigations were performed, including complete liver function tests. Complete serological profiles for hepatitis viruses A, B, C and E were evaluated. HEV immunoglobulin G was detected with highest percentage among patients with hepatitis B (56.7%), followed by patients with hepatitis C virus (52.0%), hepatitis A virus (34.1%) and combined hepatitis B and C viruses (30.0%). The detection rate among patients with non-A, non-B, non-C hepatitis was 7.1%. HEV immunoglobulin M was found in 4.5% of hepatitis A virus patients and in 3.3% of hepatitis B patients. The prevalence of HEV immunoglobulin G and immunoglobulin M correlated with the levels of hepatic aspartate aminotransferase and alanine aminotransferase in patients with dual markers of infection with hepatitis E and other viruses compared to patients with acute hepatitis due to A and C viruses. HEV serological markers are common among children with acute viral hepatitis, especially from hepatitis C and B viruses. There may be increased sensitivity to HEV coinfection in association with hepatitis B and C infections. Dual infection with HEV and other hepatotropic viruses was associated with greater elevation of aspartate and alanine aminotransferases.

  13. Alta prevalencia de la infección por el virus de hepatitis B en la comunidad indígena Japreira, Estado Zulia, Venezuela High prevalence of hepatitis B infection in Amerindians in Japreira, Zulia State, Venezuela

    Directory of Open Access Journals (Sweden)

    Francisca Monsalve-Castillo

    2008-05-01

    Full Text Available A fin de conocer la prevalencia de la infección por el virus de hepatitis B (VHB en la comunidad indígena Japreira, Venezuela, y determinar las pautas de su adquisición en función de la edad y sexo, se seleccionaron 149 individuos de un total de 300. Se detectó por métodos serológicos la presencia de anticuerpos totales del VHB (anti-HBc total, y en las positivas se investigó la presencia del antígeno de superficie (HBsAg y del antígeno "e" del VHB (HBeAg. La prevalencia de anti-HBc total fue de 72,9% en el sexo femenino y 81,1% en el masculino, la prevalencia de HBsAg fue elevada (61,1% en el sexo masculino, sólo cuatro de los portadores de HBsAg fueron positivos para HBeAg. Los resultados obtenidos indican un grado elevado de endemia para esta infección y que su diseminación comienza a temprana edad. El factor involucrado en la adquisición y diseminación del virus seria la vía sexual. Hacinamiento, contacto intercorpóreo con fluidos biológicos, prácticas sociales, y características de la cepa viral circulante podrían estar involucradas en la alta cronicidad observada en la comunidad indígena Japreira.The aim of this study was to determine the prevalence of hepatitis B virus (HBV infection in the Japreira indigenous community, Venezuela, and its relationship to age and gender. An intentional, non-probabilistic sample of 149 individuals was selected from a total of 300. All samples were studied for the presence of total HBV antibodies (total anti-HBc, and the positive samples were tested for HBV surface and "e" antigens (HBsAg, HBeAg. Overall prevalence rates of total anti-HBc were 72.9% in females and 81.1% in males. The highest prevalence of HBsAg was observed in males 26-35 years of age. Only four of the 44 HBsAg carriers were positive for HBeAg. The results showed a high endemic HBV infection rate and indicated that its spread begins at early ages. Sexual transmission may be the main route for spread of the virus

  14. Hepatitis C Virus Genotypes

    Directory of Open Access Journals (Sweden)

    Kayhan Azadmanesh

    2005-09-01

    Full Text Available IntroductionHepatitis C virus (HCV is an important cause of chronic liver disease. HCV causes 20% of acute hepatitis cases, 70% of all chronic hepatitis cases, 40% of all cases of liver cirrhosis, 60% of hepatocellular carcinomas, and 30% of liver transplants in Europe(1. It is also recognized as the leading cause of liver transplantation in the world(2. Only 20% of infected individuals will recover from this viral infection, while the rest become chronically infected(3. While the majority of chronically infected individuals never exhibit symptoms, approximately 10-30% of these patients will eventually develop cirrhosis or hepatocellular carcinoma, both of which are associated with significant morbidity and mortality(4.More than 170 million people worldwide are chronically infected with HCV. According to WHO report in 2002, chronic liver diseases were responsible for 1.4 million deaths, including 796,000 due to cirrhosis and 616,000 due to primary liver cancer. At least 20% of these deaths are probably attributable to HCV infection- more than 280,000 deaths(5, 6. The prevalence of chronic HCV infection in general population varies greatly in different parts of the world, being estimated between 0.1 and 5%, with a peak prevalence of 20- 25% in Egypt. HCV prevalence seems to be less than 1% in Iran, which is much lower than most of the neighboring countries(7. HCV was the first virus discovered by molecular cloning method without the direct use of biologic or biophysical methods. This was accomplished by extracting, copying into cDNA, and cloning all the nucleic acid from the plasma of a chimpanzee infected with non- A, non-B hepatitis by contaminated factor XIII concentrate(8. The HCV genome is a positive-sense, singlestranded RNA genome approximately 10 kb long. It has marked similarities to those of members of the genera Pestivirus and Flavivirus. Different HCV isolates from around the world show substantial nucleotide sequence variability

  15. Alteraciones hidrocarbonadas en los pacientes con infección crónica por el virus de la hepatitis C estudio de prevalencia y de los mecanismos etiopatogénicos /

    OpenAIRE

    Lecube Torelló, Albert

    2006-01-01

    Consultable des del TDX Títol obtingut de la portada digitalitzada Existen cada vez más evidencias de que el virus de la hepatitis C favorece el desarrollo de diabetes. Objetivos: 1.- Analizar la prevalencia de las alteraciones del metabolismo hidrocarbonado (diabetes y glucemia anómala en ayunas) en los pacientes con infección crónica por el VHC (n=498) y compararla con la que presentan los pacientes con otras enfermedades hepáticas (n=144), considerando el grado de lesión hepática (he...

  16. Hepatitis A Virus in Transplants

    Centers for Disease Control (CDC) Podcasts

    2017-05-17

    Dr. Monique Foster, a CDC epidemiologist, discusses an unusual case of hepatitis A virus in a transplant patient.  Created: 5/17/2017 by National Center for Emerging and Zoonotic Infectious Diseases (NCEZID).   Date Released: 5/17/2017.

  17. Epidemiology of Hepatitis B and Hepatitis C Virus infections among ...

    African Journals Online (AJOL)

    Abstract. Hepatitis B and hepatitis C virus infection are common in Nigeria; where they ... the epidemiology of HBV and HCV infection among HIV Counseling and Testing (HCT) ... Clients who declined to sign the consent form were excluded.

  18. Extrahepatic manifestations of hepatitis E virus.

    Science.gov (United States)

    Kamar, Nassim; Marion, Olivier; Abravanel, Florence; Izopet, Jacques; Dalton, Harry R

    2016-04-01

    Hepatitis E virus can cause acute, fulminant and chronic hepatitis and has been associated with a range of extrahepatic manifestations. Guillain-Barré syndrome, neuralgic amyotrophy and encephalitis are the main neurological manifestations associated with acute and chronic hepatitis E virus infection. Renal injuries have been also reported, including membranoproliferative glomerulonephritis with or without cryoglobulinemia and membranous glomerulonephritis. Acute pancreatitis, haematological disorders and other autoimmune extrahepatic manifestations of hepatitis E virus, such as myocarditis and thyroiditis, have been also reported. In this comprehensive article, we review all published reports describing hepatitisvirus-associated extrahepatic manifestations.

  19. Desperately seeking hepatitis C virus

    OpenAIRE

    Moreno-Otero, Ricardo

    2008-01-01

    Spanish investigators described recently the so-called occult hepatitis C virus (HCV) infection, emphasizing the detection of genomic and antigenomic HCV RNA strands in liver and peripheral blood mononuclear cells. Therefore, the persistence of viral replication in occult HCV infection should be considered as a putative source of infection among family members and patients undergoing invasive procedures, transfusion or transplantation. Additionally, the most worrisome finding is that an occul...

  20. Desperately seeking hepatitis C virus

    Institute of Scientific and Technical Information of China (English)

    Ricardo Moreno-Otero

    2008-01-01

    Spanish investigators described recently the so-called occult hepatitis C virus (HCV) infection, emphasizing the detection of genomic and antigenomic HCV RNA strands in liver and peripheral blood mononuclear cells. Therefore, the persistence of viral replication in occult HCV infection should be considered as a putative source of infection among family members and patients undergoing invasive procedures, transfusion or transplantation. Additionally, the most worrisome finding is that an occult HCV infection may persist in patients with sustained virological response.

  1. Xenotransplantation and Hepatitis E virus.

    Science.gov (United States)

    Denner, Joachim

    2015-01-01

    Xenotransplantation using pig cells, tissues and organs may be associated with the transmission of porcine microorganisms to the human recipient. Some of these microorganisms may induce a zoonosis, that is an infectious disease induced by microorganisms transmitted from another species. With exception of the porcine endogenous retroviruses (PERVs), which are integrated in the genome of all pigs, the transmission of all other microorganisms can be prevented by specified or designated pathogen-free (spf or dpf, respectively) production of the animals. However, it is becoming clear in the last years that the hepatitis E virus (HEV) is one of the viruses which are difficult to eliminate. It is important to note that there are differences between HEV of genotypes (gt) 1 and gt2 on one hand and HEV of gt3 and gt4 on the other. HEV gt1 and gt2 are human viruses, and they induce hepatitis and in the worst case fatal infections in pregnant women. In contrast, HEV gt3 and gt4 are viruses of pigs, and they may infect humans, induce commonly only mild diseases, if any, and are harmless for pregnant women. The goal of this review was to evaluate the risk posed by HEV gt3 and gt4 for xenotransplantation and to indicate ways of their elimination from pigs in order to prevent transmission to the human recipient.

  2. Molecular biology of hepatitis B virus infection

    National Research Council Canada - National Science Library

    Seeger, Christoph; Mason, William S

    2015-01-01

    Human hepatitis B virus (HBV) is the prototype of a family of small DNA viruses that productively infect hepatocytes, the major cell of the liver, and replicate by reverse transcription of a terminally redundant viral RNA, the pregenome...

  3. Coinfección de hepatitis B e infección por VIH

    OpenAIRE

    María Paz León-Bratti

    2008-01-01

    La infección por el virus de inmunodeficiencia humana (VIH) modifica el curso de la infección por el virus de la hepatitis B (HBV) por varios mecanismos: aumentando la tasa de cronicidad, prolongando la viremia por HBV y aumentando la morbilidad relacionada con hepatopatía. El tratamiento de ambas infecciones debería hacerse en forma coordinada, para evitar el surgimiento de resistencia en el VIH, el HBV o ambos, así como alteraciones mayores en las enzimas hepáticas. Las monoterapias con lam...

  4. Cytokine Signatures Discriminate Highly Frequent Acute Hepatitis a Virus and Hepatitis E Virus Coinfections from Monoinfections in Mexican Pediatric Patients.

    Science.gov (United States)

    Realpe-Quintero, Mauricio; Copado-Villagrana, Edgar Daniel; Trujillo-Ochoa, Jorge Luis; Alvarez, Angel Hilario; Panduro, Arturo; Fierro, Nora Alma

    2017-07-01

    The frequency of hepatitis A virus and hepatitis E virus infections and their cytokine profiles were analyzed in Mexican pediatric patients with acute hepatitis. A high frequency of coinfections was found. Significant overexpression of interleukin (IL)-4, IL-12, IL-13 and interferon-gamma during hepatitis A virus monoinfections and limited secretion of cytokines in hepatitis E virus infections were observed.

  5. Hepatitis autoinmune precedida por infección aguda por citomegalovirus en una mujer inmunocompetente

    Directory of Open Access Journals (Sweden)

    María Vares González

    2012-05-01

    Full Text Available El diagnóstico diferencial de las hepatitis es amplio y complejo, y con mucha frecuencia corresponde al médico internista filiar la etiología de la misma. De etiopatogenia no claramente establecida, lo que caracteriza a la hepatitis autoinmune (HAI es la pérdida de tolerancia inmune frente a los antígenos de los hepatocitos, conduciendo a la destrucción del parénquima hepático por linfocitos T autorreactivos. El papel de ciertos virus como factores favorecedores de la disregulación autoinmune ha sido propuesto previamente, en base a lo demostrado por los estudios de investigación y a la evidencia clínica. A continuación se expone un caso de HAI precedido por una infección aguda por CMV, lo que otorga al caso un interés particular, pues su incidencia es excepcional, existiendo sólo tres casos recogidos en la literatura (dos de ellos en pacientes sanos de 17 años, y otro en un varón inmunodeprimido trasplantado de médula ósea.

  6. Hepatitis B virus taxonomy and hepatitis B virus genotypes

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    Hepatitis B virus (HBV) is a member of the hepadnavirus family. Hepadnaviruses can be found in both mammals (orthohepadnaviruses) and birds (avihepadnaviruses).The genetic variability of HBV is very high. There are eight genotypes of HBV and three clades of HBV isolates from apes that appear to be additional genotypes of HBV. Most genotypes are now divided into subgenotypes with distinct virological and epidemiological properties. In addition, recombination among HBV genotypes increases the variability of HBV. This review summarises current knowledge of the epidemiology of genetic variability in hepadnaviruses and, due to rapid progress in the field,updates several recent reviews on HBV genotypes and subgenotypes.

  7. Medicinal herbs for hepatitis C virus infection

    DEFF Research Database (Denmark)

    Liu, Jianping; Manheimer, Eric; Tsutani, Kiichiro

    2003-01-01

    The aim of this study was to assess beneficial and harmful effects of medicinal herbs for hepatitis C virus (HCV) infection.......The aim of this study was to assess beneficial and harmful effects of medicinal herbs for hepatitis C virus (HCV) infection....

  8. Hepatitis A virus infection presenting with seizures.

    Science.gov (United States)

    Cam, Sebahat; Ertem, Deniz; Koroglu, Ozge Altun; Pehlivanoglu, Ender

    2005-07-01

    Hepatitis A infection rarely causes extrahepatic manifestations. Here we present a 5-year-old patient with an initial complaint of nuchal rigidity and convulsions during the course of hepatitis A infection. Because hepatitis A virus RNA was demonstrated in the cerebrospinal fluid, it was thought that convulsions might be related to this viral infection.

  9. Prevalence of hepatitis B virus among immunocompromised ...

    African Journals Online (AJOL)

    Prevalence of hepatitis B virus among immunocompromised individuals attending Nnamdi ... PROMOTING ACCESS TO AFRICAN RESEARCH ... Hepatitis B is an infectious inflammatory illness of the liver caused by the hepatitis B ... Rwanda (3); Senegal (6); Sierra Leone (1); South Africa (96); South Sudan (1); Sudan (3) ...

  10. Hepatitis B virus and hepatitis C virus infection inhealthcare workers

    Institute of Scientific and Technical Information of China (English)

    2016-01-01

    Approximately 3 million healthcare workers per yearreceive an injury with an occupational instrument, witharound 2000000 exposures to hepatitis B virus (HBV)and 1000000 to hepatitis C virus (HCV). Although aneffective HBV vaccine has been available since theearly eighties, and despite the worldwide applicationof universal vaccination programs started in the earlynineties, HBV still remains a prominent agent of morbidityand mortality. There is no vaccine to limit thediffusion of HCV infection, which progresses to chronicityin the majority of cases and is a major cause of morbidityand mortality worldwide due to a chronic liverdisease. Healthcare workers are frequently exposed by amucosal-cutaneous or percutaneous route to accidentalcontact with human blood and other potentially infectiousbiological materials while carrying out their occupationalduties. Mucosal-cutaneous exposure occurswhen the biological material of a potentially infectedpatient accidentally comes in contact with the mucousmembranes of the eyes or mouth or with the skin of ahealthcare worker. Percutaneous exposure occurs whenan operator accidentally injures himself with a sharpcontaminated object, like a needle, blade or other sharpmedical instrument. About 75% of the total occupationalexposure is percutaneous and 25% mucosal-cutaneous,the risk of infecting a healthcare worker being higherin percutaneous than in mucosal-cutaneous exposure.All healthcare workers should be considered for HBVvaccination and should meticulously apply the universalprophylactic measures to prevent exposure to HBV andHCV.

  11. Exposición ocupacional al virus de hepatitis C Occupational exposure to hepatitis C virus

    Directory of Open Access Journals (Sweden)

    Eduardo Warley

    2006-04-01

    Full Text Available La transmisión ocupacional de virus de hepatitis C (VHC es un área de creciente preocupación dada la falta de profilaxis y la poca información de su prevalencia en el medio hospitalario. Sobre 128 exposiciones ocupacionales ocurridas en el Hospital Diego Paroissien entre 1999 y 2003 hubieron 8 casos de exposición a VHC (6.3% y un caso de seroconversión posterior a la exposición (0.8%. No existiendo en la actualidad terapia preventiva para VHC resulta de gran interés la posibilidad de tratamiento de la infección aguda. La mayor parte de los autores coincide en recomendar el tratamiento del episodio agudo de hepatitis por VHC basado en la evidencia actual, aunque aún no está bien definida la mejor estrategia diagnóstica y terapéutica. El acatamiento de las Normas de Precauciones Universales sigue siendo en la actualidad la más importante medida preventiva para evitar la infección ocupacional por VHC en el personal de salud y la de mejor equilibrio costo-beneficio.Occupational exposure to Hepatitis C virus is an area of growing concern due to a lack of prophylaxis and limited knowledge regarding prevalence in hospital environment. Between 1999 and 2003, a total of 128 occupational exposures to this virus were registered in Diego Paroissien Hospital, eight of which led to hepatitis (6.3% and one case to serum conversion (0.8%. Currently there is no preventive therapy and great interest is focused on acute infection therapy the effectiveness of which is still controversial. This study reinforces the fact that adherence to the Universal Precautions is still the most important preventive measure for health care workers, and the most cost beneficial.

  12. ORAL MANIFESTATIONS OF HEPATITIS C VIRUS

    Directory of Open Access Journals (Sweden)

    Vladimir E. Panov

    2013-10-01

    Full Text Available Hepatitis C virus (HCV infection is a serious public health problem. New infections continue to occur, and morbidity and mortality are increasing. The date reported that 3% of infected world population are affected.Morbidity associated with hepatitis C virus infection can involve a variety of extrahepatic conditions including the oral region. Some of the oral manifestation are oral disease like lichen planus and Sjögren-like sialadenitis , other affects the dental status, and side effect of the virus therapy. The aim of this review is to summarize the oral sings, accompanying hepatitis C virus.

  13. Seroprevalencia de infección por virus C de la hepatitis en población reclusa del noroeste de España al ingreso en prisión

    Directory of Open Access Journals (Sweden)

    1998-01-01

    Full Text Available FUNDAMENTO: Las prisiones españolas albergan un elevado número de personas con prácticas de riesgo para la infección por virus de la hepatitis C (VHC. El objeto de este trabajo es conocer la prevalencia de esta infección en la población reclusa del noroeste de España y sus factores asociados. MÉTODOS: Se estudia a las personas ingresadas en siete centros penitenciarios del noroeste español. Se recogieron variables socio-demográficas, penitenciarias y factores de riesgo para la infección por VHC. Se realizó determinación de anticuerpos frente a VHC (EIA e INNO-LIA HCV III, virus de la hepatitis B (VHB (EIA y virus de la inmunodeficiencia humana (VIH (EIA y Western-Blott. El análisis de los factores asociados se basó en regresión logística. RESULTADOS: El 47,9% de los estudiados presentaron anticuerpos frente a VHC. Destacó la mayor prevalencia en: UDVP (89,6%, los que compartieron jeringuillas (94%, los infectados por VIH (92,7%, los portadores de antígeno Australia (65,1% y de anticuerpos frente al antígeno del core del VHB (79,8%, aquellos con ingresos previos en prisión (60,9 %, los solteros (54,8 %, los gitanos (52 %, los trabajadores no cualificados (50,4 %, los que no habían obtenido el graduado escolar (50,9 %, los tatuados (66,7 % y aquellos con antecedentes de autolesiones (79,3 %. En el análisis de regresión logística las variables asociadas a la infección por VHC fueron: UDVP (OR=33,3; I.C.95%=25-50, HBcAc (+ (OR=4,1; I.C.95%=2,9-6,3, no graduado escolar (OR=1,6; I.C.95%=1,1-2,5, infección por VIH (OR=2,4; I.C.95%=1,1-5,3, edad (OR=0,98; I.C.95%=0,96-1,00, meses en prisión (OR=1,011;I.C.95%=1,004-1,019 y antecedentes de estancias previas en prisión (OR= 2,3; I.C.95%=1,5-3,6. CONCLUSIONES: La prevalencia de infección por VHC en presos es muy elevada. Se aconseja potenciar las medidas preventivas (programas de reducción del daño y la elaboración de protocolos de seguimiento clínico-analítico de los

  14. Quasispecies of Hepatitis B Virus

    Institute of Scientific and Technical Information of China (English)

    Jun; Cheng; Min; Quan; Min; Li; Shun-ai; Liu; Qi; Wang

    2012-01-01

    Hepatitis B virus(HBV) circulates in blood and replicates in the presence of quasispecies. During HBV replication, HBV DNA polymerase lacks fidelity and proofreading function partly because its exonuclease activity is either absent or deficient. Therefore, HBV genome is mutated with unusually high frequency. And these mutations can affect more than one open reading frame due to overlapping genes. Otherwise, natural substitutions, deletions or insertions involving the Cp/ENⅡ locus in the X gene can significantly alter the extent of viral replication activity. Particular selection pressures such as host immune system and antiviral therapy readily select out escape mutants from this pre-existing quasispecies pool. Antiviral drug resistance in chronic hepatitis B(CHB) can be caused by the viral mutation frequency, the intrinsic mutability of the antiviral target site, the selective pressure exerted by the drug, the magnitude and rate of virus replication, the overall replication fitness of the mutant, the genetic barrier of the compound and the availability of replication space. Potent inhibition of HBV replication could be able to prevent the development of drug resistance because mutagenesis is replication dependent. Viral load may decline to a point where the continued production of quasispecies with the potential to resist new drug treatments no longer occurs, if viral replication can be suppressed for a sufficient length of time.

  15. [Occult hepatitis C virus infection].

    Science.gov (United States)

    Carreño García, Vicente; Nebreda, Javier Bartolomé; Aguilar, Inmaculada Castillo; Quiroga Estévez, Juan Antonio

    2011-03-01

    Occult hepatitis C virus (HCV) infection is characterized by the detection of HCV-RNA in liver in the absence of anti-HCV and serum HCV-RNA determined by conventional techniques. The development of a new enzyme immunoassay for the detection of antibodies against a conserved epitope in the HCV core protein, together with the detection of HCV-RNA in peripheral blood mononuclear cells and in serum after concentrating the viral particles by ultracentrifugation, allow diagnosis of more than 90% of patients with occult HCV without the need to perform a liver biopsy. Histological damage in occult HCV infection ranges from minimal changes to liver cirrhosis and hepatocellular carcinoma, although in general this disease is less severe than classical chronic hepatitis C. A significant prevalence of occult HCV infection has been identified in risk groups such as hemodialysis patients and the family members of patients with occult hepatitis C. This occult HCV infection can also be found in subjects without clinical or biochemical evidence of liver disease. Copyright © 2011 Elsevier España S.L. All rights reserved.

  16. Characteristics of hepatitis viruses among Egyptian children with acute hepatitis.

    Science.gov (United States)

    Youssef, Ahmed; Yano, Yoshihiko; El-Sayed Zaki, Maysaa; Utsumi, Takako; Hayashi, Yoshitake

    2013-04-01

    Hepatitis viral infection is hyperendemic in Egypt, western Asia and Africa. However, little is known about the status of hepatitis viruses among rural Egyptian children. Therefore, this study sought to examine the prevalence and characteristics of hepatitis viruses among symptomatic Egyptian children. Serological and molecular analyses of hepatitis viral infection were conducted in 33 children hospitalised at Mansoura University with symptomatic hepatic dysfunction (mean ± standard deviation age, 9.7±3.4 years; alanine aminotransferase level, 130±68 IU/ml). Eleven children (33%) were positive for anti-haemagglutination-IgM and were diagnosed with acute hepatitis A. Hepatitis B surface antigen (HBsAg) and anti‑hepatitis C virus (HCV) were detected in 9 (27%) and 7 (21%) children, respectively, indicating acute-on-chronic infection with hepatitis viruses. None of the children was positive for anti‑hepatitis B core antigen-IgM. Phylogenetic analysis confirmed that all HBVs belonged to genotype D (subgenotype D1) and that HCV belonged to genotypes 4a and 1g. HBV-DNA was detected in 9 children (27%) in the pre-S/S region and in 16 children (48%) in the core promoter/precore region. The Y134F amino acid mutation in the 'α' determinant region was detected in all of the patients. The A1762T/G1764A double mutation, and the T1846A and G1896A single mutations were common in children with occult HBV infection. In conclusion, hepatitis viral infection, including acute-on-chronic infection with HCV and HBV, is common in Egyptian children hospitalised with acute hepatitis.

  17. Infecção pelo vírus da hepatite C em gestantes em Mato Grosso do Sul, 2005-2007 Infección por el virus de la hepatitis C en gestantes en Mato Grosso do Sul, Centro-Oeste de Brasil, 2005-2007 Hepatitis C virus infection among pregnant women in Central-Western Brazil, 2005-2007

    Directory of Open Access Journals (Sweden)

    Clarice Souza Pinto

    2011-10-01

    Full Text Available O estudo teve por objetivo estimar a prevalência da infecção e genótipo do vírus da hepatite C (HCV, bem como determinar a subnotificação de casos. O total de 115.386 gestantes atendidas pelo Programa Estadual de Proteção à Gestante de Mato Grosso do Sul foi submetido à coleta de sangue para a detecção de anti-HCV, de 2005 a 2007. A prevalência da infecção pelo HCV foi de 1,07 casos/1.000. As amostras positivas foram submetidas à detecção do HCV-RNA e genotipadas. O genótipo 1 foi encontrado em 73% das amostras, 24,3% pertenciam ao genótipo 3 e 2,7% ao genótipo 2. A subnotificação de casos de hepatite C foi de 35,5%.El estudio tuvo por objetivo estimar la prevalencia de la infección y genotipo del virus de la hepatitis C (HCV, así como determinar la subnotificación de casos. El total de 115.386 gestantes atendidas por el Programa Estatal de Protección a la Gestante de Mato Grosso do Sul (Centro-Oeste de Brasil fueron sometidas a la colecta de sangre para la detección de anti-HCV, de 2005 a 2007. La prevalencia de la infección por el HCV fue de 1,07 casos/1000. Las muestras positivas fueron sometidas a la detección del HCV-RNA y genotipadas. El genotipo 1 fue encontrado en 73% de las muestras, 24,3% pertenecían al genotipo 3 y 2,7% al genotipo 2. La subnotificación de casos de hepatitis C fue de 35,5%.The study was aimed at estimating the prevalence of infection with and the genotype of hepatitis C virus (HCV, and to determine the extent of underreporting of HCV cases. A total of 115,386 pregnant women seen by the Program for Protection of Pregnancy [Programa Estadual de Proteção à Gestante] of the state of Mato Grosso do Sul, Central-Western Brazil, were tested for anti-HCV antibodies between 2005 and 2007. Prevalence of HCV infection was 1.07 cases per thousand. Positive samples were tested for HCV RNA and genotyped. Genotype 1 was detected in 73% of samples, genotype 3 in 24.3%, and genotype 2 in 2

  18. Valoración del estado nutricional y de la absorción intestinal en pacientes asintomáticos infectados por el virus de la inmunodeficiencia humana (VIH con y sin hepatitis C crónica Assessment of nutritional status and of intestinal absorption in asymptomatic patients infected with the human immunodeficiency virus (HIV with ans without chronic hepatitis

    Directory of Open Access Journals (Sweden)

    M.ª P. Ortega García

    2006-08-01

    Full Text Available Objetivo: Comparar el estado nutricional y la capacidad de absorción intestinal en pacientes VIH asintomáticos con y sin hepatitis C crónica. Material y métodos: 15 pacientes (9 hombres y 6 mujeres seropositivos para el VIH en estadio A1-A2 se subdividen en dos grupos, grupo A VIH asintomáticos (n=7 y grupo B VIH asintomáticos con hepatitis C crónica (n=8. El estado nutricional se determinó mediante valores ponderales de peso y talla, % peso ideal e índice de masa corporal (IMC, pliegue cutáneo del tríceps, circunferencia muscular del brazo, dinamometría y análisis de la composición corporal medida por bioimpedancia eléctrica. La valoración de la capacidad de absorción intestinal se realizó mediante el test de la D-xilosa en orina recogida durante 5 horas tras la administración oral en ayunas de 5 gramos de D-xilosa. El análisis estadístico de los datos se realizó con el paquete estadístico SPSS (V11.0. Resultados: No existen diferencias estadísticamente significativas en el estado nutricional de los pacientes de ambos grupos. Los pacientes VIH asintomáticos con hepatitis C crónica eliminan menos cantidad de D-xilosa en orina durante las 5 horas posteriores a la ingesta de 5 gramos, siendo esta diferencia significativa estadísticamente. De los 8 pacientes del grupo VIH asintomáticos con hepatitis C crónica, tres (37,5% presentaron malabsorción (menos de 1,2 gramos de Dxilosa en orina. Por el contrario no se evidenció alteración en la absorción de la D-xilosa en los pacientes del grupo A Discusión: La población VIH asintomática estudiada presenta un estado nutricional dentro de los valores normales para la población española. No hemos encontrado diferencias significativas entre población VIH asintomática con y sin hepatitis C crónica. La alteración de la capacidad de absorción intestinal en pacientes VIH asintomáticos con hepatitis C crónica observada en este estudio debe ser considerada por sus

  19. Hepatitis C Virus and Hepatocellular Carcinoma

    Directory of Open Access Journals (Sweden)

    Masao Omata

    2013-01-01

    Full Text Available Hepatitis C virus (HCV, a hepatotropic virus, is a single stranded-positive RNA virus of ~9,600 nt. length belonging to the Flaviviridae family. HCV infection causes acute hepatitis, chronic hepatitis, cirrhosis and hepatocellular carcinoma (HCC. It has been reported that HCV-coding proteins interact with host-cell factors that are involved in cell cycle regulation, transcriptional regulation, cell proliferation and apoptosis. Severe inflammation and advanced liver fibrosis in the liver background are also associated with the incidence of HCV-related HCC. In this review, we discuss the mechanism of hepatocarcinogenesis in HCV-related liver diseases.

  20. Acute hepatitis with nontyphoidal salmonella and hepatitis E virus coinfection

    Directory of Open Access Journals (Sweden)

    Yu-Ting Kuo

    2014-09-01

    Full Text Available A 65-year-old Taiwanese man presented with dark urine for 5 days before admission to hospital and with fever on the 2nd day of admission to hospital. Laboratory studies showed acute hepatitis with hyperbilirubinemia. Acute hepatitis with nontyphoidal salmonella and hepatitis E virus coinfection was diagnosed. The fever subsided after treatment with ceftriaxone and cefepime. His serum bilirubin reached its peak value on the 3rd week after admission to hospital and then gradually returned to the normal range. To the best of our knowledge, acute hepatitis E coinfection with nontyphoidal salmonella has not been reported previously.

  1. Diseño de un algoritmo para la inclusión de unidades de bancos de sangre positivas para Anti-HBc y sin infección por el virus de la hepatitis B

    Directory of Open Access Journals (Sweden)

    Sandra Vega

    2016-06-01

    Full Text Available Introducción: Una de las mayores causas de descarte de unidades transfusionales en los bancos de sangre es la infección por el virus de la hepatitis B (VHB. Objetivo: Diseñar un algoritmo estadístico con base en los títulos para anti-HBs y anti-HBc contra el VHB en sueros de donantes de sangre, con el fin de evitar el descarte de unidades sanguíneas de donantes que resolvieron la infección por el virus. Materiales y métodos: 700 alícuotas de suero de donantes del año 2015 fueron suministradas por el Hemocentro del Hospital universitario de Santander (HUS para realizar titulaciones de anti-HBs y anti-HBc. Se busca cuantificar los títulos de anticuerpos se realizará en sueros utilizando ensayos inmunoenzimáticos competitivo (ELISA, siguiendo el protocolo de la casa comercial Diapro. Adicionalmente, se realizará extracción de ácido desoxirribonucleico (ADN con el método de columnas de silica gel (Ultra Sense kit Virus QIAamp a partir de suero siguiendo el protocolo de la casa comercial. El material genético del virus será amplificado por ensayo de PCR anidado utilizando dos tipos de cebadores; un par externo (HBS1 hacia adelante y HBS2 inversa y un par interno (HBS3 hacia adelante y HBS4 inversa, siguiendo el protocolo previamente estandarizado por nuestro laboratorio y obteniendo un producto final de 1100 pares de base. Se establecerá el punto de corte de acuerdo, con lo cual se procederá a crear un algoritmo estadístico utilizando el método de análisis por correspondencia con las variables “Anti-HBc-anti-HBs y DNA viral” teniendo en cuenta cada una de las modalidades de la tabla, cercanía/lejanía entre los puntos calculados (punto de corte. Resultados: Mediante la cuantificación de anticuerpos anti-HBs y anti-HBc se determinará un punto de corte en las unidades de sangre que no tengan el DNA viral siendo estas útiles en caso de llegar a ser transfundidas. Conclusiones: En Santander existen aproximadamente 2’061

  2. Seroprevalence of Hepatitis B Virus among Human ...

    African Journals Online (AJOL)

    This study was carried out to determine the prevalence of hepatitis B virus ... The two groups compared well as regards age, sex, occupation and social class. However, widows has significantly higher prevalence amongst the HIV patients.

  3. Infecciones respiratorias por virus emergentes

    OpenAIRE

    García García , Mª Luz

    2008-01-01

    El trabajo motivo de esta Tesis fue diseñado para aportar información acerca de la circulación en España de los virus respiratorios emergentes, rinovirus, metapneumovirus y bocavirus así como de su comportamiento clínico-epidemiológico. Con la finalidad de mejorar el diagnóstico de las infecciones respiratorias graves en el niño hemos planteado un trabajo clínico y de laboratorio, que amplíe el conocimiento de la etiología, las manifestaciones clínicas y epidemiológicas de los virus respir...

  4. [Extrahepatic manifestations of hepatitis C virus infection].

    Science.gov (United States)

    Roca, Bernardino

    2004-10-01

    Hepatitis C virus predominantly affects the liver, although it may also produce a number of extrahepatic manifestations, such as mixed cryoglobulinemia, salivary and lacrimal gland dysfunction, and several types of kidney disease. The pathogenesis of these conditions is not completely understood, but immunologic mechanisms are involved in many cases. In some patients with hepatitis C virus infection, the extrahepatic manifestations predominate and their proper diagnosis and management is very important.

  5. [Prevention of virus hepatitis A to E].

    Science.gov (United States)

    Cornberg, M; Manns, M P

    2011-03-01

    Infection with hepatitis viruses can lead to acute hepatitis with the risk of developing liver failure. Chronic viral hepatitis may evolve into liver cirrhosis and hepatocellular carcinoma. Thus, prevention of viral hepatitis and its sequels is essential. Vaccination against hepatitis A is successful in almost all individuals. Protective antibodies maintain for at least 20 years. Booster vaccinations are not necessary. Since the introduction of hepatitis A vaccines, the incidence of new HAV-infections has declined significantly. Hepatitis B vaccines are safe and highly effective. Special populations such as dialysis patients or immunocompromised patients require special vaccine schedules. New vaccines with improved adjuvants are currently being tested in clinical trials. So far there is no hepatitis C vaccine on the horizon. Prophylaxis of HCV-infections relies primarily on hygiene measures. Early therapy of acute hepatitis C can prevent chronic hepatitis C. HDV-infection can only be established if HBsAg is present. Thus, prevention of hepatitis B or elimination of HBsAg means prevention of hepatitis delta. Hepatitis E vaccines have been evaluated in phase III studies. The development of HEV vaccines becomes more relevant since chronic HEV infections have been reported in immunosuppressed individuals.

  6. Hepatitis E virus and neurological injury

    NARCIS (Netherlands)

    Dalton, H.R.; Kamar, N.; Eijk, J.J.J. van; McLean, B.N.; Cintas, P.; Bendall, R.P.; Jacobs, B.C.

    2016-01-01

    Hepatitis E is hyperendemic in many developing countries in Asia and Africa, and is caused by hepatitis E virus (HEV) genotypes 1 and 2, which are spread via the faecal-oral route by contaminated water. Recent data show that HEV infection is also endemic in developed countries. In such geographical

  7. Extrahepatic manifestations of hepatitis C virus infection.

    Science.gov (United States)

    Zignego, Anna Linda; Craxì, Antonio

    2008-08-01

    Hepatitis C virus may cause hepatic and extrahepatic diseases. Extrahepatic manifestations range from disorders for which a significant association with viral infection is supported by epidemiologic and pathogenetic data, to anecdotal observations without clear proof of causality. This article describes the diagnosis and treatment of these diseases.

  8. Hepatitis E virus and neurological injury

    NARCIS (Netherlands)

    Dalton, H.R.; Kamar, N.; Eijk, J.J.J. van; McLean, B.N.; Cintas, P.; Bendall, R.P.; Jacobs, B.C.

    2016-01-01

    Hepatitis E is hyperendemic in many developing countries in Asia and Africa, and is caused by hepatitis E virus (HEV) genotypes 1 and 2, which are spread via the faecal-oral route by contaminated water. Recent data show that HEV infection is also endemic in developed countries. In such geographical

  9. Prevalence of hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus and hepatitis E virus as causes of acute viral hepatitis in North India: a hospital based study.

    Science.gov (United States)

    Jain, P; Prakash, S; Gupta, S; Singh, K P; Shrivastava, S; Singh, D D; Singh, J; Jain, A

    2013-01-01

    Acute viral hepatitis (AVH) is a major public health problem and is an important cause of morbidity and mortality. The aim of the present study is to determine the prevalence of hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV) and hepatitis E virus (HEV) as causes of AVH in a tertiary care hospital of North India. Blood samples and clinical information was collected from cases of AVH referred to the Grade I viral diagnostic laboratory over a 1-year period. Samples were tested for hepatitis B surface antigen, anti-HCV total antibodies, anti-HAV immunoglobulin M (IgM) and anti-HEV IgM by the enzyme-linked immunosorbent assay. PCR for nucleic acid detection of HBV and HCV was also carried out. Those positive for HBV infection were tested for anti-HDV antibodies. Fisher's exact test was used and a P hepatitis cases, 62 (23.22%) patients presented as acute hepatic failure. HAV (26.96%) was identified as the most common cause of acute hepatitis followed by HEV (17.97%), HBV (16.10%) and HCV (11.98%). Co-infections with more than one virus were present in 34 cases; HAV-HEV co-infection being the most common. HEV was the most important cause of acute hepatic failure followed by co-infection with HAV and HEV. An indication towards epidemiological shift of HAV infection from children to adults with a rise in HAV prevalence was seen. To the best of our knowledge, this is the first report indicating epidemiological shift of HAV in Uttar Pradesh.

  10. Genotipos virales en pacientes con infección por el virus de la hepatitis C (VHC en Medellín

    Directory of Open Access Journals (Sweden)

    Ana Arango

    2001-04-01

    Full Text Available

    La infección con VHC es la causa más común de hepatitis viral crónica en EE.UU (1. En nuestra ciudad no se ha realizado ninguna evaluación de las características genotípicas del VHC. Nuestro propósito fue describir los genotipos en un grupo de pacientes con infección por VHC en

  11. Genetic Diversity and Molecular evolution of Hepatitis C Virus

    NARCIS (Netherlands)

    S. Noppornpanth (Suwanna)

    2008-01-01

    textabstractHepatitis C virus (HCV), an enveloped positive stranded RNA virus, is the causative agent of non-A, non-B (NANB) hepatitis (27). The virus was identified and characterized by molecular cloning techniques using serum from a NANB hepatitis virus infected chimpanzee (15) and based on the si

  12. Hepatitis C Virus: Assembly and Release of Virus Particles

    OpenAIRE

    Jones, D. M.; McLauchlan, J

    2010-01-01

    Hepatitis C virus is a blood-borne virus that typically establishes a chronic infection in the liver, which often results in cirrhosis and hepatocellular carcinoma. Progress in understanding the complete virus life cycle has been greatly enhanced by the recent availability of a tissue culture system that produces infectious virus progeny. Thus, it is now possible to gain insight into the roles played by viral components in assembly and egress and the cellular pathways that contribute to virio...

  13. Hepatitis C Virus: Assembly and Release of Virus Particles

    OpenAIRE

    Jones, D.M.; McLauchlan, J.

    2010-01-01

    Hepatitis C virus is a blood-borne virus that typically establishes a chronic infection in the liver, which often results in cirrhosis and hepatocellular carcinoma. Progress in understanding the complete virus life cycle has been greatly enhanced by the recent availability of a tissue culture system that produces infectious virus progeny. Thus, it is now possible to gain insight into the roles played by viral components in assembly and egress and the cellular pathways that contribute to virio...

  14. Hepatic disorder in Zika virus infection

    Institute of Scientific and Technical Information of China (English)

    Viroj Wiwanitkit

    2016-01-01

    Zika virus infection is the present global problem. This arbovirus infection can cause acute ilness and affect fetus in utero. However, there can be other additional clinical manifestation including to the hepatic disorder. In this short commentary article, the author brielfy discusses on the liver problem due to Zika virus infection.

  15. The history of hepatitis C virus (HCV)

    DEFF Research Database (Denmark)

    Bukh, Jens

    2016-01-01

    The discovery of hepatitis C virus (HCV) in 1989 permitted basic research to unravel critical components of a complex life cycle for this important human pathogen. HCV is a highly divergent group of viruses classified in 7 major genotypes and a great number of subtypes, and circulating in infected...

  16. [Progress in research of occult hepatitis B virus infection].

    Science.gov (United States)

    Huang, X Y; Shi, Q F; Huang, T

    2017-05-10

    Occult hepatitis B virus infection is a worldwide public health problem, which seriously affects the clinical diagnosis of hepatitis B and threatens the safety of blood transfusion. The concept of occult hepatitis B virus infection, the pathogenesis of occult hepatitis B virus infection, the prevalence of occult hepatitis B virus infection in different groups, including healthy population and different patients, and the possibility of transmission were summarized. The prevalence of occult hepatitis B virus infection was found in healthy population and different patients, and there is possibility of occult hepatitis B virus infection to be transmitted through blood transfusion. The paper provides a comprehensive introduction of the pathogenesis and prevalence of occult hepatitis B virus infection. More attention should be paid to occult hepatitis B virus infection.

  17. Prevalence of human immunodeficiency virushepatitis B virus co ...

    African Journals Online (AJOL)

    Azhani Mandiwana

    determine the prevalence of HIV–HBV co-infection amongst HAART eligible adult ... hepatitis B virus (HBV).2,3 Primary modes of the HIV–HBV co- ... due to treatment failure. .... antibody to hepatitis B core (Immunoglobulin [Ig] M, G fractions),.

  18. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection

    Directory of Open Access Journals (Sweden)

    Keeffe Emmet B

    2005-09-01

    Full Text Available Abstract Hepatitis B virus (HBV and hepatitis C virus (HCV coinfection is not uncommon as a result of similar routes of infection. Patients who are coinfected represent a unique group with diverse serologic profiles. Combined chronic hepatitis B and C leads to more severe liver disease and an increased risk of hepatocellular carcinoma. Furthermore, coinfected patients represent a treatment challenge. No standard recommendations exist for treatment of viral hepatitis due to dual HBV/HCV infection, and therefore treatment must be individualized based on patient variables such as serologic and virologic profiles, patient's prior exposure to antiviral treatment, and the presence of other parenterally transmitted viruses such as hepatitis D virus and human immunodeficiency virus. The natural history and treatment of patients with HBV and HCV coinfection is reviewed.

  19. Innate immune recognition of hepatitis B virus

    Institute of Scientific and Technical Information of China (English)

    Hong-Yan; Liu; Xiao-Yong; Zhang

    2015-01-01

    Hepatitis B virus(HBV) is a hepatotropic DNA virus and its infection results in acute or chronic hepatitis. It is reported that the host innate immune system contributes to viral control and liver pathology, while whether and how HBV can trigger the components of innate immunity remains controversial. In recent years, the data accumulated from HBV-infected patients, cellular and animal models have challenged the concept of a stealth virus for HBV infection. This editorial focuses on the current findings about the innate immune recognition to HBV. Such evaluation could help us to understand HBV immunopathogenesis and develop novel immune therapeutic strategies to combat HBV infection.

  20. Immune Response in Hepatitis B Virus Infection

    Science.gov (United States)

    Tan, Anthony; Koh, Sarene; Bertoletti, Antonio

    2015-01-01

    Hepatitis B virus (HBV) can replicate within hepatocytes without causing direct cell damage. The host immune response is, therefore, not only essential to control the spread of virus infection, but it is also responsible for the inflammatory events causing liver pathologies. In this review, we discuss how HBV deals with host immunity and how we can harness it to achieve virus control and suppress liver damage. PMID:26134480

  1. Hepatitis C Virus and Alcohol

    Science.gov (United States)

    Siu, Larry; Foont, Julie; Wands, Jack R.

    2010-01-01

    This review will focus on the prevalence of hepatitis c virus (HCV) infection in alcoholics with and without liver disease. Evidence will be presented to demonstrate that ethanol and chronic HCV infection synergistically accelerate liver injury. Some of the major postulated mechanisms responsible for disease progression include high rates of apoptosis, lipid peroxidation, and generation of free radicals and reactive oxygen species with reduced antioxidant capacity of the liver. Acquisition and persistence of HCV infection may be due to the adverse effects of ethanol on humoral and cellular immune responses to HCV. Dendritic cells (DC) appear to be one of the major targets for ethanol’s action and DC dysfunction impairs the ability of the host to generate viral specific cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) immune responses. There is a relationship between increased alcohol intake and decreased response to interferon (IFN) therapy, which may be reversed by abstinence. Clinical studies are needed to optimize treatment responses in alcoholic patients with chronic HCV infection. PMID:19387918

  2. Hepatites pós-transfusionais na cidade de Campinas, SP, Brasil: I. Incidência, agentes etiológicos e aspectos clínico-epidemiológicos da hepatite por vírus C Post-transfusional hepatitis in the city of Campinas, SP, Brazil: I. Incidence, etiological agents and clinical-epidemiological aspects of hepatitis C virus

    Directory of Open Access Journals (Sweden)

    Fernando Lopes Gonçales Júnior

    1993-02-01

    Full Text Available Seguimos ambulatorialmente, por no mínimo 180 dias, 111 receptores de transfusões, para avaliarmos a ocorrência de hepatites pós-transfusionais e os agentes etiológicos envolvidos com esta doença, na cidade de Campinas, Estado de São Paulo, Brasil. No final diagnosticamos esta hepatite em 18 (16,2% receptores. Destes, tivemos 16 (89% casos devido ao vírus da hepatite C, 1 (5,5% causado pelo vírus da hepatite B e 1 (5,5% caso restante, sem etiologia determinada, 15 meses após a transfusão. O período de incubação da hepatite por vírus C (HVC foi de 71 dias, em média; e 23% dos indivíduos com esta hepatite permaneceram com aumento de AST/ALT por mais de 6 meses. Observou-se soroconversão tardia para o anti-HCV em 71,4% dos receptores, que ocorreu, em média, 135 dias após a transfusão. Uma dosagem de ALT e uma pesquisa do anti-HCV, aos 3 e 6 meses, após a transfusão, diagnosticariam, respectivamente, 71 e 93% dos casos que desenvolveram HVC pós-transfusionais.We have followed up 111 transfusion receptors in the ambulatory, for at least 180 days, in order to evaluate the occurence of post-transfusional hepatitis and the etiological agents involved in the disease in the city of Campinas, state of São Paulo, Brazil. At the end of the study we have diagnosed this hepatitis in 18 (16.2% subjects. Out of these 18 subjects, 16 (89% were caused by hepatitis C virus, 1 (5.5% caused by hepatitis B virus and 1 (5.5% with undetermined etiology, 15 months after transfusion. The average incubation period of HCV was 71 days and 23% of the HCV positive receptors remained with increased AST/ ALT for more than 6 months. Late serum conversion was observed for anti-HCV in 71.4% of the subjects, averaging 135 days after the transfusion. An ALT dosage and anti-HCV determination, 3 and 6 months after transfusion would diagnose, respectively, 71 and 93% of the cases which developed post-transfusional HCV.

  3. Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus.

    Science.gov (United States)

    Littlejohn, Margaret; Locarnini, Stephen; Yuen, Lilly

    2016-01-04

    Members of the family Hepadnaviridae fall into two subgroups: mammalian and avian. The detection of endogenous avian hepadnavirus DNA integrated into the genomes of zebra finches has revealed a deep evolutionary origin of hepadnaviruses that was not previously recognized, dating back at least 40 million and possibly >80 million years ago. The nonprimate mammalian members of the Hepadnaviridae include the woodchuck hepatitis virus (WHV), the ground squirrel hepatitis virus, and arctic squirrel hepatitis virus, as well as a number of members of the recently described bat hepatitis virus. The identification of hepatitis B viruses (HBVs) in higher primates, such as chimpanzee, gorilla, orangutan, and gibbons that cluster with the human HBV, as well as a number of recombinant forms between humans and primates, further implies a more complex origin of this virus. We discuss the current theories of the origin and evolution of HBV and propose a model that includes cross-species transmissions and subsequent recombination events on a genetic backbone of genotype C HBV infection. The hepatitis delta virus (HDV) is a defective RNA virus requiring the presence of the HBV for the completion of its life cycle. The origins of this virus remain unknown, although some recent studies have suggested an ancient African radiation. The age of the association between HDV and HBV is also unknown.

  4. Hepatitis C virus infection and risk of coronary artery disease

    DEFF Research Database (Denmark)

    Roed, Torsten; Lebech, Anne-Mette; Kjaer, Andreas

    2012-01-01

    Several chronic infections have been associated with cardiovascular diseases, including Chlamydia pneumoniae, human immunodeficiency virus and viral hepatitis. This review evaluates the literature on the association between chronic hepatitis C virus (HCV) infection and the risk of coronary artery...

  5. HCVpro: Hepatitis C virus protein interaction database

    KAUST Repository

    Kwofie, Samuel K.

    2011-12-01

    It is essential to catalog characterized hepatitis C virus (HCV) protein-protein interaction (PPI) data and the associated plethora of vital functional information to augment the search for therapies, vaccines and diagnostic biomarkers. In furtherance of these goals, we have developed the hepatitis C virus protein interaction database (HCVpro) by integrating manually verified hepatitis C virus-virus and virus-human protein interactions curated from literature and databases. HCVpro is a comprehensive and integrated HCV-specific knowledgebase housing consolidated information on PPIs, functional genomics and molecular data obtained from a variety of virus databases (VirHostNet, VirusMint, HCVdb and euHCVdb), and from BIND and other relevant biology repositories. HCVpro is further populated with information on hepatocellular carcinoma (HCC) related genes that are mapped onto their encoded cellular proteins. Incorporated proteins have been mapped onto Gene Ontologies, canonical pathways, Online Mendelian Inheritance in Man (OMIM) and extensively cross-referenced to other essential annotations. The database is enriched with exhaustive reviews on structure and functions of HCV proteins, current state of drug and vaccine development and links to recommended journal articles. Users can query the database using specific protein identifiers (IDs), chromosomal locations of a gene, interaction detection methods, indexed PubMed sources as well as HCVpro, BIND and VirusMint IDs. The use of HCVpro is free and the resource can be accessed via http://apps.sanbi.ac.za/hcvpro/ or http://cbrc.kaust.edu.sa/hcvpro/. © 2011 Elsevier B.V.

  6. Oscillations in serum ferritin associated with antiviral therapy in chronic hepatitis C Oscilaciones de la ferritina sérica asociadas al tratamiento antiviral en la hepatitis crónica por virus C

    Directory of Open Access Journals (Sweden)

    J. M. Ladero

    2009-01-01

    Full Text Available Background: hyperferritinemia is often found in patients with chronic hepatitis C (CHC and is predictive of poorer response to antiviral therapy. Objective: to investigate changes in ferritinemia during and after antiviral therapy. Patients and methods: serum ferritin levels were measured in 262 CHC patients (163 males, mean age 48.5 years ± 10.1 before and during antiviral therapy, and six months post-treatment in all 154 patients whit undetectable serum HCV-RNA after therapy completion. Results: baseline serum ferritin was higher in patients with primary therapeutic failure than in those reaching sustained viral response (330 ± 291 ng/mL vs. 211 ± 192 ng/mL, p = 0.002. Serum ferritin transiently increased during therapy from baseline (257 ± 242 ng/mL vs. 875 ± 630 ng/mL, p Antecedentes: la hiperferritinemia es frecuente en los enfermos con hepatitis crónica C (HCC y reduce las probabilidades de respuesta al tratamiento antiviral. Objetivo: investigar las variaciones de la ferritina sérica durante y después del tratamiento y su relación con la respuesta al mismo. Pacientes y métodos: la ferritina sérica se ha medido en 262 enfermos con HCC (163 hombres, edad media 48,5 años ± 10,1 antes y durante el tratamiento antiviral, y a los 6 meses de finalizado en los 154 enfermos con viremia indetectable al final del tratamiento. Resultados: la ferritina sérica basal era más alta en enfermos con fracaso terapéutico primario que en los que consiguieron respuesta viral sostenida (RVS (330 ± 291 ng/ml vs. 211 ± 192 ng/ml, p = 0,002. La ferritina sérica aumentó transitoriamente durante el tratamiento (257 ± 242 ng/ml vs. 875 ± 630 ng/ml, p < 0,001. La ferritina sérica descendió a valores inferiores a los basales seis meses después de finalizado el tratamiento en los pacientes con RVS (117 ± 102 ng/ml vs. 211± 192 ng/ml, p < 0,001 y, en menor grado, en los que sufrieron recidiva viral (217 ± 174 ng/ml vs. 257 ± 221 ng/m, p = 0

  7. Pathogenesis of hepatitis B virus infection

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    Infection with hepatitis B virus (HBV) leads to a wide spectrum of clinical presentations ranging from an asymptomatic carrier state to self-limited acute or fulminant hepatitis to chronic hepatitis with progression to cirrhosis and hepatocellular carcinoma. Infection with HBV is one of the most common viral diseases affecting man. Both viral factors as well as the host immune response have been implicated in the pathogenesis and clinical outcome of HBV infection. In this review, we will discuss the impact of virus-host interactions for the pathogenesis of HBV infection and liver disease. These interactions include the relevance of naturally occurring viral variants for clinical disease, the role of virus-induced apoptosis for HBV-induced liver cell injury and the impact of antiviral immune responses for outcome of infection.

  8. Insulin resistance, steatosis and hepatitis C virus

    OpenAIRE

    Mangia, Alessandra; Ripoli, Maria

    2013-01-01

    Epidemiological studies have shown an increased occurrence of metabolic disorders such as insulin resistance (IR) and steatosis in patients with hepatitis C virus (HCV) infection. IR is believed to represent one of the central clinical features of the “metabolic syndrome” and the major pathogenetic factor for type 2 diabetes mellitus. In patients with chronic HCV hepatitis, IR may have several dangerous consequences such as accelerated progression of liver fibrosis, resistance to antiviral th...

  9. Evaluación de la fibrosis hepática en la hepatitis crónica por virus C mediante la aplicación prospectiva del Sabadell's NIHCED score: Sabadell's Non Invasive, Hepatitis C Related-Cirrhosis Early Detection Score Prospective evaluation of liver fibrosis in chronic viral hepatitis C infection using the Sabadell NIHCED: non-invasive hepatitis C related cirrhosis early detection index

    Directory of Open Access Journals (Sweden)

    G. Bejarano

    2009-05-01

    Full Text Available Introducción: la hepatitis crónica por VHC cursa de forma asintomática desarrollando cirrosis hepática y sus complicaciones en un 20-40% de los casos. En estudios previos se ha demostrado que la fibrosis avanzada es un factor pronóstico fundamental. El método gold standard para la valoración del grado de fibrosis es la biopsia hepática. Nuestro grupo ha validado un índice predictivo, el NIHCED (Sabadell's Non Invasive, Hepatitis C related-Cirrosis Early Detection Score, basado en datos demográficos, analíticos y ecográficos para determinar la presencia de cirrosis. Objetivo: nuestro objetivo es el de evaluar si el NIHCED predice la presencia de fibrosis avanzada en los pacientes con hepatitis crónica por virus C. Material y métodos: estudio prospectivo donde se incluyeron pacientes con hepatitis crónica por VHC. Se les realizó una biopsia hepática y el NIHCED. El grado de fibrosis se correlacionó con el valor del NIHCED mediante curva de ROC y el coeficiente de correlación de Spearman. Resultados: se incluyeron un total de 321 pacientes (ratio hombre/mujer 1,27 con una edad media de 48 ± 14 años. La biopsia hepática mostró que 131 (30,5% no tenían fibrosis o era expansión portal, mientras que 190 (69,5% tenían fibrosis avanzada o cirrosis. Para un punto de corte de 6 puntos, la sensibilidad fue del 72%, especificidad del 76,3%, VPP del 81%, VPN del 63,7% y una precisión diagnóstica del 72,5%, con un área bajo la curva fue de 0,787 y un coeficiente de correlación de Spearman de r = 0,65. Conclusiones: el NIHCED predice la presencia de fibrosis avanzada en un elevado porcentaje de pacientes sin necesidad de realizar biopsia hepática.Introduction: liver disease resulting from chronic hepatitis C virus (HCV infection follows an asymptomatic course towards cirrhosis and its complications in 20-40% of cases. Earlier studies demonstrated that advanced fibrosis is a prognostic factor. The "gold standard" for the evaluation

  10. [Therapy of hepatitis B virus carriers].

    Science.gov (United States)

    Bereza, N M; Petiĭ, S I

    1986-01-01

    Examination of 200 gastroenterological patients with a suspected chronic diffuse liver disease has demonstrated that only in 18.9% of the patients with chronic hepatitis, the disease was induced by the virus. Based on the experience gained with the treatment of 7 patients with chronic hepatitis B it is concluded that sanitation may be performed with levamisole. However, the data obtained in the course of the 5-year observation over sanitation of HBsAg carriers (25 subjects) do not provide any convincing evidence in favour of levamisole sanitation. The authors hold that at the blood transfusion stations the prophylaxis of serum hepatitis falls short of ideal. Selection of the donors according to CCIE does not give any guarantee against the viral hepatitis B carrier state. Like patients with viral hepatitis B, the HBsAg carriers badly need active prophylactic-and-treatment medical examination with the use of the antiviral agents.

  11. Hepatitis C virus infection in nephrology patients.

    Science.gov (United States)

    Rostaing, Lionel; Izopet, Jacques; Kamar, Nassim

    2013-10-01

    Hepatitis C virus (HCV) infection leads to chronic liver disease, but also to extra-hepatic manifestations. Directory of Open Access Journals (DOAJ), Google Scholar, Pubmed (NLM), LISTA (EBSCO) and Web of Science have been searched. Herein, we provide an overview of renal diseases related to HCV and their therapies, as well as the treatment options available for HCV (+)/RNA (+) dialysis patients. We will not mention, however, HCV infection-related complications in the post-kidney transplantation setting. Extra-hepatic manifestations of HCV infection include mixed cryoglobulinemia, lymphoproliferative disorders, and renal disease. HCV infection has been reported in association with distinct histological patterns of glomerulonephritis in native kidneys.

  12. Clinical and virological improvement of hepatitis B virus-related or hepatitis C virus-related chronic hepatitis with concomitant hepatitis A virus infection.

    Science.gov (United States)

    Sagnelli, Evangelista; Coppola, Nicola; Pisaturo, Mariantonietta; Pisapia, Raffaella; Onofrio, Mirella; Sagnelli, Caterina; Catuogno, Antonio; Scolastico, Carlo; Piccinino, Felice; Filippini, Pietro

    2006-06-01

    We evaluated the clinical and virological characteristics of hepatitis A virus infection in persons concomitantly infected with hepatitis B virus (HBV) or hepatitis C virus (HCV). We enrolled 21 patients with acute hepatitis A and chronic hepatitis with no sign of liver cirrhosis, 13 patients who were positive for hepatitis B surface antigen (case B group), 8 patients who were anti-HCV positive (case C group), and 21 patients with acute hepatitis A without a preexisting liver disease (control A group). Two control groups of patients with chronic hepatitis B (control B group) or C (control C group) were also chosen. All control groups were pair-matched by age and sex with the corresponding case group. Fulminant hepatitis A was never observed, and hepatitis A had a severe course in 1 patient in the case B group and in 1 patient in the control A group. Both patients recovered. On admission, HBV DNA was detected in 1 patient in the case B group (7.7%) and in 13 patients (50%) in the control B group; HCV RNA was found in no patient in the case C group and in 16 patients (81.2%) in the control C group. Of 9 patients in the case B group who were followed up for 6 months, 3 became negative for hepatitis B surface antigen and positive for hepatitis B surface antibody, 2 remained positive for hepatitis B surface antigen and negative for HBV DNA, and 4 became positive for HBV DNA with a low viral load [corrected] Of 6 patients in the case C group who were followed up for 6 months, 3 remained negative for HCV RNA, and 3 had persistently low viral loads. Concomitant hepatitis A was always self-limited, associated with a marked inhibition of HBV and HCV genomes, and possibly had a good prognosis for the underlying chronic hepatitis.

  13. Seroepidemiology of hepatitis A and hepatitis B virus in Luxembourg.

    Science.gov (United States)

    Mossong, J; Putz, L; Patiny, S; Schneider, F

    2006-08-01

    A prospective seroepidemiological survey was carried out in Luxembourg in 2000-2001 to determine the antibody status of the Luxembourg population against hepatitis A virus (HAV) and hepatitis B virus (HBV). One of the objectives of this survey was to assess the impact of the hepatitis B vaccination programme, which started in May 1996 and included a catch-up campaign for all adolescents aged 12-15 years. Venous blood from 2679 individuals was screened for the presence of antibodies to HAV antigen and antibodies to hepatitis B surface antigen (anti-HBs) using an enzyme immunoassay. Samples positive for anti-HBs were tested for antibody to hepatitis B core antigen (anti-HBc) using a chemiluminiscent microparticle immunoassay to distinguish between individuals with past exposure to vaccine or natural infection. The estimated age-standardized anti-HAV seroprevalence was 42.0% [95% confidence interval (CI) 39.8-44.1] in the population >4 years of age. Seroprevalence was age-dependent and highest in adult immigrants from Portugal and the former Yugoslavia. The age-standardized prevalence of anti-HBs and anti-HBc was estimated at 19.7% (95% CI 18.1-21.3) and 3.16% (95% CI 2.2-4.1) respectively. Anti-HBs seroprevalence exceeding 50% was found in the cohorts targeted by the routine hepatitis B vaccination programme, which started in 1996. Our study illustrates that most young people in Luxembourg are susceptible to HAV infection and that the hepatitis B vaccination programme is having a substantial impact on population immunity in children and teenagers.

  14. Hepatitis e virus: Western Cape, South Africa

    NARCIS (Netherlands)

    R.G. Madden (Richie); Wallace, S. (Sebastian); M. Sonderup; Korsman, S. (Stephen); Chivese, T. (Tawanda); Gavine, B. (Bronwyn); Edem, A. (Aniefiok); Govender, R. (Roxy); English, N. (Nathan); Kaiyamo, C. (Christy); Lutchman, O. (Odelia); A.A. Eijck (Annemiek); S.D. Pas (Suzan); Webb, G.W. (Glynn W); Palmer, J. (Joanne); Goddard, E. (Elizabeth); Wasserman, S. (Sean); H.R. Dalton (Harry); C.W. Spearman

    2016-01-01

    textabstractAIM To conduct a prospective assessment of anti-hepatitis E virus (HEV) IgG seroprevalence in the Western Cape Province of South Africa in conjunction with evaluating risk factors for exposure. METHODS Consenting participants attending clinics and wards of Groote Schuur, Red Cross Childr

  15. Hepatitis C virus infection management in 2012.

    NARCIS (Netherlands)

    Gulick, J.J. van; Lamers, M.H.; Drenth, J.P.H.

    2012-01-01

    Hepatitis C virus (HCV) is the most common infectious cause of chronic liver disease in Europe. With the introduction of interferon based therapy in combination with ribavirin treatment of chronic HCV has become feasible. This therapy has become the standard of care for patients with HCV and dependi

  16. Hepatitis e virus: Western Cape, South Africa

    NARCIS (Netherlands)

    R.G. Madden (Richie); Wallace, S. (Sebastian); M. Sonderup; Korsman, S. (Stephen); Chivese, T. (Tawanda); Gavine, B. (Bronwyn); Edem, A. (Aniefiok); Govender, R. (Roxy); English, N. (Nathan); Kaiyamo, C. (Christy); Lutchman, O. (Odelia); A.A. Eijck (Annemiek); S.D. Pas (Suzan); Webb, G.W. (Glynn W); Palmer, J. (Joanne); Goddard, E. (Elizabeth); Wasserman, S. (Sean); H.R. Dalton (Harry); Spearman, C.W. (C Wendy)

    2016-01-01

    textabstractAIM To conduct a prospective assessment of anti-hepatitis E virus (HEV) IgG seroprevalence in the Western Cape Province of South Africa in conjunction with evaluating risk factors for exposure. METHODS Consenting participants attending clinics and wards of Groote Schuur, Red Cross Childr

  17. Neuralgic amyotrophy and hepatitis E virus infection

    NARCIS (Netherlands)

    J.J.J. van Eijk (Jeroen); R.G. Madden (Richie); A.A. Eijck (Annemiek); J.G. Hunter (Jeremy); J.H.J. Reimerink (Johan); R.P. Bendall (Richard); S.D. Pas (Suzan); V. Ellis (Vic); N. van Alfen (Nens); L. Beynon (Laura); L. Southwell (Lucy); B. McLean (Brendan); B.C. Jacobs (Bart); B.G.M. van Engelen (Baziel); H.R. Dalton (Harry)

    2014-01-01

    textabstractObjective: To determine whether there is an association between an acute preceding hepatitis E virus (HEV) infection and neuralgic amyotrophy (NA), and if so, whether patients with HEV-related NA differ from patients without an associated HEV infection. Methods: HEV testing was conducted

  18. Neuralgic amyotrophy and hepatitis E virus infection

    NARCIS (Netherlands)

    Eijk, J.J.J. van; Madden, R.G.; Eijk, A.A. van der; Hunter, J.G.; Reimerink, J.H.; Bendall, R.P.; Pas, S.D.; Ellis, V.; Alfen, N. van; Beynon, L.; Southwell, L.; McLean, B.; Jacobs, B.C.; Engelen, B.G.M. van; Dalton, H.R.

    2014-01-01

    OBJECTIVE: To determine whether there is an association between an acute preceding hepatitis E virus (HEV) infection and neuralgic amyotrophy (NA), and if so, whether patients with HEV-related NA differ from patients without an associated HEV infection. METHODS: HEV testing was conducted in a retros

  19. Controversies about occult hepatitis B virus infection

    Institute of Scientific and Technical Information of China (English)

    Ersan Ozaslan; Tugrul Purnak

    2009-01-01

    We read with great interest the paper written by Shi et al, reviewing the molecular characteristics and stages of chronic hepatitis B virus (HBV) infection. We think that some points in the definition of occult HBV infection (OBI) and their conclusion about the management of OBI may need further considerations.

  20. Hepatitis e virus: Western Cape, South Africa

    NARCIS (Netherlands)

    R.G. Madden (Richie); Wallace, S. (Sebastian); M. Sonderup; Korsman, S. (Stephen); Chivese, T. (Tawanda); Gavine, B. (Bronwyn); Edem, A. (Aniefiok); Govender, R. (Roxy); English, N. (Nathan); Kaiyamo, C. (Christy); Lutchman, O. (Odelia); A.A. Eijck (Annemiek); S.D. Pas (Suzan); Webb, G.W. (Glynn W); Palmer, J. (Joanne); Goddard, E. (Elizabeth); Wasserman, S. (Sean); H.R. Dalton (Harry); C.W. Spearman

    2016-01-01

    textabstractAIM To conduct a prospective assessment of anti-hepatitis E virus (HEV) IgG seroprevalence in the Western Cape Province of South Africa in conjunction with evaluating risk factors for exposure. METHODS Consenting participants attending clinics and wards of Groote Schuur, Red Cross

  1. Hepatitis C virus host cell interactions uncovered

    DEFF Research Database (Denmark)

    Gottwein, Judith; Bukh, Jens

    2007-01-01

      Insights into virus-host cell interactions as uncovered by Randall et al. (1) in a recent issue of PNAS further our understanding of the hepatitis C virus (HCV) life cycle, persistence, and pathogenesis and might lead to the identification of new therapeutic targets. HCV persistently infects 180...... million individuals worldwide, causing chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. The only approved treatment, combination therapy with IFN- and ribavirin, targets cellular pathways (2); however, a sustained virologic response is achieved only in approximately half of the patients...... treated. Therefore, there is a pressing need for the identification of novel drugs against hepatitis C. Although most research focuses on the development of HCV-specific antivirals, such as protease and polymerase inhibitors (3), cellular targets could be pursued and might allow the development of broad...

  2. Hepatitis C virus host cell interactions uncovered

    DEFF Research Database (Denmark)

    Gottwein, Judith; Bukh, Jens

    2007-01-01

      Insights into virus-host cell interactions as uncovered by Randall et al. (1) in a recent issue of PNAS further our understanding of the hepatitis C virus (HCV) life cycle, persistence, and pathogenesis and might lead to the identification of new therapeutic targets. HCV persistently infects 180...... million individuals worldwide, causing chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. The only approved treatment, combination therapy with IFN- and ribavirin, targets cellular pathways (2); however, a sustained virologic response is achieved only in approximately half of the patients...... treated. Therefore, there is a pressing need for the identification of novel drugs against hepatitis C. Although most research focuses on the development of HCV-specific antivirals, such as protease and polymerase inhibitors (3), cellular targets could be pursued and might allow the development of broad...

  3. Hepatitis C Virus and Antiviral Drug Resistance

    Science.gov (United States)

    Kim, Seungtaek; Han, Kwang-Hyub; Ahn, Sang Hoon

    2016-01-01

    Since its discovery in 1989, hepatitis C virus (HCV) has been intensively investigated to understand its biology and develop effective antiviral therapies. The efforts of the previous 25 years have resulted in a better understanding of the virus, and this was facilitated by the development of in vitro cell culture systems for HCV replication. Antiviral treatments and sustained virological responses have also improved from the early interferon monotherapy to the current all-oral regimens using direct-acting antivirals. However, antiviral resistance has become a critical issue in the treatment of chronic hepatitis C, similar to other chronic viral infections, and retreatment options following treatment failure have become important questions. Despite the clinical challenges in the management of chronic hepatitis C, substantial progress has been made in understanding HCV, which may facilitate the investigation of other closely related flaviviruses and lead to the development of antiviral agents against these human pathogens. PMID:27784846

  4. Regulation of hepatic innate immunity by hepatitis C virus

    OpenAIRE

    Stacy M Horner; Gale, Michael

    2013-01-01

    Hepatitis C virus (HCV) is a global public health problem involving chronic infection of the liver in over 170 million people. Chronic HCV causes liver disease and is linked with liver cancer. Viral innate immune evasion strategies and human genetic determinants underlie the transition of acute HCV infection to viral persistence and the support of chronic infection. Host genetic factors, such as sequence polymorphisms in IFNL3, a gene in the host interferon system, can influence both the outc...

  5. the Study of Hepatitis B Virus Reactivation

    Institute of Scientific and Technical Information of China (English)

    2014-01-01

    Hepatitis B virus (HBV) reactivation after chemotherapy or immunosuppressive therapy is a cause of liver-related morbidity and mortality. Not all chronic hepatitis B patients will lead to HBV reactivation. The incidence is 0.3%-30.2%according to the reports. The mechanism of HBV reactivation is still unclear, but it is believed that the viral load is increasing due to the suppression of immune response. No uniform diagnostic criteria are available. HBV reactivation can be confirmed by an increase of serum HBV DNA level. Recently, awareness of reactivation of occult HBV has been improved, especially in HBV endemic area. Preemptive antiviral therapy was the best approach to prevent the HBV reactivation. HBV reactivation can lead to acute hepatitis, severe hepatitis and acute liver failure. Therefore, it is worthy of great attention and further study. Antiviral therapy is safe and effective to prevent HBV reactivation.

  6. Linking hepatitis C virus infection to pre-1994 blood transfusions in female patients.

    Science.gov (United States)

    Ramos Flores, Christian; Echeagaray, Ernesto; Castañeda, Guadalupe; Vargas, Maria de Lourdes; Montes-González, Raúl; Luna, Susana; Díaz, Laura; Torres, Oscar

    2017-03-15

    La mayor parte de las transfusiones se llevan a cabo en mujeres. La introducción en los bancos de sangre de las técnicas serológicas disminuyó la incidencia de infección por virus de hepatitis C después de una transfusión. En México, las pacientes que se transfundieron antes de 1994 están en riesgo de presentar una infección por virus de hepatitis C. El objetivo de este estudio fue medir la asociación entre el antecedente transfusional antes de 1994 e infección por virus de hepatitis C en mujeres atendidas en la zona metropolitana de Guadalajara, México.

  7. Hepatitis B virus genotypes:an overview

    Institute of Scientific and Technical Information of China (English)

    Mamun-Al Mahtab; Salimur Rahman; Mobin Khan; Fazal Karim

    2008-01-01

    BACKGROUND: Hepatitis B virus (HBV) infection is a major cause of mortality and morbidity globally. The quest continues to identify viral factors that inlfuence disease progression and severity as well as responses to treatment of HBV infection. Based on variations in HBV, the virus has been divided into a number of genotypes. DATA SOURCES: Review of published literature on HBV genotypes. RESULTS: HBV genotypes are likely to be important in determining the severity and progression of HBV-induced liver disease as well as responses to different anti-viral agents. CONCLUSION: Although HBV genotyping is not yet recommended for routine use in treating HBV infection, available data suggest that, as in hepatitis C virus infection, HBV genotyping is also likely to become a routine investigation for HBV treatment, perhaps in the not too distant future.

  8. Hepatitis C Virus Antibodies and Vitiligo Disease

    Directory of Open Access Journals (Sweden)

    Z Jadali

    2005-06-01

    Full Text Available Vitiligo is a common skin disorder, characterized by depigmented patches due to selective destruction of melanocytes. The etiology of this disease is unknown. A number of hypotheses including viral theory have been proposed to explain the etiology. To determine the prevalence of antibody to hepatitis C virus infection in vitiligo patients, the present study was performed. Third generation ELISA test was used for detection of antibodies to HCV in human sera. All normal controls were anti-HCV negative whereas only one patient was positive for anti-HCV and there was no significant difference in the prevalence of anti-HCV between patients and controls. These results indicate that hepatitis C virus has not a direct causal role in the pathogenesis of vitiligo, however, this does not rul out a "hit and run" virus induced disease.

  9. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen

    Science.gov (United States)

    Smith, Geoffrey L.; Mackett, Michael; Moss, Bernard

    1983-04-01

    Potential live vaccines against hepatitis B virus have been produced. The coding sequence for hepatitis B virus surface antigen (HBsAg) has been inserted into the vaccinia virus genome under control of vaccinia virus early promoters. Cells infected with these vaccinia virus recombinants synthesize and excrete HBsAg and vaccinated rabbits rapidly produce antibodies to HBsAg.

  10. Noninvasive Monitoring of Hepatic Damage from Hepatitis C Virus Infection

    Directory of Open Access Journals (Sweden)

    J. Alavez-Ramírez

    2011-01-01

    Full Text Available The mathematical model for the dynamics of the hepatitis C proposed in Avendaño et al. (2002, with four populations (healthy and unhealthy hepatocytes, the viral load of the hepatitis C virus, and T killer cells, is revised. Showing that the reduced model obtained by considering only the first three of these populations, known as basic model, has two possible equilibrium states: the uninfected one where viruses are not present in the individual, and the endemic one where viruses and infected cells are present. A threshold parameter (the basic reproductive virus number is introduced, and in terms of it, the global stability of both two possible equilibrium states is established. Other central result consists in showing, by model numerical simulations, the feasibility of monitoring liver damage caused by HCV, avoiding unnecessary biopsies and the undesirable related inconveniences/imponderables to the patient; another result gives a mathematical modelling basis to recently developed techniques for the disease assessment based essentially on viral load measurements.

  11. The extrahepatic manifestations of hepatitis B virus.

    Science.gov (United States)

    Baig, Saeeda; Alamgir, Mohiuddin

    2008-07-01

    Hepatitis B Virus (HBV) leads to a number of hepatic complications, from acute to chronic hepatitis, cirrhosis and hepatocellular carcinoma, is a well-established fact. Upcoming clinical research, over the years, associates numerous extrahepatic manifestations during the acute and chronic episodes of hepatitis B with significant morbidity and mortality. A causal relationship between HBV and serious autoimmune disorders has also been observed among certain susceptible vaccine recipients in a defined temporal period following immunization. The cause of these extrahepatic manifestations is generally believed to be immune mediated. The most commonly described include skin rash, arthritis, arthralgia, glomerulonephritis, polyarteritis nodosa, and papular acrodermatitis etc. The serum-sickness like "arthritis-dermatitis" prodrome has also been observed in approximately one-third of patients acquiring HBV infections. Skin manifestations of HBV infection typically present as palpable purpura reported to be caused by chronic HBV, although this association remains controversial. To consider the relationship between HBV and other clinically significant disorders as well as serious autoimmune disorders among certain vaccine recipients is the topic of this review. Variable factors that influence extrahepatic manifestation are discussed, including possible synergy between hepatitis B virus and the immune system.

  12. SEROPREVALENCE OF HEPATITIS C VIRUS IN HEPATIC DISORDERS

    Directory of Open Access Journals (Sweden)

    Syeda Amtul

    2015-03-01

    Full Text Available Seroprevalence of Hepatitis C virus among hepatic disorder patients. Various hepatic disorders like Hepatitis, cirrhosis & HCC cause multi organ failure leading to death. The most important viral cause of hepatic disorders after HBV is HCV. Hence this study is conducted to aid in early detection & treatment & its prevention in community. The study is conducted on 100 confirmed hepatic disorder patients from Gastro intestinal ward of Osmania General Hospital, Hydera bad. ELISA was done at Osmania General Hospital & Osmania Medical College, Hyderabad PCR was done at Deccan College of Medical Sciences, Hyderabad. Third generation ELISA containing an antigen derived from the Non - structural NS5 region which encodes as RNA polymerase was used. Principle of the test: Sandwich principle - Enzyme immune assay. Guanidine Isothyocyanite Method (GITC of PCRELISA: Total No: of anti HCV antibody positive cases in our study were 5% &HBV +HCV cases were 1%.All positive cases were abov e the age of 40 yrs.HCV positivity ratio among Male: Female was1:1.45.HCV was detected to be maximum in HCC (20%.followed by Hepatitis (9% & then Cirrhosis (7%. PCR: All the 5 anti HCV antibody positive cases detected by ELISA were also detected to be p ositive for HCV - RNA by RT - PCR in all samples. The sample positive for HBV+HCV by ELISA also showed positive for HBV DNA by PCR and HCV RNA by RT - PCR Various hepatic disorders like CAH, Cirrhosis and HCC caused by HBV and HCV have become a major public heal th problem throughout the world.HCC is one of the ten most common cancers in the world and is the only cancer which can be prevented by vaccination.HCV infection can be transmitted by blood transmission, injectable drugs, perinatally, improperly sterilized dialysis equipment, unprotected sex with infected partner specially MSM group and with other STDs & HIV Hence this study is conducted to aid in early detection and treatment and its prevention in community Comparison of

  13. Autoimmune Diseases Co-Existing with Hepatitis C Virus Infection

    Directory of Open Access Journals (Sweden)

    Zohreh Jadali

    2010-12-01

    Full Text Available Autoimmunity and viral infections are closely associated fields, and viruses have been proposed as a likely aetiological, contributory or triggering factors of systemic autoimmune diseases. Hepatitis C virus seems to be the virus usually associated with the appearance of autoimmune diseases, and the relationship between chronic hepatitis C virus infection and some autoimmune disease has been studied. For some of these disorders their association with hepatitis C virus infection is well recognized while for others it remains probable or weak. Examples of autoimmune phenomena observed in chronic hepatitis C virus infection include rheumatoid arthritis, thyroid disease, cryoglobulinaemia, immune thrombocytopenic purpura, systemic lupus erythematosus and sjogren syndrome. To date, the etiological role and the pathogenetic involvement of the hepatitis C infection remains unknown.The aim of this study is to assess the presence of different autoimmune manifestations of hepatitis C virus infection reported in literature.

  14. Induced immunity against hepatitis B virus

    Institute of Scientific and Technical Information of China (English)

    2015-01-01

    Prevention of hepatitis B virus (HBV) infection with itsconsequent development of HBV chronic liver diseaseand hepatocellular carcinoma is a global mandatorygoal. Fortunately, safe and effective HBV vaccines arecurrently available. Universal hepatitis B surface antigenHBV vaccination coverage is almost done. Growingknowledge based upon monitoring and surveillance of HBV vaccination programs has accumulated and thepolicy of booster vaccination has been evaluated. Thisreview article provides an overview of the natural historyof HBV infection, immune responses and the future ofHBV infection. It also summarizes the updated sources,types and uses of HBV vaccines, whether in the preclinicalphase or in the post-field vaccination.

  15. Hepatitis C virus:A global view

    Institute of Scientific and Technical Information of China (English)

    Amal; Ahmed; Mohamed; Tamer; A; Elbedewy; Magdy; El-Serafy; Naglaa; El-Toukhy; Wesam; Ahmed; Zaniab; Ali; El; Din

    2015-01-01

    Hepatitis C virus(HCV) is a global challenge; 130-175 million are chronically infected. Over 350000 die each year from HCV. Chronic HCV is the primary cause of cirrhosis, hepatocellular carcinoma(HCC), and end-stage liver disease. Management of chronic HCV is aimed at preventing cirrhosis, reducing the risk of HCC, and treating extra hepatic complications. New treatments for chronic HCV has been devoted based on direct-acting antivirals, as pegylated interferon(peginterferon) is responsible for many side effects and limits treatment access. Sofosbuvir is the first compound to enter the market with Peginterferon-free combination regimens.

  16. Hepatitis viruses and hepatocellular carcinoma

    African Journals Online (AJOL)

    proto-oncogene (or other gene concerned with cell growth, cycling or .... small proportion of the anti-HCV-positive patients with HCC have not had cirrhosis, ..... Abelson murine leukemia virus encoded protein present in transformed fibroblasts ...

  17. Food and environmental routes of Hepatitis E virus transmission

    NARCIS (Netherlands)

    Poel, van der W.H.M.

    2014-01-01

    Abstract Hepatitis E virus (HEV), genus Hepevirus, family hepeviridae is a main cause of epidemic hepatitis in developing countries and single cases of hepatitis in higher income countries. There are at least four HEV genotypes which have different epidemiologic and clinical features. Hepatitis E vi

  18. Food and environmental routes of Hepatitis E virus transmission

    NARCIS (Netherlands)

    Poel, van der W.H.M.

    2014-01-01

    Abstract Hepatitis E virus (HEV), genus Hepevirus, family hepeviridae is a main cause of epidemic hepatitis in developing countries and single cases of hepatitis in higher income countries. There are at least four HEV genotypes which have different epidemiologic and clinical features. Hepatitis E vi

  19. Antiviral therapy for hepatitis B virus associated hepatic failure

    Institute of Scientific and Technical Information of China (English)

    Yu-Ming Wang; Ying-Zi Tang

    2009-01-01

    BACKGROUND: Chronic hepatitis B virus (HBV) infection remains a major global health issue, and the prognosis of patients with HBV-associated fulminant hepatic failure is extremely poor. The application of antiviral therapies has led to signiifcant improvements in patient outcomes. This article aimed to review the current strategies in antiviral treatment of HBV-associated fulminant hepatic failure. DATA SOURCES: Literature search was conducted using PubMed on the related subjects. Part of the data was from the most recent work of the authors' laboratory. RESULTS: Hepatitis B immunoglobulin in prevention of recurrent HBV infection after orthotopic liver transplantation (OLT) has been proven effective. However, its cost is high, and signiifcant side effects have been found to induce viral mutations. Lamivudine has a potent suppression for HBV replication and an excellent safety proifle in decompensated cirrhotic patients, but its major drawback is the high rate of drug-resistance. Adefovir is effective for lamivudine-resistance strains in the post-OLT situation, and its drug-resistance rate is relatively low. Combination therapies such as hepatitis B immunoglobulin combined with lamivudine and lamivudine combined with adefovir have been widely adopted for prophylaxis against HBV recurrence of infection after OLT. Entecavir, telbivudine, tenofovir and other newer agents have been widely used in antiviral therapy. CONCLUSIONS: The prognosis of HBV-associated ful-minant hepatic failure is being transformed by developments in antiviral therapy. However, it should be noticed that HBV is controlled but never eliminated, and drug-resistance still remains a major issue. Hopefully, newer strategies may help to solve these problems.

  20. Occult hepatitis B virus and hepatitis C virus infections.

    Science.gov (United States)

    Carreño, Vicente; Bartolomé, Javier; Castillo, Inmaculada; Quiroga, Juan Antonio

    2008-01-01

    Occult HBV infection is a well-recognised clinical entity characterised by the detection of HBV-DNA in serum and/or in liver in the absence of detectable hepatitis B surface antigen (HBsAg). Occult HBV infection has been described not only in patients who have resolved an acute or chronic HBV infection but also in patients without any serological markers of a past HBV infection. Occult HBV infection in patients with chronic HCV infection may induce more severe liver disease and lower response rate to interferon treatment. The existence of occult HCV infections has been also reported more recently. Occult HCV infection is characterised by the presence of HCV-RNA in liver and peripheral blood mononuclear cells in the absence of detectable serum HCV-RNA. Occult HCV infection may occur under two different clinical situations: in hepatitis C antibody-(anti-HCV) negative and serum HCV-RNA-negative patients with abnormal liver function tests and in anti-HCV-positive patients who have no detectable serum HCV-RNA and who have normal liver enzymes. The clinical relevance of occult HCV infections is still under investigation.

  1. SEROPREVALENCE AND RISK FACTORS OF HEPATITIS C VIRUS ...

    African Journals Online (AJOL)

    Dr Oboro VO

    Key words: Hepatitis C virus, seroprevalence, patients, blood donors, risk factors. INTRODUCTION .... this regard that will aid HCV control measures and prevent associated .... Hepatitis Band C in doctors and dentists in. Nigeria Qt. J. Med.

  2. Immune-mediated Liver Injury in Hepatitis B Virus Infection

    National Research Council Canada - National Science Library

    In Soo Oh; Su-Hyung Park

    2015-01-01

    Hepatitis B virus (HBV) is responsible for approximately 350 million chronic infections worldwide and is a leading cause of broad-spectrum liver diseases such as hepatitis, cirrhosis and liver cancer...

  3. Molecular Virology of Hepatitis E Virus

    Science.gov (United States)

    Ahmad, Imran; Holla, R. Prasida; Jameel, Shahid

    2011-01-01

    This review details the molecular virology of the hepatitis E virus (HEV). While replicons and in vitro infection systems have recently become available, a lot of information on HEV has been generated through comparisons with better-studied positive-strand RNA viruses and through subgenomic expression of viral open reading frames. These models are now being verified with replicon and infection systems. We provide here the current knowledge on the HEV genome and its constituent proteins - ORF1, ORF2 and ORF3. Based on the available information, we also modify the existing model of the HEV life cycle. PMID:21345356

  4. Immunological alterations in hepatitis C virus infection.

    Science.gov (United States)

    Calvaruso, Vincenza; Craxì, Antonio

    2013-12-21

    A higher prevalence of immunological processes has recently been reported in patients with hepatitis C virus (HCV) infection, focusing the attention of physicians and researchers on the close association between HCV and immune disorders. HCV lymphotropism represents the most important step in the pathogenesis of virus-related immunological diseases and experimental, virologic, and clinical evidence has demonstrated a trigger role for HCV both in systemic autoimmune diseases, such as rheumatoid arthritis, Sjögren syndrome, hemolytic anemia and severe thrombocytopenia, and in organ-specific autoimmune diseases, such as autoimmune hepatitis, thyroid disorders and diabetes. This review will outline the principal aspects of such HCV-induced immunological alterations, focusing on the prevalence of these less characterized HCV extrahepatic manifestations.

  5. [Hepatitis C virus infection and alcohol].

    Science.gov (United States)

    Campollo, Octavio

    2002-10-01

    It was thought that HCV infection was very frequent among alcoholics; some even though that this disease affected nearly 35% of this group. Now there seems to be a consensus among the main investigator groups that the correlation of hepatitis C and alcohol increases the risk of complications, cirrhosis and liver cancer included. Moreover, it's now certain that among patients with HCV infection, alcohol consumption increases the risk of death from live diseases during the first 10 years of the disease. Alcoholism is also considered a predisposing factor for HCV infection, but not for hepatitis B virus infection. Prospective studies about post-transfusional hepatitis C showed the risk of cirrhosis increases from 7.8 to 31.1 times if the patient consumed significant amounts of alcohol (> 80 g a day). One of the recommendations for every patient with HCV infection is to abstain from drinking alcohol.

  6. Hepatitis B virus burden in developing countries.

    Science.gov (United States)

    Zampino, Rosa; Boemio, Adriana; Sagnelli, Caterina; Alessio, Loredana; Adinolfi, Luigi Elio; Sagnelli, Evangelista; Coppola, Nicola

    2015-11-14

    Hepatitis B virus (HBV) infection has shown an intermediate or high endemicity level in low-income countries over the last five decades. In recent years, however, the incidence of acute hepatitis B and the prevalence of hepatitis B surface antigen chronic carriers have decreased in several countries because of the HBV universal vaccination programs started in the nineties. Some countries, however, are still unable to implement these programs, particularly in their hyperendemic rural areas. The diffusion of HBV infection is still wide in several low-income countries where the prevention, management and treatment of HBV infection are a heavy burden for the governments and healthcare authorities. Of note, the information on the HBV epidemiology is scanty in numerous eastern European and Latin-American countries. The studies on molecular epidemiology performed in some countries provide an important contribution for a more comprehensive knowledge of HBV epidemiology, and phylogenetic studies provide information on the impact of recent and older migratory flows.

  7. Update on occult hepatitis B virus infection.

    Science.gov (United States)

    Makvandi, Manoochehr

    2016-10-21

    The event of mutations in the surface antigen gene of hepatitis B virus (HBV) results in undetectable hepatitis B surface antigen with positive/negative anti-hepatitis B core (anti-HBc) antibody status in serum and this phenomenon is named occult hepatitis B infection (OBI). The presence of anti-HBc antibody in serum is an important key for OBI tracking, although about 20% of OBI cases are negative for anti-HBc antibody. The diagnosis of OBI is mainly based on polymerase chain reaction (PCR) and real-time PCR assays. However, real-time PCR is a more reliable method than PCR. OBI is a great issue for the public health problem and a challenge for the clinical entity worldwide. The persistence of OBI may lead to the development of cirrhosis and hepatocellular carcinoma. With regard to OBI complications, the screening of HBV DNA by the highly sensitive molecular means should be implemented for: (1) patients with a previous history of chronic or acute HBV infection; (2) patients co-infected with hepatitis C virus/human immunodeficiency virus; (3) patients undergoing chemotherapy or anti-CD20 therapy; (4) recipients of organ transplant; (5) blood donors; (6) organ transplant donors; (7) thalassemia and hemophilia patients; (8) health care workers; (9) patients with liver related disease (cryptogenic); (10) hemodialysis patients; (11) patients undergoing lamivudine or interferon therapy; and (12) children in time of HBV vaccination especially in highly endemic areas of HBV. Active HBV vaccination should be implemented for the close relatives of patients who are negative for OBI markers. Thus, the goal of this review is to evaluate the rate of OBI with a focus on status of high risk groups in different regions of the world.

  8. Update on occult hepatitis B virus infection

    Science.gov (United States)

    Makvandi, Manoochehr

    2016-01-01

    The event of mutations in the surface antigen gene of hepatitis B virus (HBV) results in undetectable hepatitis B surface antigen with positive/negative anti-hepatitis B core (anti-HBc) antibody status in serum and this phenomenon is named occult hepatitis B infection (OBI). The presence of anti-HBc antibody in serum is an important key for OBI tracking, although about 20% of OBI cases are negative for anti-HBc antibody. The diagnosis of OBI is mainly based on polymerase chain reaction (PCR) and real-time PCR assays. However, real-time PCR is a more reliable method than PCR. OBI is a great issue for the public health problem and a challenge for the clinical entity worldwide. The persistence of OBI may lead to the development of cirrhosis and hepatocellular carcinoma. With regard to OBI complications, the screening of HBV DNA by the highly sensitive molecular means should be implemented for: (1) patients with a previous history of chronic or acute HBV infection; (2) patients co-infected with hepatitis C virus/human immunodeficiency virus; (3) patients undergoing chemotherapy or anti-CD20 therapy; (4) recipients of organ transplant; (5) blood donors; (6) organ transplant donors; (7) thalassemia and hemophilia patients; (8) health care workers; (9) patients with liver related disease (cryptogenic); (10) hemodialysis patients; (11) patients undergoing lamivudine or interferon therapy; and (12) children in time of HBV vaccination especially in highly endemic areas of HBV. Active HBV vaccination should be implemented for the close relatives of patients who are negative for OBI markers. Thus, the goal of this review is to evaluate the rate of OBI with a focus on status of high risk groups in different regions of the world. PMID:27818588

  9. Hepatitis E Virus and Related Viruses in Animals.

    Science.gov (United States)

    Thiry, D; Mauroy, A; Pavio, N; Purdy, M A; Rose, N; Thiry, E; de Oliveira-Filho, E F

    2017-02-01

    Hepatitis E is an acute human liver disease in healthy individuals which may eventually become chronic. It is caused by the hepatitis E virus (HEV) and can have a zoonotic origin. Nearly 57,000 people die yearly from hepatitis E-related conditions. The disease is endemic in both developing and developed countries with distinct epidemiologic profiles. In developing countries, the disease is associated with inadequate water treatment, while in developed countries, transmission is associated with animal contact and the ingestion of raw or uncooked meat, especially liver. All human HEV are grouped into at least four genotypes, while HEV or HEV-related viruses have been identified in an increasing number of domestic and wild animal species. Despite a high genetic diversity, only one single HEV serotype has been described to date for HEV genotypes 1-4. The discovery of new HEV or HEV-related viruses leads to a continuing increase in the number of genotypes. In addition, the genome organization of all these viruses is variable with overlapping open reading frames (ORF) and differences in the location of ORF3. In spite of the role of some domestic and wild animals as reservoir, the origin of HEV and HEV-related viruses in humans and animals is still unclear. This review discusses aspects of the detection, molecular virology, zoonotic transmission and origin of HEV and HEV-related viruses in the context of 'One Health' and establishes a link between the previous and the new taxonomy of this growing virus family. © 2015 Blackwell Verlag GmbH.

  10. Hepatitis B Virus e Antigen Variants

    Directory of Open Access Journals (Sweden)

    2005-01-01

    Full Text Available More than 300 million people worldwide are chronically infected with hepatitis B virus (HBV. Considering the very short generation time for a virus, and the high error rate associated with the reverse transcription step of HBV replication, decades of HBV infection are probably equivalent to million years of human evolution. The most important selective force during the natural course of HBV infection appears to be the immune response. The development of anti-HBe antibody in hepatitis B patients usually correlates with reduction of HBV viremia. As a consequence, escape mutants of anti-HBe are selected. The core promoter mutants express less HBe antigen (HBeAg through transcriptional down regulation, while precore mutants express truncated products. We recently identified additional mutations that modulate HBeAg translation initiation, proteolytic cleavage, and secondary structure maintenance through a disulfide bond. The core promoter mutants have been associated with the development of fulminant hepatitis during acute infection and liver cancer during chronic infection. Consistent with their enhanced pathogenicity, core promoter mutants were found to replicate at up to 10-fold higher levels in transfected human hepatoma cells than the wild-type virus. Moreover, some core promoter mutants are impaired in virion secretion due to missense mutations in the envelope gene. These virological properties may help explain enhanced pathogenicity of core promoter mutants in vivo.

  11. Hepatitis viruses exploitation of host DNA methyltransferases functions.

    Science.gov (United States)

    Pazienza, Valerio; Panebianco, Concetta; Andriulli, Angelo

    2016-08-01

    Hepatitis B virus (HBV), hepatitis C virus (HCV) and Delta (HDV) infections are a global health burden. With different routes of infection and biology, HBV, HCV and HDV are capable to induce liver cirrhosis and cancer by impinging on epigenetic mechanisms altering host cell's pathways. In the present manuscript, we reviewed the published studies taking into account the relationship between the hepatitis viruses and the DNA methyltransferases proteins.

  12. Acute hepatitis due to dengue virus in a chronic hepatitis patient

    OpenAIRE

    Souza, L J; Coelho, J.M.C. de O.; Silva,E. J.; Abukater,M.; Almeida,F.C.R.; A. S. Fonte; L.A Souza

    2008-01-01

    We present a case of acute hepatitis caused by dengue virus, with a significant increase in aspartate transferase and alanine transferase levels in a chronic hepatitis patient attended at the Cane Sugar Planters Hospital of Campos dos Goytacazes, RJ.

  13. Acute sporadic hepatitis E virus infection in southern China.

    Science.gov (United States)

    Tan, D; Im, S W; Yao, J L; Ng, M H

    1995-09-01

    The hepatitis E virus is responsible for epidemic and sporadic hepatitis in northwestern China, but its role as a cause of acute sporadic hepatitis in southern China has not been reported. We applied the most practical current methods for diagnosis of hepatitis E virus infection, IgM and IgG anti-HEV detection by enzyme linked immunosorbent assay, to investigate the prevalence of hepatitis E virus infection among acute sporadic hepatitis. Anti-HEV IgM was found in 1 of 26 (3.8%), 4 of 20 (20.0%), 4 of 19 (21.1%), and 51 of 142 (35.9%), with acute hepatitis A, B, C and non-ABC, respectively. Anti-HEV IgM was not detectable in healthy subjects, while IgG anti-HEV was found in 14 of 77 healthy subjects (18.2%) and was long-lasting. Ninety-one cases without any evidence of hepatitis A, B or C infections and anti-HEV IgM were tentatively classified as non-A, B, C, D, E (non-ABCDE) hepatitis. By comparison with non-ABCDE, cases with hepatitis E were more frequently icteric and exhibited higher alanine aminotransferase levels (92.2% vs. 45.1%, 770 iu/l vs 377 iu/l, respectively, p hepatitis E virus infections. However, 14 of 91 (15.4%) cases with non-ABCDE developed to chronicity (p Hepatitis E virus infection is sporadic as well as endemic in southern China. Only IgM anti-HEV but not IgG anti-HEV can be used as an appropriate marker of acute hepatitis E virus infection. Superinfection of hepatitis E virus with other types of hepatitis viruses is frequent in this area. While the disease was associated with more severe clinical manifestations, patients usually recovered completely.

  14. Seroprevalence of avian hepatitis E virus and avian leucosis virus subgroup J in chicken flocks with hepatitis syndrome, China

    OpenAIRE

    Sun, Yani; Du, Taofeng; Liu, Baoyuan; Syed, Shahid Faraz; Chen, Yiyang; Li, Huixia; Wang, Xinjie; Zhang, Gaiping; Zhou, En-Min; Zhao, Qin

    2016-01-01

    Background From 2014 to 2015 in China, many broiler breeder and layer hen flocks exhibited a decrease in egg production and some chickens developed hepatitis syndrome including hepatomegaly, hepatic necrosis and hemorrhage. Avian hepatitis E virus (HEV) and avian leucosis virus subgroup J (ALV-J) both cause decreasing in egg production, hepatomegaly and hepatic hemorrhage in broiler breeder and layer hens. In the study, the seroprevalence of avian HEV and ALV-J in these flocks emerging the di...

  15. High prevalence of occult hepatitis C virus infection in patients with chronic hepatitis B virus infection.

    Science.gov (United States)

    Castillo, Inmaculada; Bartolomé, Javier; Quiroga, Juan Antonio; Carreño, Vicente

    2013-08-01

    Hepatitis C virus (HCV) infection in the absence of detectable antibodies against HCV and of viral RNA in serum is called occult HCV infection. Its prevalence and clinical significance in chronic hepatitis B virus (HBV) infection is unknown. HCV RNA was tested for in the liver samples of 52 patients with chronic HBV infection and 21 (40 %) of them were positive for viral RNA (occult HCV infection). Liver fibrosis was found more frequently and the fibrosis score was significantly higher in patients with occult HCV than in negative ones, suggesting that occult HCV infection may have an impact on the clinical course of HBV infection.

  16. Avian hepatitis E virus, vaccines and methods of protecting against avian hepatitis-splenomegaly syndrome and mammalian hepatitis E

    OpenAIRE

    2009-01-01

    The present invention relates to a novel isolated avian hepatitis E virus having a nucleotide sequence set forth in SEQ ID NO:1 or its complementary strand. The invention further concerns immunogenic compositions comprising this new virus or recombinant products such as the nucleic acid and vaccines that protect an avian or mammalian species from viral infection or hepatitis-splenomegaly syndrome caused by the hepatitis E virus. Also included in the scope of the invention is a method for prop...

  17. Hepatitis C virus core protein induces hepatic steatosis via Sirt1-dependent pathway.

    Science.gov (United States)

    Zhang, Chuanhai; Wang, Jingjing; Zhang, Hanlin; Liu, Shunai; Lee, Hyuek Jong; Jin, Wanzhu; Cheng, Jun

    2017-09-12

    Hepatic steatosis is a common feature of patients with chronic hepatitis C. Previous reports have shown that the overexpression of hepatitis C virus core-encoding sequences (hepatitis C virus genotypes 3a and 1b) significantly induces intracellular triglyceride accumulation. However, the underlying mechanism has not yet been revealed. To investigate whether Sirt1 is involved in hepatitis C virus-mediated hepatic steatosis, the overexpression of hepatitis C virus core 1b protein and Sirt1 and the knockdown of Sirt1 in HepG2 cells were performed. To confirm the results of the cellular experiment liver-specific Sirt1 KO mice with lentivirus-mediated hepatitis C virus core 1b overexpression were studied. Our results show that hepatitis C virus core 1b protein overexpression led to the accumulation of triglycerides in HepG2 cells. Notably the expression of PPARγ2 was dramatically increased at both the mRNA and protein levels by hepatitis C virus core 1b overexpression. The protein expression of Sirt1 is an upstream regulator of PPARγ2 and was also significantly increased after core 1b overexpression. In addition, the overexpression or knockdown of Sirt1 expression alone was sufficient to modulate p300-mediated PPARγ2 deacetylation. In vivo studies showed that hepatitis C virus core protein 1b-induced hepatic steatosis was attenuated in liver-specific Sirt1 KO mice by downregulation of PPARγ2 expression. Sirt1 mediates hepatitis C virus core protein 1b-induced hepatic steatosis by regulation of PPARγ2 expression. © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

  18. [Hepatitis E virus: Blood transfusion implications].

    Science.gov (United States)

    Gallian, P; Piquet, Y; Assal, A; Djoudi, R; Chiaroni, J; Izopet, J; Tiberghien, P

    2014-11-01

    Hepatitis E virus (HEV) is a non-enveloped RNA virus transmitted by the fecal-oral route. Autochthonous hepatitis E occurring in developed countries is caused by genotypes 3 and 4 and is a zoonotic infection. Humans are infected mostly after ingestion of undercooked meat from infected animals. Most HEV 3 and 4 infections are clinically inapparent. However, genotype 3 (HEV 3) can lead to chronic hepatitis in immuno-compromised patients such as organ-transplant recipients and patients with haematological malignancies. In Europe, HEV 3 is implicated in transfusion-transmitted HEV infection. In France, as observed in several European countries, prevalence of HEV RNA and specific IgG antibodies are high indicating that viral circulation is important. The systematic HEV NAT screening of blood donations used for preparation of solvent detergent plasma indicate that 1 to 2218 donation is infected by HEV RNA. The need or implementation's impacts of safety measures to prevent HEV transmission by blood transfusion are under reflexion by French's health authorities. The HEV NAT screening is the only available tool of prevention. Alternative strategies are under investigation including individual or mini pool NAT testing all or part of blood donations. Copyright © 2014 Elsevier Masson SAS. All rights reserved.

  19. Hepatitis B virus and hepatitis C virus in pregnant Sudanese women

    Directory of Open Access Journals (Sweden)

    Karsany Mubarak S

    2007-10-01

    Full Text Available Abstract Background The epidemiology of viral hepatitis during pregnancy is essential for health planners and programme managers. While much data exist concerning viral hepatitis during pregnancy in many African countries, no proper published data are available in Sudan. Aim The study aimed to investigate the sero-prevalance and the possible risk factors for hepatitis B virus (HBV and hepatitis C virus (HCV among antenatal care attendants in central Sudan. Methods During 3 months from March–June 2006, sera were collected from pregnant women at Umdurman Maternity Hospital in Sudan, and they were tested for markers of hepatitis B virus (HBVsAg and HCV. Results HBVsAg was detected in 41 (5.6% out 728 women, Anti-HCV was detected in 3 (0.6% out of 423 women, all of them were not aware of their condition. Age, parity, gestational age, residence, history of blood transfusion, dental manipulations, tattooing and circumcision did not contribute significantly to increased HBVsAg sero-positivity. Conclusion Thus 5.6% of pregnant women were positive for HBVsAg irrespective of their age, parity and socio-demographic characteristics. There was low prevalence of Anti-HCV.

  20. Neutralizing antibodies in hepatitis C virus infection

    Institute of Scientific and Technical Information of China (English)

    Mirjam B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Fran(c)oise Stoll-Keller; Michel Doffo(e)l; Thomas F Baumert

    2007-01-01

    Hepatitis C virus (HCV) is a major cause of hepatitis world-wide. The majority of infected individuals develop chronic hepatitis which can then progress to liver cirrhosis and hepatocellular carcinoma. Spontaneous viral clearance occurs in about 20%-30% of acutely infected individuals and results in resolution of infection without sequaelae. Both viral and host factors appear to play an important role for resolution of acute infection. A large body of evidence suggests that a strong, multispecific and long-lasting cellular immune response appears to be important for control of viral infection in acute hepatitis C. Due too the lack of convenient neutralization assays,the impact of neutralizing responses for control of viral infection had been less defined. In recent years, the development of robust tissue culture model systems for HCV entry and infection has finally allowed study of antibody-mediated neutralization and to gain further insights into viral targets of host neutralizing responses.In addition, detailed analysis of antibody-mediated neutralization in individual patients as well as cohorts with well defined viral isolates has enabled the study of neutralizing responses in the course of HCV infection and characterization of the impact of neutralizing antibodies for control of viral infection. This review will summarize recent progress in the understanding of the molecular mechanisms of antibody-mediated neutralization and its impact for HCV pathogenesis.(C) 2007 The WJG Press. All rights reserved.

  1. Hepatitis B virus S gene escape mutants

    Directory of Open Access Journals (Sweden)

    Purdy Michael

    2007-01-01

    Full Text Available Hepatitis B virus (HBV can be classified into nine immunological subtypes or eight genotypes. The most prevalent genotypes in Asia are genotypes B and C. HBV is transmitted parenteraly and can produce either asymptomatic or symptomatic disease. Although the consequences of acute hepatitis B can be severe, serious sequelae are associated with chronic infections. HBV seroprevalence ranges from intermediate (2%-7% to high (≥8% levels in Asia. Several strategies for the control and prevention of HBV infection have been found to be efficacious. They include vaccination and the administration of HBIG, interferon-a and nucleoside/nucleotide analogues. However, these procedures also apply selective pressures on HBV in infected individuals leading to the generation and accumulation of mutations in the S gene. Most of these mutations occur in the major hydrophilic region (MHR of the S gene. These mutations create public health concerns as they can be responsible for reactivation of hepatitis B and occult hepatitis B infection. The inability to detect occult infections means that these individuals may become blood donors. This suggests that new strategies for donor evaluation and selection may need to be developed to protect the blood supply.

  2. Hepatitis C Virus-Induced Mitochondrial Dysfunctions

    Directory of Open Access Journals (Sweden)

    Birke Bartosch

    2013-03-01

    Full Text Available Chronic hepatitis C is characterized by metabolic disorders and a microenvironment in the liver dominated by oxidative stress, inflammation and regeneration processes that lead in the long term to hepatocellular carcinoma. Many lines of evidence suggest that mitochondrial dysfunctions, including modification of metabolic fluxes, generation and elimination of oxidative stress, Ca2+ signaling and apoptosis, play a central role in these processes. However, how these dysfunctions are induced by the virus and whether they play a role in disease progression and neoplastic transformation remains to be determined. Most in vitro studies performed so far have shown that several of the hepatitis C virus (HCV proteins localize to mitochondria, but the consequences of these interactions on mitochondrial functions remain contradictory, probably due to the use of artificial expression and replication systems. In vivo studies are hampered by the fact that innate and adaptive immune responses will overlay mitochondrial dysfunctions induced directly in the hepatocyte by HCV. Thus, the molecular aspects underlying HCV-induced mitochondrial dysfunctions and their roles in viral replication and the associated pathology need yet to be confirmed in the context of productively replicating virus and physiologically relevant in vitro and in vivo model systems.

  3. Occult hepatitis B virus infection in Egypt

    Institute of Scientific and Technical Information of China (English)

    2015-01-01

    The emerging evidence of the potentially clinicalimportance of occult hepatitis B virus (HBV) infection(OBI) increases the interest in this topic. OBI mayimpact in several clinical contexts, which include thepossible transmission of the infection, the contributionto liver disease progression, the development ofhepatocellular carcinoma, and the risk of reactivation.There are several articles that have published on OBI inEgyptian populations. A review of MEDLINE databasewas undertaken for relevant articles to clarify theepidemiology of OBI in Egypt. HBV genotype D is theonly detectable genotype among Egyptian OBI patients.Higher rates of OBI reported among Egyptian chronicHCV, hemodialysis, children with malignant disorders, andcryptogenic liver disease patients. There is an evidenceof OBI reactivation after treatment with chemotherapy.The available data suggested that screening for OBI mustbe a routine practice in these groups of patients. Furtherstudies needed for better understand of the epidemiologyof OBI among Egyptian young generations after the eraof hepatitis B vaccination.

  4. Putative Novel Genotype of Avian Hepatitis E Virus, Hungary, 2010

    OpenAIRE

    Bányai, Krisztián; Tóth, Ádám György; Ivanics, Éva; Glávits, Róbert; Szentpáli-Gavallér, Katalin; Dán, Ádám

    2012-01-01

    To explore the genetic diversity of avian hepatitis E virus strains, we characterized the near-complete genome of a strain detected in 2010 in Hungary, uncovering moderate genome sequence similarity with reference strains. Public health implications related to consumption of eggs or meat contaminated by avian hepatitis E virus, or to poultry handling, require thorough investigation.

  5. Putative novel genotype of avian hepatitis E virus, Hungary, 2010.

    Science.gov (United States)

    Bányai, Krisztián; Tóth, Ádám György; Ivanics, Éva; Glávits, Róbert; Szentpáli-Gavallér, Katalin; Dán, Ádám

    2012-08-01

    To explore the genetic diversity of avian hepatitis E virus strains, we characterized the near-complete genome of a strain detected in 2010 in Hungary, uncovering moderate genome sequence similarity with reference strains. Public health implications related to consumption of eggs or meat contaminated by avian hepatitis E virus, or to poultry handling, require thorough investigation.

  6. Hepatitis C virus: risk factors and disease progression

    NARCIS (Netherlands)

    Grady, B.P.X.

    2015-01-01

    Hepatitis C virus (HCV) is a single-stranded RNA virus and was first identified in 1989 as a cause for transfusion-associated non-A, non-B hepatitis. Transmission of HCV occurs predominantly via blood-to-blood contact. After acute infection about 75% of those infected progress to a persistent infect

  7. Attempts to transmit hepatitis B virus to chimpanzees by arthropods

    African Journals Online (AJOL)

    infective blood-virus mixture in experiment 1 was inoculated intravenously into .... pans of C. leetularius would not inactivate the virus present, whereas this would occur in ... blacks with viral hepatitis admined to Johannesburg hospitals,18 and among .... studies for a hepatitis B vaccine trial in Kaogwaoe. S Afr MedJ 1983; ...

  8. Phyllanthus species for chronic hepatitis B virus infection

    DEFF Research Database (Denmark)

    Yun, Xia; Luo, Hui; Liu, Jian Ping

    2011-01-01

    Phyllanthus species for patients with chronic hepatitis B virus (HBV) infection have been assessed in clinical trials, but no consensus regarding their usefulness exists.......Phyllanthus species for patients with chronic hepatitis B virus (HBV) infection have been assessed in clinical trials, but no consensus regarding their usefulness exists....

  9. Seroprevalence and Correlates of Hepatitis C Virus Infection in ...

    African Journals Online (AJOL)

    Seroprevalence and Correlates of Hepatitis C Virus Infection in Secondary ... PROMOTING ACCESS TO AFRICAN RESEARCH ... Background: Although children comprise a small fraction of the burden of hepatitis C virus (HCV) infections, which ... Senegal (6); Sierra Leone (1); South Africa (96); South Sudan (1); Sudan (3) ...

  10. Mathematical solutions for Hepatitis B virus infection in Nigeria ...

    African Journals Online (AJOL)

    Mathematical solutions for Hepatitis B virus infection in Nigeria. ... PROMOTING ACCESS TO AFRICAN RESEARCH ... transmission dynamics and control of hepatitis B virus (HBV) infection in Nigeria using mathematical ... Rwanda (3); Senegal (6); Sierra Leone (1); South Africa (96); South Sudan (1); Sudan (3); Swaziland ...

  11. Hepatitis B Virus Vaccination Status of Laboratory Workers in ...

    African Journals Online (AJOL)

    Hepatitis B Virus Vaccination Status of Laboratory Workers in Nigerian Hospitals. ... PROMOTING ACCESS TO AFRICAN RESEARCH ... This study aimed to evaluate the frequency of Hepatitis B virus vaccine uptake among ... Senegal (6); Sierra Leone (1); South Africa (96); South Sudan (1); Sudan (3); Swaziland (3) ...

  12. Chronic hepatitis E virus infection in liver transplant recipients

    NARCIS (Netherlands)

    Haagsma, Elizabeth B.; van den Berg, Arie P.; Porte, Robert J.; Benne, Cornelis A.; Vennema, Harry; Reimerink, Johan H. J.; Koopmans, Marion P. G.

    2008-01-01

    Hepatitis E virus (HEV) infection is known to run a self-limiting course. Sporadic cases of acute hepatitis due to infection with HEV genotype 3, present in pig populations, are increasingly recognized. Zoonotic transmission seems infrequent. The entity of unexplained chronic hepatitis after liver t

  13. Universal screening for chronic hepatitis C virus.

    Science.gov (United States)

    Shiffman, Mitchell L

    2016-01-01

    Chronic hepatitis C virus (HCV) infection affects an estimated 123 million persons worldwide and is the leading cause of cirrhosis and hepatocellular carcinoma in most countries. Approximately 75% of persons with chronic HCV were born between the years 1945-1965 and screening of patients in this birth cohort is now advocated. Unfortunately, these recommendations are not readily applied and a sizable population of infected persons who could benefit from treatment fall outside the birth cohort. Universal screening for HCV would be optimal. However, the primary limitation once patients are identified is accessing treatment which remains restricted in most countries.

  14. Seroepidemiology of hepatitis A virus in Kuwait

    Institute of Scientific and Technical Information of China (English)

    Jameela Alkhalidi; Bader Alenezi; Seham Al-mufti; Entisar Hussain; Haifa Askar; Nyingi Kemmer; Guy W Neff

    2009-01-01

    AIM: To find the current seroepidemiology of hepatitis A virus (HAV) in Kuwait. METHODS: A total of 2851 Kuwaitis applying for new jobs were screened. RESULTS: HAV-positive cases were 28.8%; 59% were males and 41% were females. The highest prevalence was in the Ahmadi area. High prevalence was among the group of non-educated rather than educated parents. This is the first study in Kuwait demonstrating the shifting epidemiology of HAV.CONCLUSION: This study reflects the need of the Kuwaiti population for an HAV vaccine.

  15. Prevalence of occult hepatitis B virus infection

    Institute of Scientific and Technical Information of China (English)

    Maria Luisa Gutiérrez-García; Conrado M Fernandez-Rodriguez; Jose Luis Lledo-Navarro; Ingrid Buhigas-Garcia

    2011-01-01

    Occult hepatitis B virus (HBV) infection (OBI) is characterized by the persistence of HBV DNA in the liver tissue in individuals negative for the HBV surface antigen. The prevalence of OBI is quite variable depending on the level of endemic disease in different parts of the world,the different assays utilized in the studies, and the different populations studied. Many studies have been carried out on OBI prevalence in different areas of the world and categories of individuals. The studies show that OBI prevalence seems to be higher among subjects at high risk for HBV infection and with liver disease than among individuals at low risk of infection and without liver disease.

  16. Sofosbuvir treatment and hepatitis C virus infection

    Institute of Scientific and Technical Information of China (English)

    2016-01-01

    Hepatitis C virus (HCV) infection is a serious problemworldwide. The use of interferon-based therapy hasmade HCV eradication challenging. The recent appearanceof direct-acting antiviral agents (DAAs) haschanged HCV therapy. Combining the use of DAAs withpeginterferon and ribavirin has improved treatmentefficacy. Furthermore, the combination of different orallyadministered DAAs has enabled interferon-free therapywith much higher efficacy and safety. In particular,sofosbuvir, a nucleotide-based NS5B inhibitor, preventsHCV RNA synthesis by acting as a "chain terminator".Treatment with sofosbuvir has attained an extremelyhigh rate of sustained virologic response. The currentreview summarizes the efficacy and safety of sofosbuvirtherapy.

  17. Extrahepatic Manifestations of Hepatitis C Virus.

    Science.gov (United States)

    Viganò, Mauro; Colombo, Massimo

    2015-12-01

    Chronic infection with the hepatitis C virus (HCV) is a major cause of liver disease worldwide and is also responsible for extrahepatic manifestations (EHMs) involving the skin, kidneys, salivary glands, eyes, thyroid, and immune system. Mixed cryoglobulinemia is the prototype EHM related to HCV infection. Although these HCV-related EHMs may contribute to significant rates of morbidity affecting patient's quality of life and survival, most of these complications can reverse after HCV eradication by interferon therapy. This notwithstanding, individual patients may have an irreversible injury in various organs that is not reversed by a cure of the HCV infection.

  18. Natural killer cells in hepatitis B virus infection.

    Science.gov (United States)

    Wu, Shao-fei; Wang, Wen-jing; Gao, Yue-qiu

    2015-01-01

    Natural killer cells are a unique type of lymphocytes with cytotoxic capacity, and play important roles against tumors and infections. Recently, natural killer cells have been increasingly valued in their effects in hepatitis B virus infection. Since hepatitis B virus is not cytopathic, the subsequent antiviral immune responses of the host are responsible for sustaining the liver injury, which may result in cirrhosis and even hepatocellular carcinoma. Many studies have confirmed that natural killer cells participate in anti-hepatitis B virus responses both in the early phase after infection and in the chronic phase via cytolysis, degranulation, and cytokine secretion. However, natural killer cells play dichotomic roles: they exert antiviral and immunoregulatory functions whilst contribute to the pathogenesis of liver injury. Here, we review the roles of natural killer cells in hepatitis B virus infection, introducing novel therapeutic strategies for controlling hepatitis B virus infection via the modulation of natural killer cells. Copyright © 2015 Elsevier Editora Ltda. All rights reserved.

  19. Mutaciones asociadas a la resistencia del virus de la hepatitis C frente a los nuevos tratamientos

    OpenAIRE

    Orviz García, Eva

    2015-01-01

    En los últimos años, el tratamiento de la hepatitis C ha experimentado un cambio histórico que se traduce en una modificación del abordaje terapéutico de los pacientes infectados por este virus. Sin embargo, la aparición de nuevos fármacos de acción directa contra el virus de la hepatitis C puede generar nuevas mutaciones de resistencia no conocidas hasta ahora, haciendo que su eficacia se reduzca y aumente el fracaso terapéutico. El objetivo de este trabajo ha sido profundizar en aquellos es...

  20. Recent advances in Hepatitis E virus.

    Science.gov (United States)

    Meng, X J

    2010-03-01

    Hepatitis E virus (HEV), the causative agent of hepatitis E, belongs to the family Hepeviridae. At least four major genotypes of HEV have been recognized: genotypes 1 and 2 are restricted to humans and associated with epidemics in developing countries, whereas genotypes 3 and 4 are zoonotic and infect humans and several other animals in both developing and industrialized countries. Besides humans, strains of HEV have been genetically identified from swine, chickens, sika deer, mongeese, and rabbits. The genome of HEV consists of three open reading frames (ORFs): ORF1 codes for nonstructural proteins, ORF2 codes for capsid protein, and ORF3 codes for a small multifunctional protein. The ORF2 and ORF3 proteins are translated from a single bicistronic mRNA and overlap each other but neither overlaps ORF1. The recent determination of the 3D crystal structure of the HEV capsid protein should facilitate the development of vaccines and antivirals. The identification and characterization of animal strains of HEV from pigs and chickens and the demonstrated ability of cross-species infection by swine HEV raise public health concerns for zoonosis. Accumulating evidence indicated that hepatitis E is a zoonotic disease and pigs and more likely other animal species are reservoirs for HEV. This article provides an overview of the recent advances in hepatitis E and its causative agent, including nomenclature and genomic organization, gene expression and functions, 3D structure of the virions, changing perspectives on higher mortality during pregnancy and chronic hepatitis E, animal reservoirs, zoonotic risk, food safety, and novel animal models.

  1. Genotyping of occult hepatitis B virus infection in Egyptian hemodialysis patients without hepatitis C virus infection.

    Science.gov (United States)

    Esmail, Mona A; Mahdi, Wafaa K M; Khairy, Rasha M; Abdalla, Nilly H

    2016-01-01

    Occult hepatitis B viral infection is the presence of hepatitis B viral nucleic acids in the serum and/or liver in the absence of hepatitis B surface antigen. The study aimed to determine the prevalence of occult hepatitis B virus infection among hepatitis C virus-negative hemodialysis patients and to identify their genotypes. of 144 patients on maintenance hemodialysis, 50 hepatitis B surface antigen and hepatitis C virus nucleic acid-negative patients were selected according to strict inclusion criteria to avoid the effect of confounding variables. The following investigations were done: serum AST and ALT; HBsAg; HBcAb; HCV-Ab; HCV-RNA; and HBV-DNA. Positive hepatitis B viral nucleic acid was confirmed in 12/144 (8.3%) hemodialysis patients and 12/50 (24%) in our study group (occult infection). Mean hemodialysis periods for negative patients and occult hepatitis B virus patients were 27.3±18.8 and 38.4±8.14 months, respectively, and this difference was significant (p-value=0.02). Mean alanine transaminase levels were 20.27±5.5IU/L and 25.3±9.6 in negative patients and occult infection patients, respectively. This difference was non-significant. Aspartate transaminase levels were 21.4±10.2IU/L and 27.3±4.6IU/L, respectively, in negative patients and infected patients; this difference was significant (p-value=0.03). Half (6/12) of the positive samples belonged to genotype 'B', 33.3% (4/12) to 'C', and 16.6% (2/12) to genotype 'D'. OBI is likely among hemodialysis patients even without HCV coinfection (24%). Genotype D cannot be the only genotype distributed in Upper Egypt, as the current study reported relatively new results that 50% of the patients with occult B carry genotype B, 33.3% carry genotype C and only 16.6% carry genotype D. Copyright © 2015 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.

  2. Fulminant hepatitis B virus : recurrence after liver transplantation in two patients also infected with hepatitis delta virus

    NARCIS (Netherlands)

    Marsman, W A; Wiesner, R H; Batts, K P; Poterucha, J J; Porayko, M K; Niesters, H G; Zondervan, P E; Krom, R A

    Liver transplantation for hepatitis B virus (HBV)-related liver disease is complicated by HBV recurrence and, consequently, poor patient and graft survival. Patients transplanted for hepatitis delta virus (HDV)-related cirrhosis are reported to have a diminished incidence of HBV recurrence and

  3. Fulminant hepatitis B virus : recurrence after liver transplantation in two patients also infected with hepatitis delta virus

    NARCIS (Netherlands)

    Marsman, W A; Wiesner, R H; Batts, K P; Poterucha, J J; Porayko, M K; Niesters, H G; Zondervan, P E; Krom, R A

    1997-01-01

    Liver transplantation for hepatitis B virus (HBV)-related liver disease is complicated by HBV recurrence and, consequently, poor patient and graft survival. Patients transplanted for hepatitis delta virus (HDV)-related cirrhosis are reported to have a diminished incidence of HBV recurrence and impro

  4. Fulminant hepatitis B virus : recurrence after liver transplantation in two patients also infected with hepatitis delta virus

    NARCIS (Netherlands)

    Marsman, W A; Wiesner, R H; Batts, K P; Poterucha, J J; Porayko, M K; Niesters, H G; Zondervan, P E; Krom, R A

    1997-01-01

    Liver transplantation for hepatitis B virus (HBV)-related liver disease is complicated by HBV recurrence and, consequently, poor patient and graft survival. Patients transplanted for hepatitis delta virus (HDV)-related cirrhosis are reported to have a diminished incidence of HBV recurrence and impro

  5. Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients

    Directory of Open Access Journals (Sweden)

    Caterina Sagnelli

    2014-04-01

    Full Text Available AIM: To evaluate changes in liver histology in patients with human immunodeficiency virus/hepatitis C virus coinfection non-responders to a suboptimal Interferon+Ribavirine regimen. MATERIALS AND METHODS: We investigated 49 patients with two sequential liver biopsies: 18 were non-responders to Interferon+Ribavirine treatment (Group hepatitis C virus Rx administered after the 1st liver biopsy who underwent a 2nd liver biopsy after a median period of 3.92 year and 31 were patients who remained untreated for hepatitis C virus disease (Group hepatitis C virus untreated after the 1st liver biopsy because of refusal and underwent a 2nd liver biopsy after a median period of 5.05-years. Most patients in both groups were under highly active antiretroviral therapy. At the time of 1st liver biopsy similar degrees of necro-inflammation, fibrosis and steatosis were observed in both groups. Changes in liver lesions between 1st and 2nd liver biopsys were adjusted for different intervals between liver biopsys by a mathematic formula. RESULTS: Liver fibrosis did not change in 88.9% of patients in Group hepatitis C virus Rx and in 77.4% in Group hepatitis C virus untreated. A marked deterioration in liver fibrosis was observed in 5 (16% patients in Group hepatitis C virus untreated and in none in Group hepatitis C virus treated. Necro-inflammation and steatosis remained substantially unchanged in both groups. CONCLUSION: Liver histology remained substantially unchanged in human immunodeficiency virus/hepatitis C virus patients non-responder to anti-hepatitis C virus therapy over 4 years observation, suggesting an effective anti-hepatitis C virus early treatment for all hepatitis C virus/human immunodeficiency virus coinfected patients who can reasonably tolerate therapy.

  6. Chaperones in hepatitis C virus infection

    Institute of Scientific and Technical Information of China (English)

    2016-01-01

    The hepatitis C virus (HCV) infects approximately 3% ofthe world population or more than 185 million peopleworldwide. Each year, an estimated 350000-500000deaths occur worldwide due to HCV-associated diseasesincluding cirrhosis and hepatocellular carcinoma. HCV isthe most common indication for liver transplantation inpatients with cirrhosis worldwide. HCV is an envelopedRNA virus classified in the genus Hepacivirus in theFlaviviridae family. The HCV viral life cycle in a cellcan be divided into six phases (1) binding and internalization;(2) cytoplasmic release and uncoating; (3)viral polyprotein translation and processing; (4) RNAgenome replication; (5) encapsidation (packaging) andassembly; and (6) virus morphogenesis (maturation)and secretion. Many host factors are involved in theHCV life cycle. Chaperones are an important group ofhost cytoprotective molecules that coordinate numerouscellular processes including protein folding, multimericprotein assembly, protein trafficking, and proteindegradation. All phases of the viral life cycle requirechaperone activity and the interaction of viral proteinswith chaperones. This review will present our currentknowledge and understanding of the role of chaperonesin the HCV life cycle. Analysis of chaperones in HCVinfection will provide further insights into viral/hostinteractions and potential therapeutic targets for bothHCV and other viruses.

  7. INFEKSI VIRUS HEPATITIS B DAN HEPATITIS C PADA PENDERITA HEPATITIS KRONIS DAN HEMODIALISIS DI JAKARTA

    Directory of Open Access Journals (Sweden)

    Djoko Yuwono

    2012-10-01

    Full Text Available Virus Hepatitis C dan Hepatitis B merupakan penyebab hepatitis kronik aktif yang dapat berkembang menjadi hepatoselular karsinoma. Untuk mengetahui peranan kedua jenis virus tersebut sebagai penyebab hepatoselular karsinoma, telah dilakukan pemeriksaan HbsAg, anti-VHC dan RNA-VHC pada 17 penderita hepatitis kronis. 19 Pasien hemodialisis dan 198 donor darah PMI. Pemeriksaan HbsAg dilakukan dengan RPHA Cell: pemeriksaan anti-VHC dengan dipstik anti-VHC kit diagnotik produksi NTB Mataram, Lombok. Deteksi RNA-VHC dilakukan dengan teknik RT-PCR, menggunakan primer spesifik untuk daerah 5'NCR. Hasil pemeriksaan menunjukkan bahwa pada penderita hepatitis kronis ditemukan 5 orang (23,5% positif HbsAg dan 1 orang (5,8% anti-VHC. Pada penderita hemodialisis ditemukan 14 orang (73,6% positif anti-VHC, persentase anti-VHC meningkat sesuai dengan meningkatnya frekuensi hemodialisis. Pada donor darah PMI ditemukan 5 orang (2,2% positif HbsAg dan tidak satupun ditemukan anti-VHC positif.

  8. Hepatitis C virus and neurological damage

    Institute of Scientific and Technical Information of China (English)

    Shilu; Mathew; Muhammed; Faheem; Sara; M; Ibrahim; Waqas; Iqbal; Bisma; Rauff; Kaneez; Fatima; Ishtiaq; Qadri

    2016-01-01

    Chronic hepatitis C virus(HCV) infection exhibits a wide range of extrahepatic complications, affecting various organs in the human body. Numerous HCV patients suffer neurological manifestations, ranging from cognitive impairment to peripheral neuropathy. Overexpression of the host immune response leads to the production of immune complexes, cryoglobulins, as well as autoantibodies, which is a major pathogenic mechanism responsible for nervous system dysfunction. Alternatively circulating inflammatory cytokines and chemokines and HCV replication in neurons is another factor that severely affects the nervous system. Furthermore, HCV infection causes both sensory and motor peripheral neuropathy in the mixed cryoglobulinemia as well as known as an important risk aspect for stroke. These extrahepatic manifestations are the reason behind underlying hepatic encephalopathy and chronic liver disease. The brain is an apt location for HCV replication, where the HCV virus may directly wield neurotoxicity. Other mechanisms that takes place by chronic HCV infection due the pathogenesis of neuropsychiatric disorders includes derangement of metabolic pathways of infected cells, autoimmune disorders, systemic or cerebral inflammation and alterations in neurotransmitter circuits. HCV and its pathogenic role is suggested by enhancement of psychiatric and neurological symptoms in patients attaining a sustained virologic response followed by treatment with interferon; however, further studies are required to fully assess the impact of HCV infection and its specific antiviral targets associated with neuropsychiatric disorders.

  9. The Laboratory Diagnosis of Hepatitis B Virus

    Directory of Open Access Journals (Sweden)

    Mel Krajden

    2005-01-01

    Full Text Available Hepatitis B virus (HBV chronically infects approximately 250,000 Canadians and 350 million people worldwide. Without intervention, approximately 15% to 40% of chronically infected individuals will eventually develop cirrhosis, end-stage liver disease or hepatocellular carcinoma, or require liver transplantation. The availability and extensive use of the HBV vaccine has dramatically reduced the number of incident infections in Canada and worldwide. Effective therapeutic agents have been and continue to be developed to treat chronic infection. The present review provides a comprehensive overview of diagnostic tests for HBV infection and immunity, and elaborates on HBV risk factors, vaccine prevention and therapeutic monitoring. HBV diagnosis is accomplished by testing for a series of serological markers of HBV and by additional testing to exclude alternative etiological agents such as hepatitis A and C viruses. Serological tests are used to distinguish acute, self-limited infections from chronic HBV infections and to monitor vaccine-induced immunity. Nucleic acid testing for HBV-DNA is increasingly being used to quantify HBV viral load and measure the effectiveness of therapeutic agents. Given the multitude of available tests and the complexity of clinical management, there is a critical need for greater coordination among clinicians, diagnostic laboratory personnel and researchers to define optimal laboratory diagnostic and monitoring assays so that the appropriate tests are used to maximize prevention and optimize treatment outcomes.

  10. Oral manifestations of hepatitis C virus infection.

    Science.gov (United States)

    Carrozzo, Marco; Scally, Kara

    2014-06-28

    Extrahepatic manifestations (EHMs) of hepatitis C virus (HCV) infection can affect a variety of organ systems with significant morbidity and mortality. Some of the most frequently reported EHM of HCV infection, involve the oral region predominantly or exclusively. Oral lichen planus (OLP) is a chronic inflammatory condition that is potentially malignant and represents cell-mediated reaction to a variety of extrinsic antigens, altered self-antigens, or super antigens. Robust epidemiological evidence support the link between OLP and HCV. As the virus may replicate in the oral mucosa and attract HCV-specific T lymphocytes, HCV may be implicated in OLP pathogenesis. Sjögren syndrome (SjS) is an autoimmune exocrinopathy, characterized by dryness of the mouth and eyes and a multitude of other systemic signs and symptoms. SjS patients have also an increased risk of non-Hodgkin lymphoma. Patients with chronic hepatitis C do frequently have histological signs of Sjögren-like sialadenitis with mild or even absent clinical symptoms. However, it is still unclear if HCV may cause a disease mimicking SjS or it is directly responsible for the development of SjS in a specific subset of patients. Oral squamous cell carcinoma is the most common oral malignant tumour and at least in some part of the world could be linked to HCV.

  11. A rat model for hepatitis E virus

    Science.gov (United States)

    Mishra, Niraj; Verbeken, Erik; Ramaekers, Kaat; Dallmeier, Kai

    2016-01-01

    ABSTRACT Hepatitis E virus (HEV) is one of the prime causes of acute viral hepatitis, and chronic hepatitis E is increasingly recognized as an important problem in the transplant setting. Nevertheless, the fundamental understanding of the biology of HEV replication is limited and there are few therapeutic options. The development of such therapies is partially hindered by the lack of a robust and convenient animal model. We propose the infection of athymic nude rats with the rat HEV strain LA-B350 as such a model. A cDNA clone, pLA-B350, was constructed and the infectivity of its capped RNA transcripts was confirmed in vitro and in vivo. Furthermore, a subgenomic replicon, pLA-B350/luc, was constructed and validated for in vitro antiviral studies. Interestingly, rat HEV proved to be less sensitive to the antiviral activity of α-interferon, ribavirin and mycophenolic acid than genotype 3 HEV (a strain that infects humans). As a proof-of-concept, part of the C-terminal polymerase sequence of pLA-B350/luc was swapped with its genotype 3 HEV counterpart: the resulting chimeric replicon replicated with comparable efficiency as the wild-type construct, confirming that LA-B350 strain is amenable to humanization (replacement of certain sequences or motifs by their counterparts from human HEV strains). Finally, ribavirin effectively inhibited LA-B350 replication in athymic nude rats, confirming the suitability of the rat model for antiviral studies. PMID:27483350

  12. A rat model for hepatitis E virus

    Directory of Open Access Journals (Sweden)

    Yannick Debing

    2016-10-01

    Full Text Available Hepatitis E virus (HEV is one of the prime causes of acute viral hepatitis, and chronic hepatitis E is increasingly recognized as an important problem in the transplant setting. Nevertheless, the fundamental understanding of the biology of HEV replication is limited and there are few therapeutic options. The development of such therapies is partially hindered by the lack of a robust and convenient animal model. We propose the infection of athymic nude rats with the rat HEV strain LA-B350 as such a model. A cDNA clone, pLA-B350, was constructed and the infectivity of its capped RNA transcripts was confirmed in vitro and in vivo. Furthermore, a subgenomic replicon, pLA-B350/luc, was constructed and validated for in vitro antiviral studies. Interestingly, rat HEV proved to be less sensitive to the antiviral activity of α-interferon, ribavirin and mycophenolic acid than genotype 3 HEV (a strain that infects humans. As a proof-of-concept, part of the C-terminal polymerase sequence of pLA-B350/luc was swapped with its genotype 3 HEV counterpart: the resulting chimeric replicon replicated with comparable efficiency as the wild-type construct, confirming that LA-B350 strain is amenable to humanization (replacement of certain sequences or motifs by their counterparts from human HEV strains. Finally, ribavirin effectively inhibited LA-B350 replication in athymic nude rats, confirming the suitability of the rat model for antiviral studies.

  13. Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection

    Institute of Scientific and Technical Information of China (English)

    Farah; Bokharaei; Salim; Hossein; Keyvani; Afsaneh; Amiri; Fatemeh; Jahanbakhsh; Sef; idi; Ramin; Shakeri; Farhad; Zamani

    2010-01-01

    AIM:To investigate the presence of mixed infection and discrepancy between hepatitis C virus(HCV) genotypes in plasma,peripheral blood mononuclear cells(PBMCs),and liver biopsy specimens.METHODS:From September 2008 up to April 2009,133 patients with chronic hepatitis C referred to Firouzgar Hospital for initiation of an antiviral therapy were recruited in the study.Five milliliters of peripheral blood was collected from each patient and liver biopsy was performed in those who gave consent or had indications...

  14. Prevalence of Hepatitis Virus Infections in an Institution for Persons with Developmental Disabilities.

    Science.gov (United States)

    Woodruff, Bradley A.; Vazquez, Elizabeth

    2002-01-01

    A study involving 1,235 residents of Sonoma Developmental Center found 3 residents had hepatitis C virus infections, and 633 had past or current hepatitis B virus infections. The prevalence of hepatitis B virus infection rose rapidly with longer residence in institutions. Hepatitis A virus infection had occurred in 494 residents. (Contains…

  15. Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection.

    Science.gov (United States)

    Khattab, Mahmoud Aboelneen; Eslam, Mohammed; Alavian, Seyed Moayed

    2010-01-01

    Hepatitis C virus infection is an emerging disease and a public health problem in the world. There are accumulating data regarding extra hepatic manifestation of HCV, such as rheumatologic manifestations, endocrine, hematologic, dermatologic, renal, neurologic, and systemic manifestations. The therapy of them needs more attention to some exacerbations of extra hepatic manifestation and in some situation it needs different approaches. In this review we tried to provide latest evidence for extra hepatic manifestation and management of them.

  16. Review: Occult hepatitis C virus infection: still remains a controversy.

    Science.gov (United States)

    Vidimliski, Pavlina Dzekova; Nikolov, Igor; Geshkovska, Nadica Matevska; Dimovski, Aleksandar; Rostaing, Lionel; Sikole, Aleksandar

    2014-09-01

    Occult hepatitis C virus (HCV) infection is characterized by the presence of HCV RNA in the liver cells or peripheral blood mononuclear cells of the patients whose serum samples test negative for HCV RNA, with or without presence of HCV antibodies. The present study reviews the existing literature on the persistence of occult hepatitis C virus infection, with description of the clinical characteristics and methods for identification of occult hepatitis C. Occult hepatitis C virus infection was detected in patients with abnormal results of liver function tests of unknown origin, with HCV antibodies and HCV RNA negativity in serum, and also in patients with spontaneous or treatment-induced recovery from hepatitis C. The viral replication in the liver cells and/or peripheral blood mononuclear cells was present in all clinical presentations of occult hepatitis C. The peripheral blood mononuclear cells represent an extra-hepatic site of HCV replication. The reason why HCV RNA was not detectable in the serum of patients with occult hepatitis C, could be the low number of circulating viral particles not detectable by the diagnostic tests with low sensitivity. It is uncertain whether occult hepatitis C is a different clinical entity or just a form of chronic hepatitis C virus infection. Data accumulated over the last decade demonstrated that an effective approach to the diagnosis of HCV infection would be the implementation of more sensitive HCV RNA diagnostic assays, and also, examination of the presence of viral particles in the cells of the immune system.

  17. Cardiac Disorder in an Iranian Child With Hepatitis A Virus

    Directory of Open Access Journals (Sweden)

    Soleimani

    2015-10-01

    Full Text Available Introduction Hepatitis A is one of the most common types of viral hepatitis among children worldwide. Many infected individuals, especially younger children, are asymptomatic. It is usually transmitted by food or water contaminated with infected feces. Extra-hepatic manifestations of acute hepatitis A virus (HAV are very rare. Case Presentation We present a 14-year-old girl who was referred to our hospital due to jaundice, abdominal pain, weakness, and lethargy. After laboratory testing, HAV was confirmed in the patient. However, she had significant bradycardia with hypotension, which is very rare in HAV infection. Conclusions Hepatitis A causes an acute infection. The patients usually recover after a few weeks or months. Fulminant hepatitis can be observed in HAV infection but chronic infection does not exist. Extrahepatic complications and cardiac disorders are often reported in association with hepatitis C and B viruses, but they are very rare in HAV infections.

  18. Expresión y purificación del antígeno preS1/2 y su utilidad en el estudio de la patogenia de la infección por el virus de la hepatitis B

    Directory of Open Access Journals (Sweden)

    Masyelly D. Rojas P

    2013-05-01

    Full Text Available El preS1/2 es parte de las proteínas de envoltura del virus de la hepatitis B (VHB, con funciones importantes en la inmunopatogenia de la enfermedad. Para su estudio es necesario contar con la proteína pura y así dilucidar su participación en el daño generado en el tejido hepático. Para ello se procedió a la expresión del preS1/2 previamente clonado en el vector peT3d, en la cepa de E coli HMS174 (DE3, seguido por su purificación mediante columnas de afinidad hacia residuos de histidina (6xhistidina y finalmente sometidas a liberación de contaminantes mediante el uso de columnas de afinidad hacia endotoxina y filtración por centrifugación, de esta manera utilizarla para evaluar su efecto sobre hepatocitos humanos. El procedimiento utilizado permitió obtener 1,5 mg de proteína pura funcionalmente estable por cada litro de medio de cultivo. En este trabajo se describe un método sencillo de expresión y purificación del preS1/2 recombinante y se evidencia la obtención de un producto intacto, con potencial uso en estudios funcionales y futuros ensayos terapéuticos Expression and purification of preS1/2 antigen and its usefulness in the hepatitis B virus pathogenesis study Abstract The preS1/2 belongs to the envelope proteins of the hepatitis B virus (HBV, and has an important role in the pathogenesis of the disease. A pure protein is important for their study, and thus elucidates their involvement in the liver tissue damage observed during the diseases. For this purpose preS1/2 previously cloned into the pET3d was expressed in E. coli strain HMS174 (DE3, subsequent was purified by affinity columns histidine residues (6xhistidine and finally treated to release contaminants by using affinity columns endotoxin and filtration by centrifugation, thereby used it to assess their effect on human hepatocytes. The procedure yielded 1,5 mg pure protein per liter of culture medium, functionally stable. In this paper we describe a simple method

  19. DEVELOPMENT OF A MOLECULAR METHOD TO IDENTIFY HEPATITIS E VIRUS

    Science.gov (United States)

    Hepatitis E virus (HEV) is a waterborne emerging pathogen that causes significant illness in the developing world. Thus far, an HEV outbreak has not been reported in the U.S., although a swine variant of the virus is common in Midwestern hogs. Because viruses isolated from two ...

  20. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope.

    Science.gov (United States)

    Bonino, F; Heermann, K H; Rizzetto, M; Gerlich, W H

    1986-01-01

    Hepatitis delta virus (HDV)-associated particles were purified from the serum of an experimentally infected chimpanzee by size chromatography and by density centrifugation. Hepatitis delta antigen (HDAg) was detected after mild detergent treatment at a column elution volume corresponding to 36-nm particles and banded at a density of 1.25 g/ml. The serum had an estimated titer of 10(9) to 10(10) HDV-associated particles and had only a 10-fold excess of hepatitis B surface antigen (HBsAg) not associated with HDAg. Therefore, HDV appears to be much more efficiently packed and secreted than is its helper virus, hepatitis B virus (HBV), which is usually accompanied by a 1,000-fold excess of HBsAg. The protein compositions of the HDAg-containing particles were analyzed by immunoblotting with HDAg-, HBsAg-, and hepatitis B core antigen-specific antisera and monoclonal antibodies to HBV surface gene products. The HBsAg envelope of HDAg contained approximately 95% P24/GP27s, 5% GP33/36s, and 1% P39/GP42s proteins. This protein composition was more similar to that of the 22-nm particles of HBsAg than to that of complete HBV. The significant amount of GP33/36s suggests that the HBsAg component of the HDV-associated particle carries the albumin receptor. Two proteins of 27 and 29 kilodaltons which specifically bound antibody to HDAg but not HBV-specific antibodies were detected in the interior of the 36-nm particle. Since these proteins were structural components of HDAg and were most likely coded for by HDV, they were designated P27d and P29d. Images PMID:3701932

  1. [Protein subunit vaccines: example of vaccination against hepatitis B virus].

    Science.gov (United States)

    Degos, F

    1995-06-15

    Hepatitis B vaccine has been used for over 10 years. It is efficient and safe. Protection of risk groups against hepatitis B virus infection is now achieved and vaccination of newborns and adolescents is a main public health problem. Bad responders are well characterized and immunomodulatory interventions (cytokines) must be tested in these patients. Response to hepatitis B vaccine is genetically determined and the possibility of vaccine induced escape mutants should lead to careful epidemiological studies of the spread of hepatitis B virus infection.

  2. Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes

    Institute of Scientific and Technical Information of China (English)

    Conrado M Fernandez-Rodriguez; Maria Luisa Gutierrez; José Luis Lledó; Maria Luisa Casas

    2011-01-01

    Persistence of hepatitis B virus-DNA in the sera, peripheral blood mononuclear cells or in the liver of hepatitis B surface antigen (HBsAg)-negative patients with or without serological markers of previous exposure (antibodies to HBsAg and/or to HB-core antigen) defines the entity called occult hepatitis B infection (OBI). Co-infection with hepatitis B and hepatitis C viruses is frequent in highly endemic areas. While this co-infection increases the risk of liver disease progression, development of cirrhosis and hepatocellular carcinoma and also increases the rate of therapeutic failure to interferon-based treatments than either virus alone, a potentially negative effect of OBI on clinical outcomes and of therapeutic response to current antiviral regimes of patients with chronic hepatitis C remains inconclusive.

  3. [Porphyrin excretion in patients with chronic hepatitis C virus infection].

    Science.gov (United States)

    Armas-Merino, R; Wolff, C; Parraguez, A; Soto, J R

    1997-03-01

    The high prevalence of chronic hepatitis C virus infection in patients with porphyria cutanea tarda, specially in those without family history of the disease, suggests that this could be an acquired disease and one of the most frequent extra hepatic manifestations of hepatitis C virus infection. To study the excretion of porphyrins and its precursors in cirrhotic patients with and without hepatitis C virus infection. Eighteen patients with cirrhosis Child-Pough A, eight infected with hepatitis C virus, were studied. Urinary excretion of [symbol see text] aminolevulinic acid, porphobilinogen, coproporphyrins, uroporphyrins and fecal excretion of coproporphyrins and protoporphyrins were measured. Red blood cell protoporphyrin was also measured. There were no differences in the measured parameters between patients with or without hepatitis C virus infection. No patient had uroporphyrin excretion values over the normal range. Some patients had slight elevations in some parameters, but always below the values observed in porphyrias. In these group of patients, hepatitis C virus infection of its associated liver disease, do not cause detectable alterations in porphyrin metabolism.

  4. Significance of blood analysis in hemophiliacs co-infected with human immunodeficiency virus and hepatitis viruses

    Institute of Scientific and Technical Information of China (English)

    Fang Shen; Qin Huang; Hong-Qing Sun; Reena Ghildyal

    2007-01-01

    AIM:To study the effect of hepatitis virus infection on cirrhosis and liver function markers in HIV-infected hemophiliacs.METHODS:We have analyzed the immunological,liver function and cirrhosis markers in a cohort of hemophiliacs co-infected with human immunodeficiency virus (HIV) and hepatitis viruses.RESULTS:There was no difference in immunological markers among co-infected patients and patients infected with HIV only and those co-infected with one or more hepatitis virus. Although liver function and cirrhosis markers remained within a normal range,there was a worsening trend in all patients co-infected with hepatitis virus C (HCV),which was further exacerbated in the presence of additional infection with hepatitis virus B (HBV).CONCLUSION:Co-infection with HIV,HBV and HCV leads to worsening of hyaluronic acid and liver function markers. Increases in serum hyaluronic acid may be suggestive of a predisposition to liver diseases.

  5. Epidemiology of hepatitis C virus infection

    Institute of Scientific and Technical Information of China (English)

    Miriam J Alter

    2007-01-01

    Globally, hepatitis C virus (HCV) has infected an estimated 130 million people, most of whom are chronically infected. HCV-infected people serve as a reservoir for transmission to others and are at risk for developing chronic liver disease, cirrhosis, and primary hepatocellular carcinoma (HCC). It has been estimated that HCV accounts for 27% of cirrhosis and 25% of HCC worldwide. HCV infection has likely been endemic in many populations for centuries. However, the wave of increased HCV-related morbidity and mortality that we are now facing is the result of an unprecedented increase in the spread of HCV during the 20th century.Two 20th century events appear to be responsible for this increase; the widespread availability of injectable therapies and the illicit use of injectable drugs.

  6. Hepatitis C virus infection and apoptosis

    Institute of Scientific and Technical Information of China (English)

    Richard Fischer; Thomas Baumert; Hubert E Blum

    2007-01-01

    Apoptosis is central for the control and elimination of viral infections. In chronic hepatitis C virus (HCV) infection,enhanced hepatocyte apoptosis and upregulation of the death inducing ligands CD95/Fas, TRAIL and TNFα occur.Nevertheless, HCV infection persists in the majority of patients. The impact of apoptosis in chronic HCV infection is not well understood. It may be harmful by triggering liver fibrosis, or essential in interferon (IFN)induced HCV elimination. For virtually all HCV proteins,pro- and anti-apoptotic effects have been described,especially for the core and NS5A protein. To date, it is not known which HCV protein affects apoptosis in vivo and whether the infectious virions act pro- or antiapoptotic. With the availability of an infectious tissue culture system, we now can address pathophysiologically relevant issues. This review focuses on the effect of HCV infection and different HCV proteins on apoptosis and of the corresponding signaling cascades.

  7. Treatment of hepatitis C virus infection

    Institute of Scientific and Technical Information of China (English)

    Kilian Weigand; Wolfgang Stremmel; Jens Encke

    2007-01-01

    Acute and chronic hepatitis C virus (HCV) infection remains a serious health problem worldwide, however,there has been advancement in the treatment of HCV infection due to standard treatment using pegylated interferon and ribavirin. The literature indicates that therapy for HCV is becoming more individualized. In addition to considering genotype and viral RNA levels before treatment, achievement of an early virologic response (EVR) and a rapid virologic response (RVR) is now possible during therapy. Moreover, problem patients,such as non-responders, relapsers, HIV or HBV coinfected patients, patients with liver cirrhosis, and preor post-liver transplantation patients are an increasing fraction of the patients requiring treatment. This article reviews the literature regarding standard treatments and problem patients with acute and chronic HCV infection.It also includes discussion on contraindications and side effects of treatment with interferon and ribavirin, as well as new drug development.

  8. Seroprevalences of Hepatitis B Virus and Hepatitis C Virus among Participants of an Asian Health Fair in the Lower Mainland, British Columbia

    Directory of Open Access Journals (Sweden)

    Stephen Ip

    2015-01-01

    Full Text Available BACKGROUND: The seroprevalences of hepatitis B virus (HBV and hepatitis C virus (HCV are 0.4% and 0.8%, respectively, in Canada, but varying rates have been reported in different populations.

  9. Dual Infection with Hepatitis B and Epstein-Barr Virus Presenting with Severe Jaundice, Coagulopathy, and Hepatitis B Virus Chronicity Outcome.

    Science.gov (United States)

    Rao, Sirish C; Ashraf, Imran; Mir, Fazia; Samiullah, Sami; Ibdah, Jamal A; Tahan, Veysel

    2017-02-16

    BACKGROUND Hepatitis B virus (HBV) has been reported as a coinfection with hepatitis C virus (HCV), hepatitis D virus (HDV), cytomegalovirus (CMV), and human immunodeficiency virus (HIV). CASE REPORT A 34-year-old female presented to our clinic with epigastric pain and severe acute hepatitis manifested as jaundice associated with hyperbilirubinemia, elevated transaminases, and coagulopathy. The patient was diagnosed with acute HBV with Epstein-Barr virus (EBV) coinfection leading to subsequent chronic hepatitis B. CONCLUSIONS To our knowledge, this patient case is the first reported case of HBV and EBV coinfection reported in the literature. HBV and EBV coinfection may cause severe acute hepatitis with HBV chronicity.

  10. Viral and host factors related with histopathologyc activity in patients with chronic hepatitis B and moderate or intermittently elevated alanine aminotransferase levels Influencia de factores virales y del huésped en la actividad histológica en pacientes con hepatitis crónica por virus de la hepatitis B y elevación moderada o intermitente de alanina aminotransferasa

    Directory of Open Access Journals (Sweden)

    E. Molina Pérez

    2010-09-01

    Full Text Available Objective: viral and host factors are related with progression of pathological lesion in chronic hepatitis B. We analyzed these factors in patients with moderate or intermittently elevated ALT levels, and its threshold that determinate significant histological activity. Patients and methods: retrospective analyses of viral and host parameters in 89 consecutive chronic hepatitis B patients biopsied because of moderate or intermittently elevated ALT levels [1-2 x ULN (ULN = 39 IU/mL] and/or DNA-HBV > 2 x 10³ IU/mL in AntiHBe+ patients. It was analyzed age, gender, ALT levels, HBeAg, viral load and genotype. It was considered advanced histological lesion a Knodell Score (KS > 7 and histological lesion indicating treatment, lobular inflammation ≥ 2 or fibrosis ≥ 2 according to Scheuer Classification. Results: KS > 7 and histological lesion indicating treatment was found in 47.8 and 60.7% respectively. It was observed relationship between age, male gender, ALT levels and viral load with histological damage (p ULN (69.1 vs. 47.1%, p = 0.04. There were not significant upper frequencies of advanced lesion when a cut-off of 40 years or DNA-HBV > 2 x 10³ IU/mL viral load or serological status HBeAg was considerate. Histological activity was lesser in genotype D patients than those infected with others genotypes (p Objetivo: analizar factores virales y del huésped relacionados con actividad histológica en un subgrupo de pacientes con hepatitis crónica B y elevación intermitente o moderada de alanina aminotransferasa (ALT, y el umbral que determine daño histológico indicativo de tratamiento. Pacientes y métodos: análisis retrospectivo de parámetros virales y del huésped en 89 pacientes con hepatitis crónica B biopsiados consecutivamente por elevación intermitente o moderada de ALT [1-2 x USN (USN = 39 UI/mL]. Fueron analizados edad, sexo, ALT, HBeAg, carga viral y genotipo. Se consideró como lesion histologica avanzada un Índice de

  11. Occult hepatitis B virus infection in Egyptian hemodialysis patients with or without hepatitis C virus infection

    Directory of Open Access Journals (Sweden)

    Hisham Ismail

    2010-08-01

    Full Text Available Hisham Ismail1*, Mohamed Soliman2, Nahed Ismail31Department of Molecular Diagnosis, GEBR Institute, 2Department of Clinical Pathology, College of Medicine, Menoufia University, Menoufia, Egypt; 3Department of Pathology and Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee, USA *Current affiliation: College of Medicine, Qassim University, Saudi ArabiaAbstract: Hepatitis B virus (HBV and hepatitis C virus (HCV infections are frequent in patients with end-stage renal disease who are on maintenance hemodialysis. There are limited data about the prevalence of occult HBV infection in patients on long-term hemodialysis. Occult HBV is defined as positive HBV DNA in the blood in the absence of hepatitis B surface ­antigen in the serum. In this study, we determined the prevalence of occult HBV in hemodialysis patients with or without HCV infection. The study included 116 patients with end-stage renal disease on chronic hemodialysis, of whom 64 patients were HCV RNA positive (Group 1, and 52 were HCV RNA negative (Group 2. We found that four of 64 (6.3% hemodialysis patients with HCV infection (Group 1 had occult HBV, while only two of 52 (3.8% hemodialysis patients without HCV (Group 2 had occult HBV. We then examined whether gender-matched ­hemodialysis patients with positive HBV DNA in the two hemodialysis groups differed in specific parameters, ie, age, degree of liver dysfunction, and presence of ­coinfection with schistosomiasis, a common parasitic infection of the liver. We found no significant difference between the groups having positive HBV DNA with regard to serum levels of liver enzymes, aspartate transaminase, albumin, and hepatitis B core antigen (P > 0.05. However, we detected significantly higher levels of alanine transaminase, a prolonged duration of hemodialysis, and higher levels of schistosomal antibodies in Group 1 than in Group 2. Interestingly, we found that the presence of schistosomal

  12. Hepatitis B virus infection in Indonesia

    Science.gov (United States)

    Yano, Yoshihiko; Utsumi, Takako; Lusida, Maria Inge; Hayashi, Yoshitake

    2015-01-01

    Approximately 240 million people are chronically infected with hepatitis B virus (HBV), 75% of whom reside in Asia. Approximately 600000 of infected patients die each year due to HBV-related diseases or hepatocellular carcinoma (HCC). The endemicity of hepatitis surface antigen in Indonesia is intermediate to high with a geographical difference. The risk of HBV infection is high in hemodialysis (HD) patients, men having sex with men, and health care workers. Occult HBV infection has been detected in various groups such as blood donors, HD patients, and HIV-infected individuals and children. The most common HBV subgenotype in Indonesia is B3 followed by C1. Various novel subgenotypes of HBV have been identified throughout Indonesia, with the novel HBV subgenotypes C6-C16 and D6 being successfully isolated. Although a number of HBV subgenotypes have been discovered in Indonesia, genotype-related pathogenicity has not yet been elucidated in detail. Therefore, genotype-related differences in the prognosis of liver disease and their effects on treatments need to be determined. A previous study conducted in Indonesia revealed that hepatic steatosis was associated with disease progression. Pre-S2 mutations and mutations at C1638T and T1753V in HBV/B3 have been associated with advanced liver diseases including HCC. However, drug resistance to lamivudine, which is prominent in Indonesia, remains obscure. Although the number of studies on HBV in Indonesia has been increasing, adequate databases on HBV infection are limited. We herein provided an overview of the epidemiology and clinical characteristics of HBV infection in Indonesia. PMID:26478663

  13. HEPATITIS C VIRUS INFECTION AND LYMPHOMA

    Directory of Open Access Journals (Sweden)

    Emmanuel Bachy

    2010-03-01

    Full Text Available Apart from its well known role as an etiological agent for non-A and non-B viral hepatitis, there is growing evidence that hepatitis C virus is associated to B-cell non-Hodgkin lymphoma. The association between HCV and lymphoproliferative disorders has been recently postulated based on epidemiological data, biological studies and clinical observations. Although various subtypes of lymphomas appear to be associated to HCV, diffuse large B-cell lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia and marginal zone lymphoma appeared to be particularly represented among HCV-positive patients.  The causative role of HCV in those disorders has been further supported by the response to anti-viral therapy. Despite a better understanding of pathophysiological processes at stake leading from HCV infection to overt lymphoma, many issues still need to be further elucidated. Although HCV has been demonstrated to directly infect peripheral blood mononuclear cells both in vitro and, in some cases, in vivo, a strong body of evidence rather supports the hypothesis of an indirect transformation mechanism by which sustained antigenic stimulation leads from oligoclonal to monoclonal expansion and sometimes to lymphoma, probably through secondary oncogenic events. Here, we review epidemiological and biological studies, as well as clinical data on antiviral therapy, linking HCV-infection to B-cell non-Hodgkin lymphoma.

  14. Hepatitis B virus infection in children.

    LENUS (Irish Health Repository)

    O'Gorman, C S

    2012-02-01

    Recent increases in Hepatitis B virus (HBV) infection prompted us to characterize HBV-infected children in Ireland and to audit management, by reviewing prospectively gathered data. Of 46 children (29 [63%] male), median age at presentation was 8.1 years (range 0.6-17.6), monitoring duration was 22.5 months (range 1-101), 23\\/46 (50%) were European (including 9 [19.6%] Irish), 15 (32.6%) African and 9 (19.6%) Asian. Acquisition was vertical (25\\/46 [54.3%]), horizontal (5\\/46 [10.9%]), unknown (16\\/46 [34.8%]). HBV-DNA was >100,000,000 cpm in 20\\/32 (62.5%) with chronic infection. Hepatitis B e antigen (HBeAg) was detected in 32\\/44 (72.7%). We estimate that universal neonatal vaccination (UNV-HBV) could have prevented 22% of cases, and could limit further horizontal HBV spread. This supports the recent introduction of UNV-HBV.

  15. Hepatitis B virus infection in immigrant populations

    Institute of Scientific and Technical Information of China (English)

    2015-01-01

    Hepatitis B virus (HBV) is the most common cause ofhepatitis worldwide, with nearly 350 million peoplechronically infected and 600000 deaths per year dueto acute liver failure occurring during acute hepatitisor, more frequently, in HBV-related liver cirrhosis orhepatocellular carcinoma. Ongoing immigration fromcountries with a high HBV endemicity to those with a lowHBV endemicity warrants particular attention to preventthe spread of HBV infection to the native population.This review article analyzes the epidemiology andvirological and clinical characteristics of HBV infectionin immigrant populations and in their host countries,and suggests prophylactic measures to prevent thespread of this infection. Among the immigrants fromdifferent geographical areas, those from South East Asiaand sub-Saharan Africa show the highest prevalencesof hepatitis B surface antigen (HBsAg) carriers, inaccordance with the high endemicity of the countriesof origin. The molecular characteristics of HBV infectionin immigrants reflect those of the geographical areasof origin HBV genotype A and D predominate inimmigrants from Eastern Europe, B and C in those fromAsia and genotype E in those from Africa. The literaturedata on the clinical course and treatment of HBsAgpositiveimmigrants are scanty. The management ofHBV infection in immigrant populations is difficult andrequires expert personnel and dedicated structures fortheir assistance. The social services, voluntary operatorsand cultural mediators are essential to achieve optimizedpsychological and clinical intervention.

  16. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.

    Science.gov (United States)

    Rehermann, Barbara; Bertoletti, Antonio

    2015-02-01

    Hepatitis B virus (HBV) and hepatitis C virus (HCV) cause a large proportion of acute and chronic liver disease worldwide. Over the past decades many immunological studies defined host immune responses that mediate spontaneous clearance of acute HBV and HCV infection. However, host immune responses are also relevant in the context of treatment-induced clearance of chronic HBV and HCV infection. First, the pretreatment level of interferon-stimulated genes as well as genetic determinants of innate immune responses, such as single nucleotide polymorphisms near the IFNL3 gene, are strong predictors of the response to interferon-alpha (IFN-α)-based therapy. Second, IFN-α, which has been a mainstay of HBV and HCV therapy over decades, and ribavirin, which has also been included in interferon-free direct antiviral therapy for HCV, modulate host immune responses. Third, both IFN-α-based and IFN-α-free treatment regimens of HBV and HCV infection alter the short-term and long-term adaptive immune response against these viruses. Finally, treatment studies have not just improved the clinical outcomes, but also provided opportunities to study virus-host interaction. This review summarizes our current knowledge on how a patient's immune response affects the treatment outcome of HBV and HCV infection and how innate and adaptive immune responses themselves are altered by the different treatment regimens.

  17. Occult hepatitis C virus infection is more common than hepatitis B infection in maintenance hemodialysis patients

    OpenAIRE

    Jain, Pankaj; Nijhawan, Sandeep

    2008-01-01

    Patients of end stage renal disease on maintenance hemodialysis were enrolled to study the prevalence of occult and dual hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and non-occult hepatitis B and C virus infection. One hundred and two patients were enrolled. Thirty patients had HCV infection, three of them were positive in anti-HCV. So, 27 (90%) of HCV-positive patients had occult HCV infection. Eleven (11%) patients had HBV infection. Five patients were positive in anti-HBc...

  18. IFNL4 affects clearance of hepatitis C virus

    Science.gov (United States)

    Scientists have discovered a new human interferon gene, Interferon Lambda 4 (IFNL4), that affects clearance of the hepatitis C virus. They also identified an inherited genetic variant within IFNL4 that predicts how people respond to treatment for hepatit

  19. Awareness And Preventive Measures Against Hepatitis B Virus ...

    African Journals Online (AJOL)

    Awareness And Preventive Measures Against Hepatitis B Virus Infection Among Dental ... Results: A high level of awareness and knowledge of HBV infection was ... to be compliantwith an inventory of standard infection control procedures.

  20. A winning war against hepatitis B virus infection in China

    Institute of Scientific and Technical Information of China (English)

    JIA Ji-dong; ZHUANG Hui

    2007-01-01

    @@ Hepatitis B virus (HBV) infection is a worldwide health problem.According to WHO estimation,about 2 billion people globally have been infected With HBV and 350 million of them have chronic HBV infection.1

  1. seroprevalence of hepatitis c virus antibodies amongst blood donors ...

    African Journals Online (AJOL)

    Dr Oboro VO

    SEROPREVALENCE OF HEPATITIS C VIRUS ANTIBODIES AMONGST BLOOD ... Conclusion: HCV infection is not uncommon in our environment hence the need to emphasize it's routine ... HCV antibody screening was done over a four-.

  2. An Immunoabsorption Column Conifguration for Hepatitis B Virus

    Institute of Scientific and Technical Information of China (English)

    2013-01-01

    Objective To conifgure an immunoabsorption column for hepatitis B virus. Methods Being activated by epichlorohydrin, the human antibody HBsAb-IgG was bound to the carrier of agarose gel. The configuration process was as follows: the synthesis of epoxide matrix, the synthesis and activation of amino matrix, the synthesis of aldehydic matrix, the synthesis of immunoabsorption matrix, the end capping and reduction of unbound aldehydic, the blocking of unbound mass and the iflling of the column. Results The bound rate of activated agarose gel and antibody HBsAb-IgG is 85.07%. By plasma adsorption experiment, it is revealed that the immunoabsorption column can absorb and eliminate 58.97%of HBsAg and 53.1%of hepatitis B virus particles in extracorporeal plasma. Conclusions The immunoabsorption column for hepatitis B virus can absorb and eliminate HBsAg and hepatitis B virus particles in extracorporeal plasma.

  3. Genus Phyllanthus for chronic hepatitis B virus infection

    DEFF Research Database (Denmark)

    Liu, J; Lin, Haili; McIntosh, H

    2001-01-01

    To evaluate the efficacy and safety of genus Phyllanthus for chronic hepatitis B virus (HBV) infection we performed a systematic review of randomized clinical trials. Randomized trials comparing genus Phyllanthus vs. placebo, no intervention, general nonspecific treatment, other herbal medicine...

  4. Coinfection with Hepatitis B and C Viruses among HIV Positive ...

    African Journals Online (AJOL)

    Coinfection with Hepatitis B and C Viruses among HIV Positive Pregnant Women in Enugu South East, Nigeria. ... PROMOTING ACCESS TO AFRICAN RESEARCH. AFRICAN JOURNALS ONLINE (AJOL) · Journals · Advanced Search ...

  5. Interleukin 28B genetic polymorphism and hepatitis B virus infection.

    Science.gov (United States)

    Takahashi, Toru

    2014-09-14

    Interleukin (IL) 28B genetic polymorphism is significantly associated with the sustained virological response rate in patients with chronic hepatitis C treated with pegylated interferon-α (PEG-IFN) plus ribavirin and with spontaneous hepatitis C virus clearance. However, a consensus on the relationship between IL28B genetic polymorphism and the favorable outcome of chronic hepatitis B virus infection defined by hepatitis B e antigen seroconversion, and/or hepatitis B surface antigen seroclearance in patients treated with interferon or PEG-IFN has not been reached. Several reports failed to show a positive association, while some studies demonstrated a positive association in certain subject settings. More prospective studies including large cohorts are needed to determine the possible association between IL28B genetic polymorphism and the outcome of interferon or PEG-IFN treatment for chronic hepatitis B.

  6. Prevalence of Hepatitis G Virus in Liver Disease

    Directory of Open Access Journals (Sweden)

    Hitoshi Takagi

    1999-01-01

    Full Text Available The prevalence of hepatitis G virus (HGV in liver disease of non-A, -B, -C viral hepatitis, hepatitis B and hepatitis C was determined. Two of 44 patients (4.5% with liver injury without any hepatitis A, B or C marker were positive for HGV. One of five cases of hepatocellular carcinoma was positive for HGV. One of three cases with fulminant hepatitis was positive for HGV. This case was negative at the onset of fulminant hepatitis and became positive after plasmapheresis. No patient with acute (n=8 or chronic (n=5 hepatitis or liver cirrhosis (n=8 was positive for HGV in non-A, -B, -C liver disease. One of 30 patients with various HBV-positive liver diseases and nine (17.3 of 52 patients with type C liver disease were positive for HGV. In patients with hepatitis C, four (28.6% of 14 HGV-co-infected patients were complicated with diabetes mellitus compared with four (10.5% of 38 single hepatitis C virus (HCV-infected patients (not significant. In 12 HGV-positive patients, eight of 10 (80% had a history of blood transfusion. In HCV-positive patients, co-infection with HGV was not a risk factor in patients with diabetes mellitus as a complication. HGV appeared to cause non-A, -B, -C hepatitis rarely, and its main route of infection was blood transfusion.

  7. Hepatitis E Virus (HEV) Infection in Ireland

    LENUS (Irish Health Repository)

    Hickey, C

    2016-09-01

    Hepatitis E virus (HEV) is a single stranded RNA virus causing infection worldwide. In developing countries HEV genotypes 1 and 2 spread faeco-orally via water. Recently, infections with HEV have been detected in Europe and North America in patients with no travel history. These are food-borne HEV genotypes 3 and 4, a pig-associated zoonosis. Most infections are asymptomatic but morbidity and chronic infection may occur with prior liver disease or immunosuppression. International seroprevalence rates vary and with improved diagnostics have increased. To determine the current prevalence in this region we studied anonymised serum samples submitted in 2015 for routine testing. We detected anti-HEV IgG in 16\\/198 (8%) individuals, highest rate in 40-59 year olds (43.8%). This is higher than reported for the same region in 1995 (0.4%) using a previous generation assay. This study provides evidence of HEV circulation in Ireland and reinforces the need for ongoing surveillance.

  8. Hepatitis A virus infection: Epidemiology and genetic diversity

    OpenAIRE

    Báez Triana, Paula Andrea; Navas Navas, María Cristina

    2015-01-01

    Hepatitis A virus infection is a global public health problem. The virus has a wide range of distribution and it is the main cause of acute hepatitis transmitted by the enteric route in Latin America. The viral particle is stable under environmental conditions and conserves its infectivity for several weeks, enabling its transmission by contaminated water and food. Worldwide, different epidemiological patterns have been identified, which may change over time by modification of social and e...

  9. Fibromyalgia-associated hepatitis C virus infection.

    Science.gov (United States)

    Rivera, J; de Diego, A; Trinchet, M; García Monforte, A

    1997-09-01

    The objective was to determine whether there might be an association between hepatitis C virus (HCV) chronic infection and fibromyalgia (FM). We determined the prevalence of HCV infection in 112 FM patients, in comparison with matched rheumatoid arthritis (RA) patients from the out-patient clinic of a teaching tertiary care general hospital. Furthermore, we looked for evidence of FM in 58 patients diagnosed with chronic hepatitis due to HCV, compared with matched surgery clinic patients, HCV antibodies were determined by enzyme-linked immunosorbent assay (ELISA) and recombinant immunoblot assay (RIBA). Serum RNA of HCV (HCV-RNA) was determined by polymerase chain reaction. In the group of FM patients, HCV antibodies were found by ELISA in 17 (15.2%) patients and in six (5.3%) of the RA controls (P < 0.05). RIBA was positive in 16 and indeterminate in one of the FM patients. Serum HCV-RNA was found in 13 of these FM patients. In eight (47%) FM patients, alanine aminotransferase (ALT) was normal, although HCV-RNA was detected in four (50%) of them. In the group of patients with chronic hepatitis due to HCV, all patients had HCV antibodies and the presence of HCV-RNA in serum. Within these patients, 31 (53%) had diffuse musculoskeletal pain, while six (10%) fulfilled FM diagnostic criteria. In the control group, 13/58 (22%) had diffuse musculoskeletal pain (P < 0.001), whereas only one female patient (1.7%) fulfilled FM criteria (P < 0.05). Serum ALT was 51.7 +/- 38.4 in FM patients, whereas it was 122 +/- 76.3 in patients with HCV chronic hepatitis but without FM (P < 0.001). There were no statistical differences in autoimmune markers between patients with and without FM. These data suggest that there exists an association between FM and active HCV infection in some of our patients. FM is not associated with liver damage or autoimmune markers in these patients. HCV infection should be considered in FM patients even though ALT elevations were absent.

  10. Hepatitis E Virus Mutations: Functional and Clinical Relevance

    OpenAIRE

    Hoang van Tong; Nghiem Xuan Hoan; Bo Wang; Heiner Wedemeyer; C.-Thomas Bock; Velavan, Thirumalaisamy P.

    2016-01-01

    Highlights • HEV causes acute hepatitis and recently comes into focus because of persistent infection in immunocompromised patients. • HEV variability can be associated with clinical pathogenesis and transmission dynamics. • Mutations in the HEV genome can influence HEV physiology and virus-host interaction. • HEV mutations and variability are likely associated with fulminant hepatic failure and chronic hepatitis E. • The Y1320H and G1634R/K mutations in the RdRp domain contribute to antivira...

  11. Epidemiology and Prevention of Hepatitis B Virus Infection

    OpenAIRE

    HOU Jinlin; Liu, Zhihua; Gu, Fan

    2005-01-01

    Hepatitis B is one of the most common infectious diseases globally. It has been estimated that there are 350 million chronic hepatitis B virus (HBV) carriers worldwide. The prevalence of chronic HBV infection varies geographically, from high (>8%), intermediate (2-7%) to low (

  12. Epidemiology and Prevention of Hepatitis B Virus Infection

    Directory of Open Access Journals (Sweden)

    2005-01-01

    Full Text Available Hepatitis B is one of the most common infectious diseases globally. It has been estimated that there are 350 million chronic hepatitis B virus (HBV carriers worldwide. The prevalence of chronic HBV infection varies geographically, from high (>8%, intermediate (2-7% to low (

  13. Prevention of mother to child transmission of hepatitis B virus ...

    African Journals Online (AJOL)

    Prevention of mother to child transmission of hepatitis B virus infection in Nigeria: A ... the interventions of hepatitis B vaccinations and immunoglobulins in settings ... starting anti-viral therapy for pregnant women with HBeAg positivity and high ...

  14. Hepatitis C virus infection of cholangiocarcinoma cell lines

    NARCIS (Netherlands)

    Fletcher, Nicola F.; Humphreys, Elizabeth; Jennings, Elliott; Osburn, William; Lissauer, Samantha; Wilson, Garrick K.; van Ijzendoorn, Sven C. D.; Baumert, Thomas F.; Balfe, Peter; Afford, Simon; McKeating, Jane A.

    2015-01-01

    Hepatitis C virus (HCV) infects the liver and hepatocytes are the major cell type supporting viral replication. Hepatocytes and cholangiocytes derive from a common hepatic progenitor cell that proliferates during inflammatory conditions, raising the possibility that cholangiocytes may support HCV re

  15. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption

    DEFF Research Database (Denmark)

    Dore, Gregory J; Soriano, Vicente; Rockstroh, Jürgen

    2010-01-01

    BACKGROUND: The impact of antiretroviral therapy (ART) interruption in HIV-hepatitis B virus (HBV)-coinfected patients was examined in the Strategic Management of AntiRetroviral Therapy (SMART) study. METHODS: Plasma HBV DNA was measured in all hepatitis B surface antigen-positive (HBV.......0002), nondetectable HBV DNA at baseline (P = 0.007), and black race (P = 0.03). Time to ART reinitiation was shorter (7.5, 15.6, and 17.8 months; P hepatitis C virus-positive and non-HBV/hepatitis...... C virus participants in the drug conservation arm. No hepatic decompensation events occurred among HBV-positive participants in either arm. CONCLUSION: HBV DNA rebound following ART interruption is common and may be associated with accelerated immune deficiency in HIV-HBV-coinfected patients....

  16. Liver histology in co-infection of hepatitis C virus (HCV and Hepatitis G virus (HGV

    Directory of Open Access Journals (Sweden)

    STRAUSS Edna

    2002-01-01

    Full Text Available As little is known about liver histology in the co-infection of hepatitis C virus (HCV and hepatitis G virus (HGV, HGV RNA was investigated in 46 blood donors with hepatitis C, 22 of them with liver biopsy: co-infection HCV / HGV (n = 6 and HCV isolated infection (n = 16. Besides staging and grading of inflammation at portal, peri-portal and lobular areas (Brazilian Consensus, the fibrosis progression index was also calculated. All patients had no symptoms or signs of liver disease and prevalence of HGV / HCV co-infection was 15.2%. Most patients had mild liver disease and fibrosis progression index, calculated only in patients with known duration of infection, was 0.110 for co-infection and 0.130 for isolated HCV infection, characterizing these patients as "slow fibrosers". No statistical differences could be found between the groups, although a lesser degree of inflammation was always present in co-infection. In conclusion co-infection HCV / HGV does not induce a more aggressive liver disease, supporting the hypothesis that HGV is not pathogenic.

  17. Molecular characterization of suppression of hepatitis B virus transcription by hepatitis C virus core protein

    Institute of Scientific and Technical Information of China (English)

    王海林; 颜子颖; 侯云德; 金冬雁

    1997-01-01

    To further elucidate the molecular mechanisms underlying the suppression of hepatitis B virus (HBV) expression by the hepatitis C virus (HCV) core protein, five molecular clones of HCV cDNA sequence con-taining the 5’ noncoding (5’NC) and the core regions have been isolated from Chinese HBV- and HCV-coinfected pa-tients. Sequence comparison and phylogenetic analysis showed that the HCV sequence cloned from coinfected individu-als is indistinguishable from that identified in other patients. Cotransfection assay confirmed that the core protein ex-pressed from one of the cloned sequence is capable of suppressing the expression of hepatitis B surface and e antigens (HBsAg and HBeAg, respectively). Deletion mapping revealed that the C-terminal hydrophobic region of the HCV core is necessary for the suppression. Results from reporter assays demonstrated that HCV core protein interacts with the HBV C promoter and enhancer II elements and down-regulates the transcription of HBV as well as other cellular and het

  18. Molecular biology and pathogenesis of hepatitis E virus

    Indian Academy of Sciences (India)

    Vivek Chandra; Shikha Taneja; Manjula Kalia; Shahid Jameel

    2008-11-01

    The hepatitis E virus (HEV) is a small RNA virus and the etiological agent for hepatitis E, a form of acute viral hepatitis. The virus has a feco-oral transmission cycle and is transmitted through environmental contamination, mainly through drinking water. Recent studies on the isolation of HEV-like viruses from animal species also suggest zoonotic transfer of the virus. The absence of small animal models of infection and efficient cell culture systems has precluded virological studies on the replication cycle and pathogenesis of HEV. A vaccine against HEV has undergone successful clinical testing and diagnostic tests are available. This review describes HEV epidemiology, clinical presentation, pathogenesis, molecular virology and the host response to HEV infection. The focus is on published literature in the past decade.

  19. The serology of hepatitis C virus in relation to post-transfusion hepatitis.

    Science.gov (United States)

    Williams, A E; Dodd, R Y

    1990-01-01

    Natural history studies conducted over the past 15 years have shown that parenterally transmitted non-A non-B hepatitis infection frequently results in an indolent chronic disease with serious long-term consequences. The recent identification of nucleic acid sequences comprising the genome of hepatitis C virus (HCV) has allowed the development of a serological assay based upon recombinant viral proteins specifically associated with the major agent of non-A, non-B hepatitis infection. The HCV antibody assays have now been applied to sera from blood donors worldwide, as well as various population samples with increased hepatitis risk in the course of clinical trials conducted in both Europe and the United States. Data from these studies provide further encouragement that assays based on the hepatitis C virus recombinant proteins are highly specific for the major agent of non-A non-B hepatitis and will provide a firm basis for blood donor screening and future diagnostic tests.

  20. Prevalence of Anti-Hepatitis E Virus Antibodies and First Detection of Hepatitis E Virus in Wild Boar in Slovenia

    NARCIS (Netherlands)

    Žele, Diana; Fernandes Barry, Aline; Honing-Hakze, van der Renate; Vengušt, Gorazd; Poel, Van Der W.H.M.

    2016-01-01

    Hepatitis E is an emerging zoonotic disease caused by hepatitis E virus (HEV). In this study, we investigated HEV presence in a wild boar (Sus scrofa) population of Slovenia. A total of 288 wild boar serum samples were collected throughout the country, and HEV infection was investigated by serolo

  1. Infection with hepatitis A, B, C, and delta viruses among patients with acute hepatitis in Mongolia.

    Science.gov (United States)

    Tsatsralt-Od, Bira; Takahashi, Masaharu; Endo, Kazunori; Buyankhuu, Osorjin; Baatarkhuu, Oidov; Nishizawa, Tsutomu; Okamoto, Hiroaki

    2006-05-01

    One hundred ten consecutive patients (60 males and 50 females; age, mean +/- standard deviation [SD], 22.6 +/- 6.4 years; range 16-48 years) who were clinically diagnosed with sporadic acute hepatitis between December 2004 and January 2005 in Ulaanbaatar, Mongolia, were studied. IgM antibodies to hepatitis A virus were detected in 18 patients (16.4%), IgM antibodies to hepatitis B core (anti-HBc IgM) in 38 patients (34.5%) including two patients with concurrent hepatitis delta virus (HDV) infection, and hepatitis C virus RNA in nine patients (8.2%). There were 30 hepatitis B virus (HBV) carriers who had detectable hepatitis B surface antigen and antibodies to HDV but were negative for anti-HBc IgM, suggesting that they acquired type D acute hepatitis due to superinfection of HDV on a background of chronic HBV infection. None had IgM antibodies to hepatitis E virus (HEV). Consequently, 16.4, 32.7, 6.4, 1.8, and 27.3% of the patients were diagnosed as having acute hepatitis of type A, B, C, type B + D (HBV/HDV coinfection), and type D (superinfection of HDV), respectively. The cause of hepatitis was not known in the remaining 17 patients (15.5%). All 18 HAV isolates were genotyped as IA, all 9 HCV isolates were genotyped as 1b, and all 32 HDV isolates were classified into genotype I. The distribution of HBV genotypes among the 67 HBV isolates was A (1.5%, n = 1) and D (98.5%, n = 66). The present study indicates that de novo infections of HAV, HBV, HCV, and HDV are prevalent among young adults in Mongolia. Copyright 2006 Wiley-Liss, Inc.

  2. The Chimpanzee Model for Hepatitis B Virus Infection

    Science.gov (United States)

    Wieland, Stefan F.

    2015-01-01

    Even before the discovery of hepatitis B virus (HBV), it was known that chimpanzees (Pan troglodytes) are susceptible to human hepatitis viruses. The chimpanzee is the only primate animal model for HBV infections. Much like HBV-infected human patients, chimpanzees can develop acute and chronic HBV infections and consequent hepatitis. Chimpanzees also develop a cellular immune response similar to that observed in humans. For these reasons, the chimpanzee has proven to be an invaluable model for investigations on HBV-driven disease pathogenesis and also the testing of novel antiviral therapies and prophylactic approaches. PMID:26033082

  3. High incidences of malignant lymphoma in patients infected with hepatitis B or hepatitis C virus.

    Science.gov (United States)

    Iwata, Hiroshi; Matsuo, Keitaro; Takeuchi, Kengo; Kishi, Yukiko; Murashige, Naoko; Kami, Masahiro

    2004-03-01

    It is still not clear whether there is an association between malignant lymphomas and hepatitis B or hepatitis C virus infections. Most studies from Italy and Japan support this association, but studies from other countries generally do not. We conducted a hospital-based case-control study to evaluate this association and show a significant association between the development of malignant lymphoma and infections by these viruses.

  4. Release of Virus from Lymphoid Tissue Affects Human Immunodeficiency Virus Type 1 and Hepatitis C Virus Kinetics in the Blood

    NARCIS (Netherlands)

    Müller, Viktor; Marée, Athanasius F.M.; Boer, R.J. de

    2000-01-01

    Kinetic parameters of human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) infections have been estimated from plasma virus levels following perturbation of the chronically infected (quasi-) steady state. We extend previous models by also considering the large pool of virus

  5. Cluster of cases of acute hepatitis associated with hepatitis E virus infection acquired in the Netherlands.

    NARCIS (Netherlands)

    Widdowson, MA; Jaspers, WJ; Poel, van der WH; Verschoor, F.; Husman, AM de Roda; Winter, HL; Zaaijer, H.L.; Koopmans, M

    2003-01-01

    Increasing evidence suggests that hepatitis E virus (HEV) infection may occur in developed countries and that swine may act as a reservoir. We report a cluster of 2 confirmed cases and 1 presumptive case of hepatitis associated with HEV. The typed strain from 1 case was related to HEV strains found

  6. Cluster of cases of acute hepatitis associated with hepatitis E virus infection acquired in the Netherlands.

    NARCIS (Netherlands)

    Widdowson, MA; Jaspers, WJ; Poel, van der WH; Verschoor, F.; Husman, AM de Roda; Winter, HL; Zaaijer, H.L.; Koopmans, M

    2003-01-01

    Increasing evidence suggests that hepatitis E virus (HEV) infection may occur in developed countries and that swine may act as a reservoir. We report a cluster of 2 confirmed cases and 1 presumptive case of hepatitis associated with HEV. The typed strain from 1 case was related to HEV strains found

  7. Hepatitis

    Institute of Scientific and Technical Information of China (English)

    2010-01-01

    2010349 Relationships between serum hepatitis B virus load in mothers,free maternal DNA in peripheral blood of newborns and hepatitis B virus infection of newborns. WEI Junni(魏俊妮),et al. Dept Epidemiol,Shanxi Med Univ,Taiyuan 030001. Chin J Infect Dis 2010;28(5):297-300. Objective To study the relationships between serum hepatitis B virus (HBV) DNA level

  8. [Epidemiology of hepatitis E virus infection in Spain].

    Science.gov (United States)

    Echevarría, José Manuel; Fogeda, Marta; Avellón, Ana

    2015-04-01

    The general features of the epidemiology and ecology of hepatitis E virus in Spain are already known after 20 years of investigations. Genotype 3 strains, mainly from sub-genotype 3f, circulated among swine livestock and certain wild mammals, and would be sporadically transmitted to humans through direct contact with the reservoirs or by consumption of foods derived from them. Bivalve shellfish contaminated by hepatitis E virus from sewage could also play a role in transmission. Although the interpretation of results from seroprevalence studies in low endemic settings is still controversial, antibody to hepatitis E virus displays an overall prevalence less than 10% among the population of Spain, increasing significantly with age. From the, approximately, 150 cases of acute hepatitis E recorded in the international literature, males older than 40 years, suffering a mild, locally acquired disease predominate. In addition, hepatitis E might be more frequent in the North of the country than in other regions. Although the disease does not usually have a great clinical relevance, the occasional finding of cases of fulminant hepatitis, and of ribavirin-resistant, chronic hepatitis E virus infections among the immunocompromised would recommend the surveillance of the infection by the public health authority and a better implementation of specific diagnostic procedures in clinical laboratories. Copyright © 2013 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

  9. Hepatitis B virus infection: Is patient tailored treatment feasible?

    NARCIS (Netherlands)

    W.F. Leemans (Wim)

    2008-01-01

    textabstractThe hepatitis B virus (HBV) belongs to the family of hepadna viridae and has a diameter of 42-47 nm. The virus particle encloses a partially double-stranded DNA genome with a length of approximately 3200 base pairs. Within the viral DNA genome four open reading frames (ORFs) can be ident

  10. Evolutionary origins of hepatitis A virus in small mammals

    NARCIS (Netherlands)

    J.-F. Drexler (Jan-Felix); V.M. Corman (Victor); A.N. Lukashev (Alexander); J.M.A. van den Brand (Judith); A. Gmyl (Anatoly); S. Brunink (Sebastian); A. Rasche (Andrea); N. Seggewi (Nicole); H. Feng (Hui); L.M.E. Leijten (Lonneke); P. Vallo (Peter); T. Kuiken (Thijs); A. Dotzauer (Andreas); R.G. Ulrich (Rainer); S.M. Lemon (Stanley M.); C. Drosten (Christian)

    2015-01-01

    textabstractHepatitis A virus (HAV) is an ancient and ubiquitous human pathogen recovered previously only from primates. The sole species of the genus Hepatovirus, existing in both enveloped and nonenveloped forms, and with a capsid structure intermediate between that of insect viruses and mammalian

  11. Evolutionary origins of hepatitis A virus in small mammals

    NARCIS (Netherlands)

    J.-F. Drexler (Jan-Felix); V.M. Corman (Victor); A.N. Lukashev (Alexander); J.M.A. van den Brand (Judith); A. Gmyl (Anatoly); S. Brunink (Sebastian); A. Rasche (Andrea); N. Seggewi (Nicole); H. Feng (Hui); L.M.E. Leijten (Lonneke); P. Vallo (Peter); T. Kuiken (Thijs); A. Dotzauer (Andreas); R.G. Ulrich (Rainer); S.M. Lemon (Stanley M.); C. Drosten (Christian)

    2015-01-01

    textabstractHepatitis A virus (HAV) is an ancient and ubiquitous human pathogen recovered previously only from primates. The sole species of the genus Hepatovirus, existing in both enveloped and nonenveloped forms, and with a capsid structure intermediate between that of insect viruses and mammalian

  12. Hepatitis E Virus Variant in Farmed Mink, Denmark

    DEFF Research Database (Denmark)

    Krog, Jesper Schak; Breum, Solvej Østergaard; Jensen, Trine Hammer

    2013-01-01

    Hepatitis E virus (HEV) is a zoonotic virus for which pigs are the primary animal reservoir. To investigate whether HEV occurs in mink in Denmark, we screened feces and tissues from domestic and wild mink. Our finding of a novel HEV variant supports previous findings of HEV variants in a variety...

  13. Hepatoma polarization limits CD81 and hepatitis C virus dynamics

    NARCIS (Netherlands)

    Harris, H. J.; Clerte, C.; Farquhar, M. J.; Goodall, M.; Hu, K.; Rassam, P.; Dosset, P.; Wilson, G. K.; Balfe, P.; IJzendoorn, S. C.; Milhiet, P. E.; McKeating, J. A.

    2013-01-01

    Many viruses target the polarized epithelial apex during host invasion. In contrast, hepatitis C virus (HCV) engages receptors at the basal surface of hepatocytes in the polarized liver parenchyma. Hepatocyte polarization limits HCV entry by undefined mechanism(s). Given the recent reports highlight

  14. Hepatitis B virus infection in Nigeria - A review

    Directory of Open Access Journals (Sweden)

    G O Emechebe

    2009-01-01

    Full Text Available Background:Hepatitis B virus infection is a pandemic and chronic infection may lead to chronic liver diseases which are often lethal. This review was done to assess the status of hepatitis B virus infection in Nigeria. Materials and Method:Source of information was mainly from published works in Nigeria and elsewhere. The information was extracted over period of 5 months from May to December 2007. Result: Since over 30years when pioneer works were done in Nigeria to the recent tunes the prevalence of hepatitis B virus infection has remained very high. In Nigeria, the transmission of hepatitis B virus occurs mainly during childhood and all the risk factors (like blood transfusion, sexual promiscuity, lower socioecomic status etc implicated elsewhere in the spread of the virus in the general population also play role in Nigeria. Conclusion: Reduction in the of hepatitis B virus infection could be achieved by public enlightenment campaign, mass immunization of the children and adults at risk while antiviral drugs and immunostimulatory therapy should be provided for those already infected.

  15. Hepatitis C Virus Life Cycle and Lipid Metabolism

    Directory of Open Access Journals (Sweden)

    Costin-Ioan Popescu

    2014-12-01

    Full Text Available Hepatitis C Virus (HCV infects over 150 million people worldwide. In most cases HCV infection becomes chronic, causing liver disease ranging from fibrosis to cirrhosis and hepatocellular carcinoma. HCV affects the cholesterol homeostasis and at the molecular level, every step of the virus life cycle is intimately connected to lipid metabolism. In this review, we present an update on the lipids and apolipoproteins that are involved in the HCV infectious cycle steps: entry, replication and assembly. Moreover, the result of the assembly process is a lipoviroparticle, which represents a peculiarity of hepatitis C virion. This review illustrates an example of an intricate virus-host interaction governed by lipid metabolism.

  16. Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    Chun-Feng Lee; Zhi-Qiang Ling; Ting Zhao; Kuan-Rong Lee

    2008-01-01

    AIM: To identify biomarkers indicating virus-specific hepatocarcinogenic process, differential mRNA expres-sion in 32 patients with hepatitis B virus (HBV)-/hepa-titis C virus (HCV)-associated hepatocellular carcinoma (HCC) were investigated by means of cDNA microar-rays comprising of 886 genes.METHODS: Thirty two HCC patients were divided into two groups based on viral markers: hepatitis B virus positive and HCV positive. The expression profiles of 32 pairs of specimens (tumorous and surrounding non-tumorous liver tissues), consisting of 886 genes were analyzed.RESULTS: Seven up-regulated genes in HBV-associat-ed HCC comprised genes involved in protein synthesis (RPS5), cytoskeletal organization (KRT8), apoptosis related genes (CFLAR), transport (ATP5F1), cell mem-brane receptor related genes (IGFBP2), signal trans-duction or transcription related genes (MAP3K5), and metastasis-related genes (MMP9). The up-regulated genes in HCV-infected group included 4 genes: VIM (cell structure), ACTB (cell structure), GAPD (glycolysis) and CD58 (cell adhesion). The expression patterns of the 11 genes, identified by cDNA microarray, were con-firmed by quantitative RT-PCR in 32 specimens.CONCLUSION: The patterns of all identified genes were classified based on the viral factor involved in HBV- and HCV-associated HCC. Our results strongly suggest that the pattern of gene expression in HCC is closely associated with the etiologic factor. The present study indicates that HBV and HCV cause hepato-carcinogenesis by different mechanisms, and provide novel tools for the diagnosis and treatment of HBV-and HCV-associated HCC.

  17. cDNA clone of hepatitis A virus encoding a virulent virus: induction of viral hepatitis by direct nucleic acid transfection of marmosets.

    OpenAIRE

    Emerson, S U; Lewis, M; Govindarajan, S. (Srinath); M. Shapiro(Physics Division, Lawrence Berkeley National Laboratory and University of California, Berkeley CA, United States of America); Moskal, T; Purcell, R. H.

    1992-01-01

    Direct inoculation of marmoset livers with an in vitro transcription mixture containing cDNA and full-length genomic RNA transcripts of hepatitis A virus resulted in acute viral hepatitis. Elevations in serum levels of liver enzymes were correlated with appearance of antibody to hepatitis A virus. Genomes of infectious hepatitis A virus isolated from the feces of transfected marmosets contained the same mutation as the cDNA template used for transfection. Liver biopsies confirmed that the vir...

  18. Deep sequencing in the management of hepatitis virus infections.

    Science.gov (United States)

    Quer, Josep; Rodríguez-Frias, Francisco; Gregori, Josep; Tabernero, David; Soria, Maria Eugenia; García-Cehic, Damir; Homs, Maria; Bosch, Albert; Pintó, Rosa María; Esteban, Juan Ignacio; Domingo, Esteban; Perales, Celia

    2016-12-28

    The hepatitis viruses represent a major public health problem worldwide. Procedures for characterization of the genomic composition of their populations, accurate diagnosis, identification of multiple infections, and information on inhibitor-escape mutants for treatment decisions are needed. Deep sequencing methodologies are extremely useful for these viruses since they replicate as complex and dynamic quasispecies swarms whose complexity and mutant composition are biologically relevant traits. Population complexity is a major challenge for disease prevention and control, but also an opportunity to distinguish among related but phenotypically distinct variants that might anticipate disease progression and treatment outcome. Detailed characterization of mutant spectra should permit choosing better treatment options, given the increasing number of new antiviral inhibitors available. In the present review we briefly summarize our experience on the use of deep sequencing for the management of hepatitis virus infections, particularly for hepatitis B and C viruses, and outline some possible new applications of deep sequencing for these important human pathogens.

  19. Hepatitis C virus and cardiovascular: A review

    Directory of Open Access Journals (Sweden)

    Salvatore Petta

    2017-03-01

    Full Text Available Chronic hepatitis C virus (HCV infection is a systemic disease that leads to increased risks of cirrhosis and its complications, as well as extrahepatic disturbances, including immune-related disorders and metabolic alterations such as insulin resistance and steatosis. Recent accumulating evidence suggests that HCV infection can increase cardiovascular risk, and that viral eradication can improve cardiovascular outcomes in the clinical setting. These data are strengthened by evidence identifying potential mechanisms (indirectly linking HCV infection to vascular damage. However, the high prevalence of both HCV infection and cardiovascular alterations, as well as the presence of contrasting results not identifying any association between HCV infection and cardiovascular dysfunction, provides uncertainty about a direct association of HCV infection with cardiovascular risk. Further studies are needed to clarify definitively the role of HCV infection in cardiovascular alterations, as well as the impact of viral eradication on cardiovascular outcomes. These features are now more attractive, considering the availability of new, safe, and very effective interferon-free antiviral agents for the treatment of HCV infection. This review aims to discuss carefully available data on the relationship between HCV infection and cardiovascular risk.

  20. Hepatitis B virus-induced oncogenesis

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    Hepatocellular carcinoma (HCC) is one of the most common cancers in the world with an annual incidence of more than 500000 in the year 2000. Its incidence is rising in many countries. Recently, it has been estimated that about 53% of HCC cases in the world are related to hepatitis B virus (HBV). The epidemiological association of HBV with HCC is well established. In recent studies,it was revealed that HBsAg carriers have a 25-37times increased risk of developing HCC as compared to non-infected people. At present, HBV-associated carcinogenesis can be seen as a multi-factorial process that includes both direct and indirect mechanisms that might act synergistically. The integration of HBV DNA into the host genome occurs at early steps of clonal tumor expansion. The integration has been shown in a number of cases to affect a variety of cancerrelated genes and to exert insertional mutagenesis. The permanent liver inflammation, induced by the immune response, resulting in a degeneration and regeneration process confers to the accumulation of critical mutations in the host genome. In addition to this, the regulatory proteins HBx and the PreS2 activators that can be encoded by the integrate exert a tumor promoter-like function resulting in positive selection of cells producing a functional regulatory protein. Gene expression profiling and proteomic techniques may help to characterize the molecular mechanisms driving HBV-associated carcinogenesis, and thus potentially identify new strategies in diagnosis and therapy.

  1. Clinical relevance of hepatitis B virus variants

    Institute of Scientific and Technical Information of China (English)

    2015-01-01

    The hepatitis B virus (HBV) is a global public health problem with more than 240 million people chronicallyinfected worldwide, who are at risk for end-stage liverdisease and hepatocellular carcinoma. There are anestimated 600000 deaths annually from complications ofHBV-related liver disease. Antiviral therapy with nucleos/tide analogs (NA) targeting the HBV polymerase (P) caninhibit disease progression by long-term suppression ofHBV replication. However, treatment may fail with firstgeneration NA therapy due to the emergence of drugresistantmutants, as well as incomplete medicationadherence. The HBV replicates via an error-prone reversetranscriptase leading to quasispecies. Due to overlappingopen reading frames mutations within the HBV P cancause concomitant changes in the HBV surface gene (S )and vice versa. HBV quasispecies diversity is associatedwith response to antiviral therapy, disease severity andlong-term clinical outcomes. Specific mutants havebeen associated with antiviral drug resistance, immuneescape, liver fibrosis development and tumorgenesis.An understanding of HBV variants and their clinicalrelevance may be important for monitoring chronichepatitis B disease progression and treatment response.In this review, we will discuss HBV molecular virology,mechanism of variant development, and their potentialclinical impact.

  2. Hepatitis C virus genotypes in Myanmar.

    Science.gov (United States)

    Win, Nan Nwe; Kanda, Tatsuo; Nakamoto, Shingo; Yokosuka, Osamu; Shirasawa, Hiroshi

    2016-07-21

    Myanmar is adjacent to India, Bangladesh, Thailand, Laos and China. In Myanmar, the prevalence of hepatitis C virus (HCV) infection is 2%, and HCV infection accounts for 25% of hepatocellular carcinoma. In this study, we reviewed the prevalence of HCV genotypes in Myanmar. HCV genotypes 1, 3 and 6 were observed in volunteer blood donors in and around the Myanmar city of Yangon. Although there are several reports of HCV genotype 6 and its variants in Myanmar, the distribution of the HCV genotypes has not been well documented in areas other than Yangon. Previous studies showed that treatment with peginterferon and a weight-based dose of ribavirin for 24 or 48 wk could lead to an 80%-100% sustained virological response (SVR) rates in Myanmar. Current interferon-free treatments could lead to higher SVR rates (90%-95%) in patients infected with almost all HCV genotypes other than HCV genotype 3. In an era of heavy reliance on direct-acting antivirals against HCV, there is an increasing need to measure HCV genotypes, and this need will also increase specifically in Myanmar. Current available information of HCV genotypes were mostly from Yangon and other countries than Myanmar. The prevalence of HCV genotypes in Myanmar should be determined.

  3. Hepatitis C Virus Infection and Mixed Cryoglobulinemia

    Directory of Open Access Journals (Sweden)

    Gianfranco Lauletta

    2012-01-01

    Full Text Available Hepatitis C virus (HCV chronic infection is recognized as the major cause of mixed cryoglobulinemia (MC. Its persistence represents a continuous stimulus for host immune system with production of circulating immune complexes (ICs, one-third of them with cryoprecipitate property. Several factors contribute to the biological activities of ICs, many of which are not completely known. Among them, complement factors play a crucial role in the cold-insoluble ICs-mediated vasculitis, involving primarily small blood vessels in different tissues including skin, kidney, peripheral, and central nervous system. Liver represents the major target of HCV infection with inflammatory infiltrates, resembling secondary lymphoid follicles. Cytokine like CXCL13 contribute to B-cell homing in intraportal lymphoid aggregates, in which B-cell clonal selection may arise. B-cell clonal expansion starts as an antigen-driven event and expands towards indolent and malignant B-cell proliferation. Occurrence of intrahepatic B-cell clonalities correlates with extrahepatic clinical manifestations of HCV infection. In this context, cryoglobulinemic patients should be considered a peculiar HCV-infected population that needs a clinical multidisciplinary approach and more articulated therapeutic measures.

  4. Multiplex hydrolysis probe real-time PCR for simultaneous detection of hepatitis A virus and hepatitis E virus.

    Science.gov (United States)

    Qiu, Feng; Cao, Jingyuan; Su, Qiudong; Yi, Yao; Bi, Shengli

    2014-05-30

    Detection of hepatitis viral infections has traditionally relied on the circulating antibody test using the enzyme-linked immunosorbent assay. However, multiplex real-time PCR has been increasingly used for a variety of viral nucleic acid detections and has proven to be superior to traditional methods. Hepatitis A virus (HAV) and hepatitis E virus (HEV) are the major causes of acute hepatitis worldwide; both HAV and HEV infection are a main public health problem. In the present study, a one-step multiplex reverse transcriptase quantitative polymerase chain reaction assay using hydrolysis probes was developed for simultaneously detecting HAV and HEV. This novel detection system proved specific to the target viruses, to be highly sensitive and to be applicable to clinical sera samples, making it useful for rapid, accurate and feasible identification of HAV and HEV.

  5. Prevalence of Hepatitis A virus (HAV) and Hepatitis E virus (HEV) in the patients presenting with acute viral hepatitis.

    Science.gov (United States)

    Joon, A; Rao, P; Shenoy, S M; Baliga, S

    2015-02-01

    Hepatitis A virus (HAV) and Hepatitis E virus (HEV) are both enterically transmitted, resulting in acute viral hepatitis (AVH) in developing countries. They pose major health problems in our country. This study was done to determine prevalence of HAV and HEV in patients presenting with AVH and the co-infection of HAV and HEV in these patients. A cross-sectional study of 2-years duration was conducted in the Department of Microbiology, KMC, Mangalore. A non-random sampling of 958 patients presenting with AVH was considered in the study. On the basis of history, serum samples were analysed for IgM anti-HAV and IgM anti-HEV for the detection of HAV and HEV, respectively using commercially available ELISA kits. Data collected was analysed by using Statistical Package for the Social Sciences (SPSS) version 11.5. The seroprevalence of HAV- and HEV-positive patients were 19.31% and 10.54%, respectively. The seroprevalence of both HAV and HEV in patients with acute viral hepatitis was 11.5%. The prevalence of HAV and HEV among males (68% and 31%) was higher than in females (31% and 20%) and was predominantly seen among young adults. These infections were predominantly seen during end of monsoons and beginning of winter. Though the prevalence of HAV is much higher than that of HEV, co-infection rate of 11.5% mandates the screening for HEV which will be of immense importance in pregnant women and improving levels of personal hygiene among higher socio-economic population. These data will be essential for planning of future vaccination strategies and for better sanitation programme in this part of the country.

  6. Efficient inhibition of hepatitis B virus replication by hepatitis delta virus ribozymes delivered by targeting retrovirus

    Directory of Open Access Journals (Sweden)

    Chen Long-Hua

    2010-03-01

    Full Text Available Abstract Background Hepatitis delta virus (HDV ribozyme is an attractive molecular tool that can specifically recognize and catalyze the self-cleavage of the viral RNA phosphodiester backbone. However, a major obstacle in the medical application of the HDV ribozyme is the lack of specificity in the delivery of the ribozyme to defined target cells. Results The objective of this study was to determine whether retroviral vectors can deliver the HDV ribozyme into the target cells and to elucidate whether HDV ribozyme plays a role in hepatitis B virus (HBV replication. In our study, the transduction of helper-free pseudotyped retrovirus, which showed a broad host range, in human hepatoma cells was performed under 2 conditions, that is, in the presence of polymerized human serum albumin (pHSA and in the absence of pHSA. The transduction ability in the presence of pHSA was higher than in the absence of pHSA. Moreover, HBsAg and HBeAg levels after transductions with pHSA were significantly lower than those in the absence of pHSA, thus indicating that the recombinant retrovirus had HBV-specific cleavage activity and targeted HepG2215 cells. Conclusions These data suggest that this system provides a new approach for targeting hepatocytes and has a great potential in gene therapy for HBV infection.

  7. MiR-122 in hepatitis B virus and hepatitis C virus dualinfection

    Institute of Scientific and Technical Information of China (English)

    Kyoungsub Song; Chang Han; Srikanta Dash; Luis A Balart; Tong Wu

    2015-01-01

    Hepatitis B virus (HBV) and hepatitis C virus (HCV)infections are the most common causes of chronicliver diseases and hepatocelluar carcinomas. Overthe past few years, the liver-enriched microRNA-122(miR-122) has been shown to differentially regulateviral replication of HBV and HCV. It is notable that thelevel of miR-122 is positively and negatively regulatedby HCV and HBV, respectively. Consistent with the welldocumentedphenomenon that miR-122 promotes HCVaccumulation, inhibition of miR-122 has been shown asan effective therapy for the treatment of HCV infectionin both chimpanzees and humans. On the other hand,miR-122 is also known to block HBV replication, andHBV has recently been shown to inhibit miR-122expression; such a reciprocal inhibition betweenmiR-122 and HBV suggests an intriguing possibilitythat miR-122 replacement may represent a potentialtherapy for treatment of HBV infection. As HBV andHCV have shared transmission routes, dual infection isnot an uncommon scenario, which is associated withmore advanced liver disease than either HBV or HCVmono-infection. Thus, there is a clear need to furtherunderstand the interaction between HBV and HCVand to delineate the role of miR-122 in HBV/HCV dualinfection in order to devise effective therapy. This reviewsummarizes the current understanding of HBV/HCVdual infection, focusing on the pathobiological role andtherapeutic potential of miR-122.

  8. Expression and characterization of hepatitis C virus core protein fused to hepatitis B virus core antigen

    Institute of Scientific and Technical Information of China (English)

    杨莉; 王春林; 汪垣; 李光地

    1999-01-01

    Recombinant plasmids were constructed by fusing the gene fragments encoding the full-length (1-191aa) and the truncated (1-40aa and 1-69aa) HCV core proteins (HCc) respectively to the core gene of HBV at the position of amino acid 144 and expressed in E. coli. The products were analyzed by ELISA, Western blotting as well as the immunization of the mice. The results showed that those fusion proteins (B144C191, B144C69, B144C40) possessed the dual antigenicity and immunogenicity of both hepatitis B virus core antigen (HBcAg) and hepatitis C virus core protein (HCc). Analysis by electron microscopy and CsCl density gradient ultra-centrifugation revealed that similar to the HBcAg itself, all fusion proteins were able to form particles. Comparison of the antigenicity and immunogenicity of those fusion proteins showed that the length of HCc gene fused to HBeAg had no much effect on the antigenicity and immunogenicity of HBcAg, however, B144C69 and B144C40 induced higher titres antibodies against HCc than B14d

  9. Hepatitis C Virus in Arab World: A State of Concern

    Directory of Open Access Journals (Sweden)

    Mohamed A. Daw

    2012-01-01

    Full Text Available Hepatitis C virus has been considered to be one of the most important devastating causes of chronic hepatitis, cirrhosis, and hepatic cellular carcinoma. The prevalence of such virus varies greatly over the world. Arab world has a unique geography and consists over nineteen countries who share the same heritage and customs and do speak the same language. In this area, the epidemiology of hepatitis C is not well understandable. Hepatitis C virus was found to be endemic in Arabia. The serostatus of such virus was found to be variable among these countries with uniform patterns of genotypes. Such prevalence varies tremendously according to the risk factors involved. Blood and blood products, haemodialysis, intravenous, and percutaneous drug users, and occupational, habitual, and social behavior were found to be the important factors involved. Hepatitis C will have major social, economic, and even political burdens on such young and dynamic societies. Thus, strategies and clear policy of intervention are urgently needed to combat the consequences of HCV both regionally and at state level of each country.

  10. Linking hepatitis C virus infection to pre-1994 blood transfusions in female patients

    Directory of Open Access Journals (Sweden)

    Christian Ramos Flores

    2017-03-01

    Full Text Available Resumen INTRODUCCIÓN La mayor parte de las transfusiones se llevan a cabo en mujeres. La introducción en los bancos de sangre de las técnicas serológicas disminuyó la incidencia de infección por virus de hepatitis C después de una transfusión. En México, las pacientes que se transfundieron antes de 1994 están en riesgo de presentar una infección por virus de hepatitis C. El objetivo de este estudio fue medir la asociación entre el antecedente transfusional antes de 1994 e infección por virus de hepatitis C en mujeres atendidas en la zona metropolitana de Guadalajara, México. MÉTODOS Estudio observacional, analítico, de casos y controles, en el que se incluyeron mujeres sanas y mujeres con infección por hepatitis vírica tipo C, en las cuales se determinó el antecedente transfusional antes y después de 1994. El grupo de casos lo conforman 150 mujeres con diagnóstico serológico y confirmatorio de hepatitis C, en tanto el grupo control son 150 mujeres sanas con serología negativa. RESULTADOS Se encontró un odds ratio de 9,07 (intervalo de confianza 95% 5,37 – 15,3; p<0,001, una proporción de casos expuestos de 0,72, de controles expuestos de 0,22, una fracción atribuible poblacional de 0,64 (intervalo de confianza 0,53 – 0,73 y una fracción atribuible en expuestos de 0,88 (intervalo de confianza 0,81 – 0,93. CONCLUSIONES En las mujeres, el haber tenido una transfusión antes de 1994 en la zona metropolitana de Guadalajara, representa un riesgo 9,07 veces mayor de infección por virus de la hepatitis C que no tener antecedente transfusional en esa fecha.

  11. The role of human T cell lymphotrophic virus type 1, hepatitis B virus and hepatitis C virus coinfections in leprosy

    Directory of Open Access Journals (Sweden)

    Paulo Roberto Lima Machado

    2012-12-01

    Full Text Available Leprosy spectrum and outcome is associated with the host immune response against Mycobacterium leprae. The role of coinfections in leprosy patients may be related to a depression of cellular immunity or amplification of inflammatory responses. Leprosy remains endemic in several regions where human T cell lymphotrophic virus type 1 (HTLV-1, hepatitis B virus (HBV or hepatitis C virus (HCV are also endemic. We have evaluated the evidence for the possible role of these viruses in the clinical manifestations and outcomes of leprosy. HTLV-1, HBV and HCV are associated with leprosy in some regions and institutionalization is an important risk factor for these viral coinfections. Some studies show a higher prevalence of viral coinfection in lepromatous cases. Although HBV and HCV coinfection were associated with reversal reaction in one study, there is a lack of information about the consequences of viral coinfections in leprosy. It is not known whether clinical outcomes associated with leprosy, such as development of reactions or relapses could be attributed to a specific viral coinfection. Furthermore, whether the leprosy subtype may influence the progression of the viral coinfection is unknown. All of these important and intriguing questions await prospective studies to definitively establish the actual relationship between these entities.

  12. [Gallbladder motor activity in patients with virus hepatitis B].

    Science.gov (United States)

    Mamos, Arkadiusz; Wichan, Paweł; Chojnacki, Jan; Grzegorczyk, Krzysztof

    2003-12-01

    In acute stage of virus hepatitis B patients often complain of dyspeptic discomfort. They may be a consequence of alimentary tract motor activity disorders including these of gallbladder. Routine ultrasonography in an early phase of virus hepatitis often reveals gallbladder wall thickening what may confirm the above thesis. Thus, a group of 15 patients in an acute phase of virus hepatitis B was subjected to examinations. Gallbladder motor activity was assessed by ultrasonographic method determining its total volume and ejection fraction and volume after test meal stimulus. First examination was performed in the first week since the appearance of yellowing of the walls, successive in 4 and 8 week of the disease. Obtained results were compared to the values obtained in the group of 25 healthy volunteers. It was found out that gallbladder volume was significantly decreased and ejection fraction increased in the acute phase of virus hepatitis B than in the controls. This may speak for gallbladder hyperreactivity in patients in the course of virus hepatitis B. These disorders decreased during two-month observation but even in the 8 week the investigated parameters differed from those found in the control group.

  13. Extrahepatic manifestations of chronic hepatitis C virus infection.

    Science.gov (United States)

    Cacoub, Patrice; Gragnani, Laura; Comarmond, Cloe; Zignego, Anna Linda

    2014-12-15

    Hepatitis C virus (HCV) infected patients are known to be at risk of developing liver complications i.e. cirrhosis and liver cancer. However, the risks of morbidity and mortality are underestimated because they do not take into account non-liver consequences of chronic hepatitis C virus infection. Numerous extrahepatic manifestations have been reported in up to 74% of patients, from perceived to disabling conditions. The majority of data concern hepatitis C virus-related autoimmune and/or lymphoproliferative disorders, from mixed cryoglobulinaemia vasculitis to frank lymphomas. More recently, other hepatitis C virus-associated disorders have been reported including cardiovascular, renal, metabolic, and central nervous system diseases. This review aims to outline most of the extrahepatic manifestations that are currently being investigated, including some of autoimmune and/or lymphoproliferative nature, and others in which the role of immune mechanisms appears less clear. Beyond the liver, hepatitis C virus chronic infection should be analyzed as a multifaceted systemic disease leading to heavy direct and indirect costs. The accurate consideration of extrahepatic consequences of such a systemic infection significantly increases the weight of its pathological burden. The need for effective viral eradication measures is underlined.

  14. Relationship between hepatitis B virus infection and hepatic metastasis in non-small cell lung cancer

    Institute of Scientific and Technical Information of China (English)

    Fei Gao; Lin Jia; Xiaobo Du; Yun Wang; Jianjun Han

    2014-01-01

    Objective:The purpose of the study was to explore the relationship between hepatitis B virus (HBV) infec-tion and hepatic metastasis in non-smal celllung cancer (NSCLC). Methods:Four hundred and eighty cases of NSCLC were retrospectively analyzed from January 2003 to January 2010, and the prevalence of hepatic metastasis of NSCLC in patients with and without hepatitis B virus infection were compared. Results:In the HBV carriers’ group, the prevalence of synchronous hepatic metastasis and metachronous hepatic metastasis were 13.2%and 5.9%, respectively. Meanwhile in the non-HBV group, those were 21.6%and 9.5%respectively. A significant dif erence between the two groups was found (P<0.05). Conclusion:The prevalence of synchronous hepatic metastasis and metachronous hepatic metastasis in non-smal celllung cancer with HBV infection are lower than those in non-HBV infection group. Hepatic metastasis is infrequent in HBV infected cases of NSCLC.

  15. Unfolded protein response in hepatitis C virus infection

    Directory of Open Access Journals (Sweden)

    Shiu-Wan eChan

    2014-05-01

    Full Text Available Hepatitis C virus (HCV is a single-stranded, positive-sense RNA virus of clinical importance. The virus establishes a chronic infection and can progress from chronic hepatitis, steatosis to fibrosis, cirrhosis and hepatocellular carcinoma. The mechanisms of viral persistence and pathogenesis are poorly understood. Recently the unfolded protein response (UPR, a cellular homeostatic response to endoplasmic reticulum (ER stress, has emerged to be a major contributing factor in many human diseases. It is also evident that viruses interact with the host UPR in many different ways and the outcome could be pro-viral, anti-viral or pathogenic, depending on the particular type of infection. Here we present evidence for the elicitation of chronic ER stress in HCV infection. We analyze the UPR signaling pathways involved in HCV infection, the various levels of UPR regulation by different viral proteins and finally, we propose several mechanisms by which the virus provokes the UPR.

  16. [Occult hepatitis B virus infection in chronic hepatitis C].

    Science.gov (United States)

    Jang, Jae Young; Park, Eui Ju

    2013-09-01

    Occult HBV infection is defined as the presence of HBV DNA in the liver (with or without detectable or undetectable HBV DNA in the serum) of individuals testing negative for HBsAg. Studies on occult HBV infection in hepatitis C patients have reported highly variable prevalence, because the prevalence of occult HBV infection varies depending on the hepatitis B risk factors and methodological approaches. The most reliable diagnostic approach for detecting occult HBV detection is through examination of liver DNA extracts. HCV has been suspected to strongly suppress HBV replication up to the point where it may be directly responsible for occult HBV infection development. However, more data are needed to arrive at a definitive conclusion regarding the role of HCV in inducing occult HBV infection. Occult HBV infection in chronic hepatitis C patients is a complex biological entity with possible relevant clinical implications. Influence of occult HBV infection on the clinical outcomes of chronic hepatitis C may be considered negative. However, recent studies have shown that occult HBV infection could be associated with the development of hepatocellular carcinoma and contribute to the worsening of the course of chronic liver disease over time in chronic hepatitis C patients. Nevertheless, the possible role of occult HBV infection in chronic hepatitis C is still unresolved and no firm conclusion has been made up until now. It still remains unclear how occult HBV infection affects the treatment of chronic hepatitis C. Therefore, in order to resolve current controversies and understand the pathogenic role and clinical impacts of occult HBV infection in chronic hepatitis C patients, well-designed clinical studies are needed.

  17. Infección por virus West Nile

    National Research Council Canada - National Science Library

    Pérez Ruiz, Mercedes; Sanbonmatsu Gámez, Sara; Ángel Jiménez Clavero, Miguel

    2011-01-01

    ... por virus West Nile Mercedes Pérez Ruiz a, *, Sara Sanbonmatsu Gámez a y Miguel Ángel Jiménez Clavero b a Servicio de Microbiología, Hospital Universitario Virgen de las Nieves, Gr...

  18. Medicinal herbs for hepatitis C virus infection. Protokol for a Cochrane Review

    DEFF Research Database (Denmark)

    Liu, J P; Manheimer, E; Tsutani, K;

    2001-01-01

    Hepatitis C virus (HCV) infection is a serious health problem world-wide. Medicinal herbs are increasingly being used for hepatitis C.......Hepatitis C virus (HCV) infection is a serious health problem world-wide. Medicinal herbs are increasingly being used for hepatitis C....

  19. Hepatitis E virus antibodies among patients with hemophilia, blood donors, and hepatitis patients.

    Science.gov (United States)

    Zaaijer, H L; Mauser-Bunschoten, E P; ten Veen, J H; Kapprell, H P; Kok, M; van den Berg, H M; Lelie, P N

    1995-07-01

    The presence of antibodies to hepatitis E virus (HEV) was studied among hemophiliacs, blood donors, and hepatitis patients. Four of 296 (1.4%) hemophiliacs and 5 of 1,275 (0.4%) donors were confirmed as positive for HEV antibodies (difference was not significant: P = 0.07). Parenteral transmission of HEV to hemophiliacs was thus rare or nonexistent. Seven of 187 hepatitis patients were found with HEV antibodies (IgG and IgM). Six persons fell ill shortly after arriving from HEV-endemic countries. The seventh patient, without a history of travel, represents a case of nontropical hepatitis E. Consequently, hepatitis E should be considered in patients suffering from acute non-ABC hepatitis, even in industrialized countries.

  20. Extrahepatic immune related manifestations in chronic hepatitis C virus infection.

    Science.gov (United States)

    Tampaki, Maria; Koskinas, John

    2014-09-21

    The association of chronic hepatitis C with immune related syndromes has been frequently reported. There is a great range of clinical manifestations affecting various systems and organs such as the skin, the kidneys, the central and peripheral nervous system, the musculoskeletal system and the endocrine glands. Despite the high prevalence of immune related syndromes in patients with chronic hepatitis C, the exact pathogenesis is not always clear. They have been often associated with mixed cryoglobulinemia, a common finding in chronic hepatitis C, cross reaction with viral antigens, or the direct effect of virus on the affected tissues. The aim of this review is to analyze the reported hepatitis C virus immune mediated syndromes, their prevalence and clinical manifestations and to discuss the most supported theories regarding their pathogenesis.

  1. Hepatitis

    Science.gov (United States)

    ... inflammation of the liver.” This inflammation can be caused by a wide variety of toxins, drugs, and metabolic diseases, as well as infection. There are at least 5 hepatitis viruses. Hepatitis A is contracted when a child eats food or drinks water that is contaminated with the virus or has ...

  2. 21 CFR 610.47 - Hepatitis C virus (HCV) “lookback” requirements.

    Science.gov (United States)

    2010-04-01

    ... 21 Food and Drugs 7 2010-04-01 2010-04-01 false Hepatitis C virus (HCV) âlookbackâ requirements... Disease Agents § 610.47 Hepatitis C virus (HCV) “lookback” requirements. (a) If you are an establishment... after a donor tests reactive for evidence of hepatitis C virus (HCV) infection when tested under §...

  3. Hepatitis D virus and hepatitis B virus infection in Amerindian communities of the Amazonas state, Colombia.

    Science.gov (United States)

    di Filippo Villa, Diana; Cortes-Mancera, Fabian; Payares, Edra; Montes, Neyla; de la Hoz, Fernando; Arbelaez, Maria Patricia; Correa, Gonzalo; Navas, Maria-Cristina

    2015-10-24

    In Colombia, cases of Hepatitis D virus (HDV) infection have been officially described since 1985 mainly in Amerindian population from Sierra Nevada de Santa Marta (North Caribbean Coast), Uraba (North West), and Amazon (South East). The last official report of a clinical case of HDV infection in Colombia was registered in 2005. The aims of this study were to identify cases of HDV and/or Hepatitis B virus (HBV) infection in asymptomatic Amerindians from Amazonas state, South East Colombia, and to describe the circulating viral genotypes in this population. The study population was recruited in 19 Amerindian communities in the Amazonas state. Individuals over 18 years old were screened by rapid test for Hepatitis B surface Antigen (HBsAg). Blood samples obtained from individuals positives for HBsAg in the rapid-test assay were analyzed for HBsAg, anti-HBc, anti-HDV IgM/IgG by ELISA. The detection of HBV DNA and HDV RNA was performed by PCR amplification. The viral genotype was determined by sequencing and phylogenetic analysis. A total of 23/861 individuals were positive for HBsAg detection by rapid test. Serological and/or molecular markers of HDV infection were demonstrated in 43.5 % (10/23) of samples from Amerindians. The phylogenetic analysis demonstrated the exclusive circulation of HBV subgenotype F1b of and HDV 3 in this population. A high frequency of HBV/HDV infection was found in Amerindian population from Amazonas State, Colombia (43.5 %, 10/23). Nine cases were identified in a population of 861 asymptomatic Amerindian individuals; one symptomatic case (with diagnosis of end-stage hepatic disease) was also identified in the study. The circulation of HDV 3 and HBV subgenotype F1b suggests a constant flow of these viral genotypes as a result of the interaction of the Amerindian populations from Amazon basin. Further studies are necessary to confirm whether HBV subgenotype F1b is the prevalent in the population from South East region in Colombia.

  4. Evidence of hepatitis E virus transmission by renal graft.

    Science.gov (United States)

    Pourbaix, Annabelle; Ouali, Nacera; Soussan, Patrick; Roque Afonso, Anne Marie; Péraldi, Marie-Noelle; Rondeau, Eric; Peltier, Julie

    2017-02-01

    Hepatitis E virus (HEV) can cause chronic infection among immunocompromised patients, especially solid organ transplant recipients, and can evolve to cirrhosis. Several modes of transmission are known. Here we describe the first two cases, to our knowledge, of HEV infection transmitted by a kidney graft from the same infected donor that led to chronic hepatitis. Consequently, systematic screening of donors by HEV serology and HEV RNA detection by polymerase chain reaction, particularly in endemic regions, should be considered.

  5. Using Bovine Viral Diarrhea Virus (BVDV) As Surrogate for Human Hepatitis C Virus

    Science.gov (United States)

    This test is designed to validate virucidal effectiveness claims for a product to be registered as a virucide. It determines the potential of the test agent to disinfect hard surfaces contaminated with human Hepatitis C virus (HCV).

  6. Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission

    Energy Technology Data Exchange (ETDEWEB)

    Stevens, C.E.; Taylor, P.E.; Tong, M.J.; Toy, P.T.; Vyas, G.N.; Nair, P.V.; Weissman, J.Y.; Krugman, S.

    1987-05-15

    A yeast-recombinant hepatitis B vaccine was licensed recently by the Food and Drug administration and is now available. To assess the efficacy of the yeast-recombinant vaccine, the authors administered the vaccine in combination with hepatitis B immune globulin to high-risk newborns. If infants whose mothers were positive for both hepatitis B surface antigen and the e antigen receive no immunoprophylaxis, 70% to 90% become infected with the virus, and almost all become chronic carriers. Among infants in this study who received hepatitis B immune globulin at birth and three 5-/sup +/g doses of yeast-recombinant hepatitis B vaccine, only 4.8% became chronic carriers, a better than 90% level of protection and a rate that is comparable with that seen with immune globulin and plasma-derived hepatitis B vaccine. Hepatitis surface antigen and antibodies were detected by radioimmunoassay. These data suggest that, in this high-risk setting, the yeast-recombinant vaccine is as effective as the plasma-derived vaccine in preventing hepatitis B virus infection and the chronic carrier state.

  7. Detection of SENV Virus in Healthy, Hepatitis B- and Hepatitis C-Infected Individuals in Yazd Province, Iran

    OpenAIRE

    Hosseini, Sayedeh Azimeh; Bouzari, Majid

    2016-01-01

    Background: SEN virus (SENV) is the latest virus proposed as a cause of unknown hepatitis cases. Among nine detected genotypes of the virus, genotypes D and H are more frequent in hepatitis cases of unknown origin. The aim of this study was to determine the frequency of SENV-D and SENV-H genotypes in the sera of healthy individuals and hepatitis B and C patients. Methods: Totally, 200 serum samples from healthy individuals as well as 50 hepatitis B and 50 hepatitis C patients were collected. ...

  8. Hepatitis fulminante en la Sierra Nevada: Una forma de superinfección del virus delta con el virus de la hepatitis B.

    Directory of Open Access Journals (Sweden)

    Alvaro Villanueva

    1992-06-01

    Full Text Available Durante septiembre de 1980 a octubre de 1983, se realizó un estudio seroepidemiológico para hepatitis A y B, en 258 personas en una ciudad (Santa Marta población de 250.000 y tres pequeños municipios (Santa Rosalía, Julio Zawady y Aracataca, poblaciones de 768, 800 y 5.000 habitantes respectivamente. La presencia de hepatitis A se encontró en un 77 a 93% (IgG Hepatitis A. Hbs Ag o Anti-Hbs Ag en 30.5% de la población en dos municipios (Santa Rosalía y Julio Zawady, en 2.5% en el municipio de Aracataca y 48.5% en la ciudad de Santa Marta. La presencia del Agente Delta (Anti-delta en el suero se determinó también en estas mismas poblaciones, encontrándose ausente en la ciudad y uno de los municipios (Aracataca, en contraste con una prevalencia de 13.7% y 22% en Julio Zawady y Santa Rosalía (P: 0.0001. Se excluyeron por historia clínica, antecedentes de drogadicción, transfusiones, o prácticas homosexuales, como mecanismos de transmisión de los virus B y delta. En veinte pacientes con diagnóstico histopalógico de hepatitis fulminante y en quienes se descartaron otras etiologías se demostró la presencia serológica de los virus de la hepatitis By Delta. De estos veinte, diez provenían de Julio Zawady y los otros diez de Santa Rosalía. La evolución clínica de esta enfermedad fue indistinguible de otras causas de falla hepática aguda. La mortalidad de estas formas fulminantes de hepatitis alcanzaron hasta un 65%. Los corticoides no modificaron el curso de esta enfermedad. La población joven mostró mayor compromiso y peor diagnóstico (P:0.033. La hepatitis fulminante de la Sierra Nevada de Santa Marta es el resultado de la superinfección con el virus Delta sobre la infección virus B. La aparición simultánea de casos intrafamiliares sugiere una relación importante entre los grupos comprometidos, aunque la forma exacta de transmisión permanece aún desconocida.

  9. [Extrahepatic manifestations of hepatitis C virus: the thyroid disorders].

    Science.gov (United States)

    Antonelli, Alessandro; Ferri, Clodoveo; Fallahi, Poupak; Ferrari, Silvia Martina; Ghinoi, Alessandra; Mascia, Maria Teresa; Ferrannini, Ele

    2005-01-01

    The prevalence of thyroid disorders has been studied in patients with chronic hepatitis C virus (HCV) infection by many studies. In general, thyroid dysfunction in chronic C hepatitis may include all forms of thyroid alterations, i.e. hypothyroidism and hyperthyroidism, Hashimoto's disease and isolated increases in antithyroid autoantibodies. The prevalence of various thyroid disorders and serum anti-thyroid autoantibodies is generally higher in chronic hepatitis type C than in hepatitis B or D or control series. The results of most studies in patients with hepatitis C confirm a higher prevalence of autoimmune thyroid involvement and hypothyroidism than in controls. More recently, some epidemiological studies have suggested a possible association between HCV and thyroid cancer. These last data need to be confirmed by other studies, but seem to be sufficient to suggest careful thyroid monitoring during the follow-up of patients with HCV infection.

  10. Hepatitis C virus (HCV) infection in Africa: a review

    OpenAIRE

    Karoney, Mercy Jelagat; Siika, Abraham Mogisi

    2013-01-01

    Hepatitis C virus (HCV) is a viral pandemic and a leading cause of chronic liver disease. This review highlights the epidemiology and management of Hepatitis C in Africa. We searched for articles on medline using the terms, “Hepatitis C”, “Prevalence”, “Epidemiology”, “Africa” and “Treatment”. The bibliographies of the articles found were used to find other references. We included articles published after 1995 only. The data was summarized and presented in tables and figures. Africa has the h...

  11. Zoonotic Hepatitis E Virus: Classification, Animal Reservoirs and Transmission Routes

    Science.gov (United States)

    Doceul, Virginie; Bagdassarian, Eugénie; Demange, Antonin; Pavio, Nicole

    2016-01-01

    During the past ten years, several new hepatitis E viruses (HEVs) have been identified in various animal species. In parallel, the number of reports of autochthonous hepatitis E in Western countries has increased as well, raising the question of what role these possible animal reservoirs play in human infections. The aim of this review is to present the recent discoveries of animal HEVs and their classification within the Hepeviridae family, their zoonotic and species barrier crossing potential, and possible use as models to study hepatitis E pathogenesis. Lastly, this review describes the transmission pathways identified from animal sources. PMID:27706110

  12. Validación de la técnica de determinación de proteínas totales por el método microcoomassie a doble longitud de onda para la muestra de producto terminado del antígeno de la nucleocápsida del virus de la hepatitis C

    Directory of Open Access Journals (Sweden)

    Maelys Miyares

    2013-08-01

    Full Text Available En el Centro de Ingeniería Genética y Biotecnología se obtuvo una formulación para un candidato vacunal del virus de la hepatitis C (VHC. Es un plásmido para la inmunización con ADN que contiene los genes de los tres antígenos estructurales del virus, mezclado con una variante truncada recombinante de la nucleocápsida del VHC como adyuvante molecular. Ambos compuestos se formularon en bulbos separados y se mezclaron en el momento de la inmunización. En el laboratorio de Desarrollo Analítica se validó la técnica de determinación de proteínas totales por el método de microcoomassie para la muestra de producto terminado (PT del antígeno de la nucleocápsida del virus de la hepatitis C (HCcAg. Los parámetros validados fueron: especificidad, linealidad, rango, exactitud, precisión y estabilidad de la muestra de PT, bajo dos condiciones diferentes de almacenamiento. El método resultó ser específico para la cuantificación del HCcAg, sin interferencias del placebo de la muestra, a diluciones superiores a 1:8. La curva del microcoomasie fue lineal en el rango de trabajo de 5-40 µg/mL. Se demostró la exactitud del método (recuperación 100 ± 10%. En la evaluación del sistema se cumplieron los criterios de aceptación establecidos para la precisión: repetibilidad (CV £ 5% y precisión intermedia (CV £ 10%. El PT es estable a (4 ºC y 22-25 ºC durante los tiempos estudiados sin alteración en la concentración del HCcAg. La validación fue satisfactoria y el método fue adecuado para cuantificar proteínas en la muestra de PT. Este resultado permite dar cumplimiento a las especificaciones establecidas para este producto.

  13. Biological impact of hepatitis B virus X-hepatitis C virus core fusion gene on

    Institute of Scientific and Technical Information of China (English)

    Ma Zhen; Qin-Hai Shen; Guo-Min Chen; Da-Zhi Zhang

    2008-01-01

    AIM: To investigate the biological impact of hepatitis B virus X- hepatitis C virus core (HBV X-HCV C) fusion gene on hepatoma cells.METHODS: The recombinant adenoviruses AdXC,Ad-X and Ad-C expressing HBV X-HCV C fusion gene,HBVX gene and HCV C gene were constructed,respectively.Hepatoma cells were infected with different recombinant adenoviruses.MTT,colonyforming experiment,FCM,TUNEL assay were performed to observe the biological impact of the HBV X-HCV C fusion gene on liver cells.RESULTS: MTT showed that the Ad-XC group cells grew faster than the other group cells.Colony-forming experiment showed that the colony-forming rate for the Ad-XC group cells was significantly higher than that for the other group cells.FCM analysis showed that Ad-XC/Ad-X/Ad-C infection enhanced the progression of GIS phase in the HepG2 cell cycle.The apoptosis index of the Ad-XC,Ad-X,Ad-C group cells was significantly lower than that of the AdO and control group cells.Semi-quantitative RT-PCR showed that the expression level of c-myc was the highest in AdXC infected cells.Tumor formation was found at the injected site of mice inoculated with Ad-XC-infected LO2 cells,but not in control mice.CONCLUSION: Ad-XC,Ad-X and Ad-C facilitate the proliferation activity of HepG2 cells and inhibit their apoptosis in vitro.The effect of Ad-XC is significantly stronger than that of Ad-X and Ad-C.Up-regulation of c-myc may be one of the mechanisms underlying the synergism of HBVX and HCV C genes on hepatocarcinogenesis in athymic nude mice.

  14. Genotype characterization of occult hepatitis B virus strains among Egyptian chronic hepatitis C patients.

    Science.gov (United States)

    Kishk, R; Atta, H Aboul; Ragheb, M; Kamel, M; Metwally, L; Nemr, N

    2014-03-13

    Chronic hepatitis C virus (HCV) infection combined with occult hepatitis B virus (HBV) infection has been associated with increased risk of hepatitis, cirrhosis and hepatocellular carcinoma. This study aimed to determine the prevalence of occult HBV infection among Egyptian chronic HCV patients, the genotype and occurrence of surface gene mutations of HBV and the impact of co-infection on early response to treatment. The study enrolled 162 chronic HCV patients from Ismailia Fever Hospital, Egypt, who were HBV surface antigen-negative. All patients were given clinical assessment and biochemical, histological and virological examinations. HBV-DNA was detectable in sera from 3 patients out of the 40 patients who were positive for hepatitis B core antibody. These 3 patients were responsive to combination therapy at treatment week 12; only 1 of them had discontinued therapy by week 24. HBV genotype D was the only detectable genotype in those patients, with absence of "a" determinant mutations among those isolates.

  15. Three Cases of Radiation-Induced Hepatitis B Virus Reactivation after Hepatic Tomotherapy: Case Report

    Energy Technology Data Exchange (ETDEWEB)

    Kong, Moon Kyoo; Hong, Seong Eon; Kim, Byung Ho; Choi, Jin Hyun [Kyung Hee University College of Medicine, Seoul (Korea, Republic of)

    2011-03-15

    Radiation-induced liver disease (RILD) has been characterized as a veno-occlusive disease with anicteric elevation of alkaline phosphatase (ALP). However, some RILD patients present with elevated transaminase levels rather than with anicteric elevation of ALP, and these findings are common in the Asia-Pacific region where hepatitis B virus (HBV) infection is associated with 70-90% of hepatocelluar carcinoma (HCC) cases. In addition, the development of RILD is more common in patients with hepatitis B virus-related HCC. These findings indicate that susceptibility to RILD might be different in HBV carriers and non-carriers, and moreover, RILD in patients with HBV-related HCC might be associated with another unique pathogenesis such as HBV reactivation. However, HBV reactivation after hepatic irradiation has been reported in only a few studies. This study reports three cases of HBV reactivation after hepatic tomotherapy for management of HCC.

  16. Stimulation of Cellular Proliferation by Hepatitis B Virus X Protein

    Directory of Open Access Journals (Sweden)

    Charles R. Madden

    2001-01-01

    Full Text Available Chronic infection with the hepatitis B virus (HBV is a known risk factor in the development of human hepatocellular carcinoma (HCC. The HBV-encoded X protein, HBx, has been investigated for properties that may explain its cancer cofactor role in transgenic mouse lines. We discuss here recent data showing that HBx is able to induce hepatocellular proliferation in vitro and in vivo. This property of HBx is predicted to sensitize hepatocytes to other HCC cofactors, including exposure to carcinogens and to other hepatitis viruses. Cellular proliferation is intimately linked to the mechanism(s by which most tumor-associated viruses transform virus-infected cells. The HBx alteration of the cell cycle provides an additional mechanism by which chronic HBV infection may contribute to HCC.

  17. Cytokine profiles and hepatic injury in occult hepatitis C versus chronic hepatitis C virus infection.

    Science.gov (United States)

    Mousa, N; Eldars, W; Eldegla, H; Fouda, O; Gad, Y; Abousamra, N; Elmasry, E; Arafa, M

    2014-01-01

    Occult hepatitis C virus (HCV) infection is a new entity that should be considered when diagnosing patients with abnormal liver functions of unknown origin. This work was carried out to evaluate T-helper 1/T-helper 2 (Th1/Th2) cytokine profiles in patients with occult HCV infection versus chronic hepatitis C (CHC) infection, also to investigate any association between theses cytokines and liver histological features in both groups. Serum levels of Th1 cytokines (IL-2, IFN-gamma) and Th2 (IL-4 and IL-10) were measured in 35 patients with occult HCV infection compared to 50 patients with chronic hepatitis C infection and 30 healthy controls. We have found that Th1 cytokines were significantly increased in patients with CHC infection than in both occult HCV infection and control groups (p less than 0.001). On the other hand, serum IL-4 levels were higher in occult HCV infection than in CHC and control groups (p less than 0.001). Furthermore, serum IL-10 levels were higher in both patient groups vs control group (pless than 0.001), with no significant difference between CHC and occult HCV groups. Finally, only serum IL-10 levels were significantly higher among patients with high activity (A2-A3) than those with low activity (A0-A1) in both CHC and occult HCV groups (p=0.038, p=0.025, respectively). Patients with occult HCV infection exhibited a distinct immunoregulatory cytokine pattern that is shifted towards the Th2 arm.

  18. Occult hepatitis C virus infection is more common than hepatitis B infection in maintenance hemodialysis patients

    Institute of Scientific and Technical Information of China (English)

    Pankaj Jain; Sandeep Nijhawan

    2008-01-01

    Patients of end stage renal disease on maintenance hemodialysis were enrolled to study the prevalence of occult and dual hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and non-occult hepatitis B and C virus infection. One hundred and two patients were enrolled. Thirty patients had HCV infection, three of them were positive in anti-HCV. So, 27 (90%) of HCVpositive patients had occult HCV infection. Eleven (11%)patients had HBV infection. Five patients were positive in anti-HBc or HBV-DNA, but negative in HBsAg (occult HBV infection). Three (3%) patients had dual HBV and HCV infection. None of the patients showed changes in viral markers during the follow-up of 8 mo on average (1-12 mo).

  19. Avian hepatitis E virus in chickens, Taiwan, 2013.

    Science.gov (United States)

    Hsu, Ingrid W-Y; Tsai, Hsiang-Jung

    2014-01-01

    A previously unidentified strain of avian hepatitis E virus (aHEV) is now endemic among chickens in Taiwan. Analysis showed that the virus is 81.5%-86.5% similar to other aHEVs. In Taiwan, aHEV infection has been reported in chickens without aHEV exposure, suggesting transmission from asymptomatic cases or repeated introduction through an unknown common source(s).

  20. MOLECULAR-EPIDEMIOLOGICAL FEATURES OF HEPATITIS B VIRUS

    Directory of Open Access Journals (Sweden)

    V. V. Gerasimova

    2015-01-01

    Full Text Available Abstract. Hepatitis B virus is a serious issue of public health services all over the world, particularly in Russia and its regions. The cause can be determined due to its higher incidence rate in different ethnic and geographical groups, variety of manifestation of clinical forms as well as outcomes. According to WHO data, about 50 million people in the world are annually infected with hepatitis B virus. Development of molecular-genetic methods of research has allowed to expand representations about the activator biology. Genetic variability of hepatitis B virus genome has been subject to identification of 10 various geographically widespread genotypes designated by letters from A to J. In a number of genotypes subgenotypes differing from one another on 4–8% full genome sequences are revealed. In the work a table of geographical prevalence of various genotypes of hepatitis B virus in the world is presented. The geographic distribution of genotypes of hepatitis B virus is closely connected with endemic regions and indigenous population, living there. So the genotypes B and C are connected with the population of Asian countries, genotypes A and D are extended among European countries and in the USA. The genotype D is considered to be a prevailing type among patients with hepatitis B in several regions of Turkey. The phylogenetic analysis of nucleotide sequences of hepatitis B virus isolates in African regions has shown presence of three subgenotypes — А1, А2, А3. In the countries of Asia the following six subgenotypes B are noted: В1 in Japan, В2–В5 and В7 in East Asia Subgenotip B6 is found among indigenous population living in the Arctic regions, including Alaska, northern Canada and Greenland. The genotype C has five serotypes (С1–С5 which are extended in East and South East Asia. The genotype D, also has five subgenotypes (D1–D5 which are extended in Africa, India, the Mediterranean region, Europe. Genotype F has four

  1. Chimeric hepatitis B virus core particles with parts or copies of the hepatitis C virus core protein.

    OpenAIRE

    Yoshikawa, A.; Tanaka, T; Hoshi, Y.; Kato, N; K. Tachibana; Iizuka, H; Machida, A; Okamoto, H; Yamasaki, M.; Miyakawa, Y

    1993-01-01

    Either parts or multiple copies of the core gene of hepatitis C virus (HCV) were fused to the 3' terminus of the hepatitis B virus (HBV) core gene with 34 codons removed. As many as four copies of HCV core protein (720 amino acids) were fused to the carboxy terminus of truncated HBV core protein (149 amino acids) without preventing the assembly of HBV core particles. Chimeric core particles were sandwiched between monoclonal antibody to HBV core and that to HCV core, thereby indicating that a...

  2. Chimeric hepatitis B virus core particles with parts or copies of the hepatitis C virus core protein.

    OpenAIRE

    Yoshikawa, A.; Tanaka, T; Hoshi, Y.; Kato, N.; Tachibana, K; Iizuka, H.; Machida, A; Okamoto, H; Yamasaki, M.; Miyakawa, Y

    1993-01-01

    Either parts or multiple copies of the core gene of hepatitis C virus (HCV) were fused to the 3' terminus of the hepatitis B virus (HBV) core gene with 34 codons removed. As many as four copies of HCV core protein (720 amino acids) were fused to the carboxy terminus of truncated HBV core protein (149 amino acids) without preventing the assembly of HBV core particles. Chimeric core particles were sandwiched between monoclonal antibody to HBV core and that to HCV core, thereby indicating that a...

  3. Four-year follow up of hepatitis C patients vaccinated against hepatitis B virus

    Institute of Scientific and Technical Information of China (English)

    Slawomir Chlabicz; Tadeusz Wojciech Lapinski; Anna Grzeszczuk; Danuta Prokopowicz

    2005-01-01

    AIM: Patients with chronic hepatitis C have been recommended to receive vaccinations against hepatitis B. Our study aimed at evaluating the hepatitis B immunogenicity and efficacy against hepatitis B virus infection 4 years after primary immunization series in a group of patients with chronic hepatitis C.METHODS: We recruited 36 out of 48 hepatitis C virus (HCV) infected individuals who were vaccinated against hepatitis B virus (20 μg of recombinant HBsAg at 0-1-6mo schedule) in 1998. Here we measured anti-HBs titers and anti-HBc 4 years after delivery of the third dose of primary immunization series.RESULTS: After 4 years a total of 13/36 (36%) HCV infected patients had seroprotective titers of anti-HBs compared with 9/10 (90%) in the control group, (P<0.05).Similarly the mean concentration of anti-HBs found in hepatitis C patients was significantly lower than that found in healthy subjects (18.3 and 156.0 mIU/mL respectively (P<0.05). None of the HCV infected patients or controls became infected with HBV during the study period as confirmed by anti-HBc negativity.CONCLUSION: We demonstrated that 4 years after HBV immunizations' more than 60% of vaccinated HCV patients did not maintain seroprotective levels of anti-HBs, which might put them at risk of clinically significant breakthrough infections. Further follow-up studies are required to clarify whether memory B and T lymphocytes can provideprotection in chronic hepatitis C patients in the absence or inadequate titers of anti-HBs.

  4. Clinical features of vascular disorders associated with chronic hepatitis virus infection.

    Science.gov (United States)

    Nishida, Naoshi; Kudo, Masatoshi

    2014-01-01

    Hepatitis virus infections can be accompanied by extrahepatic manifestations that may be caused by the host's immune reaction to the viral infection. Vascular involvement is one of these manifestations and is occasionally associated with life-threatening conditions due to systemic organ failure. The unique profile of hepatitis-related vascular involvement is associated with infection by different types of hepatitis viruses. For example, polyarteritis nodosa is more frequently reported in patients with chronic hepatitis B than those with chronic hepatitis C. Similarly, membranous nephropathy is a notable manifestation among hepatitis B virus-positive patients. In contrast, patients infected with hepatitis C virus are at risk for cryoglobulinemia and membranoproliferative glomerulonephritis. Antiviral therapy is necessary to control these kinds of vasculitis related to hepatitis virus infections; however, immunosuppressive agents may be required to treat severe cases. New antiviral drugs for viral hepatitis could improve the prognosis of vascular and renal involvement.

  5. Internist diagnosis and management of chronic hepatitis B virus infection.

    Science.gov (United States)

    McMahon, Brian J; Block, Joan; Haber, Barbara; London, Thomas; McHugh, James A; Perrillo, Robert; Neubauer, Richard

    2012-11-01

    Chronic infection with the hepatitis B virus can lead to hepatocellular carcinoma and cirrhosis in up to 25% of infected individuals. As many as 2 million individuals in the US may have chronic hepatitis B infection, most of whom immigrated to the US from hepatitis B-endemic regions of the world. A 2010 report from the Institute of Medicine noted that two thirds of patients with hepatitis B are unaware of their infection, and most health care providers do not screen for hepatitis B or know how to manage hepatitis B-positive patients. In 2010, the Hepatitis B Foundation convened a group of primary care providers to consider the existing evidenced-based recommendations and strategies for implementation of hepatitis B screening into routine practice. The group designed an easy-to-use algorithm for screening, initial evaluation, ongoing management, and referral to a subspecialist when appropriate. Internal medicine specialists, including primary care providers and subspecialists, need to understand the steps they can take to address this often under-recognized disorder. Copyright © 2012 Elsevier Inc. All rights reserved.

  6. Hepatitis (For Parents)

    Science.gov (United States)

    ... of three viruses: the hepatitis A virus the hepatitis B virus the hepatitis C virus In some rare cases, ... also called serum hepatitis) is caused by the hepatitis B virus (HBV). HBV can cause a wide range of ...

  7. Molecular epidemiology of gibbon hepatitis B virus transmission

    NARCIS (Netherlands)

    S. Noppornpanth (Suwanna); B.L. Haagmans (Bart); P. Bhattarakosol; P. Ratanakorn; H.G.M. Niesters (Bert); Y. Poovorawan (Yong); A.D.M.E. Osterhaus (Albert)

    2003-01-01

    textabstractAlthough transmission of human hepatitis B virus (HBV) variants to nonhuman primates is well documented, it remains to be elucidated whether nonhuman primate HBV is transmissible to humans. The prevalence and transmission routes of gibbon HBV were analysed in 101 captive gibbons in Thail

  8. Cloned genomes of infectious hepatitis C viruses and uses thereof

    DEFF Research Database (Denmark)

    2007-01-01

    The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays...

  9. Detection of Hepatitis A Virus RNA in Saliva

    OpenAIRE

    Mackiewicz, Vincent; Dussaix, Elisabeth; Le Petitcorps, Marie-France; Roque-Afonso, Anne Marie

    2004-01-01

    Hepatitis A virus (HAV) is shed in feces but also in saliva. HAV RNA was detected in saliva in five out of six acutely infected patients with HAV viremia. Serum and saliva sequences were identical. The simplicity of obtaining material allows the recommendation of the use of saliva for investigation of outbreaks.

  10. Analysis of Avian Hepatitis E Virus from Chickens, China

    OpenAIRE

    Zhao, Qin; Zhou, En Min; Dong, Shi Wei; Qiu, Hong Kai; Zhang, Lu; Hu, Shou Bin; Zhao, Fei Fei; Jiang, Shi Jin; Sun, Ya Ni

    2010-01-01

    Avian hepatitis E virus (HEV) has been identified in chickens; however, only 4 complete or near-complete genomic sequences have been reported. We found that the near-complete genomic sequence of avian HEV in chickens from China shared the highest identity (98.3%) with avian HEV from Europe and belonged to avian HEV genotype 3.

  11. Analysis of avian hepatitis E virus from chickens, China.

    Science.gov (United States)

    Zhao, Qin; Zhou, En Min; Dong, Shi Wei; Qiu, Hong Kai; Zhang, Lu; Hu, Shou Bin; Zhao, Fei Fei; Jiang, Shi Jin; Sun, Ya Ni

    2010-09-01

    Avian hepatitis E virus (HEV) has been identified in chickens; however, only 4 complete or near-complete genomic sequences have been reported. We found that the near-complete genomic sequence of avian HEV in chickens from China shared the highest identity (98.3%) with avian HEV from Europe and belonged to avian HEV genotype 3.

  12. [Neurological symptoms with a hepatitis E virus infection

    NARCIS (Netherlands)

    Wardt, J. van de; Dubbelink, T.B. Olde; Visee, H.F.; Schneeberger, P.M.; Lutgens, S.P.; Eijk, J.J.J. van

    2016-01-01

    BACKGROUND: Infection with hepatitis E virus genotype 3 (HEV3) is an emerging zoonosis in the industrialized world. The infection usually proceeds asymptomatically. Extrahepatic sequelae including neurological symptoms have been described. CASE DESCRIPTION: A 52-year-old man presented at the emergen

  13. Regulatory T Cells in Chronic Hepatitis B Virus Infection

    NARCIS (Netherlands)

    J.N. Stoop (Jeroen Nicolaas)

    2007-01-01

    textabstractWorldwide 400 million people suffer from chronic hepatitis B virus (HBV) infection and approximately 1 million people die annually from HBV-related disease. To clear HBV, an effective immune response, in which several cell types and cytokines play a role, is important. It is known that p

  14. Hepatitis E Virus Genotype 3 in Humans and Swine, Bolivia

    Science.gov (United States)

    Cavallo, Annalisa; Gonzales, José Luis; Bonelli, Sara Irene; Valda, Ybar; Pieri, Angela; Segundo, Higinio; Ibañez, Ramón; Mantella, Antonia; Bartalesi, Filippo; Tolari, Francesco; Bartoloni, Alessandro

    2011-01-01

    We determined the seroprevalence of hepatitis E virus (HEV) in persons in 2 rural communities in southeastern Bolivia and the presence of HEV in human and swine fecal samples. HEV seroprevalence was 6.3%, and HEV genotype 3 strains with high sequence homology were detected. PMID:21801630

  15. Therapeutic vaccination against chronic hepatitis C virus infection

    NARCIS (Netherlands)

    Ip, Peng Peng; Nijman, Hans W.; Wilschut, Jan; Daemen, Toos

    2012-01-01

    Approximately 170 million people worldwide are chronic carriers of Hepatitis C virus (HCV). To date, there is no prophylactic vaccine available against HCV. The standard-of-care therapy for HCV infection involves a combination of pegylated interferon-α and ribavirin. This therapy, which is commonly

  16. Hepatitis C virus RNA functionally sequesters miR-122

    DEFF Research Database (Denmark)

    Luna, Joseph M; Scheel, Troels K H; Danino, Tal

    2015-01-01

    Hepatitis C virus (HCV) uniquely requires the liver-specific microRNA-122 for replication, yet global effects on endogenous miRNA targets during infection are unexplored. Here, high-throughput sequencing and crosslinking immunoprecipitation (HITS-CLIP) experiments of human Argonaute (AGO) during...

  17. A genetically humanized mouse model for hepatitis C virus infection.

    NARCIS (Netherlands)

    Dorner, M.; Horwitz, J.A.; Robbins, J.B.; Barry, W.T.; Feng, Q.; Mu, K.; Jones, C.T.; Schoggins, J.W.; Catanese, M.T.; Burton, D.R.; Law, M.; Rice, C.M.; Ploss, A.

    2011-01-01

    Hepatitis C virus (HCV) remains a major medical problem. Antiviral treatment is only partially effective and a vaccine does not exist. Development of more effective therapies has been hampered by the lack of a suitable small animal model. Although xenotransplantation of immunodeficient mice with hum

  18. [Neurological symptoms with a hepatitis E virus infection

    NARCIS (Netherlands)

    Wardt, J. van de; Dubbelink, T.B. Olde; Visee, H.F.; Schneeberger, P.M.; Lutgens, S.P.; Eijk, J.J.J. van

    2016-01-01

    BACKGROUND: Infection with hepatitis E virus genotype 3 (HEV3) is an emerging zoonosis in the industrialized world. The infection usually proceeds asymptomatically. Extrahepatic sequelae including neurological symptoms have been described. CASE DESCRIPTION: A 52-year-old man presented at the

  19. Therapeutic vaccination against chronic hepatitis C virus infection

    NARCIS (Netherlands)

    Ip, Peng Peng; Nijman, Hans W.; Wilschut, Jan; Daemen, Toos

    2012-01-01

    Approximately 170 million people worldwide are chronic carriers of Hepatitis C virus (HCV). To date, there is no prophylactic vaccine available against HCV. The standard-of-care therapy for HCV infection involves a combination of pegylated interferon-α and ribavirin. This therapy, which is commonly

  20. Hepatitis E Virus in Pork Liver Sausage, France

    NARCIS (Netherlands)

    Berto, A.; Grierson, S.; Hakze-van der Honing, van der R.W.; Martelli, F.; Johne, R.; Reetz, J.; Ulrich, R.G.; Pavio, N.; Poel, van der W.H.M.; Banks, M.

    2013-01-01

    We investigated viability of hepatitis E virus (HEV) identified in contaminated pork liver sausages obtained from France. HEV replication was demonstrated in 1 of 4 samples by using a 3-dimensional cell culture system. The risk for human infection with HEV by consumption of these sausages should be

  1. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus.

    Science.gov (United States)

    Levine, James W; Gota, Carmen; Fessler, Barri J; Calabrese, Leonard H; Cooper, Sheldon M

    2005-06-01

    There is a well established link between type II mixed cryoglobulinemia (MC) and hepatitis C virus (HCV) infection, and HCV is believed to be the cause of cryoprotein formation and tissue deposition. Successful treatment of HCV infection has resulted in resolution of cryoglobulinemia and vasculitis. We describe 4 patients who had persistent MC and vasculitis despite successful eradication of HCV with antiviral therapy.

  2. Hepatitis E Virus in Pork Liver Sausage, France

    NARCIS (Netherlands)

    Berto, A.; Grierson, S.; Hakze-van der Honing, van der R.W.; Martelli, F.; Johne, R.; Reetz, J.; Ulrich, R.G.; Pavio, N.; Poel, van der W.H.M.; Banks, M.

    2013-01-01

    We investigated viability of hepatitis E virus (HEV) identified in contaminated pork liver sausages obtained from France. HEV replication was demonstrated in 1 of 4 samples by using a 3-dimensional cell culture system. The risk for human infection with HEV by consumption of these sausages should be

  3. Hepatitis C virus expressing reporter tagged NS5A protein

    DEFF Research Database (Denmark)

    2014-01-01

    Hepatitis C reporter viruses containing Core through NS2 of prototype isolates of all major HCV genotypes and the remaining genes of isolate JFH1, by insertion of reporter genes in domain III of HCV NS5A were developed. A deletion upstream of the inserted reporter gene sequence conferred favorable...

  4. Historical epidemiology of hepatitis C virus (HCV) in selected countries

    DEFF Research Database (Denmark)

    Bruggmann, P; Berg, T; Øvrehus, A L H

    2014-01-01

    Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained thro...

  5. Resistance to hepatitis C virus: potential genetic and immunological determinants.

    Science.gov (United States)

    Mina, Michael M; Luciani, Fabio; Cameron, Barbara; Bull, Rowena A; Beard, Michael R; Booth, David; Lloyd, Andrew R

    2015-04-01

    Studies of individuals who were highly exposed but seronegative (HESN) for HIV infection led to the discovery that homozygosity for the Δ32 deletion mutation in the CCR5 gene prevents viral entry into target cells, and is associated with resistance to infection. Additionally, evidence for protective immunity has been noted in some HESN groups, such as sex workers in The Gambia. Population studies of individuals at high risk for hepatitis C virus infection suggest that an HESN phenotype exists. The body of evidence, which suggests that protective immunity allows clearance of hepatitis C virus without seroconversion is growing. Furthermore, proof-of-principle evidence from in-vitro studies shows that genetic polymorphisms can confer resistance to establishment of infection. This Review discusses the possibility that genetic mutations confer resistance against hepatitis C virus, and also explores evidence for protective immunity, including via genetically programmed variations in host responses. The data generally strengthens the notion that investigations of naturally arising polymorphisms within the hepatitis C virus interactome, and genetic association studies of well characterised HESN individuals, could identify potential targets for vaccine design and inform novel therapies.

  6. Prevalence of hepatitis G virus infection in kidney transplant recipients.

    Science.gov (United States)

    Dussol, B; Charrel, R; De Lamballerie, X; Berthezene, P; Brunet, P; De Micco, P; Raoult, D; Berland, Y

    1997-08-15

    We investigated the prevalence, risk factors, and consequences of hepatitis G virus (HGV) infection in 87 kidney transplant recipients. Infection was diagnosed with reverse transcriptase polymerase chain reaction using primers in the NS3 region of the viral genoma. Twenty-four patients (27.5%) were HGV RNA positive (HGV+ group) and 63 patients (72.5%) were HGV RNA negative (HGV- group). No statistically significant differences were found between the two groups for age, sex, transplantation and hemodialysis duration, number of kidney transplantations, serum creatinine, history of transfusions, hepatitis B and C virus infections, and percentage of patients having suffered from acute rejection. Acute and chronic hepatitis were not more prevalent in the HGV+ group than in the HGV- group. HGV infection is highly prevalent in kidney transplant recipients but does not alter liver or kidney functions. HGV contamination may be linked to nosocomial transmission during long-term hemodialysis.

  7. Investigation of Hepatitis C Virus Infection Rate of Patients in a General Hospital

    Institute of Scientific and Technical Information of China (English)

    2013-01-01

    Objective To investigate the infection rate of hepatitis C virus among the ambulatory patients and in-patients of a tertiary teaching hospital, and study the demographic factors related to the prevalence of hepatitis C virus infection. Methods All patients tested for hepatitis C virus antibody from July 2008 to July 2009 in Peking Union Medical College Hospital were enrolled in this cross-sectional analysis. The prevalence of hepatitis C virus infection was compared according to age, gender, and departments, respectively. Among patients with positive serology hepatitis C virus marker, the positivity of hepatitis C virus RNA was analysed. Results Among 29 896 subjects included, the hepatitis C virus antibody of 494 patients were positive (1.7%). When patients were divided into 9 age groups, the age speciifc prevalence of hepatitis C virus antibody were 0.2%, 1.7%, 1.2%, 1.1%, 1.5%, 1.9%,2.6%, 2.4%and 2%, respectively. The prevalence of hepatitis C virus antibody in non-surgical department and surgical department was 3%and 1%, respectively. The prevalence of hepatitis C virus antibody of males was higher than that of the females. Total of 194 patients with positive hepatitis C virus antibody were tested for hepatitis C virus RNA, the RNA level of 113 patients (58.2%) were higher than the low detection limit. Conclusions The prevalence of hepatitis C virus antibody was relatively high among patients of general tertiary hospital. Age group of 60-69, males and patients in non-surgical departments were factors associated with high rate of hepatitis C virus infection.

  8. Dual Infection with Hepatitis B and Epstein-Barr Virus Presenting with Severe Jaundice, Coagulopathy, and Hepatitis B Virus Chronicity Outcome

    Science.gov (United States)

    Rao, Sirish C.; Ashraf, Imran; Mir, Fazia; Samiullah, Sami; Ibdah, Jamal A.; Tahan, Veysel

    2017-01-01

    Patient: Female, 34 Final Diagnosis: HBV and EBV dual infection Symptoms: Jaundice • fatigue • anorexia • subjective weight loss Medication: — Clinical Procedure: — Specialty: Gastroenterology and Hepatology Objective: Rare co-existance of disease or pathology Background: Hepatitis B virus (HBV) has been reported as a coinfection with hepatitis C virus (HCV), hepatitis D virus (HDV), cytomegalovirus (CMV), and human immunodeficiency virus (HIV). Case Report: A 34-year-old female presented to our clinic with epigastric pain and severe acute hepatitis manifested as jaundice associated with hyperbilirubinemia, elevated transaminases, and coagulopathy. The patient was diagnosed with acute HBV with Epstein-Barr virus (EBV) coinfection leading to subsequent chronic hepatitis B. Conclusions: To our knowledge, this patient case is the first reported case of HBV and EBV coinfection reported in the literature. HBV and EBV coinfection may cause severe acute hepatitis with HBV chronicity. PMID:28202897

  9. Efectos sobre la salud de la contaminación de agua y alimentos por virus emergentes humanos

    Directory of Open Access Journals (Sweden)

    Sílvia Bofill-Mas

    2005-01-01

    Full Text Available El desarrollo de tecnologías moleculares aplicadas a estudios ambientales ha permitido constatar que incluso en países altamente industrializados existe una alta prevalencia de virus en el medio ambiente, lo que causa un importante impacto en la salud pública e importantes pérdidas económicas, principalmente a través de la transmisión de virus por agua y alimentos. Concentraciones significativas de virus son detectadas en las aguas vertidas al ambiente y en los biosólidos generados en plantas de tratamiento de agua residual. En este trabajo se describen las características generales de la contaminaci ón ambiental por virus, principalmente por virus emergentes, analizándose con mayor profundidad los virus de la hepatitis E (VHE y los poliomavirus humanos como los virus contaminantes ambientales de más reciente identificación en países industrializados. Se ha demostrado que existe una elevada prevalencia de los poliomavirus humanos, BK y JC, en agua residual en todos los paí- ses estudiados, lo que implica la potencial transmisión de los virus y de genes potencialmente cancerígenos por vía oral. Estudios recientes demuestran que el patrón epidemiológico de la infección por VHE en países industrializados es complejo y que una gran diversidad de cepas del VHE infecta simultáneamente a la población. El control de la contaminación viral del medio ambiente requiere la estandarización de técnicas moleculares y el desarrollo de un programa de vigilancia que permita valorar parámetros víricos y reducir la diseminación de las enfermedades establecidas y de las infecciones víricas emergentes.

  10. Effects of interferons on hepatitis C virus infection

    Directory of Open Access Journals (Sweden)

    Bojić Ivanko

    2006-01-01

    Full Text Available Introduction. The consequences of hepatitis C virus infections (chronic hepatitis, liver cirrhosis and hepatocellular carcinoma are one of the major problems in clinical medicine. The persistence of infection in spite of high specific antibody titre suggests that the virus has the ability to "escape" the immunological response. Interferon therapy. Interferons are important components of the early host response to infection. They have antiviral, antiproliferative, and immunomodulatory activities. Many viruses have developed the ability to "annul" or alleviate the action of interferon by preventing its synthesis or by interfering with signaling pathways in the cells. During acute infection some of the non-structural proteins of HCV block regulatory factors that are responsible for the synthesis of endogenous infection. Within a cell, interferon induces a number of genes to produce proteins that prevent virus replication. Among them, the most important are RNA-dependent protein kinase and the eukaryotic initiation factor. However, viral proteins, especially viral envelope proteins and nonstructural protein 5A, prevent their phosphorylation and activation which enhance virus replication. These are the facts that have to be considered when using IFN in chronic hepatitis C patients. .

  11. Hepatitis E Virus in Industrialized Countries: The Silent Threat

    Directory of Open Access Journals (Sweden)

    Pilar Clemente-Casares

    2016-01-01

    Full Text Available Hepatitis E virus (HEV is the main cause of acute viral hepatitis worldwide. Its presence in developing countries has been documented for decades. Developed countries were supposed to be virus-free and initially only imported cases were detected in those areas. However, sporadic and autochthonous cases of HEV infection have been identified and studies reveal that the virus is worldwide spread. Chronic hepatitis and multiple extrahepatic manifestations have also been associated with HEV. We review the data from European countries, where human, animal, and environmental data have been collected since the 90s. In Europe, autochthonous HEV strains were first detected in the late 90s and early 2000s. Since then, serological data have shown that the virus infects quite frequently the European population and that some species, such as pigs, wild boars, and deer, are reservoirs. HEV strains can be isolated from environmental samples and reach the food chain, as shown by the detection of the virus in mussels and in contaminated pork products as sausages or meat. All these data highlight the need of studies directed to control the sources of HEV to protect immunocompromised individuals that seem the weakest link of the HEV epidemiology in industrialized regions.

  12. Hepatitis E Virus in Industrialized Countries: The Silent Threat

    Science.gov (United States)

    Ramirez-Gonzalez, Eugenio

    2016-01-01

    Hepatitis E virus (HEV) is the main cause of acute viral hepatitis worldwide. Its presence in developing countries has been documented for decades. Developed countries were supposed to be virus-free and initially only imported cases were detected in those areas. However, sporadic and autochthonous cases of HEV infection have been identified and studies reveal that the virus is worldwide spread. Chronic hepatitis and multiple extrahepatic manifestations have also been associated with HEV. We review the data from European countries, where human, animal, and environmental data have been collected since the 90s. In Europe, autochthonous HEV strains were first detected in the late 90s and early 2000s. Since then, serological data have shown that the virus infects quite frequently the European population and that some species, such as pigs, wild boars, and deer, are reservoirs. HEV strains can be isolated from environmental samples and reach the food chain, as shown by the detection of the virus in mussels and in contaminated pork products as sausages or meat. All these data highlight the need of studies directed to control the sources of HEV to protect immunocompromised individuals that seem the weakest link of the HEV epidemiology in industrialized regions. PMID:28070522

  13. HDVDB: a data warehouse for hepatitis delta virus.

    Science.gov (United States)

    Singh, Sarita; Gupta, Sunil Kumar; Nischal, Anuradha; Pant, Kamlesh Kumar; Seth, Prahlad Kishore

    2015-01-01

    Hepatitis Delta Virus (HDV) is an RNA virus and causes delta hepatitis in humans. Although a lot of data is available for HDV, but retrieval of information is a complicated task. Current web database 'HDVDB' provides a comprehensive web-resource for HDV. The database is basically concerned with basic information about HDV and disease caused by this virus, genome structure, pathogenesis, epidemiology, symptoms and prevention, etc. Database also supplies sequence data and bibliographic information about HDV. A tool 'siHDV Predict' to design the effective siRNA molecule to control the activity of HDV, is also integrated in database. It is a user friendly information system available at public domain and provides annotated information about HDV for research scholars, scientists, pharma industry people for further study.

  14. Clinical significance of occult hepatitis B virus infection

    Institute of Scientific and Technical Information of China (English)

    Miriam Romero; Antonio Madejón; Conrado Fernández-Rodríguez; Javier García-Samaniego

    2011-01-01

    Occult hepatitis B virus (HBV) infection (OBI) is defined as the presence of HBV DNA in the liver (with or without detectable HBV DNA in serum) for individuals testing HBV surface antigen negative. Until recently, the clinical effect of OBI was unclear on the progression of liver disease; on the development of hepatocellular carcinoma; and on the risk for reactivation or transmission of HBV infection. Several studies suggest a high prevalence of OBI among patients with cryptogenic chronic liver disease, but its role in the progression to cirrhosis remains unclear. Although OBI has been well documented in human immunodeficiency virus (HIV)-positive patients, especially among those coinfected with hepatitis C virus, further studies are needed to determine its current clinical impact in HIV setting.

  15. Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis B virus.

    Directory of Open Access Journals (Sweden)

    John M Taylor

    Full Text Available Hepatitis B virus (HBV and hepatitis delta virus (HDV are major sources of acute and chronic hepatitis. HDV requires the envelope proteins of HBV for the processes of assembly and infection of new cells. Both viruses are able to infect hepatocytes though previous studies have failed to determine the mechanism of entry into such cells. This study began with evidence that suramin, a symmetrical hexasulfated napthylurea, could block HDV entry into primary human hepatocytes (PHH and was then extrapolated to incorporate findings of others that suramin is one of many compounds that can block activation of purinergic receptors. Thus other inhibitors, pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS and brilliant blue G (BBG, both structurally unrelated to suramin, were tested and found to inhibit HDV and HBV infections of PHH. BBG, unlike suramin and PPADS, is known to be more specific for just one purinergic receptor, P2X7. These studies provide the first evidence that purinergic receptor functionality is necessary for virus entry. Furthermore, since P2X7 activation is known to be a major component of inflammatory responses, it is proposed that HDV and HBV attachment to susceptible cells, might also contribute to inflammation in the liver, that is, hepatitis.

  16. Prevalence of hepatitis viruses in patients with acute hepatitis and characterization of the detected genotype 4 hepatitis E virus sequences in Mongolia.

    Science.gov (United States)

    Tsatsralt-Od, Bira; Baasanjav, Nachin; Nyamkhuu, Dulmaa; Ohnishi, Hiroshi; Takahashi, Masaharu; Okamoto, Hiroaki

    2016-02-01

    Hepatitis E is considered to be a worldwide public health problem. Although the prevalence of hepatitis E virus (HEV) antibodies in healthy individuals is noted to be 11%, no patients with acute hepatitis E have previously been identified in Mongolia. Three hundred two consecutive patients (183 males and 119 females; median age of 22.0 [Interquartile range: 18.3-25.0] years) who were clinically diagnosed with sporadic acute hepatitis during 2012-2013 in Ulaanbaatar, Mongolia, were studied. By serological and/or molecular approaches, 77 (25.5%), 93 (30.8%), 19 (6.3%), 48 (15.9%), and 12 (4.0%) of the patients were diagnosed with acute hepatitis of types A, B, C, D (superinfection of hepatitis delta virus on a background of chronic hepatitis B virus infection) and E, respectively, while the cause of hepatitis was unknown in the remaining 53 patients (17.5%). The 12 hepatitis E patients had no history of travel abroad in the 3 months before the onset of disease, and lived separately in fixed or movable houses with water supplied via pipe, tank or well, denying transmission from a common water supply. The 12 HEV isolates obtained from the patients showed high nucleotide identities of 99.7-100%, and a representative HEV isolate, MNE13-227, was closest to the Chinese isolates of genotype 4, with the highest identity of 97.3% in the 304-nt ORF2 sequence and 92.1% over the entire genome. The present study revealed the occurrence of autochthonous acute hepatitis E in Mongolia, caused by a monophyletic genotype 4 HEV strain.

  17. Superinfection of hepatitis E Virus as a cause of decompen-sation in liver cirrhosis due to hepatitis B virus

    Institute of Scientific and Technical Information of China (English)

    Manisha Jain; Anita Chakravarti; P Kar Mbbs Md

    2009-01-01

    Objevtive:Super infection with hepatitis A virus (HAV)and hepatitis E virus (HEV)in the presence of un-derlying hepatocellular injury can cause severe illness.In endemic areas such as India,however most patients already have been exposed to HAV but could still be susceptible to HEV infection.In our study we determined the seroprevalence of anti-HAV IgMand anti-HEV IgMto assess the incidence of superinfection with these vi-ruses in cirrhotic patients with the goal of defining the need for protection against these viruses and further cor-relate the presence of these viruses with the clinical course.Methods:We studied 53 patients of cirrhosis as a result of Hepatitis B virus.Apparent causes of decompensation were ruled out before their inclusion in the study group.Serum sample from these patients was tested for HBsAg,anti HBc IgG,anti HEV IgMand anti HAV IgG and IgMby commercially available ELISA kit.Liver function test was done on all the patients and correlated with various serological markers.Results:anti HBc IgG was present in all the cases of cirrhosis. Hepatitis B surface antigen was present in 20 out of 53 cases of cirrhosis.None of the patients demonstrated anti-HAV IgM,however one patient had anti-HEV IgM.Conclusion:Superinfection with HAV in adult pa-tient is uncommon in India.Prevalence of acute HEV infection in decompensated cirrhosis is low in the present study but presence of HEV superinfection in one patient corroborates the apprehension of liver function deterio-ration following superinfection with HEV virus.

  18. A homosexual japanese man with acute hepatitis due to hepatitis B virus genotype ae, concurrent with amebic colitis

    OpenAIRE

    Sakaguchi, Kohsaku; KOBASHI, HARUHIKO; Takaki,Akinobu; Kato, Jun; Nawa,Toru; Tatsukawa, Masashi; ISHIKAWA, SHIN; Iwasaki, Yoshiaki; Miyake,Yasuhiro; Shiratori, Yasushi

    2007-01-01

    We report herein a case with acute hepatitis due to hepatitis B virus genotype Ae, concurrent with amebic colitis. A 39-year-old homosexual Japanese man was admitted to our hospital with jaundice. Laboratory tests showed an elevation of transaminase and positivity for hepatitis B surface antigen and IgM-type antibody to hepatitis B core antigen. The hepatitis B virus genotype was determined to be Ae. Furthermore, a mud-like stool with blood and mucous had sometimes been noted during the past ...

  19. Epstein-Barr Virus Infection Mimicking Drug-Induced Hepatitis in a Critically ill Patient During Antituberculosis Therapy

    OpenAIRE

    Wang, Ching-Hsun; Li, Yao-Feng; Shen, Chih-Hao

    2014-01-01

    Introduction: Although hepatitis is frequently observed during antituberculosis (anti-TB) therapy, acute viral hepatitis should be ruled out first, especially in the endemic areas. In addition to common types of viral hepatitis, ie, hepatitis A, hepatitis B, and hepatitis C viruses, Epstein-Barr virus (EBV) may result in hepatitis in some cases. Case Presentation: Herein, we reported a critically ill patient who developed cholestatic hepatitis in the intensive care unit during the anti-TB the...

  20. Hepatitis C virus and type 2 diabetes

    Institute of Scientific and Technical Information of China (English)

    Francesco Negro; Mahnaz Alaei

    2009-01-01

    This review focuses on the relationship between hepat it is Cvirus (HCV) infect ion and glucose metabolism derangements. Cross-sectional and longitudinal studies have shown that the chronic HCV infection is associated with an increased risk of developing insulin resistance (IR) and type 2 diabetes (T2D). The direct effect of HCV on the insulin signaling has been analyzed in experimental models. Although currently available data should be considered as preliminary, HCV seems to affect glucose metabolism via mechanisms that involve cellular pathways that have been implicated in the host innate immune response. IR and T2D not only accelerate the histological and clinical progression of chronic hepatitis C, but also reduce the early and sustained virological response to interferonalpha-based therapy. Thus, a detailed knowledge of themechanisms underlying the HCV-associated glucose metabolism derangements is warranted, in order to improve the clinical management of chronic hepatitis C patients.

  1. Swine-like hepatitis E viruses are a cause of unexplained hepatitis in the Netherlands

    NARCIS (Netherlands)

    Herremans, M.; Vennema, H.; Bakker, J.; van der Veer, B.; Duizer, E.; Benne, C. A.; Waar, K.; Hendrixks, B.; Schneeberger, P.; Blaauw, G.; Kooiman, M.; Koopmans, M. P. G.

    2007-01-01

    Hepatitis E virus (HEV) infections in developed countries are recognized as an imported disease related to travel to endemic regions. However, increasing evidence suggests that HEV infection may also occur in the developed countries and that swine may act as a possible reservoir. To investigate the

  2. Swine-like hepatitis E viruses are a cause of unexplained hepatitis in the Netherlands

    NARCIS (Netherlands)

    Herremans, M.; Vennema, H.; Bakker, J.; van der Veer, B.; Duizer, E.; Benne, C. A.; Waar, K.; Hendrixks, B.; Schneeberger, P.; Blaauw, G.; Kooiman, M.; Koopmans, M. P. G.

    2007-01-01

    Hepatitis E virus (HEV) infections in developed countries are recognized as an imported disease related to travel to endemic regions. However, increasing evidence suggests that HEV infection may also occur in the developed countries and that swine may act as a possible reservoir. To investigate the

  3. Genotype A2/adw2 Strain of Hepatitis B Virus in Turkey

    OpenAIRE

    Sayan, Murat; Akhan, Sila Cetin; Bozdayi, Mitha

    2010-01-01

    Background and Aims Previous studies have demonstrated the dominance of genotype D subtype ayw in patients with hepatitis B virus infection in Turkey. The aim of the present study is to report, for the first time, genotype A2 subtype adw2 of hepatitis B virus in a patient who is an inactive hepatitis B carrier in Turkey. Materials and Methods Hepatitis B virus DNA isolated from the serum sample was amplified by polymerase chain reaction. The polymerase gene segment of the hepatitis B virus wa...

  4. Pathogenicity of GB virus C on virus hepatitis and hemodialysis patients

    Institute of Scientific and Technical Information of China (English)

    Wan-Fu Zhu; Li-Min Yin; Peng Li; Jian Huang; Hui Zhuang

    2003-01-01

    AIM: To determine the pathogenicity of GB virus C (GBV-C)on liver and the effects of its co-infection on the clinical features and prognosis of patients with hepatitis B and C.METHODS: Cross-sectional study was carried out in 413patients with acute, chronic hepatitis B or liver cirrhosis,and in 67 hemodialysis patients. A 20-month prospective cohort study was carried out in 95 hepatitis B and 80 hepatitis C patients. A reverse transcriptase nested polymerase chain reaction (RT-nPCR) of the 5′-noncoding region was used to detect circulating GBV-C RNA. Liver function was determined by an automated analyzer for all patients.RESULTS: The prevalence of GBV-C in the high-risk populations with the virus transmitted via blood was high,ranging from 16.2 to 28.8%. Co-infection with GBV-C in hepatitis B patients did not affect the clinical features of the disease or liver function. The dialysis patients infected with GBV-C alone did not develop functional changes to the liver.Prospective cohort study showed that GBV-C co-infection did not affect the clinical features, prognosis or negative serum conversion rate of chronic hepatitis B and C.CONCLUSION: The results suggest that GBV-C has no marked pathogenicity on liver, so it may not be a hepatitis virus.

  5. Co occurrence of Hepatitis B Virus Infection and Autoimmune Hepatitis with Marked Hepatitis B Virus Replication Following Treatment of Autoimmune Hepatitis

    Directory of Open Access Journals (Sweden)

    Tyagi I

    2015-10-01

    Full Text Available Background: Children have different natural history of Hepatitis B virus (HBV infection. They commonly develop asymptomatic chronic carrier state which is less frequently seen in adults. We describe a rare case of acute on chronic liver failure (ACLF in the course of concurrent autoimmune hepatitis (AIH and HBV infection and replication of HBV following the treatment for autoimmune hepatitis. Case Report: A 15 year old male child presented with jaundice and altered sensorium. Physical examination showed hepatosplenomegaly. The liver function tests were markedly altered. Serology was positive for anti liver kidney microsomal antibody (LKM, hepatitis B surface antigen (HBsAg and immunoglobulin M (IgM anti hepatitis B core antigen (HBc Ag. Liver biopsy showed chronic hepatitis with features of acute exacerbation. Patient was started on treatment with azathioprine and prednisolone for AIH following which clinical and biochmemical improvement was noted. After two years of continued treatment a repeat biopsy performed showed fairly reduced histological activity, but marked replication of the HBV (immunohistochemistry for HBsAg and anti HBcAg showed diffuse cytoplasmic and nuclear positivity respectively. These findings suggest viral replication although the patient was clinically stable. At six months follow-up after the second biopsy and cessation of azathioprine and prednisolone, there were raised liver enzymes and viral load, hence the patient was started on antiviral drug Entecavir to which there was good response and the patient is presently doing well. Conclusion: We describethe rare co occurrence of HBV infection and AIH with marked HBV replication following the treatment for AIH

  6. New models of hepatitis E virus replication in human and porcine hepatocyte cell lines

    Science.gov (United States)

    Hepatitis E virus (HEV) causes acute, enterically-transmitted hepatitis. It is associated with large epidemics in tropical and subtropical regions where it is endemic or with sporadic cases in non-endemic regions. Unlike other hepatitis viruses, HEV has several animal reservoirs. Phylogenetic studie...

  7. Sero-prevalence of hepatitis C virus among blood donors in Lagos ...

    African Journals Online (AJOL)

    Sero-prevalence of hepatitis C virus among blood donors in Lagos, Nigeria. ... PROMOTING ACCESS TO AFRICAN RESEARCH ... The prevalence of Hepatitis C virus (HCV), one of the causative agents of viral hepatitis was investigated. ... Senegal (6); Sierra Leone (1); South Africa (96); South Sudan (1); Sudan (3) ...

  8. [Risk of vertical transmission of hepatitis B virus in Tunisia].

    Science.gov (United States)

    Hannachi, N; Bahri, O; Ben Fredj, N; Boukadida, J; Triki, H

    2010-01-01

    The risk of vertical transmission of hepatitis B virus (HBV) varies with type of viral endemicity, degree of maternal infection and genomic characteristics of the virus. The aim of this study is to estimate this risk in Tunisia using serological and molecular methods to evaluate HBV replication, to determine viral genotypes and to detect presence of occult hepatitis in 2709 pregnant women. Serological markers were detected by ELISA methods, Genotype was determined by PCR-RFLP and occult hepatitis by nested-PCR. Four percent of women were positive for HBsAg; only 3% of them were also positive for HBeAg. Viral replication, over than 10(3) copies/ml, was detected in 61% of positive HBsAg patients. Three viral genotypes were detected: D (95%), B (3%) and A (3%). Occult hepatitis was detected in 4% of sera with "anti-HBc isolated" profile. In conclusion, the risk of vertical transmission of HBV exists in Tunisia. It increases by frequency of precore mutants, predominance of the genotype previously associated with high levels of replication and possibility of occult hepatitis B. These results show the importance of screening by serological HBV markers systematically during pregnancy with evaluation of viral replication in order to prevent vertical risk by efficient tools.

  9. The Viral Efficacy of three Disinfectants on Hepatitis B virus

    Directory of Open Access Journals (Sweden)

    Arami Sakineh

    2015-01-01

    Full Text Available   Background and Aims: Hepatitis B is an important infection route in dentistry requiring different disinfectants to prevent its transmission. The aim of this study was to compare the effects of chemical disinfectants (FD366, ISORAPID and 5% sodium hypochlorite 2/100 to remove Hepatitis B infections from the dental surfaces.   Materials and Methods: In this experimental laboratory trial, serum of 10 HBV patients was poured into microtubes, FD366, ISORAPID and hypochlorite disinfectants were added to them. PCR experiments with viral diagnostic kits were used to diagnose the virus genome. Real time PCR was used to evaluate after incubation with the disinfectants. The reductions occurred in the viral load of Hepatitis B were statistically analyzed using Kruskal-wallis and Mann-Whitney U tests .   Results: No significant antiviral efficacy was noted following the application of FD366 and ISORAPID disinfectants (P=0/07. However, hypochlorite showed the most efficacy to disinfect Hepatitis B and a significant difference was found among them (P<0.0001.   Conclusion: Under the study limitations, FD366 and ISORAPID disinfectants did not show adequate efficacy to remove Hepatitis B virus. Hypochlorite was the most effective disinfectant.

  10. Antiphospholipid antibodies in Brazilian hepatitis C virus carriers

    Directory of Open Access Journals (Sweden)

    A.M. Atta

    2008-06-01

    Full Text Available Hepatitis C, a worldwide viral infection, is an important health problem in Brazil. The virus causes chronic infection, provoking B lymphocyte dysfunction, as represented by cryoglobulinemia, non-organ-specific autoantibody production, and non-Hodgkin's lymphoma. The aim of this research was to screen for the presence of antiphospholipid autoantibodies in 109 Brazilian hepatitis C virus carriers without clinical history of antiphospholipid syndrome. Forty healthy individuals were used as the control group. IgA, IgG, and IgM antibodies against cardiolipin and β2-glycoprotein I were measured with an enzyme-linked immunosorbent assay, using a cut-off point of either 20 UPL or 20 SBU. While 24 (22.0% hepatitis C carriers had moderate titers of IgM anticardiolipin antibodies (median, 22.5 MPL; 95%CI: 21.5-25.4 MPL, only three carriers (<3% had IgG anticardiolipin antibodies (median, 23 GPL; 95%CI: 20.5-25.5 GPL. Furthermore, IgA anticardiolipin antibodies were not detected in these individuals. Male gender and IgM anticardiolipin seropositivity were associated in the hepatitis C group (P = 0.0004. IgA anti-β2-glycoprotein-I antibodies were detected in 29 of 109 (27.0% hepatitis C carriers (median, 41 SAU; 95%CI: 52.7-103.9 SAU. Twenty patients (18.0% had IgM anti-β2-glycoprotein I antibodies (median, 27.6 SMU; 95%CI: 23.3-70.3 SMU, while two patients had IgG antibodies against this protein (titers, 33 and 78 SGU. Antiphospholipid antibodies were detected in only one healthy individual, who was seropositive for IgM anticardiolipin. We concluded that Brazilian individuals chronically infected with hepatitis C virus present a significant production of antiphospholipid antibodies, mainly IgA anti-β2-glycoprotein I antibodies, which are not associated with clinical manifestations of antiphospholipid syndrome.

  11. Occult hepatitis C virus infection in Iranian hemodialysis patients

    OpenAIRE

    Eslamifar, Ali; Ramezani, Amitis; Ehteram, Hassan; Razeghi, Effat; Ahmadi, Farrokhlagha; Amini, Manouchehr; Banifazl, Mohammad; Etemadi, Gelavizh; Keyvani, Hossein; Bavand, Anahita; Aghakhani, Arezoo

    2015-01-01

    Background: Occult hepatitis C virus (HCV) infection is defined as the presence of HCV-RNA in liver or peripheral blood mononuclear cells (PBMCs) in the absence of detectable hepatitis C antibody (anti-HCV) or HCV-RNA in the serum. Low concentrations of HCV-RNA may be detected in PBMCs of hemodialysis (HD) patients and this could have a great impact on the management of HD patients. Objectives: The aim of this study was to detect the occult HCV infection in Iranian HD patients. Patients and M...

  12. Hepatitis E. virus is prevalent in the Danish pig population

    DEFF Research Database (Denmark)

    Breum, Solvej Østergaard; Hjulsager, Charlotte Kristiane; De Deus, N.;

    Hepatitis E virus (HEV) is responsible for major outbreaks of acute hepatitis in humans from developing countries, but evidence increases that also in industrialized countries locally acquired HEV infections acor. The disease usually affects young adults and has a relatively high mortality in inf...... with swine or ingestion of undercooked swine meat. The aim of this study was to clarify if HEV is prevalent in the Danish pig population. Presence of HEV was examined by detection of HEV by real time RT-PCR or serological screening for HEV antibodies....

  13. Zoonotic Aspects of Hepatitis E Virus in Denmark

    DEFF Research Database (Denmark)

    Krog, Jesper Schak

    In this thesis the epidemiology of hepatitis E virus (HEV) in Denmark was explored. Globally, four genotypes of HEV are recognized along with several species specific variants. Non-zoonotic genotypes of the virus are found in the developing world, where they cause epidemics due to fecal contamina......In this thesis the epidemiology of hepatitis E virus (HEV) in Denmark was explored. Globally, four genotypes of HEV are recognized along with several species specific variants. Non-zoonotic genotypes of the virus are found in the developing world, where they cause epidemics due to fecal...... contaminated water resources. Zoonotic genotypes have a primary reservoir in pigs worldwide. Humans infected with HEV are often asymptomatic, but can experience an acute self-limiting hepatitis. Pigs are asymptomatic and only mild lesions have been observed in the liver of infected animals. In the developed...... focuses on the viral contamination of mussels farmed in Denmark. The mussels was assayed for HEV and Rotavirus, known to occur in shellfish and cause disease. Furthermore, PCV2was also assayed as an indicator of porcine waste contamination. All samples analyzed were negative for HEV and RV, however...

  14. Coinfection of hepatitis B and hepatitis C virus in HIV-infected patients in South India

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    AIM: To screen for the co-infection of hepatitis B (HBV)and hepatitis C virus (HCV) in human immunodeficiency virus (HIV) infected patients insouthern India.METHODS: Five hundred consecutive HIV infected patients were screened for Hepatitis B Virus (HBsAg and HBV-DNA) and Hepatitis C virus (anti-HCV and HCV-RNA)using commercially available ELISA kits; HBsAg, HBeAg/anti-HBe (Biorad laboratories, USA) and anti-HCV (Murex Diagnostics, UK). The HBV-DNA PCR was performed to detect the surface antigen region (pre S-S). HCV-RNA was detected by RT-PCR for the detection of the constant 5' putative non-coding region of HCV.RESULTS: HBV co-infection was detected in 45/500 (9%)patients and HCV co-infection in 11/500 (2.2%) subjects.Among the 45 co-infected patients only 40 patients could be studied, where the detection rates of HBe was 55%(22/40), antiHBe was 45% (18/40) and HBV-DNA was 56% (23/40). Among 11 HCV co-infected subjects, 6(54.5%) were anti-HCV and HCV RNA positive, while 3(27.2%) were positive for anti-HCV alone and 2 (18%)were positive for HCV RNA alone.CONCLUSION: Since the principal routes for HIV transmission are similar to that followed by the hepatotropic viruses, as a consequence, infections with HBV and HCV are expected in HIV infected patients.Therefore, it would be advisable to screen for these viruses in all the HIV infected individuals and their sexual partners at the earliest.

  15. Hepatitis

    Institute of Scientific and Technical Information of China (English)

    2009-01-01

    2009209 Effects of chronic hepatitis B virus infection on human hepatic cytochrome P450 2C9.ZHO Fuping(周福平),et al.Dept Infect Dis,Shanghai Changzheng Hosp,Shanghai 200003.Chin J Infect Dis,2009;27(2):94-98.

  16. Hepatitis

    Institute of Scientific and Technical Information of China (English)

    1992-01-01

    920691 The determination of serum hepa-titis B virus DNA by polymerase chain rea-ction in hepatitis B patients treated withalpha-interferon. XU. Jianye(徐建业), et al.Centr Lab, Chongqing Cancer Instit, 630030.Chin J Intern Med, 1992; 31(5): 278-280. To clarify the status of HBV in serum of

  17. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.

    Science.gov (United States)

    Liu, Chun-Jen

    2014-01-01

    Dual hepatitis C virus (HCV)/hepatitis B virus (HBV) infection is not uncommon in HCV or HBV endemic areas and among subjects at risk of parenteral transmission. In patients dually infected with hepatitis C and B, the disease manifestations are usually more severe than those with either virus infection. In the past decade, the following issues have been resolved. In dually infected patients with active hepatitis C, combined pegylated interferon alfa plus ribavirin was effective, the treatment outcomes being similar to patients with HCV monoinfection. During long-term follow-up, the HCV response was sustained in around 97% of patients; and the long-term outcomes including the development of hepatocellular carcinoma and liver-related mortality were improved. However, several clinical issues remain to be resolved. First, host and viral factors influencing the long-term outcomes and treatment options in patients with dual HCV/HBV infection await further studies. Second, about 60% of dually infected patients with baseline undetectable serum HBV DNA levels develop HBV reactivation after the start of treatment. How to prevent and treat HBV reactivation should be clarified. Third, about 30% of dually infected patients lose hepatitis B surface antigen at 5 years after the end of combination therapy; the mechanisms need further investigations. Fourth, the optimal treatment strategies for dually infected patients with active hepatitis B or established cirrhosis should be explored in future clinical trials. Finally, the role of new direct-acting antiviral-based therapy for the treatment of patients with dual HCV/HBV infection also remains to be evaluated. © 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

  18. Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review

    Science.gov (United States)

    Lin, Kuan-Yin; Chen, Guan-Jhou; Lee, Yu-Lin; Huang, Yi-Chia; Cheng, Aristine; Sun, Hsin-Yun; Chang, Sui-Yuan; Liu, Chun-Eng; Hung, Chien-Ching

    2017-01-01

    Hepatitis A virus (HAV) is one of the most common infectious etiologies of acute hepatitis worldwide. The virus is known to be transmitted fecal-orally, resulting in symptoms ranging from asymptomatic infection to fulminant hepatitis. HAV can also be transmitted through oral-anal sex. Residents from regions of low endemicity for HAV infection often remain susceptible in their adulthood. Therefore, clustered HAV infections or outbreaks of acute hepatitis A among men who have sex with men and injecting drug users have been reported in countries of low endemicity for HAV infection. The duration of HAV viremia and stool shedding of HAV may be longer in human immunodeficiency virus (HIV)-positive individuals compared to HIV-negative individuals with acute hepatitis A. Current guidelines recommend HAV vaccination for individuals with increased risks of exposure to HAV (such as from injecting drug use, oral-anal sex, travel to or residence in endemic areas, frequent clotting factor or blood transfusions) or with increased risks of fulminant disease (such as those with chronic hepatitis). The seroconversion rates following the recommended standard adult dosing schedule (2 doses of HAVRIX 1440 U or VAQTA 50 U administered 6-12 mo apart) are lower among HIV-positive individuals compared to HIV-negative individuals. While the response rates may be augmented by adding a booster dose at week 4 sandwiched between the first dose and the 6-mo dose, the need of booster vaccination remain less clear among HIV-positive individuals who have lost anti-HAV antibodies. PMID:28611512

  19. [Hepatitis C virus infection in hemodialysis].

    Science.gov (United States)

    Simon, N

    1995-10-01

    The surveillance of HCV infections is now a must in the clinical management of hemodialysis patients. The natural history of HCV has shown acute hepatitis to be a constant feature although rarely symptomatic. Progression to chronicity occurs in 90% of the cases with detectable viremia in 80% of the cases. The long-term impact of the liver disease in chronic hemodialyzed patients remains to be defined. HCV is responsible for more than 90% of the non-A, non-B hepatitis case diagnosed among hemodialyzed patients. The transmission is either transfusional or nosocomial. Following recent transfusion safety regulations, the nosocomial risk became the predominant residual risk. Thus, all efforts should target HCV eradication. In the absence of specific prophylaxis, this can only be achieved by enforcement of very stringent precautions.

  20. Enfermedad por el virus Ébola medidas de bioseguridad

    Directory of Open Access Journals (Sweden)

    Kattia Bucknor Johnson

    2015-12-01

    Full Text Available El virus Ébola representa el patógeno prototipo de fiebre hemorrágica viral, causando una enfermedad severa de alta tasa de mortalidad. Esta alta mortalidad, combinada con la ausencia de vacunación y de un tratamiento específico, hace que el virus Ébola sea un patógeno importante para la salud pública. La fiebre hemorrágica de Ébola se cree es una zoonosis con persistencia del virus en especies de reservorios encontrados en áreas endémicas. A pesar de todos los esfuerzos realizados en cada brote para identificar los reservorios naturales no se conocen los huéspedes potenciales ni los artrópodos vectores. El manejo de los casos está basado en el aislamiento de los pacientes y en el uso de barreras de aislamiento, tales como ropa e implementos de protección como respiradores. Debido a su rápida propagación la OMS declaró que la enfermedad por el virus Ébola representa una emergencia de salud pública más allá de las fronteras y exhortó a la comunidad internacional a tomar las acciones necesarias para detener la epidemia.

  1. Clinical features and treatment of hepatitis B virus and hepatitis C virus co-infection among patients with acquired immune deficiency syndrome

    Institute of Scientific and Technical Information of China (English)

    杨蓉蓉

    2014-01-01

    Objective To estimate the clinical features of hepatitis B virus(HBV)and hepatitis C virus(HCV)co-infection among acquired immune deficiency syndrome(AIDS)patients and the interaction of lamivudine(3 TC)contained antiretroviral therapy(ART)with hepatitis virus replication.Methods From 2004 to 2010,199human immunodeficiency virus(HIV)/HBV coinfected patients admitted to Zhongnan Hospital of Wuhan University were enrolled,including 76 cases of HIV/HBV/HCV triple infection and 123 cases of

  2. Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?

    NARCIS (Netherlands)

    E.H.C.J. Buster (Erik); H.L.A. Janssen (Harry)

    2006-01-01

    textabstractThe availability of nucleoside analogues has broadened treatment options for chronic hepatitis B virus (HBV ) infection. Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir, while entecavir is expected to be

  3. Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?

    NARCIS (Netherlands)

    E.H.C.J. Buster (Erik); H.L.A. Janssen (Harry)

    2006-01-01

    textabstractThe availability of nucleoside analogues has broadened treatment options for chronic hepatitis B virus (HBV ) infection. Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir, while entecavir is expected to be

  4. Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.

    Science.gov (United States)

    de Ávila, Ana I; Gallego, Isabel; Soria, Maria Eugenia; Gregori, Josep; Quer, Josep; Esteban, Juan Ignacio; Rice, Charles M; Domingo, Esteban; Perales, Celia

    2016-01-01

    Lethal mutagenesis is an antiviral approach that consists in extinguishing a virus by an excess of mutations acquired during replication in the presence of a mutagen. Here we show that favipiravir (T-705) is a potent mutagenic agent for hepatitis C virus (HCV) during its replication in human hepatoma cells. T-705 leads to an excess of G → A and C → U transitions in the mutant spectrum of preextinction HCV populations. Infectivity decreased significantly in the presence of concentrations of T-705 which are 2- to 8-fold lower than its cytotoxic concentration 50 (CC50). Passaging the virus five times in the presence of 400 μM T-705 resulted in virus extinction. Since T-705 has undergone advanced clinical trials for approval for human use, the results open a new approach based on lethal mutagenesis to treat hepatitis C virus infections. If proven effective for HCV in vivo, this new anti-HCV agent may be useful in patient groups that fail current therapeutic regimens.

  5. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus

    Institute of Scientific and Technical Information of China (English)

    Mitsuyasu; Nakamura; Masanori; Ikeda; Ryota; Hokari; Nobuyuki; Kato; Toshifumi; Hibi; Soichiro; Miura

    2010-01-01

    AIM:To elucidate the effect of antioxidants,resveratrol (RVT)and astaxanthin(AXN),on hepatitis C virus(HCV) replication. METHODS:We investigated the effect of recent popular antioxidant supplements on replication of the HCV replicon system OR6.RVT is a strong antioxidant and a kind of polyphenol that inhibits replication of various viruses.AXN is also a strong antioxidant.The replication of HCV RNA was assessed by the luciferase reporter assay.An additive effect of antioxidants on antiviral effects of inter...

  6. Oral conditions associated with Hepatitis C virus infection

    Directory of Open Access Journals (Sweden)

    Seyed-Moayed Alavian

    2013-01-01

    Full Text Available Hepatitis C virus (HCV infection in more than 170 million chronically infected patients with no developed preventive vaccine is a globally important issue. In addition to expected hepatic manifestations, a number of extrahepatic manifestations, such as mixed cryoglobulinemia, glomerulonephritis, polyarteritis nodosa, rashes, renal disease, neuropathy, and lymphoma, have been reported following HCV infection, which are believed to be influenced by the virus or the host immune response. HCV combination therapy with pegylated interferon and ribavirin might be associated with side effects as well. The association of HCV with special oral conditions has also been reported recurrently; the mechanism of most of which remains unclear. This article reviews the association of HCV infection with some of the oral conditions such as oral health, Sjogren′s syndrome, lichen planus and oral cancer.

  7. Glomerular Diseases Associated with Hepatitis C Virus Infection

    Directory of Open Access Journals (Sweden)

    Miller Sara

    2000-01-01

    Full Text Available Renal diseases associated with hepatitis C virus (HCV infection are a significant problem for clinicians and diagnostic pathologists. A wide variety of disorders, including a spectrum of immune-complex glomerulonephritides, has been reported in association with hepatitis and cirrhosis caused by HCV. For some of these diseases, including membranoproliferative glomerulonephritis type I and cryoglobulinemic glomerulonephritis, plausible links between HCV and the glomerular pathology have been proposed. In other cases, the role of the virus in the pathogenesis of the renal disease is less certain. This communication catalogues the renal manifestations of HCV infection, providing clinical and pathological descriptions of the most prevalent disorders. Where available, evidence implicating HCV in the causation of the disorders is also discussed.

  8. Hepatitis E. virus is prevalent in the Danish pig population

    DEFF Research Database (Denmark)

    Breum, Solvej Østergaard; Hjulsager, Charlotte Kristiane; De Deus, N.

    Hepatitis E virus (HEV) is responsible for major outbreaks of acute hepatitis in humans from developing countries, but evidence increases that also in industrialized countries locally acquired HEV infections acor. The disease usually affects young adults and has a relatively high mortality...... in infected pregnant women. HEV sequences worldwide can be classified into four major genotypes. Genotypes 1 and 2 are causing the majority of HEV infections in humans in hyper-endemic areas. In contrast, HEV genotypes 3 and 4 identified in cases of human hepatitis with increasing prevalence in countries...... such as USA, Europe, Japan and China. There is increasing evidence for the zoonotic origin of infections with HEV genotypes 3 and 4. Swine HEV sequences closely related to human HEV sequences have been detected in many countries and in several cases the source of infection has been linked to contact...

  9. Vertical hepatitis C virus transmission:Main questions and answers

    Institute of Scientific and Technical Information of China (English)

    Grazia; Tosone; Alberto; Enrico; Maraolo; Silvia; Mascolo; Giulia; Palmiero; Orsola; Tambaro; Raffaele; Orlando

    2014-01-01

    Hepatitis C virus(HCV) affects about 3% of the world’s population and peaks in subjects aged over 40 years. Its prevalence in pregnant women is low(1%-2%) in most western countries but drastically increases in women in developing countries or with high risk behav-iors for blood-transmitted infections. Here we review clinical, prognostic and therapeutic aspects of HCV in-fection in pregnant women and their offspring infected through vertical transmission. Pregnancy-related im-mune weakness does not seem to affect the course of acute hepatitis C but can affect the progression of chronic hepatitis C. In fact, postpartum immune res-toration can exacerbate hepatic inflammation, thereby worsening the liver disease, particularly in patients with liver cirrhosis. HCV infection increases the risk of gestational diabetes in patients with excessive weight gain, premature rupture of membrane and caesarean delivery. Only 3%-5% of infants born to HCV-positive mothers have been infected by intrauterine or perinatal transmission. Maternal viral load, human immunode-ficiency virus coinfection, prolonged rupture of mem-branes, fetal exposure to maternal infected blood con-sequent to vaginal or perineal lacerations and invasive monitoring of fetus increase the risk of viral transmis-sion. Cesarean delivery and breastfeeding increases the transmission risk in HCV/human immunodeficiency virus coinfected women. The consensus is not to offer antivi-ral therapy to HCV-infected pregnant women because it is based on ribavirin(pregnancy category X) because of its embryocidal and teratogenic effects in animal spe-cies. In vertically infected children, chronic C hepatitis is often associated with minimal or mild liver disease and progression to liver cirrhosis and hepatocarcinoma is lower than in adults. Infected children may be treated after the second year of life, given the adverse effects of current antiviral agents.

  10. Hepatitis B Virus Reactivation after Partial Hepatic Irradiation Alone: A Case Report

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Bo Kyung [Dankook University College of Medicine, Cheonan (Korea, Republic of)

    2010-11-15

    Reactivation of the hepatitis B virus (HBV) is a well-recognized complication in patients with chronic HBV infection who receive cytotoxic or other immunosuppressive therapy. In cases of patients treated by radiotherapy however, only a few of such reports exist and most of these include the patients previously treated by chemotherapy or transarterial chemoembolization. The results of this study point to a case of a patient with reactivation of HBV after radiotherapy alone. This study shows the possibility of HBV reactivation by partial hepatic irradiation alone hence, special attention should be paid to patients with HBV disease.

  11. Hepatitis E Virus Superinfection and Clinical Progression in Hepatitis B Patients

    Directory of Open Access Journals (Sweden)

    Nghiem Xuan Hoan

    2015-12-01

    Full Text Available Hepatitis E virus (HEV infection may cause acute hepatitis and lead to hepatic failure in developing and developed countries. We studied HEV seroprevalences in patients with hepatitis B virus (HBV infection to understand the consequences of HEV superinfection in a Vietnamese population. This cross-sectional study was conducted from 2012 to 2013 and included 1318 Vietnamese patients with HBV-related liver diseases and 340 healthy controls. The case group included patients with acute (n = 26 and chronic hepatitis B (n = 744, liver cirrhosis (n = 160, hepatocellular carcinoma (n = 166 and patients with both liver cirrhosis and hepatocellular carcinoma (n = 222. Anti-HEV IgG and IgM antibodies were assessed in patients and controls by ELISA. HEV-RNA was identified by PCR assays and sequencing. Seroprevalences of anti-HEV IgG among hepatitis B patients and controls were 45% and 31%, respectively (adjusted P = 0.034. Anti-HEV IgM seroprevalences were 11.6% and 4.7% in patients and controls, respectively (adjusted P = 0.005. Seroprevalences were higher among the elder individuals. When stratifying for patient groups, those with liver cirrhosis had the highest anti-HEV IgG (52% and anti-HEV IgM (19% seroprevalences. Hepatitis B patients with current HEV infection had abnormal liver function tests compared to patients with past or without HEV infection. One HEV isolate was retrieved from a patient with both liver cirrhosis and hepatocellular carcinoma and identified as HEV genotype 3. This study indicates high prevalences of HEV infection in Vietnamese HBV patients and among healthy individuals and shows that HEV superinfection may influence the outcome and progression of HBV-related liver disease.

  12. New perspectives in occult hepatitis C virus infection

    OpenAIRE

    CARREÑO, VICENTE; Bartolomé, Javier; Castillo, Inmaculada; Quiroga, Juan Antonio

    2012-01-01

    Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occul...

  13. Occult Hepatitis C Virus Infection among Hemodialysis Patients

    OpenAIRE

    G. Barril; Castillo, I.; Arenas, M.D. (María Dolores); Espinosa, M; Garcia-Valdecasas, J. (Juan); Garcia-Fernandez, N. (Nuria); E Gonzalez-Parra; Alcazar, J.M. (José María); Sanchez, C.; Diez-Baylon, J.C. (José Carlos); P. MARTINEZ; Bartolome, J; Carreño, V

    2008-01-01

    Occult hepatitis C virus (HCV) infection (i.e., detectable HCV-RNA in the liver or peripheral blood mononuclear cells) in the absence of both serum HCV-RNA and anti-HCV antibodies has not been investigated in hemodialysis patients. In this study, real-time PCR and in situ hybridization was used to test for the presence of genomic and antigenomic HCV-RNA in peripheral blood mononuclear cells of 109 hemodialysis patients with abnormal levels of live...

  14. Global dynamics for a delayed hepatitis C virus infection model

    Directory of Open Access Journals (Sweden)

    Yingying Zhao

    2014-06-01

    Full Text Available In this paper, we present a delay Hepatitis C virus infection model with Beddington-DeAngelis functional response. We first introduce five reproduction numbers, and then show that the system has five possible equilibria depended on the reproductive numbers. By constructing suitable Lyapunov functionals, the global dynamics for the five equilibria of the model is completely determined by the five reproductive numbers.

  15. Aspirin inhibits hepatitis C virus entry by downregulating claudin-1.

    Science.gov (United States)

    Yin, P; Zhang, L

    2016-01-01

    Aspirin has previously been reported to inhibit hepatitis C virus (HCV) replication. The aim of this study was to investigate whether aspirin is involved in blocking HCV entry. We found that aspirin inhibits the entry of HCVpp and infectious HCV. The level of claudin-1, an HCV receptor, is reduced by aspirin. Our results extend the anti-HCV effect of aspirin to the HCV entry step and further reinforce the anti-HCV role of aspirin.

  16. Innate immune responses in hepatitis B virus (HBV) infection

    OpenAIRE

    Busca, Aurelia; Kumar, Ashok

    2014-01-01

    Hepatitis B virus (HBV) infection has a low rate of chronicity compared to HCV infection, but chronic liver inflammation can evolve to life threatening complications. Experimental data from HBV infected chimpanzees and HBV transgenic mice have indicated that cytotoxic T cells are the main cell type responsible for inhibition of viral replication, but also for hepatocyte lysis during chronic HBV infection. Their lower activation and impaired function in later stages of infection was suggested ...

  17. Molekulare Virologie am Beispiel des Hepatitis-B-Virus

    OpenAIRE

    Hildt, Eberhard; Bleifuß, E.; Brandenburg, B.; Bürckstümer, T.; Foerste, R.; Hillemann, A.; Huser, Hans; Kriegs, M; Löffelbein, F.; Malkowski, B.; Moebs, M.; Möller, C.; Rieger, M.; Roos, M.

    2003-01-01

    Die nachfolgend beschriebenen Forschungsprojekte der Nachwuchsgruppe I am Robert Koch-Institut (RKI) befassen sich am Beispiel des Hepatitis-B-Virus (HBV) mit der Charakterisierung intrazellulärer Signalkaskaden und der Analyse ihrer Bedeutung für den viralen Lebenszyklus (Replikaktionsprozess) sowie für die Entstehung von HBV assoziierten Tumoren. Darüber hinaus werden auf der Basis eines neuen, aus dem HBV-Oberflächenprotein isolierten zellpermeablen Peptides neue Strategien zum Protein- un...

  18. Transmission of hepatitis C virus infection to tree shrews

    OpenAIRE

    Xie, Z.C. (Zhi-Chun); Riezu-Boj, J.I. (José Ignacio); Lasarte, J.J. (Juan José); GUILLEN, J; Su, J. H.; Civeira, M P; Prieto, J.

    1998-01-01

    Although hepatitis C virus (HCV) infection can be reproduced in chimpanzees, these animals are rare and expensive. Tree shrews (tupaias) are small animals, closely related to primates, which adapt easily to a laboratory environment. In this work we have investigated the susceptibility of Tupaia belangeri chinensis to HCV infection. Tupaias caught in the wild in Yunnan (China) were inoculated in China with HCV genotype 1b (study A) and in Spain with a mixture of genotypes 1b, 1a, and 3 (study ...

  19. Extrahepatic manifestations of chronic hepatitis C virus infection

    OpenAIRE

    Cacoub, Patrice; Comarmond, Cloe; Domont, Fanny; Savey, Léa; Desbois, Anne claire; Saadoun, David

    2016-01-01

    International audience; During hepatitis C virus (HCV) chronic infection, extrahepatic manifestations are frequent and polymorphous. This article reports on a large cohort of patients with HCV-related autoimmune or lymphoproliferative disorders, from mixed cryoglobulinemia vasculitis to frank lymphomas. The relationship between HCV infection and such immune-related diseases has been formally demonstrated by epidemiological, clinical, immunological and pathological data, and results of therape...

  20. Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays

    Directory of Open Access Journals (Sweden)

    Ekta Gupta

    2014-01-01

    Full Text Available An estimated 3% of the world population is infected with Hepatitis C virus (HCV, a hepatotropic RNA virus, transmitted primarily via the blood route. The major modes of transmission of the virus include injection drug use, unsafe injection practices, blood transfusion etc. HCV causes chronic hepatitis in about 80% of those infected by it. The mainstay in diagnosing infection with HCV is to initially screen high risk groups for antibodies to HCV (anti-HCV. The inclusion of serum to cut-off ratio (S/CO in recent guidelines is helpful in deciding the supplemental assay to be used to confirm initially reactive screening results. Nucleic acid amplification tests (NAT are used as confirmatory tools, and also to determine viral load prior to initiating treatment. Quantitative NAT has replaced qualitative assays. Genotyping is an important tool in clinical management to predict the likelihood of response and determine the optimal duration of therapy. The impact of this infection has begun to emerge in India. The problem of professional blood donation despite an existing law against it, and flourishing unsafe injection practices, are potential sources for the spread of hepatitis C in our country. All health care practitioners need to understand how to establish or exclude a diagnosis of HCV infection and to interpret the tests correctly. In the absence of a preventive or therapeutic vaccine, and also of post-exposure prophylaxis against the virus, it is imperative to diagnose infection by HCV so as to prevent hepatic insult and the ensuing complications that follow, including primary hepatocellular carcinoma (HCC. This review aims to help blood bank staff regarding options for diagnosis and management of donors positive for HCV.

  1. Recent advances in understanding and diagnosing hepatitis B virus infection

    OpenAIRE

    Fourati, Slim; Pawlotsky, Jean-Michel

    2016-01-01

    Hepatitis B virus (HBV) infects approximately 240 million individuals worldwide. Recent advances in the virology, immunopathogenesis, and diagnosis of HBV infection are summarized in this review article. The identification of a hepatocyte-specific cellular receptor for HBV, the sodium taurocholate co-transporting polypeptide (NTCP), made it possible to develop reliable cell culture systems and better understand the early steps of the viral lifecycle. Viral and host factors involved in covalen...

  2. Hepatitis C Virus-related Arthritis: Bone Scintigraphic Appearances

    Science.gov (United States)

    Aktas, Gul Ege; Sarikaya, Ali; Kandemir, Ozan

    2017-01-01

    A symptomatic joint involvement and arthralgia are frequent in patients with chronic hepatitis C virus (HCV) infection. However, HCV infection-related arthritis (HCVrA) affects up to 4-11% of the subjects suffering from disease. We reported a patient with HCVrA presented with the commonly accepted diagnostic clinical signs and laboratory parameters. The painful joints distinctly demonstrated increased uptake of Tc-99 m methylene diphosphonate in scintigraphy and normal findings in radiography.

  3. Host-virus interactions in hepatitis B and hepatitis C infection.

    Science.gov (United States)

    Yoshio, Sachiyo; Kanto, Tatsuya

    2016-05-01

    Hepatitis B virus (HBV) and hepatitis C virus (HCV) are among the most endemic pathogens worldwide, with more than 500 million people globally currently infected with these viruses. These pathogens can cause acute and chronic hepatitis that progress to liver cirrhosis or hepatocellular carcinoma. Both viruses utilize multifaceted strategies to evade the host surveillance system and fall below the immunological radar. HBV has developed specific strategies to evade recognition by the innate immune system and is acknowledged to be a stealth virus. However, extensive research has revealed that HBV is recognized by dendritic cells (DCs) and natural killer (NK) cells. Indoleamine-2, 3-dioxygenase is an enforcer of sequential immune reactions in acute hepatitis B, and this molecule has been shown to be induced by the interaction of HBV-infected hepatocytes, DCs, and NK cells. The interleukin-28B genotype has been reported to influence HCV eradication either therapeutically or spontaneously, but the biological function of its gene product, a type-III interferon (IFN-λ3), remains to be elucidated. Human BDCA3(+)DCs have also been shown to be a potent producer of IFN-λ3 in HCV infection, suggesting the possibility that BDCA3(+)DCs could play a key role in developing therapeutic HCV vaccine. Here we review the current state of research on immune responses against HBV and HCV infection, with a specific focus on innate immunity. A comprehensive study based on clinical samples is urgently needed to improve our understanding of the immune mechanisms associated with viral control and thus to develop novel immune modulatory therapies to cure chronic HBV and HCV infection.

  4. Hepatitis B and C virus co-infections in human immunodeficiency virus positive North Indian patients

    Institute of Scientific and Technical Information of China (English)

    Swati Gupta; Sarman Singh

    2006-01-01

    AIM:To determine the prevalence of hepatitis B and C virus infections in human immunodeficiency virus (HIV) -positive patients at a tertiary care hospital in New Delhi,India.METHODS:Serum samples from 451 HIV positive patients were analyzed for HBsAg and HCV antibodies during three years (Jan 2003-Dec 2005). The control group comprised of apparently healthy bone-marrow and renal donors.RESULTS:The study population comprised essentially of heterosexually transmitted HIV infection. The prevalence rate of HBsAg in this population was 5.3% as compared to 1.4% in apparently healthy donors (P < 0.001).Though prevalence of HCV co-infection (2.43%) was lower than HBV in this group of HIV positive patients,the prevalence was significantly higher (P < 0.05) than controls (0.7%). Triple infection of HIV, HBV and HCV was not detected in any patient.CONCLUSION:Our study shows a significantly high prevalence of hepatitis virus infections in HIV infected patients. Hepatitis viruses in HIV may lead to faster progression to liver cirrhosis and a higher risk of antiretroviral therapy induced hepatotoxicity. Therefore,it would be advisable to detect hepatitis virus coinfections in these patients at the earliest.

  5. Prevalence of Hepatitis B Virus Infection in Kenya, 2007.

    Science.gov (United States)

    Ly, Kathleen N; Kim, Andrea A; Umuro, Mamo; Drobenuic, Jan; Williamson, John M; Montgomery, Joel M; Fields, Barry S; Teshale, Eyasu H

    2016-08-03

    Current estimates put the prevalence of hepatitis B virus (HBV) infection in Kenya at 5-8%. We determined the HBV infection prevalence in the human immunodeficiency virus (HIV)-negative Kenyan adult and adolescent population based on samples collected from a national survey. We analyzed data from HIV-negative participants in the 2007 Kenya AIDS Indicator Survey to estimate the HBV infection prevalence. We defined past or present HBV infection as presence of total hepatitis B core antibody (HBcAb), and chronic HBV infection (CHBI) as presence of both total HBcAb and hepatitis B surface antigen (HBsAg). We calculated crude and adjusted odds of HBV infection by demographic characteristics and risk factors using logistic regression analyses. Of 1,091 participants aged 15-64 years, approximately 31.5% (95% confidence interval [CI] = 28.0-35.3%) had exposure to HBV, corresponding to approximately 6.1 million (CI = 5.4-6.8 million) with past or present HBV infection. The estimated prevalence of CHBI was 2.1% (95% CI = 1.4-3.1%), corresponding to approximately 398,000 (CI = 261,000-602,000) with CHBI. CHBI is a major public health problem in Kenya, affecting approximately 400,000 persons. Knowing the HBV infection prevalence at baseline is important for planning and public health policy decision making and for monitoring the impact of viral hepatitis prevention programs. © The American Society of Tropical Medicine and Hygiene.

  6. Molecular Biology and Infection of Hepatitis E Virus

    Directory of Open Access Journals (Sweden)

    Yuchen Nan

    2016-09-01

    Full Text Available Hepatitis E virus (HEV is a viral pathogen transmitted primarily via fecal-oral route. In humans, HEV mainly causes acute hepatitis and is responsible for large outbreaks of hepatitis across the world. The case fatality rate of HEV-induced hepatitis ranges from 0.5 to 3% in young adults and up to 30% in infected pregnant women. HEV strains infecting humans are classified into four genotypes. HEV strains from genotype 3 and 4 are zoonotic, whereas those from genotype 1 and 2 have no known animal reservoirs. Recently, notable progress has been accomplished for better understanding of HEV biology and infection, such as chronic HEV infection, in vitro cell culture system, quasi-enveloped HEV virions, functions of the HEV proteins, mechanism of HEV antagonizing host innate immunity, HEV pathogenesis and vaccine development. However, further investigation on the cross-species HEV infection, host tropism, vaccine efficacy and HEV-specific antiviral strategy is still needed. This review mainly focuses on molecular biology and infection of HEV and offers perspective new insight of this enigmatic virus.

  7. Diagnostic strategy for occult hepatitis B virus infection

    Institute of Scientific and Technical Information of China (English)

    Sara Ocana; Maria Luisa Casas; Ingrid Buhigas; Jose Luis Lledo

    2011-01-01

    In 2008, the European Association for the study of the liver (EASL) defined occult hepatitis B virus infection (OBI) as the "presence of hepatitis B virus (HBV) DNA in the liver (with detectable or undetectable HBV DNA in the serum) of individuals testing hepatitis B surface antigen (HBsAg) negative by currently available assays". Several aspects of occult HBV infection are still poorly understood, including the definition itself and a standardized approach for laboratory-based detection, which is the purpose of this review. The clinical significance of OBI has not yet been established; however, in terms of public health, the clinical importance arises from the risk of HBV transmission. Consequently, it is important to detect high-risk groups for occult HBV infection to prevent transmission. The main issue is, perhaps, to identify the target population for screening OBI. Viremia is very low or undetectable in occult HBV infection, even when the most sensitive methods are used, and the detection of the viral DNA reservoir in hepatocytes would provide the best evaluation of occult HBV prevalence in a defined set of patients. However, this diagnostic approach is obviously unsuitable: blood detection of occult hepatitis B requires assays of the highest sensitivity and specificity with a lower limit of detection < 10 IU/mL for HBV DNA and < 0.1 ng/mL for HBsAg.

  8. Hepatitis C virus-related lymphoproliferative disorders: An overview

    Institute of Scientific and Technical Information of China (English)

    Anna Linda Zignego; Carlo Giannini; Clodoveo Ferri

    2007-01-01

    Hepatitis C virus (HCV) is a global health problem affecting 3% of the world's population (about 180 million) and a cause of both hepatic and extrahepatic diseases. B-cell lymphoproliferative disorders, whose prototype is mixed cryoglobulinemia, represent the most closely related as well as the most investigated HCV-related extrahepatic disorder. The association between extrahepatic (lymphoma) as well as hepatic malignancies (hepatocellular carcinoma) has justified the inclusion of HCV among human cancer viruses. HCV-associated manifestations also include porphyria cutanea tarda,lichen planus, nephropathies, thyreopathies, sicca syndrome, idiopathic pulmonary fibrosis, diabetes,chronic polyarthritis, sexual dysfunctions, cardiopathy/atherosclerosis, and psychopathological disorders.A pathogenetic link between HCV virus and some lymphoproliferative disorders was confirmed by their responsiveness to antiviral therapy, which is now considered the first choice treatment. The aim of the present paper is to provide an overview of extrahepatic manifestations of HCV infection with particular attention to B-cell lymphoproliferative disorders. Available pathogenetic hypotheses and suggestions about the most appropriate, currently available, therapeutic approaches will also be discussed.

  9. Autochthonous Hepatitis E Virus Infection in Europe: A Matter of Concern for Public Health?

    OpenAIRE

    Echevarría, José-Manuel

    2014-01-01

    Human hepatitis E virus (HHEV) is the proposed name for a diverse group of RNA viruses from the family Hepeviridae that cause acute hepatitis among humans. Waterborne strains are regularly imported into Europe by international travelers, and virus transmission of zoonotic strains via contaminated aliments is involved in autochthonous cases. Therefore, in Europe, hepatitis E displays a unique dual character, having features of both imported and autochthonous infections. Environmental involveme...

  10. Bilateral Linear Lichen Planus Pigmentosus Associated with Hepatitis C Virus Infection

    Directory of Open Access Journals (Sweden)

    Vasanop Vachiramon

    2010-09-01

    Full Text Available Lichen planus pigmentosus is a rare subtype of lichen planus. We report a first case of lichen planus pigmentosus with bilateral linear distribution associated with hepatitis C virus infection. The lesion was improved after sun avoidance and treatment of hepatitis C virus infection with a combination of interferon and ribavirin. This case stresses the importance of screening for hepatitis C virus infection as lichen planus pigmentosus can be an associated condition.

  11. Reconstitution of the Entire Hepatitis C Virus Life Cycle in Nonhepatic Cells

    OpenAIRE

    Da Costa, Daniel; Turek, Marine; Felmlee, Daniel,; Girardi, Erika; Pfeffer, Sébastien; Long, Gang; Bartenschlager, Ralf; Zeisel, Mirjam,; Baumert, Thomas,

    2012-01-01

    International audience; Hepatitis C virus (HCV) is a human hepatotropic virus, yet the relevant host factors restricting HCV infection to hepatocytes are only partially understood. We demonstrate that exogenous expression of defined host factors reconstituted the entire HCV life cycle in human non-hepatic 293T cells. This study shows robust HCV entry, RNA replication, and production of infectious virus in human non-hepatic cells, and highlights key host factors required for liver tropism of HCV.

  12. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.

    Science.gov (United States)

    Durantel, David; Zoulim, Fabien

    2016-04-01

    Current therapies of chronic hepatitis B (CHB) remain limited to pegylated-interferon-alpha (PegIFN-α) or any of the five approved nucleos(t)ide analogues (NUC) treatments. While viral suppression can be achieved in the majority of patients with the high-barrier-to-resistance new-generation of NUC, i.e. entecavir and tenofovir, HBsAg loss is achieved by PegIFN-α and/or NUC in only 10% of patients, after a 5-year follow-up. Attempts to improve the response by administering two different NUC or a combination of NUC and PegIFN-α have not provided a dramatic increase in the rate of functional cure. Because of this and the need of long-term NUC administration, there is a renewed interest regarding the understanding of various steps of the HBV replication cycle, as well as specific virus-host cell interactions, in order to define new targets and develop new antiviral drugs. This includes a direct inhibition of viral replication with entry inhibitors, drugs targeting cccDNA, siRNA targeting viral transcripts, capsid assembly modulators, and approaches targeting the secretion of viral envelope proteins. Restoration of immune responses is a complementary approach. The restoration of innate immunity against HBV can be achieved, with TLR agonists or specific antiviral cytokine delivery. Restoration of adaptive immunity may be achieved with inhibitors of negative checkpoint regulators, therapeutic vaccines, or autologous transfer of engineered HBV-specific T cells. Novel targets and compounds will readily be evaluated using both relevant and novel in vitro and in vivo models of HBV infection. The addition of one or several new drugs to current therapies should offer the prospect of a markedly improved response to treatments and an increased rate of functional cure. This should lead to a reduced risk of antiviral drug resistance, and to a decreased incidence of cirrhosis and hepatocellular carcinoma (HCC).

  13. Non-A, non-B hepatitis unrelated to the hepatitis C virus (non-ABC).

    Science.gov (United States)

    Alter, H J; Bradley, D W

    1995-02-01

    The history of non-ABC hepatitis is a kaleidoscope of intriguing, but often conflicting and confounding data. Studies of transfusion-associated non-ABC hepatitis are less convincing than they originally seemed. Chimpanzee cross-challenge studies, once the bastion for the theory of multiple NANB hepatitis agents, now have an alternative explanation in the impaired immune response associated with HCV infection and the ability of this agent to reinfect individuals previously assumed to be immune. Nonetheless, there are so many cases of acute and chronic NANB hepatitis that cannot currently be attributed to HCV that it is hard to avoid the implication of at least one, and possibly more, non-ABC hepatitis agents. There are now some transmission studies in small primates to support this contention, though recent chimpanzee transmission studies have been disappointingly negative. As with the hepatitis C virus, the breakthrough in this disease will not come from classic serology or virology, but from molecular biology. Similar molecular approaches to those that elucidated HCV are in progress and are promising in preliminary experiments. It is anticipated that the pace of molecular biology is such that a great deal more will be known about non-ABC in a relatively brief time, and perhaps one or more non-ABC agents will prove to be real and clinically relevant.

  14. Cultivation of Hepatitis Virus in Tissue Culture.

    Science.gov (United States)

    1979-03-01

    morbidity reports document at least 3 ,000 deaths per year from vira l hepatit is and recent ddta su~gests thatapprox i?r:~tely 10 to I4~ of pat...ients who have hepatitis B and 20 to 402~ ofpat ic nts who develop non A non B hepatit is w i l l develop chronic l iver disedse and,of these , a major...tary personnel is especial ly si grii fi cant . Many of our larcjost epi (!~Hicsof vira l hepatit is have occ i’ rrei in Naval instal lations. For

  15. Immunoprophylaxis of hepatitis B virus infection

    Directory of Open Access Journals (Sweden)

    Joshi N

    2001-01-01

    Full Text Available Hepatitis-B infection is a global health problem. The spectrum of the disease is highly variable ranging from mild disease to chronic liver diseases including hepatocellular carcinoma. There are approximately 350 million chronic Hepatitis-B surface antigen (HBsAg carriers in the world. Till date there is no effective therapy against this disease. Hence, prevention of the disease through vaccination is the only means to control the disease. Passive immunization is recommended for certain accidental exposures. Hepatitis-B immunoglobulin (HBIG contains high titers of anti-HBs prepared from pooled plasma. HBIG has been shown to be highly effective in preventing post exposure transmission. HBIG induces immunity for a short period only hence, it is recommended to have a course of active immunization following passive immunization. Active immunization is achieved using vaccination. Two generations of vaccines, 1st generation plasma derived and 2nd generation recombinant DNA vaccines are available. Both these vaccines have been used extensively in all age groups all over the world. The studies have shown that HB vaccines are clinically well tolerated, safe and highly immunogenic. Normally 3 doses of HB vaccines are recommended in 0, 1, 2 and 12 or 0, 1, 6 months schedule. The dosages and schedules may vary in certain special groups, such as infants and neonates, chronic renal failure patients on hemodialysis. Advisory committee on immunization practices (ACIP has given several guidelines regarding HB vaccination. Universal immunization of all infants and integration of HB Vaccine in the expanded program of immunization has been recommended by World Health Organization. Universal infant immunization is cost effective. Universal immunization of infants is the only strategy that will lead to the control and eradication of HBV infection in all regions of the world. Several countries have adopted this policy. But in India we have several problems in

  16. Hepatitis A virus and the origins of picornaviruses

    Science.gov (United States)

    Hu, Zhongyu; Sun, Yao; Li, Xuemei; Rowlands, David J.; Yin, Weidong; Wang, Junzhi; Stuart, David I.; Rao, Zihe; Fry, Elizabeth E.

    2016-01-01

    Hepatitis A virus (HAV) remains enigmatic, despite some 1.4 million cases worldwide annually1. It differs radically from other picornaviruses, existing in an enveloped form2 and being unusually stable, both genetically and physically3, but has proved difficult to study. We report high-resolution X-ray structures for the mature virus and empty particles. The structures of the two particles are indistinguishable, apart from some disorder on the inside of the empty particle. The full virus contains the small viral protein VP4, while the empty particle harbors only the uncleaved precursor, VP0. The smooth particle surface is devoid of depressions which might correspond to receptor binding sites. Peptide scanning data extends the previously reported VP3 antigenic site4, while structure-based predictions5 suggest further epitopes. HAV contains no pocket factor, can withstand remarkably high temperature and low pH, with empty particles being even more robust than full particles. The virus probably uncoats via a novel mechanism, being built differently to other picornaviruses. It utilizes a VP2 ‘domain swap’ characteristic of insect picorna-like viruses6,7 and structure-based phylogenetic analysis places HAV between typical picornaviruses and the insect viruses. The enigmatic properties of HAV may reflect its position as a link between ‘modern’ picornaviruses and the more ‘primitive’ precursor insect viruses, for instance HAV retains the ability to move from cell-to-cell by transcytosis8,9. PMID:25327248

  17. Detection of pathogenic viruses in sewage provided early warnings of hepatitis A virus and norovirus outbreaks.

    Science.gov (United States)

    Hellmér, Maria; Paxéus, Nicklas; Magnius, Lars; Enache, Lucica; Arnholm, Birgitta; Johansson, Annette; Bergström, Tomas; Norder, Heléne

    2014-11-01

    Most persons infected with enterically transmitted viruses shed large amounts of virus in feces for days or weeks, both before and after onset of symptoms. Therefore, viruses causing gastroenteritis may be detected in wastewater, even if only a few persons are infected. In this study, the presence of eight pathogenic viruses (norovirus, astrovirus, rotavirus, adenovirus, Aichi virus, parechovirus, hepatitis A virus [HAV], and hepatitis E virus) was investigated in sewage to explore whether their identification could be used as an early warning of outbreaks. Samples of the untreated sewage were collected in proportion to flow at Ryaverket, Gothenburg, Sweden. Daily samples collected during every second week between January and May 2013 were pooled and analyzed for detection of viruses by concentration through adsorption to milk proteins and PCR. The largest amount of noroviruses was detected in sewage 2 to 3 weeks before most patients were diagnosed with this infection in Gothenburg. The other viruses were detected at lower levels. HAV was detected between weeks 5 and 13, and partial sequencing of the structural VP1protein identified three different strains. Two strains were involved in an ongoing outbreak in Scandinavia and were also identified in samples from patients with acute hepatitis A in Gothenburg during spring of 2013. The third strain was unique and was not detected in any patient sample. The method used may thus be a tool to detect incipient outbreaks of these viruses and provide early warning before the causative pathogens have been recognized in health care. Copyright © 2014, American Society for Microbiology. All Rights Reserved.

  18. Preliminary report of hepatitis B virus genotype prevalence in Iran

    Institute of Scientific and Technical Information of China (English)

    Seyed-Moayed Alavian; Hossein Keyvani; Mahdi Rezai; Neda Ashayeri; Homa Mohammad Sadeghi

    2006-01-01

    AIM: To determine the prevalence of hepatitis B virus (HBV) genotypes in Iranian hepatitis B surface antigen (HBsAg) carriers, chronic hepatitis B and cirrhotic patients.METIHODS: A total of 109 HBsAg-positive patients were included in this study. HBV genotypes were determined by using INNO-LiPA methodology which is based on the reverse hybridization principle.RESULTS: The distribution of patients with different stages of liver disease was as follows: 95 (86.4%) chronic hepatitis, 11 (10%) liver cirrhosis, and 3 (2.7%)inactive carrier. Of the chronic hepatitis and liver cirrhosis patients, 26.4% were HBeAg-positive while 70% were HBeAg-negative. Genotype D was the only detected type found in all patients. CONCLUSION: Classifying HBV into genotypes has to be cost-effective and clinically relevant. Our study indicates that HBV genotype D prevails in the Mediterranean area, Near and Middle East, and South Asia. Continued efforts for understanding HBV genotype through international co-operation will reveal further virological differences of the genotypes and their clinical relevance.

  19. Occult hepatitis B virus infection and blood transfusion

    Institute of Scientific and Technical Information of China (English)

    Dong Hee Seo; Dong Hee Whang; Eun Young Song; Kyou Sup Han

    2015-01-01

    Transfusion-transmitted infections including hepatitis Bvirus (HBV) have been a major concern in transfusionmedicine. Implementation of HBV nucleic acid testing(NAT) has revealed occult HBV infection (OBI) in blooddonors. In the mid-1980s, hepatitis B core antibody(HBc) testing was introduced to screen blood donorsin HBV non-endemic countries to prevent transmissionof non-A and non-B hepatitis. That test remains inuse for preventing of potential transmission of HBVfrom hepatitis B surface antigen (HBsAg)-negativeblood donors, even though anti-hepatitis C virus testshave been introduced. Studies of anti-HBc-positivedonors have revealed an HBV DNA positivity rate of0%-15%. As of 2012, 30 countries have implementedHBV NAT. The prevalence of OBI in blood donors wasestimated to be 8.55 per 1 million donations, accordingto a 2008 international survey. OBI is transmissible byblood transfusion. The clinical outcome of occult HBVtransmission primarily depends on recipient immunestatus and the number of HBV DNA copies present in theblood products. The presence of donor anti-HBs reducesthe risk of HBV infection by approximately five-fold. Therisk of HBV transmission may be lower in endemic areasthan in non-endemic areas, because most recipientshave already been exposed to HBV. Blood safety forHBV, including OBI, has substantially improved, but thepossibility for OBI transmission remains.

  20. Simultaneous detection of Hepatitis B virus and Hepatitis C virus in human plasma using Taq-man chemistry

    Directory of Open Access Journals (Sweden)

    Khaja M N

    2011-07-01

    Full Text Available Designing a rapid, reliable and sensitive assay, for detection of hepatitis B virus and Hepatitis C virus variants by real-time PCR, is challenging at best. A recent approach for quantifying the viral load using the sensitive fluorescence principle, was used in this study. A total of 350 samples were collected from outpatient unit, Center for Liver Research and Diagnostics (CLRD. Complete Human HBV DNA and HCV sequences were obtained from the National Centre for Biotechnology Information (NCBI; primers and probes were designed and synthesized from core, surface and x region of Hepatitis B and UTR region of HCV. Real-time based detection was done, using standard kit and in-house generated standards and RT-PCR protocols. A standard curve was generated by using the Smart Cycler II software and serial dilution 102 to 108 of cloned viral regions, the calibration curve was linear in a range from 102 to108 cp/ml for both HBV and HCV, with R2 value of 0.999 and 0.995. Out of 100 predetermined HCV negative samples, 02 samples were found positive with in-house developed RT-PCR assay, the positivity of this sample was confirmed by sequencing the amplified product. Low cost of this assay procedure and précised sample volume will permit the assay to be implemented for routine screening of Hepatitis B and C virus mono-infection and co-infection using Real Time PCR , Nucleic acid Chip technology and Fluorescent End Point detection systems. This assay is reproducible showing limited inter and intra assay variability. Our results correlated well with the standard kit for HBV and HCV virus monitor.

  1. Trafficking of hepatitis C virus core protein during virus particle assembly.

    Directory of Open Access Journals (Sweden)

    Natalie A Counihan

    2011-10-01

    Full Text Available Hepatitis C virus (HCV core protein is directed to the surface of lipid droplets (LD, a step that is essential for infectious virus production. However, the process by which core is recruited from LD into nascent virus particles is not well understood. To investigate the kinetics of core trafficking, we developed methods to image functional core protein in live, virus-producing cells. During the peak of virus assembly, core formed polarized caps on large, immotile LDs, adjacent to putative sites of assembly. In addition, LD-independent, motile puncta of core were found to traffic along microtubules. Importantly, core was recruited from LDs into these puncta, and interaction between the viral NS2 and NS3-4A proteins was essential for this recruitment process. These data reveal new aspects of core trafficking and identify a novel role for viral nonstructural proteins in virus particle assembly.

  2. Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection.

    Science.gov (United States)

    Cho, Junhyeon; Lee, Sang Soo; Choi, Yun Suk; Jeon, Yejoo; Chung, Jung Wha; Baeg, Joo Yeong; Si, Won Keun; Jang, Eun Sun; Kim, Jin-Wook; Jeong, Sook-Hyang

    2016-11-14

    To clarify the prevalence of occult hepatitis B virus (HBV) infection (OBI) and the association between OBI and liver disease progression, defined as development of liver cirrhosis or hepatocellular carcinoma (HCC), worsening of Child-Pugh class, or mortality in cases of chronic hepatitis C virus (HCV) infection. This prospective cohort study enrolled 174 patients with chronic HCV infection (chronic hepatitis, n = 83; cirrhosis, n = 47; HCC, n = 44), and evaluated disease progression during a mean follow-up of 38.7 mo. OBI was defined as HBV DNA positivity in 2 or more different viral genomic regions by nested polymerase chain reaction using 4 sets of primers in the S, C, P and X open reading frame of the HBV genome. The overall OBI prevalence in chronic HCV patients at enrollment was 18.4%, with 16.9%, 25.5% and 13.6% in the chronic hepatitis C, liver cirrhosis and HCC groups, respectively (P = 0.845). During follow-up, 52 patients showed disease progression, which was independently associated with aspartate aminotransferase > 40 IU/L, Child-Pugh score and sustained virologic response (SVR), but not with OBI positivity. In 136 patients who were not in the SVR state during the study period, OBI positivity was associated with neither disease progression, nor HCC development. The prevalence of OBI in chronic HCV patients was 18.4%, and OBI was not associated with disease progression in South Koreans.

  3. Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection

    Science.gov (United States)

    Cho, Junhyeon; Lee, Sang Soo; Choi, Yun Suk; Jeon, Yejoo; Chung, Jung Wha; Baeg, Joo Yeong; Si, Won Keun; Jang, Eun Sun; Kim, Jin-Wook; Jeong, Sook-Hyang

    2016-01-01

    AIM To clarify the prevalence of occult hepatitis B virus (HBV) infection (OBI) and the association between OBI and liver disease progression, defined as development of liver cirrhosis or hepatocellular carcinoma (HCC), worsening of Child-Pugh class, or mortality in cases of chronic hepatitis C virus (HCV) infection. METHODS This prospective cohort study enrolled 174 patients with chronic HCV infection (chronic hepatitis, n = 83; cirrhosis, n = 47; HCC, n = 44), and evaluated disease progression during a mean follow-up of 38.7 mo. OBI was defined as HBV DNA positivity in 2 or more different viral genomic regions by nested polymerase chain reaction using 4 sets of primers in the S, C, P and X open reading frame of the HBV genome. RESULTS The overall OBI prevalence in chronic HCV patients at enrollment was 18.4%, with 16.9%, 25.5% and 13.6% in the chronic hepatitis C, liver cirrhosis and HCC groups, respectively (P = 0.845). During follow-up, 52 patients showed disease progression, which was independently associated with aspartate aminotransferase > 40 IU/L, Child-Pugh score and sustained virologic response (SVR), but not with OBI positivity. In 136 patients who were not in the SVR state during the study period, OBI positivity was associated with neither disease progression, nor HCC development. CONCLUSION The prevalence of OBI in chronic HCV patients was 18.4%, and OBI was not associated with disease progression in South Koreans. PMID:27895431

  4. Occult Hepatitis B in Patients Co-Infected With Hepatitis C and Human Immunodeficiency Viruses

    Directory of Open Access Journals (Sweden)

    Majzoobi

    2016-10-01

    Full Text Available Objectives Diagnosis of the occult hepatitis B virus (HBV infection in patients co-infected with human immunodeficiency virus (HIV and hepatitis C virus (HCV is important due to the fact that the HBV infection may have a clinical impact on liver disease in coinfected HIV/HCV patients. Isolated hepatitis B core antibody (HBcAb positive HBV infection has been reported in HIV patients. The aim of this study was to determine the occult hepatitis B in patients co-infected with HCV-HIV. Methods In a cross-sectional study, hepatitis B surface antigen (HBsAg and HBcAb tests were performed for all HIV-HCV co-infected patients, referred to the HIV Clinic of Hamadan. HBsAb was requested for HBsAg negative-HBcAb positive individuals and in the case of negative HBsAb, HBV-DNA PCR was performed. Finally the collected data was analyzed with SPSS. Results Of 103 HIV-HCV coinfected patients, both HBsAg and HBcAb were positive in 7 patients (6.8%, negative in 44 (42.7% patients and 52 (50.5% of all patients were HBsAg negative and HBcAb positive, which positivity of HBsAg had statistical correlation with positivity of HBcAb. In the last group HBsAb and HBV-DNA PCR were done, which resulted in the titer of antibody to be positive in 4 patients (7.7% and the PCR to be negative in all (100% patients. Conclusions The significant number of coinfected HIV-HCV patients only had HBcAb positive test without detectable HBV-DNA. Further studies for detection of HBV-DNA in both serum and liver biopsy specimens may help clarify the impact of HBV infection in coinfected HIV/HCV patients.

  5. Occult hepatitis C virus infection: A new form of hepatitis C

    OpenAIRE

    CARREÑO, VICENTE

    2006-01-01

    Occult hepatitis C virus (HCV) infection is a new recently characterized entity. This occult infection can be present in two different clinical situations: in anti-HCV negative, serum HCV-RNA negative patients with abnormal liver function tests and in anti-HCV positive subjects with normal values of liver enzymes and without serum HCV-RNA. This review describes recent studies of occult HCV infection in both kinds of patients.

  6. Occult hepatitis C virus infection: A new form of hepatitis C

    Institute of Scientific and Technical Information of China (English)

    Vicente Carre(n)o

    2006-01-01

    Occult hepatitis C virus (HCV) infection is a new recently characterized entity. This occult infection can be present in two different clinical situations: in anti-HCV negative,serum HCV-RNA negative patients with abnormal liver function tests and in anti-HCV positive subjects with normal values of liver enzymes and without serum HCV-RNA. This review describes recent studies of occult HCV infection in both kinds of patients.(c) 2006 The WJG Press. All rights reserved.

  7. Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation

    Directory of Open Access Journals (Sweden)

    Hsu Chen-Ming

    2009-08-01

    Full Text Available Abstract Background The pathogenesis of inflammation and fibrosis in chronic hepatitis C virus (HCV infection remains unclear. Transgenic mice with constitutive HCV core over-expression display steatosis only. While the reasons for this are unclear, it may be important that core protein production in these models begins during gestation, in contrast to human hepatitis C virus infection, which occurs post-natally and typically in adults. AIMS: To more realistically model the effect of core protein production in the adult liver, we developed a mouse with conditional expression of HCV core and examined the effect of core protein production in the adult liver. Methods Liver biopsy samples from transgenic mice with tetracycline(tet-regulated conditional core protein expression were evaluated immunohistologically. Microarray analysis of HCV core transgenic mice with steatohepatitis pointed to a role of the complement pathway. This was further explored by blocking complement activation by in vivo administration of CD55 (decay accelerating factor for complement, which inhibits activation of C3. Results Transgenic mice exhibited low, intermediate, or high HCV core protein expression when fed a permissive diet of standard chow. Aside from hepatic steatosis, hepatic inflammation and fibrosis were seen in mice with intermediate levels of core protein. Microarray analyses of inflamed liver demonstrated activation of both the complement (C3 up-regulation and coagulation pathways (fibrinogen B up-regulation. Administration of CD55 reduced hepatic inflammation. Conclusion Transgenic mice that conditionally express intermediate HCV core protein develop inflammation, steatosis, and fibrosis. These effects mediated by HCV core are reduced by administration of CD55, a regulator of the complement pathway. The model may be valuable in investigating the pathogenesis of liver inflammation in chronic hepatitis C.

  8. Research on viral dynamic models of hepatitis B virus infection

    Institute of Scientific and Technical Information of China (English)

    Lequan Min; Xisong Dong

    2004-01-01

    A mathematical model with cytotoxic cells of hepatitis B virus (HBV) infection is set up based on a basic model of virus dynamics without cytotoxic cells and experimental observation of anti-viral drug therapy for HBV infection patients. A quantitative analysis of dynamic behaviors shows that the model has three kinds of equilibrium points, which represent the patient's complete recovery without immune ability, complete recovery with immune ability, and HBV persistent infection at the end of the treatment with drug lamivudine, respectively. Our model may provide possible quantitative interpretations for the treatments of chronic HBV infections with the drug lamivudine, in particularly explain why the plasma virus of Nowak et al.'s patients turnover the original level after stopping the lamivudine treatment.

  9. Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients

    Directory of Open Access Journals (Sweden)

    Bo Feng

    Full Text Available Response-guided therapy is of limited use in developing countries because hepatitis C virus RNA detection by sensitive molecular methods is time- and labor-consuming and expen- sive. We evaluated early predictive efficacy of serum hepatitis C virus core antigen kinetics on sustained virologic response in patients with genotype 1 hepatitis C virus during pegylated interferon plus ribavirin treatment. For 478 patients recruited, hepatitis C virus RNAs were detected at baseline, and at weeks 4, 12, 24, 48, and 72 using Cobas TaqMan. Architect hepatitis C virus core antigen was performed at baseline, and weeks 4 and 12. Predictive values of hepatitis C virus core antigen on sustained virologic response were compared to hepatitis C virus RNA. In the first 12 weeks after treatment initiation the dynamic patterns of serum hepatitis C virus core antigen and hepatitis C virus RNA levels were similar in sustained virologic response, relapse, and null response patients groups. Although areas under the receiver operating characteristics curves of hepatitis C virus core antigen were lower than those of hepatitis C virus RNA at the same time points, modeling analysis showed that undetectable hepatitis C virus core antigen (rapid virological response based on hepatitis C virus core antigen had similar positive predictive value on sustained virologic response to hepatitis C virus RNA at week 4 (90.4% vs 93.3%, and hepatitis C virus core antigen decrease greater than 1 log10 IU/mL (early virological response based on hepatitis C virus core antigen had similar negative predictive value to hepatitis C virus RNA at week 12 (94.1% vs 95.Z%. Analysis on the validation group demonstrated a positive predictivevalue of 97.5% in rapid virological response based on hepatitis C virus core antigen and a negative predictive value of 100% in early virological response based on hepatitis C virus core antigen. In conclusion, hepatitis C virus core antigen is comparable to

  10. Recent advances in hepatitis C virus research and understanding the biology of the virus

    Institute of Scientific and Technical Information of China (English)

    Francoise Lunel-Fabiani

    2007-01-01

    @@ Since the identification of hepatitis C virus (HCV) genome in 1989[1], a lot of progresses have been done about the understanding of HCV biology, natural history and therapeutic options. HCV is a member of the Flaviviridae viral family. Its genome is a positive simple strand RNA molecule which shows significant genetic variability.

  11. Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011

    DEFF Research Database (Denmark)

    Christensen, Peer Brehm; Clausen, Mette Rye; Krarup, Henrik Bygum;

    2012-01-01

    The Danish Society of Infectious Diseases and Danish Society of Gastroenterology and Hepatology set up a committee in 2007 to produce national guidelines for treatment of viral hepatitis B and C. The 2011 version of the guidelines have been endorsed by the scientific societies and are presented...... is not common in Denmark. The prevalence has not been determined by national surveys, but it is estimated that 10,000-15,000 patients are chronically infected with hepatitis B and 15,000-20,000 with chronic hepatitis C. The majority of patients with HBV infection in Denmark are emigrants from high endemic...... for their chronic viral hepatitis. Clinical care: According to the Danish National Board of Health, patients with chronic viral hepatitis should be followed with regular intervals, at clinics specialized in either infectious diseases or gastroenterology/hepatology. The primary aim is to identify patients...

  12. Hepatitis B virus exposure in human immunodeficiency virus seropositive Cuban patients

    Directory of Open Access Journals (Sweden)

    Licel Rodríguez

    2000-04-01

    Full Text Available In order to estimate the prevalence of serological markers of exposure to Hepatitis B Virus (HBV, 295 subjects were selected at random from the National Registry of human immunodeficiency virus positive subjects. Evidence of exposure to HBV was defined as: testing Hepatitis B surface antigen (HBsAg and anti-Hepatitis B core antigen (anti-HBc positive or anti-HBc positive only. Overall, 133 (45.5% were positive for anti-HBc and 15 (5.1% resulted positive to HBsAg. Significant statistical association was found between male sex and exposure to HBV (p<0.01. Homosexual or bisexual behavior was found to be strongly associated to HBV exposure (p<0.001. In conclusion, the prevalence of HBV serological markers is higher in Cuban HIV positive subjects compared to the Cuban general population.

  13. HEPATITIS C VIRUS INFECTION - VIRUSOLOGICAL AND PATHOPHYSIOLOGICAL ASPECT

    Directory of Open Access Journals (Sweden)

    Marina Dinić

    2002-01-01

    Full Text Available Hepatitis C virus is a spherical particle, of icosahedral symmetry of the capsid with the lipid jacket. The virus genome is one-chain (+ RNK. Structural virus proteins are the following: protein of nucleocapsid and two glycoproteins of the jacket (El and E2. The E2 protein that induces a synthesis of neutralizing antibodies is antigenic-variable. Non-structural virus proteins (RNK polymerase, helicase, protease and others have a regulatory function in the replication process. The HCV is replicated in hepatocytes and probably in T and B lymphocytes as well. The replication is done at a low level; that is why the virus antigens are present in the serum in un-measurable concentrations.The cytotoxic CD8+ T lymphocytes have a dominant role in the pathogenesis of the hepatocyte lesion and in the virus elimination. In over 70% of the patients, after an acute infection, the HCV sets up a persistent infection causing a chronic liver disease with progressive course. The setting-up of the persistent HCV infection is a consequence of the mutations in the E2 gene that are giving rise to changes in the anti-receptor virus structure. Due to low titer of the virus antigens in the serum, the active HCV inflection can be proved only on the basis of the presence of the RNK sequence of the virus genome by the PCR method. Recent research of the HCV infection is directed towards discovering the epitope as the candidate for the HCV infection.

  14. Adaptive Immunity to Hepatitis C Virus

    Directory of Open Access Journals (Sweden)

    Françoise Stoll-Keller

    2009-09-01

    Full Text Available The precise role of adaptive immune responses in the clinical outcome of HCV infection is still only partially defined. Recent studies suggest that viral-host cell interactions during the acute phase of infection are essential for viral clearance or progression into chronic HCV infection. This review focuses on different aspects of the adaptive immune responses as determinants of the different outcomes of HCV infection, clearance or persistent infection, and outlines current concepts of HCV evasion strategies. Unravelling these important mechanisms of virus-host interaction will contribute to the development of novel strategies to prevent and control HCV infection.

  15. Hepatitis and Encephalitis due to Coxsackie Virus A9 in an Adult

    Directory of Open Access Journals (Sweden)

    Brigitte Moreau

    2011-10-01

    Full Text Available Coxsackie virus infection most commonly manifests itself in the neonatal period as a multisystem disease. This life-threatening neonatal infection has been recently treated with a new anti-picornaviral drug, pleconaril. In contrast, in adults Coxsackie virus is an uncommon source of hepatitis, but Coxsackie virus type B has been described in case reports to cause hepatitis. This is the first case report of hepatitis and encephalitis secondary to Coxsackie virus type A9 in an adult. This virus was found in a culture of the cerebrospinal fluid and was confirmed by PCR. The patient recovered completely without specific treatment.

  16. Links between human LINE-1 retrotransposons and hepatitis virus-related hepatocellular carcinoma

    Science.gov (United States)

    Honda, Tomoyuki

    2016-05-01

    Hepatocellular carcinoma (HCC) accounts for approximately 80% of liver cancers, the third most frequent cause of cancer mortality. The most prevalent risk factors for HCC are infections by hepatitis B or hepatitis C virus. Findings suggest that hepatitis virus-related HCC might be a cancer in which LINE-1 retrotransposons, often termed L1, activity plays a potential role. Firstly, hepatitis viruses can suppress host defense factors that also control L1 mobilization. Secondly, many recent studies also have indicated that hypomethylation of L1 affects the prognosis of HCC patients. Thirdly, endogenous L1 retrotransposition was demonstrated to activate oncogenic pathways in HCC. Fourthly, several L1 chimeric transcripts with host or viral genes are found in hepatitis virus-related HCC. Such lines of evidence suggest a linkage between L1 retrotransposons and hepatitis virus-related HCC. Here, I briefly summarize current understandings of the association between hepatitis virus-related HCC and L1. Then, I discuss potential mechanisms of how hepatitis viruses drive the development of HCC via L1 retrotransposons. An increased understanding of the contribution of L1 to hepatitis virus-related HCC may provide unique insights related to the development of novel therapeutics for this disease.

  17. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases

    DEFF Research Database (Denmark)

    Rambaldi, A; Jacobs, B P; Gluud, C

    2007-01-01

    Alcohol and hepatotoxic viruses cause the majority of liver diseases. Randomised clinical trials have assessed whether extracts of milk thistle, Silybum marianum (L) Gaertneri, have any effect in patients with alcoholic and/or hepatitis B or C virus liver diseases.......Alcohol and hepatotoxic viruses cause the majority of liver diseases. Randomised clinical trials have assessed whether extracts of milk thistle, Silybum marianum (L) Gaertneri, have any effect in patients with alcoholic and/or hepatitis B or C virus liver diseases....

  18. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases

    DEFF Research Database (Denmark)

    Rambaldi, A; Jacobs, B P; Iaquinto, G

    2005-01-01

    Alcohol and hepatotoxic viruses cause the majority of liver diseases. Randomised clinical trials have assessed whether extracts of milk thistle, Silybum marianum (L) Gaertneri, have any effect in patients with alcoholic and/or hepatitis B or C virus liver diseases.......Alcohol and hepatotoxic viruses cause the majority of liver diseases. Randomised clinical trials have assessed whether extracts of milk thistle, Silybum marianum (L) Gaertneri, have any effect in patients with alcoholic and/or hepatitis B or C virus liver diseases....

  19. High Prevalence of Hepatitis B Virus Markers in Romanian Adolescents With Human Immunodeficiency Virus Infection

    Directory of Open Access Journals (Sweden)

    Ruta Simona

    2005-03-01

    Full Text Available Abstract Background We evaluated the frequency of hepatitis coinfection in Romanian adolescents who were diagnosed with human immunodeficiency virus (HIV infection prior to 1995. Methods One hundred sixty-one adolescents (13–18 years of age with symptomatic HIV infection, but without signs of hepatic dysfunction, and 356 age-matched, HIV-uninfected controls underwent laboratory testing for markers of parenterally acquired hepatitis virus infection. Results Seventy-eight percent of HIV-infected adolescents had markers of past or present hepatitis B virus (HBV infection, as compared with 32% of controls (P = .0001. The prevalence of HBV replicative markers was more than 5-fold higher in HIV-infected adolescents as compared with controls: 43.4% vs 7.9% (P = .0001, respectively, for hepatitis B surface antigen (HBsAg; and 11.2% vs 2.2% (P = .0001, respectively, for hepatitis B e antigen (HBeAg. The prevalence of HBsAg chronic carriers and the presence of HBV replicative markers was significantly higher in patients with immunologically defined AIDS (CD4+ cell counts P = .02 for HBsAg and 22.8% vs 5.7%, (P = .002 for HBV DNA. After 1 year of follow-up, the proportion of those who cleared the HBeAg was considerably lower in severely immunosuppressed coinfected patients: 4.7% vs 37.1% (P = .003. Four additional HIV-infected adolescents became HBsAg-positive over the term of follow-up (incidence rate, 24.9/1000 person-years, despite a record of immunization against hepatitis B. Conclusion A substantial percentage of HIV-infected and HIV-uninfected Romanian adolescents have evidence of past or present HBV infection. In HIV-infected adolescents, the degree of immunosuppression is correlated with persistence of HBV replicative markers, even in the absence of clinical or biochemical signs of liver disease.

  20. Impact of hepatitis B virus infection on hepatic metabolic signaling pathway

    Science.gov (United States)

    Shi, Yi-Xian; Huang, Chen-Jie; Yang, Zheng-Gang

    2016-01-01

    A growing body of epidemiologic research has demonstrated that metabolic derangement exists in patients with hepatitis B virus (HBV) infection, indicating that there are clinical associations between HBV infection and host metabolism. In order to understand the complex interplay between HBV and hepatic metabolism in greater depth, we systematically reviewed these alterations in different metabolic signaling pathways due to HBV infection. HBV infection interfered with most aspects of hepatic metabolic responses, including glucose, lipid, nucleic acid, bile acid and vitamin metabolism. Glucose and lipid metabolism is a particular focus due to the significant promotion of gluconeogenesis, glucose aerobic oxidation, the pentose phosphate pathway, fatty acid synthesis or oxidation, phospholipid and cholesterol biosynthesis affected by HBV. These altered metabolic pathways are involved in the pathological process of not only hepatitis B, but also metabolic disorders, increasing the occurrence of complications, such as hepatocellular carcinoma and liver steatosis. Thus, a clearer understanding of the hepatic metabolic pathways affected by HBV and its pathogenesis is necessary to develop more novel therapeutic strategies targeting viral eradication. PMID:27688657

  1. Hepatitis E Virus Genotype 3 in Colombia: Survey in Patients with Clinical Diagnosis of Viral Hepatitis

    Science.gov (United States)

    Rendon, Julio; Hoyos, Maria Cristina; di Filippo, Diana; Cortes-Mancera, Fabian; Mantilla, Carolina; Velasquez, Maria Mercedes; Sepulveda, Maria Elsy; Restrepo, Juan Carlos; Jaramillo, Sergio; Arbelaez, Maria Patricia; Correa, Gonzalo; Navas, Maria-Cristina

    2016-01-01

    Background Hepatitis E virus is a major cause of outbreaks as well as sporadic hepatitis cases worldwide. The epidemiology of this enterically transmitted infection differs between developing and developed countries. The aims of this study were to describe HEV infection in Colombian patients and to characterize the genotype. Methods A prospective study was carried out on 40 patients aged over 15 with a clinical diagnosis of viral hepatitis, recruited from five primary health units in the city of Medellin, Colombia. Fecal samples obtained from the 40 consecutives cases were analyzed for HEV RNA using nested reverse transcription PCR for both ORF1 and ORF2-3. The amplicons were sequenced for phylogenetic analyses. Results Nine (22.5%) cases of HEV infection were identified in the study population. Three HEV strains obtained from patients were classified as genotype 3. No significant association was found between cases of Hepatitis E and the variables water drinking source, garbage collection system and contact with pigs. Conclusions This is the first prospective study of hepatitis E in Colombian patients. The circulation of the genotype 3 in this population is predictable considering the reports of the region and the identification of this genotype from pigs in the state of Antioquia, of which Medellin is the capital. Further studies are necessary to establish whether zoonotic transmission of HEV is important in Colombia. PMID:26886728

  2. Hepatitis E Virus Genotype 3 in Colombia: Survey in Patients with Clinical Diagnosis of Viral Hepatitis.

    Directory of Open Access Journals (Sweden)

    Julio Rendon

    Full Text Available Hepatitis E virus is a major cause of outbreaks as well as sporadic hepatitis cases worldwide. The epidemiology of this enterically transmitted infection differs between developing and developed countries. The aims of this study were to describe HEV infection in Colombian patients and to characterize the genotype.A prospective study was carried out on 40 patients aged over 15 with a clinical diagnosis of viral hepatitis, recruited from five primary health units in the city of Medellin, Colombia. Fecal samples obtained from the 40 consecutives cases were analyzed for HEV RNA using nested reverse transcription PCR for both ORF1 and ORF2-3. The amplicons were sequenced for phylogenetic analyses.Nine (22.5% cases of HEV infection were identified in the study population. Three HEV strains obtained from patients were classified as genotype 3. No significant association was found between cases of Hepatitis E and the variables water drinking source, garbage collection system and contact with pigs.This is the first prospective study of hepatitis E in Colombian patients. The circulation of the genotype 3 in this population is predictable considering the reports of the region and the identification of this genotype from pigs in the state of Antioquia, of which Medellin is the capital. Further studies are necessary to establish whether zoonotic transmission of HEV is important in Colombia.

  3. Hepatitis B Virus Core-Related Antigens as Markers for Monitoring Chronic Hepatitis B Infection▿

    Science.gov (United States)

    Wong, Danny Ka-Ho; Tanaka, Yasuhito; Lai, Ching-Lung; Mizokami, Masashi; Fung, James; Yuen, Man-Fung

    2007-01-01

    A sensitive chemiluminescence enzyme immunoassay has been developed for hepatitis B virus (HBV) core-related antigen (HBcrAg) detection. We aimed to investigate the usefulness of HBcrAg measurement for monitoring chronic hepatitis B disease. HBcrAg levels were measured by a chemiluminescence enzyme immunoassay in 54 untreated patients and 39 patients treated with either entecavir or lamivudine. The HBcrAg concentration correlated positively with the levels of serum HBV DNA (r = 0.820), intrahepatic total HBV DNA (r = 0.700), and covalently closed circular DNA (cccDNA) (r = 0.664; for all, P values were HBcrAg concentration was associated with a greater proportion of hepatitis B core antigen immunostaining. Although the differences were not statistically significant, patients with higher Knodell necroinflammation and fibrosis scores tended to have higher serum HBcrAg concentration levels. In the treated patients, the logarithmic reduction in HBcrAg at week 48 correlated positively with the logarithmic reduction of serum HBV DNA, intrahepatic total HBV DNA, and cccDNA. Of the 31 patients with undetectable serum HBV DNA (HBcrAg. A greater reduction in posttreatment HBcrAg concentration was associated with histological improvement and a decrease in hepatitis B core antigen immunostaining. HBcrAg concentrations of HBcrAg levels correlated with HBV virological markers and reflected the chronic hepatitis B disease activity in the liver. PMID:17942661

  4. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection.

    Science.gov (United States)

    Wong, Danny Ka-Ho; Tanaka, Yasuhito; Lai, Ching-Lung; Mizokami, Masashi; Fung, James; Yuen, Man-Fung

    2007-12-01

    A sensitive chemiluminescence enzyme immunoassay has been developed for hepatitis B virus (HBV) core-related antigen (HBcrAg) detection. We aimed to investigate the usefulness of HBcrAg measurement for monitoring chronic hepatitis B disease. HBcrAg levels were measured by a chemiluminescence enzyme immunoassay in 54 untreated patients and 39 patients treated with either entecavir or lamivudine. The HBcrAg concentration correlated positively with the levels of serum HBV DNA (r = 0.820), intrahepatic total HBV DNA (r = 0.700), and covalently closed circular DNA (cccDNA) (r = 0.664; for all, P values were HBcrAg concentration was associated with a greater proportion of hepatitis B core antigen immunostaining. Although the differences were not statistically significant, patients with higher Knodell necroinflammation and fibrosis scores tended to have higher serum HBcrAg concentration levels. In the treated patients, the logarithmic reduction in HBcrAg at week 48 correlated positively with the logarithmic reduction of serum HBV DNA, intrahepatic total HBV DNA, and cccDNA. Of the 31 patients with undetectable serum HBV DNA (HBcrAg. A greater reduction in posttreatment HBcrAg concentration was associated with histological improvement and a decrease in hepatitis B core antigen immunostaining. HBcrAg concentrations of HBcrAg levels correlated with HBV virological markers and reflected the chronic hepatitis B disease activity in the liver.

  5. Occult Hepatitis B Virus Infection in Nigerian Blood Donors and Hepatitis B Virus Transmission Risks.

    Directory of Open Access Journals (Sweden)

    Opaleye O Oluyinka

    Full Text Available Occult hepatitis B virus infection (OBI characterized by the absence of detectable HBsAg remains a potential threat in blood safety. We investigated the actual prevalence, viral factors and genotype of OBI infections in Nigerian blood donors.Serum collected from two blood banks were reconfirmed as HBsAg seronegative by ELISA. Forty HBsAg positive samples were employed as controls. HBV-DNA was amplified from all donors and viral loads were determined using quantitative real-time PCR. Antibodies to the HBV core, surface and HBe antigen (anti-HBc,anti-HBs,HBeAg were measured. The PreS/S and PreC/C regions of the HBV genome were sequenced.Of the 429 blood donors, 72(17% were confirmed as OBI by DNA detection in different reference labs and excluded the concern of possible contamination. Of the 72 OBI samples, 48(67% were positive for anti-HBc, 25(35% positive for anti-HBs, and 2(3% positive for HBeAg. Of the 72 OBI samples, 31(43% were seropositive for either anti-HBc, anti-HBs or HBeAg, 21 (30% positive for both anti-HBc and anti-HBs,one positive for both anti-HBc and HBeAg. None of the OBI samples were positive for all three serological markers. The viral load was <50copies/ml in the OBI samples and genotype E was predominant. The L217R polymorphism in the reverse transcriptase domain of the HBV polymerase gene was observed significantly higher in OBI compared with HBsAg positive individuals (P<0.0001.High incidence of OBI is relevant in high endemic areas worldwide and is a general burden in blood safety. This study signifies the high prevalence of OBI and proposes blood donor samples in Nigeria should be pre-tested for OBI by nucleic acid testing (NAT and/or anti-HBc prior to transfusion to minimize the HBV infection risk.

  6. Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus

    Directory of Open Access Journals (Sweden)

    Venkatakrishna Shyamala

    2014-01-01

    Full Text Available In the last few decades through an awareness of transfusion transmitted infections (TTI, a majority of countries have mandated serology based blood screening assays for Human immunodeficiency virus (HIV, Hepatitis C virus (HCV, and Hepatitis B virus (HBV. However, despite improved serology assays, the transfusion transmission of HIV, HCV, and HBV continues, primarily due to release of serology negative units that are infectious because of the window period (WP and occult HBV infections (OBI. Effective mode of nucleic acid technology (NAT testing of the viruses can be used to minimize the risk of TTIs. This review compiles the examples of NAT testing failures for all three viruses; analyzes the causes for failure, and the suggestions from retrospective studies to minimize such failures. The results suggest the safest path to be individual donation testing (ID format for highest sensitivity, and detection of multiple regions for rapidly mutating and recombining viruses. The role of blood screening in the context of the donation and transfusion practices in India, the donor population, and the epidemiology is also discussed. World wide, as the public awareness of TTIs increases, as the recipient rights for safe blood are legally upheld, as the possibility to manage diseases such as hepatitis through expensive and prolonged treatment becomes accessible, and the societal responsibility to shoulder the health costs as in the case for HIV becomes routine, there is much to gain by preventing infections than treating diseases.

  7. National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care.

    Science.gov (United States)

    El-Akel, W; El-Sayed, M H; El Kassas, M; El-Serafy, M; Khairy, M; Elsaeed, K; Kabil, K; Hassany, M; Shawky, A; Yosry, A; Shaker, M K; ElShazly, Y; Waked, I; Esmat, G; Doss, W

    2017-02-01

    Hepatitis C virus (HCV) infection is a major health problem in Egypt as the nation bears the highest prevalence rate worldwide. This necessitated establishing a novel model of care (MOC) to contain the epidemic, deliver patient care and ensure global treatment access. In this review, we describe the process of development of the Egyptian model and future strategies for sustainability. Although the magnitude of the HCV problem was known for many years, the HCV MOC only came into being in 2006 with the establishment of the National Committee for Control of Viral Hepatitis (NCCVH) to set up and implement a national control strategy for the disease and other causes of viral hepatitis. The strategy outlines best practices for patient care delivery by applying a set of service principles through identified clinical streams and patient flow continuums. The Egyptian national viral hepatitis treatment programme is considered one of the most successful and effective public health programmes. To date, more than one million patients were evaluated and more than 850 000 received treatment under the umbrella of the programme since 2006. The NCCVH has been successful in establishing a strong infrastructure for controlling viral hepatitis in Egypt. It established a nationwide network of digitally connected viral hepatitis-specialized treatment centres covering the country map to enhance treatment access. Practice guidelines suiting local circumstances were issued and regularly updated and are applied in all affiliated centres. This review illustrates the model and the successful Egyptian experience. It sets an exemplar for states, organizations and policy-makers setting up programmes for care and management of people with hepatitis C.

  8. Characterization of a Hepatitis B virus strain in southwestern Paraná, Brazil, presenting mutations previously associated with anti-HBs Resistance Caracterização de uma cepa de hepatite por vírus B no sudoeste do Paraná, Brasil, apresentando mutações previamente associadas à resistência anti-HBs

    Directory of Open Access Journals (Sweden)

    Dennis Armando Bertolini

    2010-02-01

    Full Text Available The present study investigated if hepatitis B virus (HBV mutants circulate in the southwestern region of the State of Paraná, Brazil, by analyzing samples from children who received immunoprophylaxis but were born to HBV carrier mothers. Samples from 25 children were screened for HBV serum markers and for HBV DNA by PCR. Only one sample was positive for HBsAg, anti-HBs and HBV DNA, although the child had been vaccinated. Analysis of the S gene sequence of this sample showed the presence of a proline at position 105, a serine at position 114, three threonines at positions 115, 116 and 140, and a glutamine at position 129. The presence of these amino acids, except for serine at position 114, has been related to monoclonal or polyclonal therapy with anti-HBs after liver transplantation, whereas the presence of threonine at position 116 has been described in immunized children from Singapore. This finding demonstrates the possible circulation of HBV strains resistant to hepatitis B immunoprophylaxis in southwestern Paraná, Brazil. The genotype of the sample was identified as genotype D, which is frequently found in the region studied. Since 36% of the children had received incomplete or no immunoprophylaxis, more extensive follow-up of children born to HBsAg-positive mothers is needed.O presente estudo investigou se mutantes do vírus da hepatite B (HBV circulam na região Sudoeste do Estado do Paraná, Brasil, analisando amostras de crianças que receberam a imunoprofilaxia por terem nascido de mães portadoras do HBV. Amostras de 25 crianças foram analisadas para os marcadores sorológicos do HBV e para o DNA-HBV por PCR. Somente uma amostra foi positiva para AgHBs, anti-HBs e DNA-HBV, apesar da criança ter sido vacinada. Análises da seqüência do gene S desta amostra mostrou a presença de uma prolina na posição 105, uma serina na posição 114, três treoninas nas posições 115, 116 e 140, e uma glutamina na posição 129. A presen

  9. Natural History and Clinical Consequences of Hepatitis B Virus Infection.

    Science.gov (United States)

    Pan, Calvin Q; Zhang, Jin X

    2005-01-01

    Despite the existence of Hepatitis B vaccination, hepatitis B virus (HBV) infection is still prevalent worldwide and accounts for significant morbidity and mortality. It is encouraging that majority of patients do recover from the acute infection, however, those that progress to chronic disease state is at great risk of developing complications such as hepatocellular carcinoma, cirrhosis and liver failure. Hepatitis B virus infection can be influenced by many factors such as host immune status, age at infection, and level of viral replication. The discovery about the existence of various genotypes and its association with different geographic distribution as well as the knowledge regarding mutant species has aid us in better understanding the nature of HBV infection and in delivering better care for patients. It is especially important to recognize those individuals with HBeAg-negative chronic HBV as they have a poorer prognosis compare with their counterparts, HBeAg-positive. Tremendous progress has been made over the years in understanding the behavior and clinical course of the disease; however, the natural history of HBV is complex and we still have much to explore and learn.

  10. Simeprevir for the treatment of hepatitis C virus infection

    Directory of Open Access Journals (Sweden)

    Izquierdo L

    2014-08-01

    Full Text Available Laure Izquierdo,1 François Helle,1 Catherine François,1,2 Sandrine Castelain,1,2 Gilles Duverlie,1,2 Etienne Brochot1,2 1Virology Research Unit, Jules Verne University of Picardie, 2Department of Virology, Amiens University Hospital, Amiens, France Abstract: Simeprevir (TMC435, Olysio™, a second-generation hepatitis C virus (HCV protease inhibitor, has been recently approved for the treatment of genotype 1 chronic hepatitis C in combination with pegylated interferon and ribavirin. This molecule has very different characteristics from first-generation protease inhibitors. Results from trials show that simeprevir is highly effective and safe, with few adverse events. We discuss the specific features of this new treatment option for HCV infection, in terms of in vitro data, pharmacological data, and clinical trials. We also discuss the impact of Q80K polymorphism at baseline. Studies evaluating interferon-free regimens with simeprevir are ongoing. Future combinations of two or more direct-acting antiviral agents, targeting different viral enzymes and with synergistic antiviral effects, will be approved, allowing treatment of pan-genotypic HCV with optimized sustained virologic responses. Simeprevir will undoubtedly be part of future treatment strategies. Keywords: simeprevir, protease inhibitor, direct-acting antiviral agent, hepatitis C virus

  11. Hepatitis A virus infection: Epidemiology and genetic diversity

    Directory of Open Access Journals (Sweden)

    Báez Triana, Paula Andrea

    2015-04-01

    Full Text Available Hepatitis A virus infection is a global public health problem. The virus has a wide range of distribution and it is the main cause of acute hepatitis transmitted by the enteric route in Latin America. The viral particle is stable under environmental conditions and conserves its infectivity for several weeks, enabling its transmission by contaminated water and food. Worldwide, different epidemiological patterns have been identified, which may change over time by modification of social and economic variables in the population such as vaccination and the improvement of hygiene and primary health conditions. This leaves new populations susceptible to infection. In Latin America the circulation of genotype I and subgenotypes A and B has been described, but more research is needed to provide the knowledge needed to manage the prevention and control plans for the worldwide reduction of the prevalence of infection. For this paper, a literature review was performed on the SciELO, PubMed and ScienceDirect databases under the search terms "Hepatitis A", "Epidemiology," "Seroprevalence" and "Infection." From the results obtained, only papers published in English and Spanish to describe epidemiological and molecular studies of interest in Latin America were included.

  12. Innate immune responses in hepatitis C virus infection.

    Science.gov (United States)

    Li, Kui; Lemon, Stanley M

    2013-01-01

    Hepatitis C virus (HCV) is a major causative agent of chronic hepatitis and hepatocellular carcinoma worldwide and thus poses a significant public health threat. A hallmark of HCV infection is the extraordinary ability of the virus to persist in a majority of infected people. Innate immune responses represent the front line of defense of the human body against HCV immediately after infection. They also play a crucial role in orchestrating subsequent HCV-specific adaptive immunity that is pivotal for viral clearance. Accumulating evidence suggests that the host has evolved multifaceted innate immune mechanisms to sense HCV infection and elicit defense responses, while HCV has developed elaborate strategies to circumvent many of these. Defining the interplay of HCV with host innate immunity reveals mechanistic insights into hepatitis C pathogenesis and informs approaches to therapy. In this review, we summarize recent advances in understanding innate immune responses to HCV infection, focusing on induction and effector mechanisms of the interferon antiviral response as well as the evasion strategies of HCV.

  13. Thermal inactivation kinetics of hepatitis A virus in spinach.

    Science.gov (United States)

    Bozkurt, Hayriye; Ye, Xiaofei; Harte, Federico; D'Souza, Doris H; Davidson, P Michael

    2015-01-16

    Leafy vegetables have been recognized as important vehicles for the transmission of foodborne viral pathogens. To control hepatitis A viral foodborne illness outbreaks associated with mildly heated (e.g., blanched) leafy vegetables such as spinach, generation of adequate thermal processes is important both for consumers and the food industry. Therefore, the objectives of this study were to determine the thermal inactivation behavior of hepatitis A virus (HAV) in spinach, and provide insights on HAV inactivation in spinach for future studies and industrial applications. The D-values calculated from the first-order model (50-72 °C) ranged from 34.40 ± 4.08 to 0.91 ± 0.12 min with a z-value of 13.92 ± 0.87 °C. The calculated activation energy value was 162 ± 11 kJ/mol. Using the information generated in the present study and the thermal parameters of industrial blanching conditions for spinach as a basis (100 °C for 120-180 s), the blanching of spinach in water at 100 °C for 120-180 s under atmospheric conditions will provide greater than 6 log reduction of HAV. The results of this study may be useful to the frozen food industry in designing blanching conditions for spinach to inactivate or control hepatitis A virus outbreaks. Copyright © 2014. Published by Elsevier B.V.

  14. Epidemiology of hepatitis B virus infection in Albania.

    Science.gov (United States)

    Resuli, Bashkim; Prifti, Skerdi; Kraja, Bledar; Nurka, Tatjana; Basho, Mimoza; Sadiku, Edita

    2009-02-21

    To assess the prevalence and socio-demographic distribution of hepatitis B virus (HBV) infection in Albania. Blood samples from 410 unselected schoolboys, 666 students, 500 military personnel, 1286 casual blood donors, 378 voluntary blood donors and 640 pregnant women (total 3880 non-vaccinated residents of rural and metropolitan areas from all over Albania; 2354 (60.7%) male and 1526 (39.3%) female; mean age of 26.3 years) were tested during 2004-2006 for hepatitis B surface antigen (HBsAg) and antibodies to hepatitis B virus (anti-HBs) by ELISA. The HBsAg and anti-HBs prevalence were 9.5% and 28.7%, respectively. The highest HBsAg prevalence was evident in the younger age group, such as in schoolchildren (11.8%) and the military (10.6%). Consequently, the anti-HBs prevalence increased with age, from 21.2% in schoolchildren (mean age: 15.7 years), to 36.3% in pregnant women (mean age: 26.3 years) and 29.7% in voluntary blood donors (mean age: 40.1 years). There were no significant differences between males and females. Despite the estimated two-fold reduction of HBsAg prevalence in the general population from about 18%-19% to 9.5%, Albania remains a highly endemic country (i.e. over 8% of HBsAg prevalence rate).

  15. Morphologic Features of Extrahepatic Manifestations of Hepatitis C Virus Infection

    Directory of Open Access Journals (Sweden)

    Huaibin M. Ko

    2012-01-01

    Full Text Available Cirrhosis and hepatocellular carcinoma are the prototypic complications of chronic hepatitis C virus infection in the liver. However, hepatitis C virus also affects a variety of other organs that may lead to significant morbidity and mortality. Extrahepatic manifestations of hepatitis C infection include a multitude of disease processes affecting the small vessels, skin, kidneys, salivary gland, eyes, thyroid, and immunologic system. The majority of these conditions are thought to be immune mediated. The most documented of these entities is mixed cryoglobulinemia. Morphologically, immune complex depositions can be identified in small vessels and glomerular capillary walls, leading to leukoclastic vasculitis in the skin and membranoproliferative glomerulonephritis in the kidney. Other HCV-associated entities include porphyria cutanea tarda, lichen planus, necrolytic acral erythema, membranous glomerulonephritis, diabetic nephropathy, B-cell non-Hodgkin lymphomas, insulin resistance, sialadenitis, sicca syndrome, and autoimmune thyroiditis. This paper highlights the histomorphologic features of these processes, which are typically characterized by chronic inflammation, immune complex deposition, and immunoproliferative disease in the affected organ.

  16. Pathogenesis of occult chronic hepatitis B virus infection

    Institute of Scientific and Technical Information of China (English)

    Rocio Aller de la Fuente; María L Gutiérrez; Javier Garcia-Samaniego; Conrado Fernández-Rodriguez; Jose Luis Lledó; Gregorio Castellano

    2011-01-01

    Occult hepatitis B infection (OBI) is characterized by hepatitis B virus (HBV) DNA in serum in the absence of hepatitis B surface antigen (HBsAg) presenting HBsAg-negative and anti-HBc positive serological patterns. Occult HBV status is associated in some cases with mutant viruses undetectable by HBsAg assays; but more frequently it is due to a strong suppression of viral replication and gene expression. OBI is an entity with world-wide diffusion. The failure to detect HBsAg, despite the persistence of the viral DNA, is due in most cases to the strong suppression of viral replication and gene expression that characterizes this "occult" HBV infection; although the mechanisms responsible for suppression of HBV are not well understood. The majority of OBI cases are secondary to overt HBV infection and represent a residual low viremia level suppressed by a strong immune response together with histological derangements which occurred during acute or chronic HBV infection. Much evidence suggests that it can favour the progression of liver fibrosis and the development of hepatocellular carcinoma.

  17. Epidemiology of hepatitis B virus infection in Albania

    Institute of Scientific and Technical Information of China (English)

    Bashkim Resuli; Skerdi Prifti; Bledar Kraja; Tatjana Nurka; Mimoza Basho; Edita Sadiku

    2009-01-01

    AIM:To assess the prevalence and socio-demographic distribution of hepatitis B virus (HBV) infection in Albania. METHODS: Blood samples from 410 unselected schoolboys, 666 students, 500 military personnel, 1286 casual blood donors, 378 voluntary blood donors and 640 pregnant women (total 3880 non-vaccinated residents of rural and metropolitan areas from all over Albania; 2354 (60.7%) male and 1526 (39.3%) female; mean age of 26.3 years) were tested during 2004-2006 for hepatitis B surface antigen (HBsAg) and antibodies to hepatitis B virus (anti-HBs) by ELISA. RESULTS: The HBsAg and anti-HBs prevalence were 9.5% and 28.7%, respectively. The highest HBsAg prevalence was evident in the younger age group, such as in schoolchildren (11.8%) and the military (10.6%).Consequently, the anti-HBs prevalence increased with age, from 21.2% in schoolchildren (mean age: 15.7 years), to 36.3% in pregnant women (mean age: 26.3 years) and 29.7% in voluntary blood donors (mean age: 40.1 years). There were no significant differences between males and females. CONCLUSION: Despite the estimated two-fold reduction of HBsAg prevalence in the general population from about 18%-19% to 9.5%, Albania remains a highly endemic country (I.e. Over 8% of HBsAg prevalence rate).

  18. Morphologic features of extrahepatic manifestations of hepatitis C virus infection.

    Science.gov (United States)

    Ko, Huaibin M; Hernandez-Prera, Juan C; Zhu, Hongfa; Dikman, Steven H; Sidhu, Harleen K; Ward, Stephen C; Thung, Swan N

    2012-01-01

    Cirrhosis and hepatocellular carcinoma are the prototypic complications of chronic hepatitis C virus infection in the liver. However, hepatitis C virus also affects a variety of other organs that may lead to significant morbidity and mortality. Extrahepatic manifestations of hepatitis C infection include a multitude of disease processes affecting the small vessels, skin, kidneys, salivary gland, eyes, thyroid, and immunologic system. The majority of these conditions are thought to be immune mediated. The most documented of these entities is mixed cryoglobulinemia. Morphologically, immune complex depositions can be identified in small vessels and glomerular capillary walls, leading to leukoclastic vasculitis in the skin and membranoproliferative glomerulonephritis in the kidney. Other HCV-associated entities include porphyria cutanea tarda, lichen planus, necrolytic acral erythema, membranous glomerulonephritis, diabetic nephropathy, B-cell non-Hodgkin lymphomas, insulin resistance, sialadenitis, sicca syndrome, and autoimmune thyroiditis. This paper highlights the histomorphologic features of these processes, which are typically characterized by chronic inflammation, immune complex deposition, and immunoproliferative disease in the affected organ.

  19. Theories about evolutionary origins of human hepatitis B virus in primates and humans

    Directory of Open Access Journals (Sweden)

    Breno Frederico de Carvalho Dominguez Souza

    2014-09-01

    Full Text Available Introduction: The human hepatitis B virus causes acute and chronic hepatitis and is considered one of the most serious human health issues by the World Health Organization, causing thousands of deaths per year. There are similar viruses belonging to the Hepadnaviridae family that infect non-human primates and other mammals as well as some birds. The majority of non-human primate virus isolates were phylogenetically close to the human hepatitis B virus, but like the human genotypes, the origins of these viruses remain controversial. However, there is a possibility that human hepatitis B virus originated in primates. Knowing whether these viruses might be common to humans and primates is crucial in order to reduce the risk to humans. Objective: To review the existing knowledge about the evolutionary origins of viruses of the Hepadnaviridae family in primates. Methods: This review was done by reading several articles that provide information about the Hepadnaviridae virus family in non-human primates and humans and the possible origins and evolution of these viruses. Results: The evolutionary origin of viruses of the Hepadnaviridae family in primates has been dated back to several thousand years; however, recent analyses of genomic fossils of avihepadnaviruses integrated into the genomes of several avian species have suggested a much older origin of this genus. Conclusion: Some hypotheses about the evolutionary origins of human hepatitis B virus have been debated since the '90s. One theory suggested a New World origin because of the phylogenetic co-segregation between some New World human hepatitis B virus genotypes F and H and woolly B virus in basal sister-relationship to the Old monkey human hepatitis World non-human primates and human hepatitis B virus variants. Another theory suggests an Old World origin of human hepatitis B virus, and that it would have been spread following prehistoric human migrations over 100,000 years ago. A third theory

  20.  Association between hepatitis B virus and chronic kidney disease: a systematic review and meta-analysis.

    Science.gov (United States)

    Fabrizi, Fabrizio; Donato, Francesca M; Messa, Piergiorgio

     Background. Hepatitis B virus infection and chronic kidney disease are prevalent and remain a major public health problem worldwide. It remains unclear how infection with hepatitis B virus impacts on the development and progression of chronic kidney disease.

  1. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe

    DEFF Research Database (Denmark)

    Soriano, Vincent; Mocroft, Amanda; Peters, Lars

    2010-01-01

    Both natural history and treatment outcome of hepatitis B virus (HBV) infection are influenced by genotypes and viral load. Information about factors determining HBV genotype distribution and viraemia in HIV/HBV-co-infected patients is scarce.......Both natural history and treatment outcome of hepatitis B virus (HBV) infection are influenced by genotypes and viral load. Information about factors determining HBV genotype distribution and viraemia in HIV/HBV-co-infected patients is scarce....

  2. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe

    DEFF Research Database (Denmark)

    Soriano, Vincent; Mocroft, Amanda; Peters, Lars

    2010-01-01

    Both natural history and treatment outcome of hepatitis B virus (HBV) infection are influenced by genotypes and viral load. Information about factors determining HBV genotype distribution and viraemia in HIV/HBV-co-infected patients is scarce.......Both natural history and treatment outcome of hepatitis B virus (HBV) infection are influenced by genotypes and viral load. Information about factors determining HBV genotype distribution and viraemia in HIV/HBV-co-infected patients is scarce....

  3. MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosis

    OpenAIRE

    Bo-Xun Jin; Yong-Hong Zhang; Wen-Jing Jin; Xiang-Ying Sun; Gui-Fang Qiao; Ying-Ying Wei; Li-Bo Sun; Wei-Hong Zhang; Ning Li

    2015-01-01

    An important unresolved clinical issue is to distinguish hepatitis B virus (HBV) infection caused chronic hepatitis and their corresponding liver cirrhosis (LC). Recent research suggests that circulating microRNAs are useful biomarkers for a wide array of diseases. We analyzed microRNA profiles in the plasmas of a total of 495 chronic hepatitis B (CHB) patients, LC patients and healthy donors and identified 10 miRNAs that were differentially expressed between CHB and LC patients. Our logistic...

  4. Hepatitis C Virus Evasion from RIG-I-Dependent Hepatic Innate Immunity

    Directory of Open Access Journals (Sweden)

    Helene Minyi Liu

    2010-01-01

    Full Text Available Exposure to hepatitis C virus (HCV usually results in persistent infection that often develops into chronic liver disease. Interferon-alpha (IFN treatment comprises the foundation of current approved therapy for chronic HCV infection but is limited in overall efficacy. IFN is a major effector of innate antiviral immunity and is naturally produced in response to viral infection when viral pathogen-associated molecular patterns (PAMPs are recognized as nonself and are bound by cellular pathogen recognition receptors (PRRs, including Toll-like receptors (TLRs and the RIG-I-like receptors (RLRs. Within hepatocytes, RIG-I is a major PRR of HCV infection wherein PAMP interactions serve to trigger intracellular signaling cascades in the infected hepatocyte to drive IFN production and the expression of interferon-stimulated genes (ISGs. ISGs function to limit virus replication, modulate the immune system, and to suppress virus spread. However, studies of HCV-host interactions have revealed several mechanisms of innate immune regulation and evasion that feature virus control of PRR signaling and regulation of hepatic innate immune programs that may provide a molecular basis for viral persistence.

  5. SPF rabbits infected with rabbit hepatitis E virus isolate experimentally showing the chronicity of hepatitis.

    Science.gov (United States)

    Han, Jian; Lei, Yaxin; Liu, Lin; Liu, Peng; Xia, Junke; Zhang, Yulin; Zeng, Hang; Wang, Lin; Wang, Ling; Zhuang, Hui

    2014-01-01

    This study focused on investigating the pathogenesis seen in specific-pathogen-free (SPF) rabbits following infection with a homologous rabbit HEV isolate (CHN-BJ-rb14) and comparing it to that seen following infection with a heterologous swine genotype 4 HEV isolate (CHN-XJ-SW13). Three of the four animals inoculated with the homologous rabbit HEV became infected, exhibiting an intermittent viremia, obvious fluctuations of liver function biomarkers alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and persistent fecal virus shedding throughout the nine month study. In addition, liver histopathology showed both chronic inflammation and some degree of fibrosis. Both positive and negative-stranded HEV RNA and HEV antigen expression were detected in liver, brain, stomach, duodenum and kidney from the necropsied rabbits. Inflammation of extrahepatic tissue (duodenum and kidney) was also observed. Three of the four rabbits inoculated with the heterologous genotype 4 swine HEV also became infected, showing similar levels of anti-HEV antibody to that generated following infection with the homologous virus isolate. The duration of both viremia and fecal shedding of virus was however shorter following infection with the heterologous virus and there was no significant elevation of liver function biomarkers. These results suggest that rabbit HEV infection may cause more severe hepatitis and prolong the course of the disease, with a possible chronic trend of hepatitis in SPF rabbits.

  6. Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants

    NARCIS (Netherlands)

    Kamar, Nassim; Garrouste, Cyril; Haagsma, Elizabeth B.; Garrigue, Valerie; Pischke, Sven; Chauvet, Cecile; Dumortier, Jerome; Cannesson, Amelie; Cassuto-Viguier, Elisabeth; Thervet, Eric; Conti, Filomena; Lebray, Pascal; Dalton, Harry R.; Santella, Robert; Kanaan, Nada; Essig, Marie; Mousson, Christiane; Radenne, Sylvie; Roque-Afonso, Anne Marie; Izopet, Jacques; Rostaing, Lionel

    2011-01-01

    BACKGROUND & AIMS: Hepatitis E virus (HEV) infection can cause chronic hepatitis in recipients of solid organ transplants. However, the factors that contribute to chronic infection and the outcomes of these patients are incompletely understood. We performed a retrospective analysis of data from 17 c

  7. Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants

    NARCIS (Netherlands)

    Kamar, Nassim; Garrouste, Cyril; Haagsma, Elizabeth B.; Garrigue, Valerie; Pischke, Sven; Chauvet, Cecile; Dumortier, Jerome; Cannesson, Amelie; Cassuto-Viguier, Elisabeth; Thervet, Eric; Conti, Filomena; Lebray, Pascal; Dalton, Harry R.; Santella, Robert; Kanaan, Nada; Essig, Marie; Mousson, Christiane; Radenne, Sylvie; Roque-Afonso, Anne Marie; Izopet, Jacques; Rostaing, Lionel

    BACKGROUND & AIMS: Hepatitis E virus (HEV) infection can cause chronic hepatitis in recipients of solid organ transplants. However, the factors that contribute to chronic infection and the outcomes of these patients are incompletely understood. We performed a retrospective analysis of data from 17

  8. [Prevention of hepatitis C virus infection in drug users].

    Science.gov (United States)

    Schulte, B; Stöver, H; Leicht, A; Schnackenberg, K; Reimer, J

    2008-10-01

    The high prevalence and incidence rates of the hepatitis C virus (HCV) infections in drug users demonstrate the urgent necessity for a coordinated national prevention strategy. In the shadow of HIV/AIDS the necessary attention to the rapid spreading of the hepatitis C in drug users was started late, without being able to reach the public attention level of HIV/AIDS. The present efforts in the primary and secondary prevention of the hepatitis C in drug users are obviously not sufficient to reduce the prevalence with long-lasting results. Substitution treatment is of central relevance in the prevention of hepatitis C in opiate-dependent subjects, but requires, as current data of the HCV incidence of substituted opiate dependents illustrate, a stronger HCV-specific accentuation. Further settings, which are relevant for the group of intravenous drug users, have to be accessed and sensitized. Furthermore structural and political efforts are necessary, in order to develop a systematic and evidence-based answer to the challenge of the HCV spreading in drug users, in particular due to the fact that a German HCV strategy is still lacking.

  9. The Natural History of Hepatitis C Virus (HCV Infection

    Directory of Open Access Journals (Sweden)

    2006-04-01

    Full Text Available Hepatitis C virus (HCV is a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma, as well as the most common indication for liver transplantation in many countries. Although the incidence of hepatitis C infection has dramatically decreased during the past decade, the worldwide reservoir of chronically infected persons is estimated at 170 million, or 3% of the global population. There is much controversy surrounding the natural history of hepatitis C infection. The rate of chronic HCV infection is affected by a person's age, gender, race, and viral immune response. Approximately 75%-85% of HCV-infected persons will progress to chronic HCV infection, and are at risk for the development of extrahepatic manifestations, compensated and decompensated cirrhosis, and hepatocellular carcinoma (HCC. The rate of progression to cirrhosis is highly variable, and is influenced by several factors, including the amount of alcohol consumption, age of initial HCV infection, degree of inflammation and fibrosis on liver biopsy, HIV and HBV coinfection, and comordid conditions. An estimated 10%-15% of HCV-infected persons will advance to cirrhosis within the first 20 years. Persons with cirrhosis are at increased risk of developing HCC. An understanding of the natural history of hepatitis C is essential to effectively manage, treat, and counsel individuals with HCV infection.

  10. Common mutations of hepatitis B virus and their clinical significance

    Directory of Open Access Journals (Sweden)

    HU Airong

    2016-06-01

    Full Text Available Hepatitis B virus (HBV tends to mutate easily due to its special structure and life cycle. Mutation changes the biological behavior of HBV and its sensitivity to antiviral drugs and even affects therapeutic effect and accelerate disease progression. The point mutations are commonly see in the pre-S/S open reading frame (ORF, which may be associated with immune escape and occult HBV infection. The G1896A mutation is often observed in the pre-C/C-ORF and is associated with the development of HBeAg-negative chronic hepatitis B (CHB, hepatocellular carcinoma (HCC, and severe chronic hepatitis (liver failure. The mutations in P-ORF mainly occur in the reverse transcriptase (RT domain and are closely related to the resistance to nucleos(tide analogues. The A1762T and G1764A mutations occur in the basal core promoter (BCP, which overlaps with X-ORF, and may be associated with HBeAg-negative CHB, HCC, and severe chronic hepatitis (liver failure. Clarification of the association between these mutations and diseases helps to develop tailor-made diagnostic and therapeutic regimens for patients with HBV infection.

  11. Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011

    DEFF Research Database (Denmark)

    Christensen, Peer Brehm; Clausen, Mette Rye; Krarup, Henrik;

    2012-01-01

    The Danish Society of Infectious Diseases and Danish Society of Gastroenterology and Hepatology set up a committee in 2007 to produce national guidelines for treatment of viral hepatitis B and C. The 2011 version of the guidelines have been endorsed by the scientific societies and are presented...... is not common in Denmark. The prevalence has not been determined by national surveys, but it is estimated that 10,000-15,000 patients are chronically infected with hepatitis B and 15,000-20,000 with chronic hepatitis C. The majority of patients with HBV infection in Denmark are emigrants from high endemic...... below. Annual updates will be available at the websites of the societies. As this present English version has been written six months after the Danish 2011 version, it contains minor changes that will be integrated in the Danish 2012 version, available at the end this year. Epidemiology: Viral hepatitis...

  12. An overview on hepatitis C virus genotypes and its control

    Directory of Open Access Journals (Sweden)

    Faisal Nouroz

    2015-10-01

    Full Text Available Hepatitis C virus (HCV is a blood borne, circular and positive single stranded virus with high spread rates. With the passage of time the frequency of HCV is increasing in different parts of the world. HCV is a major cause, which may end in liver cirrhosis and hepatocellular carcinoma. HCV has six main genotypes with many subtypes, which have variable sequence homology with each other. Symptoms can appear anytime from 2 weeks to 6 months, which include jaundice, fatigue, gray-colored stool, joint pain, belly pain, weakness, anorexia, itchy skin and dark urine. Genotyping is more significant for planning of HCV treatment period and helps to cure HCV infections. For the quantification and identification of hepatitis C virus-ribonucleic acid, many molecular techniques are performed; the most significant are HCV ELISA, quantitative HCV-RNA PCR and recombinant immunoblot assay. PCR is the major technique targeting 5′ untranslated region (UTR. HCV can be transmitted by contaminated blood, ear and nose piercing and contaminated medical instruments. To overcome the rate of HCV, guidance should be provided to make aware the persons about risk factors, transmission and prevention. Discovery and designing of new therapies and vaccines to overcome this disease are the necessity of the present era. Four types of vaccines such as vector vaccines, peptide vaccines, DNA vaccines and recombinant protein vaccines are available in clinical trials.

  13. Hepatitis E virus antibody prevalence in wildlife in Poland.

    Science.gov (United States)

    Larska, M; Krzysiak, M K; Jabłoński, A; Kęsik, J; Bednarski, M; Rola, J

    2015-03-01

    Hepatitis E is an important public health problem mostly in developing but occasionally also in industrialized countries. Domestic and wildlife animals are considered reservoirs of the hepatitis E virus (HEV). Since no information on the prevalence of autochthonous HEV infections in human and animal in Poland is available, the aim of the study was to investigate the HEV seroprevalence of different wildlife species as potential virus reservoirs in the country. No HEV antibodies were found in any of the sera collected from the red deer (Cervus elaphus), European bison (Bison bonasus), roe deer (Capreolus capreolus), elk (Alces alces), fallow deer (Dama dama), sika deer (Cervus nippon), Tatra chamois (Rupicapra rupicapra tatrica) or brown bear (Ursus arctos). HEV-specific antibodies were detected in 44.4% (95% CI 38.3-50.7) serum samples originated only from wild boars. The percentage of seropositive wild boars differed significantly between the provinces and was positively correlated with the wild boar density and rurality of the area. This study showed that HEV circulates among wild boar population in Poland, and this species should be considered as an important reservoir of the virus.

  14. Hepatitis C virus: Virology, diagnosis and management of antiviral therapy

    Institute of Scientific and Technical Information of China (English)

    Stéphane Chevaliez; Jean-Michel Pawlotsky

    2007-01-01

    Hepatitis C virus (HCV) infects approximately 170 million individuals worldwide. Prevention of HCV infection complications is based on antiviral therapy with the combination of pegylatecl interferon alfa and ribavirin.The use of serological and virological tests has become essential in the management of HCV infection in order to diagnose infection, guide treatment decisions and assess the virological response to antiviral therapy. Anti-HCV antibody testing and HCV RNA testing are used to diagnose acute and chronic hepatitis C. The HCV genotype should be systematically determined before treatment, as it determines the indication, the duration of treatment,the dose of ribavirin and the virological monitoring procedure. HCV RNA monitoring during therapy is used to tailor treatment duration in HCV genotype 1 infection, and molecular assays are used to assess the end-of-treatment and, most importantly the sustained virological response,i.e. the enlpoint of therapy.

  15. Neglected Non-Traditional Routes of Hepatitis B Virus Transmission

    Directory of Open Access Journals (Sweden)

    Ling Wang

    2016-11-01

    Full Text Available According to Chinese Guideline of Prevention and Treatment for Chronic Hepatitis B which is published in October, 2015, hepatitis B virus (HBV is mainly transmitted via injection, vertical transmission, and sexual contact, furthermore, invasive procedures including pedicure and tattooing as well as sharing shavers and toothbrushes are also regarded as risk factors. These traditional HBV transmission pathways are in accordance with the corresponding WHO guideline. However, some of the statements in the guidelines such as close contact with active HBV carriers like sharing hygiene facilities and dining together as well as bites by blood-sucking arthropod like mosquito do not transmit HBV need to be questioned because related previous studies did not support these statements.

  16. Hepatitis C Virus E2 Envelope Glycoprotein Core Structure

    Energy Technology Data Exchange (ETDEWEB)

    Kong, Leopold; Giang, Erick; Nieusma, Travis; Kadam, Rameshwar U.; Cogburn, Kristin E.; Hua, Yuanzi; Dai, Xiaoping; Stanfield, Robyn L.; Burton, Dennis R.; Ward, Andrew B.; Wilson, Ian A.; Law, Mansun

    2014-08-26

    Hepatitis C virus (HCV), a Hepacivirus, is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular carcinoma. HCV envelope glycoproteins E1 and E2 mediate fusion and entry into host cells and are the primary targets of the humoral immune response. The crystal structure of the E2 core bound to broadly neutralizing antibody AR3C at 2.65 angstroms reveals a compact architecture composed of a central immunoglobulin-fold β sandwich flanked by two additional protein layers. The CD81 receptor binding site was identified by electron microscopy and site-directed mutagenesis and overlaps with the AR3C epitope. The x-ray and electron microscopy E2 structures differ markedly from predictions of an extended, three-domain, class II fusion protein fold and therefore provide valuable information for HCV drug and vaccine design.

  17. [Pathological features of hepatocellular carcinoma carrying hepatitis C virus antigen].

    Science.gov (United States)

    Liu, B; Zhu, S; Zhang, X

    1997-10-01

    To analyze the pathological features of hepatocellular carcinomas (HCCs) carrying different hepatitis virus antigens histopathologically and systematically. PAP and ABC kits were used in the immunohistochemical study, and CAS-200 System was applied in the image cytometry. As compared with HCCs carrying HBV marker(s), the HCCs carrying HCV marker showed more cases of clear cell type (7/9 vs 4/33), better differentiation of cancers, less necrosis of hepatocytes, milder lymphocyte infiltration in the hepatic sinuses or periportal areas (P < 0.01), higher incidence of bile ductule damages, and bore a close relation to the formation of lymphoid follicle in the surrounding tissues (P < 0.05). These patients were elder, with lower grade of symptoms and better prognosis after operation. HCCs carrying only HCAg have different pathological features and clinical characteristics from which carrying HBV marker(s). The results of image cytometry are in accordance with the biological behaviour of HCC.

  18. Novel approaches towards conquering hepatitis B virus infection

    Institute of Scientific and Technical Information of China (English)

    Guo-Yi Wu; Hong-Song Chen

    2007-01-01

    Currently approved treatments for hepatitis B virus (HBV) infection include the immunomodulatory agent, IFN-a, and nucleos(t)ide analogues. Their efficacy is limited by their side effects, as well as the induction of viral mutations that render them less potent. It is thus necessary to develop drugs that target additional viral antigens. Chemicals and biomaterials by unique methods of preventing HBV replication are currently being developed, including novel nucleosides and newly synthesized compounds such as capsid assembling and mRNA transcription inhibitors. Molecular therapies that target different stages of the HBV life cycle will aid current methods to manage chronic hepatitis B (CHB) infection. The use of immunomodulators and gene therapy are also under consideration. This report summarizes the most recent treatment possibilities for CHB infection. Emerging therapies and their potential mechanisms, efficacy, and pitfalls are discussed.

  19. An overview of occult hepatitis B virus infection

    Institute of Scientific and Technical Information of China (English)

    Zeinab Nabil Ahmed Said

    2011-01-01

    Occult hepatitis B virus (HBV) infection (OBI), alternatively defined as occult hepatitis B (OHB), is a challenging clinical entity. It is recognized by two main characteristics: absence of HBsAg, and low viral replication. The previous two decades have witnessed a remarkable progress in our nderstanding of OBI and its clinical implications. Appropriate diagnostic techniques must be adopted. Sensitive HBV DNA amplification assay is the gold standard assay for detection of OBI. Viral as well as host factors are implicated in the pathogenesis of OBI. However, published data reporting the infectivity of OBI by transfusion are limited. Several aspects including OBI transmission, infectivity and its relation to the development of chronic liver diseases and hepatocellular carcinoma have to be resolved. The aim of the present review is to highlight recent data on OBI with a focus on its virological diagnosis and clinical outcome.

  20. Emphysematous Cholecystitis: A Rare Complication of Hepatitis A Virus Infection

    Directory of Open Access Journals (Sweden)

    Ahmet KARAKAS

    2015-03-01

    Full Text Available Hepatitis A virus (HAV causes an acute hepatitis associated with significant elevatation in liver enzymes. The liver is main target of HAV and extrahepatic manifestations are scarce. The diagnosis of acute HAV infection is made by the detection of anti-HAV IgM antibody in patients with the typical clinical presentation.. Here in, we present a 22-year old male presented with malaise, fever, nause, and intensive stomach ache. In physical examination, the patient had fever, jaundice, and hepatomegaly. Laboratory tests resulted in elevated liver enzymes. Abdominal ultrasonography demonstrated thickening of the gallbladder wall, and intramural air. As the patient's symptoms failed to regress in follow up laparoscopic cholecystectomy was performed. To sum up, HAV infection can be seen in all age groups, in developing countries, such as our country. It must be kept in mind that, although very rarely, HAV infections may exhibit extrahepatic complications. [Dis Mol Med 2015; 3(1.000: 5-7

  1. Mouse Models of Hepatitis B Virus Infection Comprising Host-Virus Immunologic Interactions

    Directory of Open Access Journals (Sweden)

    Tadashi Inuzuka

    2014-04-01

    Full Text Available Hepatitis B virus (HBV infection is one of the most prevalent infectious diseases associated with various human liver diseases, including acute, fulminant and chronic hepatitis; liver cirrhosis; and hepatocellular carcinoma. Despite the availability of an HBV vaccine and the development of antiviral therapies, there are still more than 350 million chronically infected people worldwide, approximately 5% of the world population. To understand the virus biology and pathogenesis in HBV-infected patients, several animal models have been developed to mimic hepatic HBV infection and the immune response against HBV, but the narrow host range of HBV infection and lack of a full immune response spectrum in animal models remain significant limitations. Accumulating evidence obtained from studies using a variety of mouse models that recapitulate hepatic HBV infection provides several clues for understanding host-virus immunologic interactions during HBV infection, whereas the determinants of the immune response required for HBV clearance are poorly defined. Therefore, adequate mouse models are urgently needed to elucidate the mechanism of HBV elimination and identify novel targets for antiviral therapies.

  2. Linkage to Care for Suburban Heroin Users with Hepatitis C Virus Infection, New Jersey, USA.

    Science.gov (United States)

    Akyar, Eda; Seneca, Kathleen H; Akyar, Serra; Schofield, Neal; Schwartz, Mark P; Nahass, Ronald G

    2016-05-01

    We identified a 41.4% prevalence of hepatitis C virus, absence of HIV, and unexpectedly high frequency of hepatitis C virus genotype 3 among suburban New Jersey heroin users 17-35 years of age during 2014-2015. Despite 2 clinicians prepared to engage these users, few were successfully linked to care and treated.

  3. Screening for Hepatitis B Virus Infection in Pregnancy : US Preventive Services Task Force Reaffirmation Recommendation Statement

    NARCIS (Netherlands)

    Calonge, Ned; Petitti, Diana B.; DeWitt, Thomas G.; Dietrich, Allen J.; Gregory, Kimberly D.; Grossman, David; Isham, George; LeFevre, Michael L.; Leipzig, Rosanne M.; Marion, Lucy N.; Melnyk, Bernadette; Moyer, Virginia A.; Ockene, Judith K.; Sawaya, George F.; Schwartz, J. Sanford; Wilt, Timothy

    2009-01-01

    Description: Reaffirmation of the 2004 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for hepatitis B virus hepatitis B virus infection in pregnancy. Methods: The USPSTF performed a brief literature update, including a search for new and substantial evidence on the benefits

  4. High prevalence and predominance of hepatitis delta virus genotype 1 infection in Cameroon.

    Science.gov (United States)

    Foupouapouognigni, Yacouba; Noah, Dominique Noah; Sartre, Michèle Tagni; Njouom, Richard

    2011-03-01

    Antibodies to the hepatitis delta virus (HDV) were found in 17.6% of 233 hepatitis B virus surface antigen-positive subjects in Cameroon. Phylogenetic analyses showed the presence of HDV-1, HDV-5, HDV-6, and HDV-7 genotypes. These results enrich the limited data on HDV prevalence and molecular diversity in Cameroon.

  5. High Prevalence and Predominance of Hepatitis Delta Virus Genotype 1 Infection in Cameroon▿

    Science.gov (United States)

    Foupouapouognigni, Yacouba; Noah, Dominique Noah; Sartre, Michèle Tagni; Njouom, Richard

    2011-01-01

    Antibodies to the hepatitis delta virus (HDV) were found in 17.6% of 233 hepatitis B virus surface antigen-positive subjects in Cameroon. Phylogenetic analyses showed the presence of HDV-1, HDV-5, HDV-6, and HDV-7 genotypes. These results enrich the limited data on HDV prevalence and molecular diversity in Cameroon. PMID:21209162

  6. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus

    DEFF Research Database (Denmark)

    Iorio, Alfonso; Marchesini, Emanuela; Awad, Tahany;

    2010-01-01

    Antiviral treatment for chronic hepatitis C may be less effective if patients are co-infected with human immunodeficiency virus (HIV).......Antiviral treatment for chronic hepatitis C may be less effective if patients are co-infected with human immunodeficiency virus (HIV)....

  7. Detection and Characterization of Hepatitis E Virus in Domestic Pigs of Different Ages in Portugal

    NARCIS (Netherlands)

    Berto, A.; Mesquita, J.R.; Hakze-van der Honing, van der R.W.; Nascimento, R.S.; Poel, van der W.H.M.

    2012-01-01

    This study represents the primary hepatitis E virus (HEV) surveillance in domestic pigs in Portugal, five pig farms were investigated in 5 different Portuguese regions, ten faecal samples were collected at four different stages of the production. All faecal samples were tested for hepatitis E virus

  8. Linkage to Care for Suburban Heroin Users with Hepatitis C Virus Infection, New Jersey, USA

    Science.gov (United States)

    Seneca, Kathleen H.; Akyar, Serra; Schofield, Neal; Schwartz, Mark P.; Nahass, Ronald G.

    2016-01-01

    We identified a 41.4% prevalence of hepatitis C virus, absence of HIV, and unexpectedly high frequency of hepatitis C virus genotype 3 among suburban New Jersey heroin users 17–35 years of age during 2014–2015. Despite 2 clinicians prepared to engage these users, few were successfully linked to care and treated. PMID:27089172

  9. Genetic diversity of Hepatitis B Virus in Indonesia: epidemiological and clinical significance

    NARCIS (Netherlands)

    Thedja, M.D.

    2012-01-01

    Hepatitis B virus (HBV) infection remains a major public health problem particularly in Asia and Pacific that belongs to hepatitis B endemic regions. With high genetic diversity of the entire genome, this DNA virus has been classified into eight genotypes, genotype A to H, and recently two new

  10. Screening for Hepatitis B Virus Infection in Pregnancy : US Preventive Services Task Force Reaffirmation Recommendation Statement

    NARCIS (Netherlands)

    Calonge, Ned; Petitti, Diana B.; DeWitt, Thomas G.; Dietrich, Allen J.; Gregory, Kimberly D.; Grossman, David; Isham, George; LeFevre, Michael L.; Leipzig, Rosanne M.; Marion, Lucy N.; Melnyk, Bernadette; Moyer, Virginia A.; Ockene, Judith K.; Sawaya, George F.; Schwartz, J. Sanford; Wilt, Timothy

    2009-01-01

    Description: Reaffirmation of the 2004 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for hepatitis B virus hepatitis B virus infection in pregnancy. Methods: The USPSTF performed a brief literature update, including a search for new and substantial evidence on the benefits

  11. Epidemiological, immunological and virological aspects of acute and chronic hepatitis C virus infections

    NARCIS (Netherlands)

    Thomas, X.V.

    2015-01-01

    Hepatitis C virus (HCV) is a single-stranded positive-sense RNA virus classified as a member of the Hepacivirus genus in the family Flavirviridae, and was first described by Choo et al. in 1989 as the causative agent of non-A-non-B post-transfusion hepatitis. HCV is a major cause of blood-borne infe

  12. Hepatitis C virus genotypes and viral ribonucleic acid titers in Nigeria

    African Journals Online (AJOL)

    Hepatitis C virus genotypes and viral ribonucleic acid titers in Nigeria. ... PROMOTING ACCESS TO AFRICAN RESEARCH ... Background and Objectives: Hepatitis C virus (HCV) is a major cause of chronic liver disease, cirrhosis ... Senegal (6); Sierra Leone (1); South Africa (95); South Sudan (1); Sudan (3); Swaziland (3) ...

  13. Effect of hepatitis C virus infection on selected laboratory values in ...

    African Journals Online (AJOL)

    Effect of hepatitis C virus infection on selected laboratory values in pregnant ... PROMOTING ACCESS TO AFRICAN RESEARCH ... Background and Objectives: Both hepatitis C and Human Immunodeficiency viruses affect laboratory indices. ... Senegal (6); Sierra Leone (1); South Africa (96); South Sudan (1); Sudan (3) ...

  14. The burden of Hepatitis B and C virus infections in patients with ...

    African Journals Online (AJOL)

    The burden of Hepatitis B and C virus infections in patients with sickle cell anaemia in Jos – Nigeria. ... PROMOTING ACCESS TO AFRICAN RESEARCH ... Patients with this disease are at increased risk of contracting hepatitis B and C virus ... Senegal (6); Sierra Leone (1); South Africa (96); South Sudan (1); Sudan (3) ...

  15. Autoimmune hepatitis in patients with human immunodeficiency virus (HIV)

    Science.gov (United States)

    Kia, Leila; Beattie, Adam; Green, Richard M.

    2017-01-01

    Abstract Rationale: Chronic liver disease is a major cause of morbidity and mortality in patients with HIV. However, autoimmune hepatitis (AIH) in patients with HIV has rarely been reported. Our aim was to evaluate a cohort of patients with HIV and AIH and identify clinical presentations and outcomes. Patient Concerns: Management of autoimmune hepatitis in context of human immunodeficiency virus, long-term outcomes, and safety in setting of underlying immunocompromised state. Diagnoses: Autoimmune Hepatitis, Human Immunodeficiency Virus, Hepatotoxicity, Liver Injury, Liver Transplantation. Interventions: We retrospectively reviewed the charts of patients with HIV and AIH based on histological, serologic, biochemical demographic, and clinical data. Outcomes: Five patients were identified with autoimmune hepatitis; 4 of 5 were women, and all were African or African-American. The age at the time of AIH diagnosis was 46.6 ± 13.4 years. All patients acquired HIV sexually and all had CD4 counts >250 cells/uL (456–1011 cells/uL) and undetectable HIV viral loads at the time of AIH diagnosis. One patient presented with acute liver failure necessitating liver transplantation and developed AIH posttransplantation. At the time of diagnosis, the AST were 350 ± 448 U/L, ALT 247 ± 190 U/L, bilirubin 7 ± 12 mg/dL, and alkaline phosphatase 126 ± 53 U/L. All patients had histologic evidence of AIH on liver biopsies. Patients were successfully treated with prednisone and azathioprine, without a decrease in CD4 <250 cells/uL, infectious complications or significant side effects. Lessons: AIH occurs in patients with well-controlled HIV. In our patient cohort, immunosuppressive therapy with prednisone and azathioprine was safe and effective in inducing remission, without significant complications or development of opportunistic infections. PMID:28207511

  16. Antibody to Hepatitis C Virus in Risk Groups in Canada

    Directory of Open Access Journals (Sweden)

    RK Chaudhary

    1992-01-01

    Full Text Available The prevalence of antibodies against hepatitis C virus (HCV was studied in hemophiliacs, hemodialysis patients, intravenous drug abusers, female prisoners, homosexuals, individuals with no markers of recent hepatitis A or B virus infections and normal individuals (federal public servants, by an enzyme immunoassay (Ortho Diagnostic Systems Inc. Repeat positive samples were further tested by recombinant immunoblot assay (RIBA HCV (Chiron Corp, California. The number of samples positive for antibodies to HCV (anti-HCV was higher with enzyme immunoassay than by RIBA HCV in most cases. A high prevalence of anti-HCV was detected in hemophiliacs by both enzyme immunoassay (68.8% and RIBA HCV (53.7%. Among intravenous drug abusers and female prisoners the prevalence rates for anti-HCV were 42.8% and 29.8%, respectively, by RIBA HCV; the results with enzyme immunoassay were only slightly higher. The prevalence rate was also high by both tests (54.2% in hemodialysis patients’ sera taken during 1980–82, when many cases of non-A,non-B hepatitis were suspected in this group. In contrast, only 14.1% of sera taken during 1990 were positive by RIBA HCV. In individuals with no markers of recent hepatitis A or B infections, 13.4% were positive by enzyme immunoassay, whereas only 4.5% were reactive by RIBA HCV. The lowest prevalence was seen in homosexuals (2.3% and normal individuals (1.2% by RIBA HCV. These results indicate a high prevalence of anti-HCV in high risk groups tested in Canada.

  17. Hepatitis G virus genomic RNA is pathogenic to Macaca mulatta

    Institute of Scientific and Technical Information of China (English)

    Hao Ren; Fen-Lu Zhu; Ming-Mei Cao; Xin-Yu Wen; Ping Zhao; Zhong-Tian Qi

    2005-01-01

    AIM: To explore the pathogenicity and infectivity of hepatitis G virus (HGV) by observing replication and expression of the virus, as well as the serological and histological changes of Macaca mulatta infected with HGV genomic RNA or HGV RNA-positive serum.METHODS: Full-length HGV cDNA clone (HGVqz) was constructed and proved to be infectious, from which HGV genomic RNA was transcribed in vitro. Macaca mulatta BY1 was intra-hepatically inoculated with HGV genomic RNA, HGV RNA-positive serum from BY1 was intravenously inoculated into Macaca mulatta BM1, and then BB1 was infected with serum from BM1. Serum and liver tissue were taken regularly, and checked with RT-PCR, in situ hybridization and other immunological, serological,histological assays.RESULTS: Serum HGV RNA was detectable in all the 3Macaca mulattas, serological and histological examinations showed the experimental animals had slightly elevated alanine transaminase (ALT) and developed HGV viremia during the infectious period. The histology, immunohistochemistry, and in situ hybridization in liver tissues of the inoculated animals demonstrated a very mild hepatitis with HGV antigen expression in cytoplasm of hepatocytes.RT-PCR and quantitative PCR results showed that HGV could replicate in liver.CONCLUSION: The genomic RNA from full-length HGV cDNA is infectious to the Macaca mulatta and can cause mild hepatitis. HGV RNA-positive serum, from HGV RNA inoculated Macaca mulatta, is infectious to other Macaca mulattas. Macaca mulatta is susceptible to the inoculated HGV, and therefore can be used as an experimental animal model for the studies of HGV infection and pathogenesis.

  18. Altered quality of life in the early stages of chronic hepatitis C is due to the virus itself

    OpenAIRE

    Strauss, Edna; Porto-Ferreira, Francisco Augusto; de Almeida-Neto, Cesar; Dias Teixeira, Maria Cristina

    2013-01-01

    Health-related quality of life (HRQOL) is impaired in chronic viral hepatitis and a direct role of the virus, although suggested, has not been demonstrated. Our aim was to evaluate HRQOL at blood donation before knowledge of the diagnosis of both hepatitis C virus (HCV) and hepatitis B virus (HBV) so as to elucidate this matter.

  19. 78 FR 67175 - Proposed Collection; 60-Day Comment Request: Incident HIV/Hepatitis B Virus Infections in South...

    Science.gov (United States)

    2013-11-08

    .../ Hepatitis B Virus Infections in South African Blood Donors: Behavioral Risk Factors, Genotypes and.../Hepatitis B virus (HBV) infections in South African blood donors: Behavioral risk factors, genotypes and... antigen detection tests) to screen blood donors for HIV and Hepatitis-B Virus (HBV), among...

  20. DEVELOPMENT OF MULTIPLEX RT-PCR FOR THE DETECTION OF REOVIRUS, HEPATITIS A VIRUS, POLIOVIRUS, NORWALK VIRUS AND ROTAVIRUS

    Science.gov (United States)

    Water sources are often found to be contaminated by enteric viruses. This is a public health concern as food and waterborne outbreaks caused by enteric viruses such as noroviruses, rotaviruses, hepatitis A virus (HAV) and enteroviruses are a common occurrence. All of these viru...

  1. Hepatitis B and A virus antibodies in alcoholic steatosis and cirrhosis

    DEFF Research Database (Denmark)

    Gluud, C; Aldershvile, J; Henriksen, J

    1982-01-01

    Sera from 74 alcoholics with cirrhosis and 63 alcoholics with steatosis were tested for antibody to hepatitis B surface antigen, to hepatitis B core antigen, and to hepatitis A virus by radioimmunoassay or enzyme-linked immunosorbent assay. No significant difference between the two groups...... of alcoholics could be found concerning the prevalence of these antibodies. The total group of patients had antibody to hepatitis B surface antigen or hepatitis B core antigen, or both, significantly (p less than 0.001) more often (26%) than sex- and age-matched controls (4%). No significant difference...... suggest that hepatitis B virus does not play a major role in the progression of alcoholic liver disease, but longitudinal studies are needed to solve this problem. The reason for the increased prevalence of antibodies to hepatitis B virus in these patients is unknown....

  2. [Blood transfusion and viral diseases. Recent acquisitions concerning viral hepatitis viruses, cytomegaloviruses and Epstein-Barr virus].

    Science.gov (United States)

    Spanò, C

    1979-02-11

    In recent years, an increasingly clear picture has been formed of the virus-induced syndromes that may follow a blood transfusion or the use of blood derivatives. Up to about 10 years ago, post-infusion infection was predominantly due to serum hepatitis. Blumberg's discovery of HBsAg (formerly known as Australia antigen) has made it possible to check and prevent viral hepatitis, type B, and to recognise such distinct forms as the mononucleosis-like syndrome caused by cytomegalic virus, infectious mononucleosis caused by EB virus, and so-called non A/non B hepatitis. A brief account of recent advances with respect to the biological features of the viruses responsible for type A and type B hepatitis, CMV and EB virus, and their behaviour in man is followed by an examination of the transfusional aspects, the methods used in their study, and the difficulties involved. The soundness of existing methods and the need for their standardisation are discussed.

  3. Molecular characterization of hepatitis E virus in patients with acute hepatitis in Venezuela.

    Science.gov (United States)

    García, Cristina Gutiérrez; Sánchez, Doneyla; Villalba, Maria Caridad Montalvo; Pujol, Flor Helene; de Los Ángeles Rodríguez Lay, Licel; Pinto, Belquis; Chacón, Elsa Patricia; Guzmán, Maria Guadalupe

    2012-07-01

    Hepatitis E virus (HEV) causes a common infection in developing countries. HEV infection occurs as outbreaks, as sporadic clinical cases and as large epidemics in endemic areas. The objective of this study was to determine the presence of HEV infection in patients with clinical suspicion of hepatitis A virus (HAV) infection, referred to the Instituto Nacional de Higiene "Rafael Rangel" in Venezuela. Seventy-four sera were tested for anti-HAV and anti-HEV IgM antibodies. HEV-RNA was amplified from anti-HEV IgM positive sera using nested reverse transcription polymerase chain reaction for ORF1 (RNA dependent RNA polymerase region) and the amplicons sequenced for phylogenetic analysis. The frequency of anti-HEV IgM was 22/74 (30%) in the samples tested. Dual infection with HAV and HEV was found in 31% (12/39) of anti-HAV IgM positive patients. Viremia was detected in 3/22 (14%) of sera positive for anti-HEV IgM. Two HEV strains were classified as genotype 1 and one as genotype 3, which were closely related to Yam 67 (north of India) and US1 isolates from the USA, respectively. These findings suggest that HEV is an important cause of acute viral hepatitis in Venezuela as a single infection or co-infection with HAV, with high morbidity in children and young adults suggesting that this infection is endemic in Venezuela. Copyright © 2012 Wiley Periodicals, Inc.

  4. Defective mutations of hepatitis D viruses in chronic hepatitis D patients

    Institute of Scientific and Technical Information of China (English)

    Jaw-Ching Wu; Sheng-Chieh Hsu; Shen-Yung Wang; Yi-Hsiang Huang; I-Jane Sheen; Hsuan-Hui Shih; Wan-Jr Syu

    2005-01-01

    AIM: To verify whether "defective" mutations existed in hepatitis D virus (HDV).METHODS: Hepatitis delta antigen (HDAg)-codingsequences were amplified using Pfu DNA polymerases with proof-reading activities from sera of five patients with chronic hepatitis D. Multiple colonies were sequenced for each patient. Pfu analyzed a total of 270 HDV clones.Three representative defective HDV clones were constructed in expression plasmids and transfected into a human hepatoma cell line. Cellular proteins were extracted and analyzed by Western blot.RESULTS: Four of five cases (80%) showed defective HDV genomes in their sera. The percentage of defective genomes was 3.7% (10/270). The majority (90%) of the defective mutations were insertions or deletions that resulted in frameshift and abnormal stop translation of the HDAg. The predicted mutated HDAg ranged from 45amino acids to >214 amino acids in length. Various domains of HDAg associated with viral replication or packaging were affected in different HDV isolates. Western blot analysis showed defected HDAg in predicted positions.CONCLUSION: "Defective" viruses do exist in chronic HDV infected patients, but represented as minor strains. The clinical significance of the "defected" HDV needs further study to evaluate.

  5. Molecular Virology of Hepatitis C Virus (HCV: 2006 Update

    Directory of Open Access Journals (Sweden)

    2006-04-01

    Full Text Available Fascinating progress in the understanding of the molecular biology of hepatitis C virus (HCV was achieved recently. The replicon system revolutionized the investigation of HCV RNA replication and facilitated drug discovery. Novel systems for functional analyses of the HCV glycoproteins allowed the validation of HCV receptor candidates and the investigation of cell entry mechanisms. Most recently, recombinant infectious HCV could be produced in cell culture, rendering all steps of the viral life cycle, including entry and release of viral particles, amenable to systematic analysis. In this review, we summarize recent advances and discuss future research directions.

  6. Hepatitis C virus relies on lipoproteins for its life cycle.

    Science.gov (United States)

    Grassi, Germana; Di Caprio, Giorgia; Fimia, Gian Maria; Ippolito, Giuseppe; Tripodi, Marco; Alonzi, Tonino

    2016-02-14

    Hepatitis C virus (HCV) infects over 150 million people worldwide. In most cases, HCV infection becomes chronic causing liver disease ranging from fibrosis to cirrhosis and hepatocellular carcinoma. Viral persistence and pathogenesis are due to the ability of HCV to deregulate specific host processes, mainly lipid metabolism and innate immunity. In particular, HCV exploits the lipoprotein machineries for almost all steps of its life cycle. The aim of this review is to summarize current knowledge concerning the interplay between HCV and lipoprotein metabolism. We discuss the role played by members of lipoproteins in HCV entry, replication and virion production.

  7. Untypeable hepatitis C virus subtypes in Pakistan: A neglected section.

    Science.gov (United States)

    Khan, Abdul Waheed; Nasim, Zeeshan; Zahir, Fazli; Ali, Shahid; Ali, Abid; Iqbal, Aqib; Munir, Iqbal

    2016-12-01

    Diagnostically untypeable subtypes contribute a considerable percent of hepatitis C virus (HCV) subtypes in Pakistan. In the present study, chronically infected HCV patients with known viremia were subjected to HCV genotyping. Among the total retrieved samples, 92.7% (64/69) were found typeable while 7.24% (5/69) were diagnostically untypeable. In conclusion, the presence of large number of untypeable HCV subtypes emphasizes the need of an updated type-specific genotyping assay and consideration of primers for proportionally rare subtypes to minimize the number of untypeable HCV subtypes.

  8. Hepatitis C virus entry and the tetraspanin CD81.

    Science.gov (United States)

    Farquhar, Michelle J; Harris, Helen J; McKeating, Jane A

    2011-04-01

    CD81, a member of the tetraspanin integral membrane protein family, has been identified as an essential receptor for HCV (hepatitis C virus). The present review highlights recent published data on the role that CD81 plays in HCV entry, including the importance of actin-dependent lateral diffusion of CD81 within the cell membrane, CD81 endocytosis and the CD81-Claudin-1 receptor complex in HCV internalization. Additional functions for CD81 in the viral life cycle and the role of HCV-CD81 interactions in HCV-induced B-cell and CNS (central nervous system) abnormalities are discussed.

  9. Association of hepatitis C virus infection and diabetes

    Institute of Scientific and Technical Information of China (English)

    Samir Rouabhia; Rachid Malek; Hocine Bounecer

    2009-01-01

    Epidemiologic studies have suggested a relation between hepatitis C virus (HCV) infection and diabetes mellitus. HCV infection is emerging as a metabolic disease, and diabetes mellitus as a risk factor for HCV infection. However, some data on the prevalence of antibodies to HCV in patients with diabetes are conflicting. These seroprevalence data should be interpreted with caution. Some potential bias may occur in those clinic-based studies that target a specific disease group. In this letter we explain some reasons for these conflicting studies.

  10. Application of hepatitis B virus replication mouse model

    Institute of Scientific and Technical Information of China (English)

    2010-01-01

    AIM:To evaluate the value of the hepatitis B virus(HBV) replication mouse model with regard to several aspects of the study of HBV biology.METHODS:To evaluate the HBV replication mouse model in detecting the efficacy of anti-HBV agents,the interferon inducer polyinosinic-polytidylin acid(polyIC) and nucleotide analogues adefovir and entecavir were administered to mice injected with wild type pHBV4.1,and the inhibiting effect of these agents on HBV DNA replication was evaluated.To identify the model's value ...

  11. Lamiridosins, hepatitis C virus entry inhibitors from Lamium album.

    Science.gov (United States)

    Zhang, Hongjie; Rothwangl, Katharina; Mesecar, Andrew D; Sabahi, Ali; Rong, Lijun; Fong, Harry H S

    2009-12-01

    Phytochemical study of the aqueous extract of the flowering tops of Lamium album led to identification of the antiviral iridoid isomers lamiridosins A and B (1, 2). These compounds were found to significantly inhibit hepatitis C virus entry (IC(50) 2.31 muM) in vitro. Studies of 14 iridoid analogues showed that, while the parent iridoid glucosides demonstrated no anti-HCV entry activity, the aglycones of shanzhiside methyl ester (4), loganin (5), loganic acid (6), geniposide (10), verbenalin (12), eurostoside (15), and picroside II (17) exhibited significant anti-HCV entry and anti-infectivity activities.

  12. Helicobacter pylori and Hepatitis C virus coinfection in Egyptian patients

    Directory of Open Access Journals (Sweden)

    El-Masry Samir

    2010-01-01

    Full Text Available Introduction: Chronic hepatitis C virus (HCV infection is a leading cause of end-stage liver disease worldwide. It has been shown that Helicobacter pylori (H. pylori plays an important role in chronic gastritis, peptic ulcer disease and gastric malignancies, and its eradication has been advocated. The association between H. pylori infection and liver cirrhosis in patients with hepatitis C virus has been documented in different parts of the world; nevertheless, no conclusive data is available in Egypt. Materials and Methods: In the present study, the status of H. pylori infection was sought in 90 patients with chronic HCV infection and in 66 HCV-free healthy controls. Results: The study showed that the H. pylori positivity was increased significantly (P = 0.03 in the HCV-infected patients when compared to that in healthy controls, where H. pylori infection was found in 50 (55.6% out of 90 of the HCV-infected patients versus 26 (39.4% out of 66 of the healthy controls. In HCV-infected patients, the prevalence of H. pylori infection was increased significantly (P = 0.04 from chronic active hepatitis to cirrhosis. H. pylori infection was present in 6/18 (33.3%, 10/21 (47.6%, 16/27 (59.3%, 18/24 (75.0% patients with chronic active hepatitis, Child-Pugh score A, Child-Pugh score B and Child-Pugh score C, respectively. More importantly, the prevalence of H. pylori infection in HCV-infected patients was increased very significantly (P = 0.003 with increasing Meld (model for end-stage liver disease score. The prevalence of H. pylori was documented in 9/28 (32.1% patients with Meld score ≤10 and in 41/62 (66.1% patients with Meld score> 10. Conclusion: It may be stated that our results collectively reflect a remarkable increase in H. pylori prevalence with advancing hepatic lesions, and the eradication treatment may prove beneficial in those patients with chronic hepatitis C.

  13. Seroprevalence of hepatitis B virus and its co-infection with hepatitis D virus and hepatitis C virus in Iranian adult population

    Directory of Open Access Journals (Sweden)

    Gholamreza Roshandel

    2007-05-01

    Full Text Available Context: Hepatitis B virus (HBV infection is one of the most prevalent public health problems worldwide (especially in developing countries. Aims: This study was carried out to determine the seroprevalence of HBV and its co-infection with hepatitis D (HDV and C (HCV viruses in the northeastern part of Iran. Setting and Design: A population-based cross-sectional study in Iran. Materials and Methods: As many as 1,850 subjects were explored for HBsAg. Anti-HDV and anti-HCV antibodies were assessed in HBsAg-positive cases. Statistical Analysis Used: Proportions were compared by Chi-square and Fisher′s exact tests. Results: The mean age of subjects was 43.86 ± 11.2 years. The age- and sex-standardized prevalence for HBsAg positivity was 9.7%. It was higher in males than in females (OR: 1.28; 95% CI: 0.9-1.7. The risk of infection in singles was significantly higher than in married cases (OR: 2.13. Eight (5.8% of HBsAg-positive cases were infected with HDV, and 17 (12.3% were positive for anti-HCV antibody. Conclusion: This study demonstrates that the prevalence of HBsAg seropositivity in Golestan province of Iran is higher than the levels reported by WHO and previous studies from Iran. It is very important, especially for health providers and policy makers, to recognize the risk factors of HBV infection and its co-infection with HDV and HCV in this area and design effective preventive programs.

  14. Identification of acute self-limited hepatitis B among patients presenting with hepatitis B virus-related acute hepatitis: a hospital-based epidemiological and clinical study.

    Science.gov (United States)

    Han, Y-N

    2009-01-01

    This study aimed to identify acute self-limited hepatitis B (ASL-HB) among patients presenting with hepatitis B virus (HBV)-related acute hepatitis. Data were available for 220 patients diagnosed with HBV-related acute hepatitis, of whom 164 had acute hepatitis B (AHB). Of these, 160 were confirmed as ASL-HB: three (1.9%) evolved to chronic hepatitis B and one (0.6%) developed fulminant hepatitis and died. Comparisons were also made between AHB and acute infections with hepatitis A (HA) and hepatitis E (HE) viruses. During the study period, the number of patients with AHB exceeded the sum of those with acute HA and acute HE infections. There was no distinct seasonal peak for AHB infection, whereas both acute HA and acute HE infections occurred more frequently in the spring. Clinical symptoms and physical signs were similar for all three types of hepatitis, but significant differences were seen in some biochemical parameters. In conclusion, this study suggests that symptomatic AHB is not rare in China but it seldom evolves to chronic hepatitis B.

  15. Molecular biology of liver disorders: the hepatitis C virus and molecular targets for drug development

    Institute of Scientific and Technical Information of China (English)

    Howard J. Worman; Feng Lin

    2000-01-01

    Molecular biology has made a tremendous impact on the diagnosis and treatment of liver diseases[1,2]. In particular, advances in molecular biology made possible the discovery of the virus that causes hepatitis C. In this review, we use hepatitis C as an example of the impact that molecular biology has made in the area of liver disorders. We emphasize how our growing understanding of the hepatitis C virus (HCV) has lead to the identification of targets for development of new treatments.

  16. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.

    Science.gov (United States)

    Moyo, Buhle; Bloom, Kristie; Scott, Tristan; Ely, Abdullah; Arbuthnot, Patrick

    2017-01-10

    Chronic infections with hepatitis B and hepatitis C viruses (HBV and HCV) account for the majority of cases of cirrhosis and hepatocellular carcinoma. Current therapies for the infections have limitations and improved efficacy is necessary to prevent complications in carriers of the viruses. In the case of HBV persistence, the replication intermediate comprising covalently closed circular DNA (cccDNA) is particularly problematic. Licensed therapies have little effect on cccDNA and HBV replication relapses following treatment withdrawal. Disabling cccDNA is thus key to curing HBV infections and application of gene editing technology, such as harnessing the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) system, has curative potential. Several studies have reported good efficacy when employing CRISPR/Cas technologies to disable HBV replication in cultured cells and in hydrodynamically injected mice. Recent advances with HCV drug development have revolutionized treatment of the infection. Nevertheless, individuals may be refractory to treatment. Targeting RNA from HCV with CRISPR/Cas isolated from Francisella novicida may have therapeutic utility. Although preclinical work shows that CRISPR/Cas technology has potential to overcome infection with HBV and HCV, significant challenges need to be met. Ensuring specificity for viral targets and efficient delivery of the gene editing sequences to virus-infected cells are particularly important. The field is at an interesting stage and the future of curative antiviral drug regimens, particularly for treatment of chronic HBV infection, may well entail use of combinations that include derivatives of CRISPR/Cas.

  17. New perspectives in occult hepatitis C virus infection.

    Science.gov (United States)

    Carreño, Vicente; Bartolomé, Javier; Castillo, Inmaculada; Quiroga, Juan Antonio

    2012-06-21

    Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases.

  18. New perspectives in occult hepatitis C virus infection

    Institute of Scientific and Technical Information of China (English)

    Vicente Carre(n)o; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga

    2012-01-01

    Occult hepatitis C virus (HCV) infection,defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays,can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology.Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection.Occult hepatitis C has been found not only in anti-HCV positive subjects with normal values of liver enzymes or in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV.This occult infection has been reported also in healthy populations without evidence of liver disease.Occult HCV infection seems to be less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma.Thus,anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylatedinterferon plus ribavirin.The persistence of very low levels of HCV RNA in serum and in PBMCs,along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C,indicate that occult HCV is a persistent infection that is not spontaneously eradicated.This is an updated report on diagnosis,epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases.

  19. Hepatitis B Virus Splice-Generated Protein Induces T-Cell Responses in HLA-Transgenic Mice and Hepatitis B Virus-Infected Patients▿

    Science.gov (United States)

    Mancini-Bourgine, Maryline; Bayard, Florence; Soussan, Patrick; Deng, Qiang; Lone, Yu-Chun; Kremsdorf, Dina; Michel, Marie-Louise

    2007-01-01

    Hepatitis B virus splice-generated protein (HBSP), encoded by a spliced hepatitis B virus RNA, was recently identified in liver biopsy specimens from patients with chronic active hepatitis B. We investigated the possible generation of immunogenic peptides by the processing of this protein in vivo. We identified a panel of potential epitopes in HBSP by using predictive computational algorithms for peptide binding to HLA molecules. We used transgenic mice devoid of murine major histocompatibility complex (MHC) class I molecules and positive for human MHC class I molecules to characterize immune responses specific for HBSP. Two HLA-A2-restricted peptides and one immunodominant HLA-B7-restricted epitope were identified following the immunization of mice with DNA vectors encoding HBSP. Most importantly, a set of overlapping peptides covering the HBSP sequence induced significant HBSP-specific T-cell responses in peripheral blood mononuclear cells from patients with chronic hepatitis B. The response was multispecific, as several epitopes were recognized by CD8+ and CD4+ human T cells. This study provides the first evidence that this protein generated in vivo from an alternative reading frame of the hepatitis B virus genome activates T-cell responses in hepatitis B virus-infected patients. Given that hepatitis B is an immune response-mediated disease, the detection of T-cell responses directed against HBSP in patients with chronic hepatitis B suggests a potential role for this protein in liver disease progression. PMID:17360751

  20. Prevalencia de la infección por el virus de hepatitis B en niños menores de 5 años de comunidades indígenas de la Amazonía peruana posterior a intervenciones mediante inmunización

    Directory of Open Access Journals (Sweden)

    César Cabezas-Sánchez

    Full Text Available Objetivos. Determinar la prevalencia de infección y de sobreprotección para virus hepatitis B (HVB en niños indígenas residentes en tres cuencas de la Amazonía peruana. Materiales y métodos. Se realizó un estudio transversal analítico en tres cuencas hidrográficas (ríos Pastaza, Morona y Bajo Urubamba, donde habitan seis pueblos indígenas: shapra, candoshi, machiguengas, yine, ashaninka y nanti. Se incluyeron niños menores de 5 años. Se aplicó una encuesta y revisión del carné de vacunación, y se obtuvo una muestra de suero que se procesó con la técnica de ELISA para detectar HBsAg, anti-HBc total y anti-HBs, definiendo “niños seroprotegidos” si fueron reactivos al anti-HBs y no reactivos al anti-HBc. Resultados. Se incluyó un total de 742 niños menores de 5 años residentes en seis comunidades indígenas, donde 380 (51,2% eran varones y 169 (22,9% de un año a menos. Sobre la vacunación contra HVB registrado por carné, solo 434 (58,5% había recibido tres dosis; 208 (38,8% recibieron la primera dosis en las primeras 24 h. No se detectaron casos con HBsAg. El 88,8% de los niños había seroconvertido, con variaciones según la población indígena entre 67 a 100% de seroconversión. Conclusiones. No se detectaron casos de infección crónica para HVB en la población evaluada. La cobertura de la vacunación mediante revisión del carné es baja en contraste el promedio de seroconversión que es alto.